Use these links to rapidly review the document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934 (Amendment No.    )

Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material under §240.14a-12
RITE AID CORPORATION
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):

No fee required

Fee paid previously with preliminary materials

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

[MISSING IMAGE: cv_ofcriteaid-4c.jpg]

[MISSING IMAGE: cv_ifcrite-4c.jpg]

[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
LETTER FROM OUR INDEPENDENT BOARD CHAIR AND INTERIM CHIEF EXECUTIVE OFFICER
June [•], 2023
This past year has been one of challenge and change for our company, and we are especially grateful for the dedication of our associates to deliver on our mission to help our customers achieve whole health for life. We know there is a fundamental consumer need for pharmacy services—for both individuals and companies. At Rite Aid, we serve these needs through both our retail and PBM businesses. We have a trusted and iconic brand, an attractive retail footprint, and a long history of serving millions of customers built over the years largely through our pharmacists. The role of the pharmacist has become an increasingly important, trusted, and efficient option for the delivery of health care services to consumers—which is part of our core value proposition.
While we have all the right ingredients for success, we have been disappointed in our financial performance. We know we need to do better to deliver value to our stockholders. That is why we have taken a series of actions, including deciding to replace our CEO, searching for a new leader, and upleveling talent in critical areas. We have also implemented an established turnaround model that is geared to drive enterprise-wide performance acceleration and is expected to chart a new course for our business. This model is highly prescriptive and programmatic, with a rapid cadence and analytical rigor. We believe that this new operating model will enable us to organize effectively and efficiently to capture value and drive growth. We are impacting all areas of the business including Pharmacy, Front End, Elixir and overall operations, which we believe will position our core business for growth longer term.
We are moving with urgency and intense focus on those opportunities, and we look forward to sharing more with you at our 2023 Annual Meeting of Stockholders. The meeting will be held on August 18, 2023, and once again will be a virtual meeting to make the meeting more accessible to all of our stockholders.
You can attend the meeting at www.virtualshareholdermeeting.com/RAD2023 by using the 16-digit control number, which appears on your Notice of Internet Availability of Proxy Materials or the instructions that accompanied your proxy materials. You will have the ability to submit questions during the meeting via the meeting website. At the meeting, stockholders will vote on the proposals set forth in the Notice of Annual Meeting and the accompanying proxy statement.
[MISSING IMAGE: ph_brucegbodakenbox-pn.jpg]
[MISSING IMAGE: ph_elizabethburrbox-pn.jpg]
We are committed to driving growth and stockholder value and appreciate your support as we continue to execute our turnaround plan. We hope you and your families are safe and well.
Thank you for your investment in Rite Aid.
Sincerely,
[MISSING IMAGE: sg_brucebodaken-bw.jpg]
[MISSING IMAGE: sg_elizabethburr-bw.jpg]
Filed by the Registrantý


Filed by a Party other than the Registranto


Check the appropriate box:


ý


Preliminary Proxy Statement


o


Confidential, for Use
BRUCE G. BODAKEN
Chair of the Commission Only (as permitted by Rule 14a-6(e)(2))
Board
ELIZABETH BURR
Interim Chief Executive Officer
Refer to the section titled “Cautionary Statement Regarding Forward-Looking Statements” for a discussion of risks and uncertainties that could cause actual results to differ materially from those projected.




o
[MISSING IMAGE: lg_riteaid-pn.jpg]


Definitive Proxy Statement


o


Definitive Additional Materials


oRite Aid Corporation
PO Box 3165
Harrisburg, PA 17105


Soliciting Material Pursuant to §240.14a-12
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
[MISSING IMAGE: tm217739d1-icon_calendarpn.jpg]WHEN
[MISSING IMAGE: ic_mic-pn.jpg]
VIRTUAL MEETING
[MISSING IMAGE: ic_pencil-pn.jpg]RECORD DATE

RITE AID CORPORATION

(Name of Registrant as Specified In Its Charter)


(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):

ý


No fee required.

o


Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)Title of each class of securities to which transaction applies:
(2)Aggregate number of securities to which transaction applies:
(3)Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4)Proposed maximum aggregate value of transaction:
(5)Total fee paid:

o


Fee paid previously with preliminary materials.

o


Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.



(1)


Amount Previously Paid:
(2)Form, Schedule or Registration Statement No.:
(3)Filing Party:
(4)Date Filed:

Table of Contents

PRELIMINARY COPY—SUBJECT TO COMPLETION

GRAPHIC

RITE AID CORPORATION
P.O. BOX 3165
HARRISBURG, PENNSYLVANIA 17105



Notice of Annual Meeting of Stockholders
To Be Held on June 25, 2009

To Our Stockholders:

What:Our 2009 Annual Meeting of Stockholders

When:


June 25, 2009 at 10:August 18, 2023
11:
30 a.m., local time
Eastern
Daylight Time
www.virtualshareholdermeeting.com/RAD2023Close of business on
June 27, 2023
AGENDA
ProposalBoard Recommendation

Where:

1

Skadden, Arps, Slate, Meagher & Flom LLP
Four Times Square, 37th Floor
New York, New York

Why:


At this Annual Meeting, we plan to:



1.


Consider and vote upon a proposal to amend our Restated CertificateElection of Incorporation to declassify our Board of Directors;



2.


Elect fivesix directors to hold office until the 20102024 Annual Meeting of Stockholders (or until
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR all of the 2012 Annual Meeting of Stockholders if Proposal No. 1 is not approved, as described in the attached proxy statement) and until their respective successors are duly elected and qualified;Board’s nominees


2

3.


Consider and vote upon a stockholder proposal, if properly presented, requesting that Rite Aid's BoardRatification of Directors provide stockholders the opportunity at each annual meeting of stockholders to vote on an advisory resolution to ratify the compensation of the named executive officers set forth in the proxy statement;



4.


Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm; andfirm
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR


3

5.


Transact such other business as may properly come beforeAdvisory vote to approve the Annual Meeting or any adjournment or postponementcompensation of our named executive officers
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
4Advisory vote on the frequency of future advisory votes to approve the compensation of our named executive officers
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
ONE YEAR
5Approval of the Annual Meeting.

        In addition, the holders of the 7% Series G Cumulative Convertible Pay-in-Kind Preferred Stockamendments to the Rite Aid Corporation Amended and 6% Series H Cumulative Convertible Pay-in-Kind Preferred Stock, voting together as a single class, separately from the holders of Common Stock, will vote to elect one director to hold office until the 2010 Annual Meeting of Stockholders (or until the 2012 Annual Meeting of Stockholders if Proposal No. 1 is not approved, as described in the attached proxy statement) and until a successor is duly elected and qualified.

        The close of business on April 28, 2009 has been fixed as the record date for determining those Rite Aid stockholders entitled to vote at the Annual Meeting. Accordingly, only stockholders of record at the close of business on that date will receive this notice of, and be eligible to vote at, the Annual Meeting and any adjournment or postponement of the Annual Meeting. The above items of business for the Annual Meeting are more fully described in the proxy statement accompanying this notice.

Your vote is important.Please read the proxy statement and the instructions on the enclosed proxy card and then, whether or not you plan to attend the Annual Meeting in person, and no matter how


Table of Contents


many shares you own, please submit your proxy promptly by telephone or via the Internet in accordance with the instructions on the enclosed proxy card, or by completing, dating and returning your proxy card in the envelope provided. This will not prevent you from voting in person at the Annual Meeting. It will, however, help to assure a quorum and to avoid added proxy solicitation costs.

        You may revoke your proxy at any time before the vote is taken by delivering to the Secretary of Rite Aid a written revocation or a proxy with a later date (including a proxy by telephone or via the Internet) or by voting your shares in person at the Annual Meeting, in which case your prior proxy would be disregarded.

By order of the Board of Directors



Secretary



Camp Hill, Pennsylvania
[May 14, 2009]


TABLE OF CONTENTS


Page

General Information

1

Questions and Answers About the Annual Meeting

1

Proposal No. 1—Amendment of Restated Certificate of Incorporation to Declassifyeliminate supermajority voting provisions

[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
6Consider and vote on a stockholder proposal to require an annual advisory vote on the compensation of Rite Aid’s directors, if properly presented at the Annual Meeting
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]
AGAINST
7Consider and vote on a stockholder proposal to adopt an executive compensation adjustment policy, if properly presented at the Annual Meeting
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]
AGAINST
In addition, we will transact any other business properly presented at the meeting, including any adjournment or postponement thereof.


VOTING
Have your proxy card or voting instruction form in hand, with your individual control number, and follow the instructions.
[MISSING IMAGE: ic_phone-pn.jpg]
PHONE
[MISSING IMAGE: tm217739d1_icon-computerpn.jpg]
INTERNET
[MISSING IMAGE: tm217739d1_icon-qrreaderpn.jpg]
MOBILE DEVICE
[MISSING IMAGE: ic_mail-pn.jpg]
MAIL
[MISSING IMAGE: ic_chat-pn.jpg]
VIRTUAL MEETING
Call
1-800-690-6903
(toll-free), 24/7
Visit
www.proxyvote.com,
24/7
Scan the
QR code
[MISSING IMAGE: tm228886d1-icon_qrcodebwlr.jpg]
Mark, sign and
date your proxy
card or voting
instruction form
and return it in
the postage-paid
envelope
During the virtual
meeting, go to

www.virtualshareholder
meeting.com/RAD2023
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE
STOCKHOLDER MEETING TO BE HELD ON AUGUST 18, 2023
Your vote is important. Please read the proxy statement carefully and submit your vote as soon as possible. The Notice of Availability is being mailed and the proxy materials made available on or about [June 29], 2023. The proxy statement and annual report, as well as the Company’s proxy card, are available at www.proxyvote.com.


[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
TABLE OF CONTENTS
Business Strategy and Performance in Fiscal Year 2023
Stockholder Engagement Efforts
Board of Directors
Board and Governance Highlights
Executive Compensation Overview
Environmental, Social & Governance Efforts
Director Nominees
Board Leadership Structure
Director Independence
Corporate Governance Practices
Board Oversight of Risk Management
Committees of the Board of Directors

7

Proposal No. 2—Election of Directors

Board Meeting Attendance
Director Nominations
Executive Sessions of Non-Management Directors
Communications with the Board of Directors

9

Proposal No. 3—Stockholder Proposal—Advisory Vote on Executive Compensation

21Environmental, Social & Governance Matters

Proposal No. 4—Ratification of the Appointment of Independent Registered Public Accounting Firm

23Corporate Governance Materials

Executive Officers

24Certain Relationships and Related Transactions

Executive Compensation

25Directors’ Compensation
Auditor Fees

Audit Committee Report
Compensation Discussion and Analysis

25

Compensation Committee Report

3356Executive Compensation Tables
56

34
58

36
58

37
60

39
61

Options

40
61

40
61

41

Audit Committee Report

4767Pay Ratio Disclosure

Equity Compensation Plan Information

Section 16(a) Beneficial Ownership Reporting Compliance

Security Ownership of Certain Beneficial Owners and Management

Certain Relationships and Related Transactions

Stockholder Proposals for the 2010 Annual Meeting of Stockholders

Incorporation by Reference

Other Matters

Independent Registered Public Accounting Firm

5780Questions and Answers
87

Important Notice Regarding Delivery of Stockholder Documents

57

Annual Report

89

Proposed Amendment to

Stockholder Proposals for the Restated Certificate2024 Annual Meeting
90Incorporation by Reference
91Other Matters
Certain Information Regarding Participation in the Solicitation of Incorporation to Declassify Our Board of Directors

Proxies
Appendix A91Annual Report
92Cautionary Statement Regarding Forward-Looking Statements

i




PRELIMINARY COPY—PROXY STATEMENT — SUBJECT TO COMPLETION


GRAPHIC

RITE AID CORPORATION
P.O. BOX 3165
HARRISBURG, PENNSYLVANIA 17105



PROXY STATEMENT



FOR THE ANNUAL MEETING OF STOCKHOLDERS
To Be Held on June 25, 2009

GENERAL INFORMATION



Important Notice Regarding DATED JUNE 16, 2023

[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
PROXY STATEMENT SUMMARY
This Proxy Statement Summary highlights information contained elsewhere in this proxy statement. This summary does not contain all of the Availability of Proxy Materials forinformation you should consider, so please read the
Stockholder Meeting entire proxy statement carefully before voting. References to be Held on June 25, 2009:

The“Rite Aid,” “Rite Aid Corporation,” the “Company,” “we,” “us,” or “our” in this proxy statement and annual reportthe accompanying notice and letters to stockholders refer to Rite Aid Corporation and/or its affiliates. Rite Aid Corporation, a Delaware corporation, owns multiple subsidiary companies which operate Rite Aid stores and pharmacies and other affiliated companies. The term “affiliates” means direct and indirect subsidiaries of Rite Aid Corporation and partnerships and joint ventures in which such subsidiaries are available athttp:                        .

Also available on the website are the Company's proxy card, as well as instruction cards
and related materials for voting sharespartners. References herein to “associates” refer to employees of common stock held in the Company's 401(k) plans.



our affiliates.

This proxy statement is being furnished to you by the Board of Directors (the "Board"“Board” or “Board of Directors”) of Rite Aid Corporation (the "Company" or "Rite Aid") to solicit your proxy to vote your shares at our 20092023 Annual Meeting of Stockholders.Stockholders (the “Annual Meeting”). The Annual Meeting will be held on June 25, 2009August 18, 2023 at 10:11:30 a.m., local time,Eastern Daylight Time, by live audio webcast at www.virtualshareholdermeeting.com/RAD2023.
The following proposals will be on the agenda for the Annual Meeting:
ProposalBoard RecommendationSee Page
1Election of six directors to hold office until the 2024 Annual Meeting of Stockholder
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR all of the Board’s nominees
2Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
3Advisory vote to approve the compensation of our named executive officers
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
4Advisory vote on the frequency of future advisory votes to approve the compensation of our named executive officers
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
ONE YEAR
5Approval of the amendments to the Rite Aid Corporation Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
6Consider and vote on a stockholder proposal to require an annual advisory vote on the compensation of Rite Aid’s directors, if properly presented at the Annual Meeting
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]
AGAINST
7Consider and vote on a stockholder proposal to adopt an executive compensation adjustment policy, if properly presented at the Annual Meeting
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]
AGAINST
In addition, we will transact any other business properly presented at the offices of Skadden, Arps, Slate, Meagher & Flom LLP, Four Times Square, 37th Floor, New York, New York. This proxy statement, the foregoing notice and the accompanying proxy card are first being mailed on or about May [14], 2009 to all holders of our common stock, par value $1.00 per share, and 7% Series G Cumulative Convertible Pay-in-Kind Preferred Stock and 6% Series H Cumulative Convertible Pay-in-Kind Preferred Stock, entitled to vote at the Annual Meeting.


QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING

Who is entitled to vote at the Annual Meeting?

        Holders of Rite Aid common stock and shares of 7% Series G Cumulative Convertible Pay-in-Kind Preferred Stock and 6% Series H Cumulative Convertible Pay-in-Kind Preferred Stock, which are collectively referred to in this proxy statement as the "LGP preferred stock," as of the close of business on the record date, April 28, 2009, will receive notice of, and be eligible to vote at, the Annual Meeting andmeeting, including any adjournment or postponement thereof.


RITE AID CORPORATION   2023 Proxy Statement | 1

PROXY STATEMENT SUMMARY
BUSINESS STRATEGY AND PERFORMANCE IN FISCAL YEAR 2023
Our Enterprise Strategy
As a healthcare company with a retail footprint operating in diverse communities throughout the country, we are positioned to create meaningful customer, client, and member experiences for the millions of the Annual Meeting. At the closelives we touch.
We are focused on three key strategic drivers of business on the record date,growth:
[MISSING IMAGE: ic_pharmacy-pn.jpg]
[MISSING IMAGE: ic_deepening-pn.jpg]
[MISSING IMAGE: ic_elixir-pn.jpg]
1.
Growing our pharmacy business by:

improving our access to networks,

strategically acquiring prescription files,

increasing medication adherence, and

making more clinical services available to our customers.
2.
Deepening our customer loyalty and engagement by:

improving our in-store experience,

optimizing our products and services,

leveraging personalized marketing and communications, and

expanding our digital solutions.
3.
Scaling our Elixir business by:

delivering on a value proposition unique to the mid-market including competitive pricing,

leveraging our platform to deliver white-label services,

optimizing our specialty pharmacy, and

improving our operational efficiency.
All of these are enabled by significant ongoing investments in our people and infrastructure, including our distributions centers, central fill operations, and systems for customer and client support.
Fiscal Year 2023 Performance and Operational Highlights(1)
$24.1B
Total Revenue
$429.2M
Adjusted EBITDA
$1.5B
Total Liquidity
6.9%
Increase in
Comparable
Same-Store
Prescriptions
(excluding COVID-19
impacts)
617K
Prescriptions Filled
Each Day, On Average
(including
immunizations), in Rite
Aid & Bartell Stores
6,300
Pharmacists Serving
Our Communities
2,300
Retail Pharmacy
Locations across 17
States
Over 60%
Growth in Third-Party
E-Commerce Business
(1)
As of March 4, 2023 (figures are rounded).

2 | RITE AID CORPORATION   2023 Proxy Statement

PROXY STATEMENT SUMMARY
STOCKHOLDER ENGAGEMENT EFFORTS
At Rite Aid, had outstanding and entitled to vote                        shares of common stock and 1,434,990.0325 shares of LGP preferred stock (which, on an as-if-converted basis, are entitled to an aggregate of 26,090,728 votes). No other shares of Rite Aid capital stock are entitled to notice of and to vote atwe believe stockholder engagement is extremely important. We regularly seek the Annual Meeting.


Table of Contents

What matters will be voted on at the Annual Meeting?

        There are four proposals that are scheduled to be considered and voted on at the Annual Meeting:

    Proposal No. 1: Amend our Restated Certificate of Incorporation to declassify our Board of Directors;

    Proposal No. 2: Elect five directors to hold office until the 2010 Annual Meeting of Stockholders (or until the 2012 Annual Meeting of Stockholders if Proposal No. 1 is not approved, as described in this proxy statement);

    Proposal No. 3: Consider a stockholder proposal requesting that Rite Aid's Board of Directors provide stockholders the opportunity at each annual meeting of stockholders to vote on an advisory resolution to ratify the compensation of the named executive officers set forth in the proxy statement; and

    Proposal No. 4: Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm.

        In addition, the holders of the LGP Preferred Stock, voting separately as a class, will vote to elect one director (the "LGP Preferred Director") to hold office until the 2010 Annual Meeting of Stockholders (or until the 2012 Annual Meeting of Stockholders if Proposal No. 1 is not approved) and until his successor is duly elected and qualified.

        Stockholders will also be asked to consider and vote at the Annual Meeting on any other matter that may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting. At this time, the Board of Directors is unaware of any matters, other than those set forth above, that may properly come before the Annual Meeting.

What are the Board's voting recommendations?

        The Board recommends that you vote "FOR" the Amendmentperspectives of our Restated Certificate of Incorporation to declassify our Board of Directors.

        The Board recommends that you vote "FOR" the nominees of the Board in the election of directors.

        The Board recommends that you vote "AGAINST" the stockholder proposal.

        The Board recommends that you vote for "FOR" the ratification of Deloitte & Touche LLP as the Company's independent registered public accounting firm.

What is the difference between holding shares as a stockholder of record and as a beneficial owner?

        If your shares are registered directly in your name with our transfer agent, American Stock Transfer & Trust Company, you are considered the "stockholder of record" with respect to those shares.

        If your shares are held in a stock brokerage account or by a bank or other nominee, those shares are held in "street name" and you are considered the "beneficial owner" of the shares. As the beneficial owner of those shares, you have the right to direct your broker, trustee or nominee how to vote your shares, and you will receive separate instructions from your broker, bank or other holder of record describing how to vote your shares.


Table of Contents

How can I vote my shares before the Annual Meeting?

If you hold your shares in your own name,you may submit a proxy by telephone, via the Internet or by mail.

    Submitting a Proxy by Telephone:  You can submit a proxy for your shares by telephone until 11:59 p.m. Eastern Daylight Time on June 24, 2009 by calling the toll-free telephone number on the enclosed proxy card, 1-888-444-0050. Telephone proxy submission is available 24 hours a day. Easy-to-follow voice prompts allow you to submit a proxy for your shares and confirm that your instructions have been properly recorded. Our telephone proxy submission procedures are designed to authenticate stockholders by using individual control numbers.

    Submitting a Proxy via the Internet:  You can submit a proxy via the Internet until 11:59 p.m. Eastern Daylight Time on June 24, 2009 by accessing the web site listed on your proxy card,www.voteproxy.com, and following the instructions you will find on the web site. Internet proxy submission is available 24 hours a day. As with telephone proxy submission, you will be given the opportunity to confirm that your instructions have been properly recorded.

    Submitting a Proxy by Mail:  If you choose to submit a proxy by mail, simply mark the enclosed proxy card, date and sign it, and return it in the postage paid envelope provided.

        By casting your vote in any of the three ways listed above, you are authorizing the individuals listed on the proxy to vote your shares in accordance with your instructions. You may also attend the Annual Meeting and vote in person.

If your shares are held in the name of a bank, broker or other nominee,you will receive instructions from the holder of record that you must follow for your shares to be voted. The availability of telephonic or Internet voting will depend on the bank's or broker's voting process. Please check with your bank or broker and follow the voting procedures your bank or broker provides to vote your shares. Also, please note that if the holder of record of your shares is a broker, bank or other nominee and you wish to vote in person at the Annual Meeting, you must request a legal proxy from your bank, broker or other nominee that holds your shares and present that proxy and proof of identification at the Annual Meeting.

If I am the beneficial owner of shares held in "street name" by my broker, will my broker automatically vote my shares for me?

        New York Stock Exchange ("NYSE") rules applicable to broker-dealers grant your broker discretionary authority to vote your shares without receiving your instructions on certain matters, which include the election of directors and the ratification of the appointment of our independent registered public accounting firm. However, your broker does not have discretionary authority to vote your shares for certain other types of matters.

How will my shares be voted if I give my proxy but do not specify how my shares should be voted?

        If you provide specific voting instructions, your shares will be voted at the Annual Meeting in accordance with your instructions. If you hold shares in your name and sign and return a proxy card without giving specific voting instructions, your shares will be voted "FOR" the Amendment of our Restated Certificate of Incorporation to declassify our Board of Directors, "FOR" the nominees of the Board in the election of directors, "AGAINST" the stockholder proposal requesting an advisory vote on executive compensation, and "FOR" the ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for fiscal year 2010.


Table of Contents

How do I vote my shares held in one of the Rite Aid 401(k) plans? What happens if I do not vote my 401(k) plan shares?

        If you are a participant in one of Rite Aid's 401(k) plans, the voter instruction card sent to you will serve as a voting instruction card to the trustee of the 401(k) plans for all shares of our common stock you own through the applicable 401(k) plan. You are entitled to instruct the plan trustee on how to vote your shares in the 401(k) plan by telephone, via the Internet or by mail as described above, except that, if you vote by mail, the card that you use will be a voting instruction card rather than a proxy card. The trustee will vote your shares held in the plans in accordance with your instructions. Your instructions will be kept confidential by the trustee and will not be disclosed to Rite Aid. Any shares held by a 401(k) plan participant for which timely instructions are not received by the trustee will be voted by the trustee in its sole discretion.

Could other matters be decided at the Annual Meeting?

        At this time, we are unaware of any matters, other than as set forth above, that may properly come before the Annual Meeting. If any other matters properly come before the Annual Meeting, the persons named in the enclosed proxy, or their duly constituted substitutes acting at the Annual Meeting or any adjournment or postponement of the Annual Meeting, will be deemed authorized to vote or otherwise act on such matters in accordance with their judgment.

Can I vote in person at the Annual Meeting?

        Yes. If you hold shares in your own name as a stockholder of record, you may come to the Annual Meeting and cast your vote at the meeting by properly completing and submitting a ballot. If you are the beneficial owner of shares held in the name of your broker, bank or other nominee, you must first obtain a legal proxy from your broker, bank or other nominee giving you the right to vote those shares and submit that proxy along with a properly completed ballot at the meeting. You can obtain directions to the annual meeting by contacting Investor Relations at (717) 975-3710.

How can I change my vote?

        You may revoke your proxy at any time before it is exercised by:

    Delivering to the Secretary a written notice of revocation, dated later than the proxy, before the vote is taken at the Annual Meeting;

    Delivering to the Secretary an executed proxy bearing a later date, before the vote is taken at the Annual Meeting;

    Submitting a proxy on a later date by telephone or via the Internet (only your last telephone or Internet proxy will be counted), before 11:59 p.m. Eastern Daylight Time on June 24, 2009; or

    Attending the Annual Meeting and voting in person (your attendance at the Annual Meeting, in and of itself, will not revoke the proxy).

        Any written notice of revocation, or later dated proxy, should be delivered to:

Rite Aid Corporation
30 Hunter Lane
Camp Hill, Pennsylvania 17011
Attention: Marc A. Strassler, Secretary

        Alternatively, you may hand deliver a written revocation notice, or a later dated proxy, to the Secretary at the Annual Meeting before we begin voting.

        If your shares of Rite Aid common stock are held by a bank, broker or other nominee, you must follow the instructions provided by the bank, broker or other nominee if you wish to change your vote.


Table of Contents

What is an "abstention" and how would it affect the vote?

        An "abstention" occurs when a stockholder sends in a proxy with explicit instructions to decline to vote regarding a particular matter. Abstentions are counted as present for purposes of determining a quorum. An abstention with respect to the election of directors is neither a vote cast "for" a nominee or a vote case "against" the nominee and, therefore, will have no effect on the outcome of the vote. Abstentions with respect to any other proposal will have the same effect as voting "against" the proposal.

What is a broker "non-vote" and how would it affect the vote?

        A broker non-vote occurs when a broker or other nominee who holds shares for another person does not vote on a particular proposal because that holder does not have discretionary voting power for the proposal and has not received voting instructions from the beneficial owner of the shares so the broker is unable to vote those uninstructed shares. Brokers will have discretionary voting power to vote shares for which no voting instructions have been provided by the beneficial owner with respect to the proposal to amend the Restated Certificate of Incorporation, the election of directors and the ratification of the appointment of the independent registered public accounting firm. Brokers will not have such discretionary voting power to vote shares with respect to the stockholder proposal. Shares that are the subject of a broker non-vote are included for quorum purposes, but a broker non-vote with respect to a proposal will not be counted as a vote represented at the meeting and entitled to vote. Broker non-votes with respect to the stockholder proposal will have no effect on the outcome of the vote.

What are the quorum and voting requirements for the proposals?

        In deciding the proposals that are scheduled for a vote at the Annual Meeting, each holder of common stock as of the record date is entitled to one vote per share of common stock and each holder of LGP preferred stock as of the record date is entitled to approximately 18.18 votes per share of LGP preferred stock (one vote per share of common stock issuable upon conversion of the LGP preferred stock). As of the record date, the LGP preferred stock was convertible into an aggregate of 26,090,728 shares of common stock. The holders of the common stock and LGP preferred stock vote together as a single class, except for those matters on which the holders of LGP preferred stock are entitled to vote as a separate class.

        In order to take action on the proposals, a quorum, consisting of the holders of                        shares (a majority of the aggregate number of shares of Rite Aid common stock and LGP preferred stock (on an as-if-converted basis) issued and outstanding and entitled to vote as of the record date for the Annual Meeting), must be present in person or by proxy. This is referred to as a "quorum." Proxies marked "Abstain" and broker "non-votes," if any, will be treated as shares that are present for purposes of determining the presence of a quorum.

    Proposal No. 1—Amendment of our Restated Certificate of Incorporation to Declassify the Board of Directors

        The affirmative vote of a majority of the outstanding shares (with Rite Aid common stock and LGP preferred stock voting together as a single class) is required to approve the amendment of our Restated Certificate of Incorporation to declassify our Board of Directors in Proposal No. 1. Any shares not voted (whether by abstention or otherwise) will have the same effect as a vote "against" the proposal.

    Proposal No. 2—Election of Directors

        The affirmative vote of a majority of the total number of votes cast (with Rite Aid common stock and LGP preferred stock voting together as a single class) is required for the election of each director


Table of Contents

nominee named in Proposal No. 2. This means that the votes cast "for" that nominee must exceed the votes cast "against" that nominee. Any shares not voted (whether by abstention or otherwise) will not be counted as votes cast and will have no effect on the outcome of the vote. For more information on the operation of our majority voting standard, see the section entitled "Corporate Governance—Majority Voting Standard and Policy."

    Proposal No. 3—Stockholder Proposal—Advisory Vote on Executive Compensation

        The affirmative vote of a majority of the shares represented at the meeting and entitled to vote (with Rite Aid common stock and LGP preferred stock voting together as a single class) is required for the approval of the stockholder proposal in Proposal No. 3. Any shares represented at the meeting and not voted (whether by abstention or otherwise) will have the same effect as a vote "against" the proposal.

    Proposal No. 4—Ratification of Independent Registered Public Accounting Firm

        The affirmative vote of a majority of the shares represented at the meeting and entitled to vote (with Rite Aid common stock and LGP preferred stock voting together as a single class) is required for the ratification of the appointment of our independent registered public accounting firm in Proposal No. 4. Any shares represented at the meeting and not voted (whether by abstention or otherwise) will have the same effect as a vote "against" the proposal.

What happens if a quorum is not present at the Annual Meeting?

        If the shares present in person or represented by proxy at the Annual Meeting are not sufficient to constitute a quorum, the stockholders by a vote of the holders of a majority of votes present in person or represented by proxy (which may be voted by the proxyholders), may, without further notice to any stockholder (unless a new record date is set), adjourn the meeting to a different time and place to permit further solicitations of proxies sufficient to constitute a quorum.

Who will count the votes?

        Officers of Rite Aid will serve as proxy tabulator and count the votes. The results will be certified by the inspectors of election.

Who will conduct the proxy solicitation and how much will it cost?

        We are soliciting proxies from stockholders on behalf ofissues important to them. Through our quarterly financial performance webcasts, analyst conferences, investor meetings and calls, we obtain and share stockholder feedback with our Board and will pay for all costs incurred by it in connection with the solicitation. In addition to solicitation by mail, the directors, officers and employees of Rite Aid and its subsidiaries may solicit proxiescommittees. This feedback from stockholders, of Rite Aid in person or by telephone, facsimile or email without additional compensation other than reimbursement for their actual expenses.

        We have retained The Altman Group, a proxy solicitation firm,including views regarding Board composition, corporate governance matters and ESG matters, is extremely valuable to assist us in the solicitation of proxies for the Annual Meeting. Rite Aid will pay The Altman Group a fee of approximately $6,500 and reimburse the firm for reasonable out-of-pocket expenses.

        Arrangements also will be made with brokerage firms and other custodians, nominees and fiduciaries for the forwarding of solicitation material to the beneficial owners of stock held of record by such persons, and we will reimburse such custodians, nominees and fiduciaries for their reasonable out-of-pocket expenses in connection with the forwarding of solicitation materials to the beneficial owners of our stock.

If you have any questions about voting your shares or attending the Annual Meeting, please call our Investor Relations Department at (717) 975-3710.


Table of Contents


PROPOSAL NO. 1

APPROVAL OF THE AMENDMENT OF OUR RESTATED CERTIFICATE OF INCORPORATION
TO DECLASSIFY OUR BOARD OF DIRECTORS

        Our Board of Directors has unanimously adopted and is submitting for stockholder approval an amendment of our Restated Certificate of Incorporation (the "Charter Amendment") that would phase-in the declassification of our Board of Directors and provide instead formanagement.

Our engagement with stockholders occurs on a continuous basis, with calls and meetings happening throughout the year. During fiscal year 2023, we continued the increased outreach we began in fiscal year 2021 and enhanced our program to also include our retail stockholder base. As in the prior year, in fiscal year 2023 we also proactively offered Company-initiated meetings to our largest stockholders, representing over 40% of our outstanding shares. These meetings included an offer to speak with the Board Chairman, the Chair of our Compensation Committee, the then CEO, and the CFO. Our Compensation Committee considers investor perspectives when making decisions on executive compensation and DEI initiatives. Additionally, in fiscal year 2023, we began an annual election of directors.

        Our current classified board structure has been in place since 1976. The Board believesretail stockholder call, providing our retail investors with the opportunity to ask and have management answer questions that its classified structure has helped assure continuityare most important to them. This event proved popular, with robust retail stockholder participation and feedback.

[MISSING IMAGE: ic_cabal-pn.jpg]
[MISSING IMAGE: ic_colab-pn.jpg]
[MISSING IMAGE: ic_grpchat-pn.jpg]
WHO WE CONTACTEDHOW WE ENGAGEDWHAT WE DISCUSSED
Multiple times during fiscal year 2023, we individually reached out to the top stockholders who collectively own approximately
40%
of our outstanding stock.
If these stockholders are interested in meeting, they are offered meetings with our Board Chairman, the Chair of the Compensation Committee, the CEO, and CFO.
We biannually invite our largest
25
stockholders
to individual meetings to discuss items of importance to them, such as executive and Board compensation, corporate governance, and ESG matters.
The Chair of the Compensation Committee and senior management are available to participate upon request. We also regularly engage with all stockholders as part of our ongoing investor relations program.

Executive compensation.

Financial performance including the decline of the prior financial benefits of COVID-19 vaccines and testing.

The importance of environmental, social and governance (ESG) initiatives, particularly related to carbon emissions reductions and renewable energy strategies.

Rite Aid’s growth and business strategy in a post-COVID-19 world.

Continued expense management and cost control.

Further reduction of debt and free cash flow generation.

Board level oversight of diversity, equity and inclusion (DEI) strategy.

Human capital management matters including hiring, training, retaining a diverse workforce, and workplace safety.

RITE AID CORPORATION   2023 Proxy Statement | 3

PROXY STATEMENT SUMMARY
BOARD OF DIRECTORS
Director Nominees
Committees
Director and Principal OccupationAgeDirector
Since
IndependentAuditCompensationNominating and
Governance
[MISSING IMAGE: ph_brucebodaken-4c.jpg]
BRUCE G. BODAKEN(1)
Former Chairman and Chief Executive
Officer, Blue Shield of California
71
2013;
[MISSING IMAGE: ic_stark-bw.jpg]
since
2018
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
[MISSING IMAGE: ph_elizabethbusyburr-4c.jpg]
ELIZABETH BURR(2)
Interim Chief Executive Officer, Rite Aid
Corporation
612019
[MISSING IMAGE: ph_bariharlam-4c.jpg]
BARI HARLAM
Co-Founder, Trouble LLC; and former
EVP, Chief Marketing Officer North
America, Hudson’s Bay Company
612020
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: ic_committee-pn.jpg]
[MISSING IMAGE: ph_robertknowling-4c.jpg]
ROBERT E. KNOWLING, JR.(2)
Chairman, Eagles Landing Partners
672018
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
[MISSING IMAGE: ph_arunnayar-4c.jpg]
ARUN NAYAR(1)
Former Executive Vice President
and Chief Financial Officer,
Tyco International
722018
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
[MISSING IMAGE: ic_calculator-bw.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
[MISSING IMAGE: ph_katequinn-4c.jpg]
KATE B. QUINN
Vice Chairman and Chief
Administrative Officer, U.S. Bancorp
(retiring June 2023)
582019
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: ic_committee-pn.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
(1)
Effective as of the Company's business strategiesAnnual Meeting, Mr. Miramontes will cease to serve on the Audit Committee and has reinforcedMr. Bodaken will begin serving on the Audit Committee. Mr. Nayar will serve as Chair of the Audit Committee.
(2)
Ms. Burr was a commitmentmember of the Audit Committee until January 7, 2023, when she was appointed Interim Chief Executive Officer. Mr. Knowling joined the Audit Committee at that time.
[MISSING IMAGE: ic_committee-pn.jpg]
Committee Chair
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
Committee Member
[MISSING IMAGE: ic_stark-bw.jpg]
Chair of the Board
[MISSING IMAGE: ic_calculator-bw.jpg]
Audit Committee Financial Expert

4 | RITE AID CORPORATION   2023 Proxy Statement

PROXY STATEMENT SUMMARY
Board Attributes*
[MISSING IMAGE: pc_attribut-pn.jpg]
*
The compositions depicted illustrate calculations effective following the Annual Meeting.
BOARD AND GOVERNANCE HIGHLIGHTS
[MISSING IMAGE: ic_checkgreen-pn.jpg]
All Board members are independent except the Interim Chief Executive Officer
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Diverse chairs for Audit, Compensation and Nominating and Governance Committees
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Independent Chair of the Board
[MISSING IMAGE: ic_checkgreen-pn.jpg]
All directors elected annually
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Majority voting for directors in uncontested elections
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Proxy access provisions in bylaws
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Holders of 10% of outstanding stock may call a special meeting of stockholders
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Mandatory director retirement age of 75
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Meaningful stock ownership requirements for the Board and executive officers
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Anti-hedging and anti-pledging policy for the Board and all associates
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Annual evaluation of the Board and committees

RITE AID CORPORATION   2023 Proxy Statement | 5

PROXY STATEMENT SUMMARY
EXECUTIVE COMPENSATION OVERVIEW
Philosophy and Objectives
Our executive compensation program is based on a pay-for-performance philosophy and is designed to long-term stockholder value. Although theseaccomplish the following goals:
[MISSING IMAGE: tm228886d2-tbl_philosopypn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]    WHAT WE DO
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]    WHAT WE DO NOT DO
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Conduct annual stockholder advisory vote on the compensation of our named executive officers
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Maintain dialogue with stockholders on various topics, including executive pay practices
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Retain an independent executive compensation consultant to the Compensation Committee
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Ensure that a significant portion of executive officer total target remuneration is at risk
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Provide annual and long-term incentive plans with performance targets aligned to business goals
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Require a designated level of stock ownership for all named executive officers and non-management directors
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Require shares subject to the annual non-management director grant to be deferred until separation from service
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Require equity awards to have a double trigger (qualifying termination of employment and change in control)
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Complete an annual incentive compensation risk assessment
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Maintain a formal clawback policy for executive officers
[MISSING IMAGE: tm228886d1-icon_crossred4c.jpg]
Provide gross-up payments to cover personal income taxes or excise taxes related to executive severance benefits
[MISSING IMAGE: tm228886d1-icon_crossred4c.jpg]
Permit executives to engage in hedging or pledging of Rite Aid securities
[MISSING IMAGE: tm228886d1-icon_crossred4c.jpg]
Reward executives for imprudent, inappropriate, or unnecessary risk-taking
[MISSING IMAGE: tm228886d1-icon_crossred4c.jpg]
Allow the repricing of equity awards without stockholder approval

6 | RITE AID CORPORATION   2023 Proxy Statement

PROXY STATEMENT SUMMARY
ENVIRONMENTAL, SOCIAL & GOVERNANCE EFFORTS
Rite Aid is committed to integrating Environmental, Social, and Governance (ESG) initiatives into our operations, not only to create value for our stockholders, customers, and associates, but also because we are important benefits, the Board recognized the growing sentiment among stockholdersdeeply invested in our communities, and the investment communityour customers want to support a company that supports their safety and our environment. As explained in favor ofour voluntary annual elections. After careful consideration, the Board determined that itESG report, our approach is appropriate to propose declassifying the Board, commencing with the 2009 Annual Meeting.

        Currently, membersbroken into four pillars: Thriving Planet, Thriving Business, Thriving Workplace and Thriving Community.

[MISSING IMAGE: ic_world-pn.jpg]
[MISSING IMAGE: ic_home-pn.jpg]
[MISSING IMAGE: ic_hand-pn.jpg]
[MISSING IMAGE: ic_houseppl-pn.jpg]
THRIVING PLANETTHRIVING BUSINESSTHRIVING WORKPLACETHRIVING COMMUNITY
Reducing our environmental impact through:

Energy and fleet fuel management

Waste reduction and minimization

Supply chain optimization
Embedding sustainability throughout our value chain through:

Responsible sourcing

Product safety, quality, health and nutrition

Drug supply chain integrity

Data security and privacy
Optimizing our associate experience, development, opportunity and well-being across our organization through:

Workforce diversity and inclusion

Associate engagement and development

Total rewards

Health and safety

Labor practices
Improving health equity, outcomes and access to care in the communities we serve through:

Efforts to improve patient health outcomes at Rite Aid, Elixir and Health Dialog

Management of controlled substances

Community involvement
[MISSING IMAGE: ic_environmental-pn.jpg]
Environmental
Some of our Boardquantitative fiscal year 2023 highlights include:
[MISSING IMAGE: tbl_environmental-pn.jpg]
Social
We continue to integrate sustainability into our sourcing process, collecting data on topics such as supplier diversity, product packaging, and chemical management to help inform sourcing decisions.
[MISSING IMAGE: ic_socialsupport-pn.jpg]
In fiscal year 2023, we continued collaborating with our own brand supplier partners to further advance our efforts in reducing and eliminating harmful chemicals in the products we sell.
Our clinical services team performed 724 health clinics in underserved areas with social vulnerability index (SVI) scores greater than 75%, demonstrating our focus on patient outcomes and access to care.
Human Capital Management Efforts
We are elected for staggered termsproud to employ over 47,000 associates as of three years. If the Charter Amendment is approved, commencing with the class of directors standing for election at the 2009 Annual Meeting, directors will stand for election for one year terms, expiring at the next succeeding annual meeting of stockholders. The directors who were elected at the 2008 Annual Meeting, whose terms will expire in 2011, and the directors who were elected at the 2007 Annual Meeting, whose terms will expire in 2010, will continue to hold office until the end of fiscal year 2023 across the terms for which they were elected. A majorityUnited States, including Puerto Rico. Our associates are key to the success of our directors will stand for electiontransformation as they are at the 2010 Annual Meetingcenter of supporting the whole health of our customers and all directors will be electedcommunities. We are optimizing our workforce through enhanced communication and engagement through the following measures:

RITE AID CORPORATION   2023 Proxy Statement | 7

PROXY STATEMENT SUMMARY

conducting annual engagement surveys on topics such as career development, well-being, compensation, benefits, recognition, leader communications, and opportunities specific to diversity, equity and inclusion efforts, in which more than 70% of our associates have participated;

continuing our efforts to attract top talent with sign-on bonuses, pay adjustments in hard to staff areas, and unlimited paid time off to certain associates;

operating as a remote-first employer for our corporate associates, allowing us to expand our talent pool and allow our corporate associates more flexibility to balance their work and family priorities;

developing success profiles for our associates to refine skills needed today and build capabilities for the future;

operating as an Accredited Provider of Continuing Pharmacy Education, which allows us to offer courses that count toward the continuing education licensing requirements of our pharmacists;

offering an accredited pharmacy technician certification program;

offering compensation and benefit programs to support, recognize and reward performance of our associates (including annual basis beginningbonuses, 401(k) plans, health care benefits, paid time off, life and disability coverage, merchandise discounts, and many other services and programs);

offering associate wellness programs and tools for whole health in areas such as mental health, condition specific management programs, and financial wellness; and

offering an associate recognition program to celebrate the achievements of our teams and create a community experience for our workforce.
Diversity, Equity & Inclusion Efforts
We are continuing to build momentum with Diversity, Equity & Inclusion (DEI) at Rite Aid and are seeing notable progress that we believe is adding value to our business. Our multi-year strategy is gaining traction with new programs and initiatives launched in fiscal year 2023, such as leadership development programs aimed specifically to advance diverse talent. We are discovering and addressing the unique needs of our workforce and empowering our people to perform at their very best.
We are taking an innovative approach to our DEI strategy, which we are executing through our recently launched Associate Experience program. The Associate Experience provides our associates with the 2011 Annual Meeting.programs, benefits, and resources that our associates have indicated are important to them, such as enhanced Total Rewards and improved information technology systems and resources. We believe the Associate Experience will enhance our talent attraction, retention, and development efforts, which will enable us to better fulfill our strategic initiatives and operational priorities.
As of December 31, 2022, 68% of associates self-reported as female. In all cases, each director will hold office until his or her successor has been electedaddition, associates reported their race/ethnicity as: White 55%; Hispanic 15%; Black 13%; Asian 12%; and qualified or until the director's earlier resignation or removal. If the Charter Amendment is approved, theOther 5%. We are proud to have a Board will adopt corresponding amendments to our Amendedwith 43% gender diversity and Restated By-Laws.

        If the Amendment is not approved by stockholders,43% ethnic/racial diversity.

Governance
[MISSING IMAGE: ic_governance-pn.jpg]
Our Nominating and Governance Committee of the Board of Directors will remain classified,has direct oversight and eachresponsibility of the directors elected at the 2009 Annual Meeting will be elected for a three-year term expiring in 2012.

        Presently, because the termsESG, while our Compensation Committee has direct oversight of the directors are staggered, the directors are removable only for cause. Upon adoption of the Charter Amendment, directors serving terms to which they were elected priorDEI. In fiscal year 2023, we provided quarterly updates to the 2009 Annual Meeting would continue to be removable only for cause until the completion of their current termsNominating and consistent with Delaware law for corporations without classified boards, directors elected at the 2009 Annual MeetingGovernance Committee on our ESG reporting, strategy, risk and thereafter will be removable "with or without cause" upon the affirmative vote of a majority of the outstanding shares entitled to vote generally in the election of directors.

        Appendix A shows the proposed changes to Section 1 of Article Eighth of the Restated Certificate of Incorporation, with deletions indicated by strikeoutsopportunity, compliance and additions indicated by underlining.

        The affirmative vote of a majority of the outstanding shares (with Rite Aid common stock and LGP Preferred Stock voting together as a single class) is required to approve the amendment to the Restated Certificate of Incorporation. Abstentions will have the same effect as votes "against" the proposal.

RECOMMENDATION

THE BOARDbenchmarking.

[MISSING IMAGE: tm217739d1_icon-computerpn.jpg]
For more information, please see Rite Aid’s 2022 CSR Report at https://s27.q4cdn.com/633053956/files/doc_downloads/2022/07/RA890751_ESG_Report_2022.pdfWebsite content is not incorporated into this proxy statement.

8 | RITE AID CORPORATION   2023 Proxy Statement

[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
PROPOSAL 1—ELECTION OF DIRECTORS
Our by-lawsBy-Laws provide that the Board of Directors may be composed of up to 15 members, with the number to be fixed from time to time by the Board. On April 8, 2009, theThe Board of Directors increasedhas fixed the number of directors from 14 to 15. Our Boardat six effective as of Directors currently is divided into three classes, with each class to be as nearly equal in number as possible. The Board of Directors currently consists of five directors whose terms expire this year, four directors whose terms expire in 2010 and five directors whose terms expire in 2011. Subject to approval of Proposal No. 1, commencing with the 2009 Annual Meeting, and the Board of Directors will be declassified andhas nominated six nominees for director at our Annual Meeting. All directors will beare elected annually for one year terms, except that directors elected prior to the 2009 Annual Meeting will continue to serve the balance of their existing three year terms. If Proposal No. 1 is not approved, directors elected at the 2009 Annual Meeting will be elected for three year terms, except as otherwise described below.

        George G. Golleher, who served as a director of the Company since 2002, retired from the Board of Directors on April 14, 2009. The Board of Directors expresses its gratitude to Mr. Golleher for his valuable contributions during his tenure on the Board. Effective April 14, 2009, the Board appointed David R. Jessick to fill the vacancy created by Mr. Golleher's resignation, and he will serve the remainder of Mr. Golleher's term, which expires in 2010.

        John T. Standley has been nominated to fill the vacancy created by the increase in the size of the Board of Directors and, so that each class of directors will be equal in number, he has been nominated to the class of directors whose terms expire in 2010.

Director Nominees

annually.

The Board of Directors, based on the recommendation of the Nominating and Governance Committee, has nominated Joseph B. Anderson, Jr., Michel Coutu, James L. Donald, John T. Standley and Marcy Symsthe following individuals to be elected directors at the Annual Meeting. The holder of the LGP Preferred Stock has informed the Company that it will elect Jonathan D. Sokoloff as the LGP Preferred Director. Meeting:

Bruce G. Bodaken

Robert E. Knowling, Jr.

Elizabeth Burr

Arun Nayar

Bari Harlam

Kate B. Quinn
Each of the nominees for director to be elected at the Annual Meeting except for Mr. Standley, currently serves as a director of the Company. Michel Coutu was designated by The Jean Coutu Group (PJC) Inc., or Jean Coutu Group, to the Nominating and Governance Committee as a director nominee pursuant to the terms of the stockholder agreement with Jean Coutu Group, effective June 4, 2007, the date of our acquisition of the Brooks and Eckerd drugstore chains (the "Brooks Eckerd Transaction").

Each director elected at the Annual Meeting will hold office until the 20102024 Annual Meeting of Stockholders or, if Proposal No. 1 is not approved, until the 2012 Annual Meeting of Stockholders (other than Mr. Standley, who, if elected, will hold office until the 2010 Annual Meeting of Stockholders). Each director elected at the Annual Meetingand will serve until his or her successor is duly elected and qualified. The other directors will remain in office for the remainder of their respective terms, as indicated below.

If any nominee at the time of election is unable or unwilling tocannot serve or is otherwise unavailable for election, and as a consequence thereof other nominees areanother nominee is designated, then the persons named in the proxyproxies or their substitutes will have the discretion and authority to vote or to refrain from voting for such other nomineesnominee in accordance with their judgment.

RECOMMENDATION

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT
YOU VOTE "FOR" THE ELECTION OF EACH OF THE NOMINEES LISTED ABOVE


Tablejudgment, or the Board may reduce the size of Contents


BOARD OF DIRECTORS

the Board.

The following table sets forth certain information as of June 1, 2023 with respect to our director nominees.
NameAgePosition with Rite AidYear First
Became Director
Bruce G. Bodaken71Chair2013
Elizabeth Burr61Interim Chief Executive Officer and Director2019
Bari Harlam61Director2020
Robert E. Knowling, Jr.67Director2018
Arun Nayar72Director2018
Kate B. Quinn58Director2019
[MISSING IMAGE: ic_chksquare-pn.gif]
The Board of Directors unanimously recommends that you vote on the enclosed proxy card FOR the election of each of our nominees listed above.

RITE AID CORPORATION   2023 Proxy Statement | 9

PROPOSAL 1—ELECTION OF DIRECTORS
Board Attributes*
[MISSING IMAGE: pc_attribut-pn.jpg]
*
The compositions depicted illustrate calculations effective following the Annual Meeting.
The Board is committed to ensuring that it is composed of a highly capable and diverse group of directors who are well-equipped to oversee the success of the business and effectively represent the interests of stockholders. As a result of strategic changes in Board composition over the last five years, approximately 33% of the director nominees asare racially or ethnically diverse and 50% of the record date.

Name
 Age Position with Rite Aid Year First
Became
Director
 Term as
Director Will
Expire(1)
 

Mary F. Sammons

  62 Chairman and Chief Executive Officer  1999  2010 

Michel Coutu

  55 Non-Executive Co-Chairman  2007  2009 

Joseph B. Anderson, Jr. 

  66 Director  2005  2009 

André Belzile

  47 Director  2007  2010 

François J. Coutu

  54 Director  2007  2011 

James L. Donald

  55 Director  2008  2009 

Michael A. Friedman, MD

  65 Director  2004  2011 

David R. Jessick

  55 Director  2009  2010 

Robert G. Miller

  65 Director  1999  2011 

Michael N. Regan

  61 Director  2007  2011 

Philip G. Satre

  60 Director  2005  2010 

Jonathan D. Sokoloff

  51 Director  1999  2009 

John T. Standley

  46 President and Chief Operating Officer    2010 

Marcy Syms

  58 Director  2005  2009 

Dennis Wood

  70 Director  2007  2011 

(1)
Directors' termsdirector nominees are women. In addition to enhancing the Board’s racial, ethnic and gender diversity, these changes bring a diversity of officethought and experience to the Board. All of the nominees of the Board, other than Ms. Burr, due to her position as interim Chief Executive Officer, are scheduledindependent directors.
Five of our six current director nominees have joined our Board since 2018, all of whom are either women or racially or ethnically diverse.
[MISSING IMAGE: fc_directors-pn.jpg]
In assessing Board composition and selecting and recruiting director candidates, the Board seeks to expire atmaintain an engaged, independent Board with broad experience and judgment that is committed to representing the annual meetinglong-term interests of stockholdersour stockholders. The Nominating and Governance Committee considers a wide range of factors, including the size of the Board, the experience and expertise of existing Board members, other positions the director candidate has held or holds (including other board memberships), and the candidate’s independence. In addition, the Nominating and Governance Committee takes into account a candidate’s ability to be heldcontribute to the diversity of background and experience represented on the Board, and it reviews its effectiveness in balancing these considerations when assessing the year indicated.

composition of the Board.


10 | RITE AID CORPORATION   2023 Proxy Statement

PROPOSAL 1—ELECTION OF DIRECTORS
Board Skills and Experiences
The chart below summarizes the qualifications, attributes, skills and experiences for each of our director nominees. The fact that we do not list a particular experience or qualification for a director nominee does not mean that nominee does not possess that particular experience or qualification.
Skills and Experiences
DirectorBoard and
Corporate
Governance
Current or
Former CEO
Finance and
Accounting
Health Care
Industry
Management
and
Business
Operations
Retail
Industry
Bruce G. Bodaken [MISSING IMAGE: ic_stark-bw.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
Elizabeth Burr
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
Bari Harlam
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
Robert E. Knowling, Jr.
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
Arun Nayar
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
Kate B. Quinn
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
Total of 6 Director Nominees632363
100%50%33%50%100%50%

RITE AID CORPORATION   2023 Proxy Statement | 11

PROPOSAL 1—ELECTION OF DIRECTORS
DIRECTOR NOMINEES
Following are the biographies for our director nominees, including information concerning the particular experience, qualifications, attributes, or skills that led the Nominating and our directors who will continueGovernance Committee and the Board to conclude that such person should serve afteron the 2009 Annual Meeting:

        Mary F. Sammons.    Ms. Sammons has been Board, as well as their Committee assignments in fiscal year 2023:

BRUCE G. BODAKEN
Mr. Bodaken shares in-depth knowledge of the health insurance and managed care industries with the Board of Directors, serving in executive leadership positions for over 20 years.
Experience

Chairman and Chief Executive Officer of Blue Shield of California from 2000 through 2012.

President and Chief Operating Officer of Blue Shield of California from 1995 to 2000, and as Executive Vice President and Chief Operating Officer from 1994 to 1995.

Senior Vice President and Associate Chief Operating Officer of F.H.P., Inc., a managed care provider, from 1990 to 1994 and held various positions at F.H.P. from 1980 to 1990.

Visiting Lecturer at the University of California School of Public Health from 2013 to 2016 teaching graduate courses on health care reform.

Visiting Scholar at the Brookings Institute from 2013 to 2015 focused on value-based care design.

Director and member of the compensation committee of iRhythm Technologies, Inc. and formerly a member of the board of directors of WageWorks, Inc.
[MISSING IMAGE: ph_brucebodaken-4c.jpg]
Age 71
Director since 2013
Chair since 2018
Committees

Executive (Chair)

Nominating and Governance
ELIZABETH BURR
Ms. Burr brings to the Board of Directors extensive experience in the health industry, innovation, business strategy, and brand management.
Experience

Current Interim Chief Executive Officer of Rite Aid Corporation.

Former President and Chief Commercial Officer at Carrot Inc., a digital health care company with solutions that combine behavioral science, clinical expertise, and proprietary technology, from 2019 through 2021.

Chief Innovation Officer and Vice President of Healthcare Trend and Innovation at Humana from 2015 to 2018, where she led the design, build, and adoption of new product platforms in digital health, provider experience, and telemedicine. Founder of Humana’ Health Ventures, Humana’s strategic venture investing practice.

Former Managing Director of Citi Ventures, Citigroup’s global venture group, from 2011—2015. Prior to Citigroup, she spent seven years in investment banking at Morgan Stanley and Credit Suisse First Boston.

Former Vice President of Global Brand Management at Gap, Inc., where she was responsible for aligning the product, store, online, advertising, and merchandising efforts for the four Gap brands around the world.

Member of the boards of directors of Mr. Cooper Group Inc., a company that provides mortgage servicing, origination, and transaction-based services, Satellite Healthcare, a nonprofit provider of kidney dialysis services, and SVB Financial Group, a company that offers investment banking and funds management services in the technology, life sciences and health care, private equity and venture capital industries.
[MISSING IMAGE: ph_elizabethbusyburr-4c.jpg]
Age 61
Director since 2019

12 | RITE AID CORPORATION   2023 Proxy Statement

PROPOSAL 1—ELECTION OF DIRECTORS
BARI HARLAM
Ms. Harlam is a former C-suite business leader, marketer, educator, and author, and a pioneer in customer loyalty who provides the Board of Directors with her experience in digital marketing and data analytics.
Experience

Co-founder of Trouble LLC, a pro-social, experience brand.

Executive Vice President, Chief Marketing Officer North America at Hudson’s Bay Company from 2018 to 2020.

Executive Vice President, Membership, Marketing and Analytics at BJ’s Wholesale Club from 2012 to 2016.

Chief Marketing Officer at Swipely, now Upserve, from 2011 to 2012.

Senior Vice President, Member Engagement at CVS Health from 2000 to 2011.

Early in her career, was a Professor at Columbia University and the University of Rhode Island, and Adjunct Professor at the Wharton School, University of Pennsylvania.

Member of the Board of Directors of Eastern Bankshares, Inc., Aterian, and OneWater Marine Inc.
[MISSING IMAGE: ph_bariharlam-4c.jpg]
Age 61
Director since 2020
Committees

Nominating and Governance (Chair)
ROBERT E. KNOWLING, JR.
Mr. Knowling brings to the Board extensive experience in executive management and leadership roles, including experience leading companies through periods of high growth and organizational turnaround. In addition, his service on a number of other public company boards of directors enables Mr. Knowling to share insights with the Board regarding corporate governance best practices.
Experience

Chairman of Eagles Landing Partners, which specializes in helping senior management formulate strategy, lead organizational transformations, and re-engineer businesses, and also serves as an advisor-coach to chief executive officers.

Chief Executive Officer of Telwares, a provider of telecommunications expense management solutions, from 2005 to 2009.

Chief Executive Officer of the New York City Leadership Academy, an independent nonprofit corporation created by Chancellor Joel I. Klein and Mayor Michael R. Bloomberg that is chartered with developing the next generation of principals in the New York City public school system, from 2001 to 2005.

Chairman and Chief Executive Officer of SimDesk Technologies, a computer software company, from 2001 to 2003.

Previously was Chairman, President and Chief Executive Officer of Covad Communications, a Warburg Pincus private equity-backed start-up company.

Serves on the board of directors of CECO Environmental Corp. and Stride, Inc. In the last five years, he served on the board of directors of Roper Technologies Inc., Citrix, Stride, and Convergys.
[MISSING IMAGE: ph_robertknowling-4c.jpg]
Age 67
Director since 2018
Committees

Audit

Compensation

RITE AID CORPORATION   2023 Proxy Statement | 13

PROPOSAL 1—ELECTION OF DIRECTORS
ARUN NAYAR
Mr. Nayar brings over 35 years of financial management experience to the Board of Directors. His experience as a chief financial officer provides useful insights into operational and financial metrics relevant to the Company’s business.
Experience

Retired in 2015 as Executive Vice President and Chief Financial Officer of Tyco International, a $10+ billion fire protection and security company, where he was responsible for managing the company’s financial risks and overseeing its global finance functions, including its tax, treasury, mergers and acquisitions, audit, and investor relations teams. Mr. Nayar joined Tyco as senior vice president and treasurer in 2008, and was also Chief Financial Officer of Tyco’s ADT Worldwide. From 2010 until 2012, Mr. Nayar was senior vice president, Financial Planning & Analysis, Investor Relations, and treasurer.

Previously was in leadership positions with PepsiCo, Inc., most recently as Chief Financial Officer of Global Operations and, before that, as vice president and assistant treasurer—Corporate Finance.

Senior Advisor to McKinsey & Company and a Senior Advisor to a private equity firm, BC Partners, from 2016 to 2020.

A member of the board of directors of Amcor Plc, a manufacturer of responsible packaging products, and GFL Environmental Inc., a leading North American environmental services company. He previously served on the board of TFI International.
[MISSING IMAGE: ph_arunnayar-4c.jpg]
Age 72
Director since 2018
Committees

Audit

Compensation

Executive
KATE B. QUINN
Ms. Quinn brings to the Board of Directors extensive experience in business strategy, marketing, customer experience, retail operations, and health benefits.
Experience

Vice Chair and Chief Administrative Officer of U.S. Bancorp since 2017, responsible for leading strategy, reputation and digital transformation, Ms. Quinn joined U.S. Bancorp in 2013 as executive vice president and Chief Strategy and Reputation Officer. She will be retiring from U.S. Bancorp in June 2023.

Former senior vice president and Chief Marketing Officer at Anthem, a health benefits company, where she directed the company’s marketing, customer communications, digital, customer experience, and retail strategies. She previously served as Anthem’s vice president of corporate marketing.

Earlier in her career, Ms. Quinn served as Chief Marketing and Strategy Officer at a division of The Hartford, following leadership roles in strategy and product development at CIGNA and PacifiCare Health Systems, respectively.

Member of Board of Trustees of United Way U.S.A. and Fastbreak Foundation. She previously served on the board of Ontrak, Inc.
[MISSING IMAGE: ph_katequinn-4c.jpg]
Age 58
Director since 2019
Committees

Compensation (Chair)

Nominating and Governance

14 | RITE AID CORPORATION   2023 Proxy Statement

[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
CORPORATE GOVERNANCE AND BOARD MATTERS
BOARD LEADERSHIP STRUCTURE
The Board has determined that Mr. Bodaken will continue to serve as Chair of the Board.
As Chair, Mr. Bodaken’s responsibilities include:

presiding at all meetings of the Board, including executive sessions of the non-management directors

the authority to call meetings of the Board and of the non-management directors

serving as liaison between the Chief Executive Officer and independent directors and facilitating communications between other members of the Board and the Chief Executive Officer (any director is free to communicate directly with any associate, including with the Chief Executive Officer; the Chair’s role is to attempt to improve such communications if they are not entirely satisfactory)

working with independent directors and the Chief Executive Officer in the preparation of and approving Board meeting agendas and schedules, and the information to be provided to the Board

chairing the annual review of the performance of the Chief Executive Officer

otherwise consulting with the Chief Executive Officer on matters relating to corporate governance and Board performance, and

if requested, ensuring that he is available, when appropriate, for consultation and direct communication with stockholders.
Company By-Laws provide that the Chair of the Board must be a director who is independent under the NYSE listing standards and the Company’s Corporate Governance Guidelines. The Board believes that separation of the Company since June 2007 and has been a memberpositions of Rite Aid's Board of Directors since December 5, 1999 and Chief Executive Officer since June 2003. Ms. Sammons was President of Rite Aid from December 1999 to September 2008. From April 1999 to December 1999, Ms. Sammons served as President and Chief Executive Officer of Fred Meyer Stores, Inc., a subsidiary of The Kroger Company. From January 1998 to April 1999, Ms. Sammons served as President and Chief Executive Officer of Fred Meyer Stores, Inc., a subsidiary of Fred Meyer, Inc. From 1985 through 1997, Ms. Sammons held several senior level positions with Fred Meyer Stores, Inc., the last being that of Executive Vice President. Ms. Sammons is also a member of the Board of the National Association of Chain Drug Stores, a trade association, is a director of StanCorp Financial Group, Inc. and is the President and a director of The Rite Aid Foundation.

        Michel Coutu.    Mr. Michel Coutu has served as the Non-Executive Co-Chairman of the Board since June 2007. He served as President of the U.S. operations of Jean Coutu Group and Chief Executive Officer of Jean Coutu USA from August 1986 until June 2007. He has also served as a member of the Board of Directors of Jean Coutu Group since December 1985. Mr. Coutu holds a degree in finance and a license in law from the University of Sherbrooke and a Masters in Business Administration from the Simon School of Business at the University of Rochester.

        Joseph B. Anderson, Jr.    Mr. Anderson has been the ChairmanChair of the Board and Chief Executive Officer best serves the needs of TAG Holdings, LLC, a manufacturing, servicethe Company and technology business since January 2002.its stockholders. The Board believes that Mr. Anderson was ChairmanBodaken will continue to provide excellent independent leadership of the Board and Chief Executive Officer of Chivas Industries, LLC from 1994 to 2002. Mr. Anderson also servesin his role as a director of Quaker Chemical Corporation,

Chair.

DIRECTOR INDEPENDENCE

Table of Contents


ArvinMeritor, Inc., Valassis Communications, Inc. and Nevada Energy (formerly Sierra Pacific Resources).

        André Belzile.    Mr. Belzile has been the Senior Vice President, Finance and Corporate Affairs of Jean Coutu Group since May 2004. Prior to serving in this position, from 1992 until May 2004 he served as Vice President and Chief Financial Officer of Cascades Inc., a producer and marketer of packaging products. Mr. Belzile is a chartered accountant who earned a bachelor's degree at Les Hautes Études Commerciales (HEC MONTRÉAL).

        François J. Coutu.    Mr. François J. Coutu has served as President and Chief Executive Officer of Jean Coutu Group since October 2007. Previously, Mr. Coutu held the positions of President of Canadian Operations and Vice Chairman of the Board from 2005 to 2007, President and Chief Executive Officer from 2002 to 2005 and President and Chief Operating Officer of Jean Coutu Group from 1992 to 2002. Mr. Coutu has been a member of the Board of Directors of Jean Coutu Group since 1985. He is a pharmacist by profession, holds a Bachelor's Degree in Administration from McGill University and a Bachelor's Degree in Pharmacy from Samford University. He was a director and chair of the Canadian Association of Chain Drug Stores, a trade association, and previously served as a member of the Board of Directors of the National Bank of Canada, where he was a member of the Human Resources and Credit Committees.

        James L. Donald.    Mr. Donald is currently a self-employed private investor. Mr. Donald was President and Chief Executive Officer and a director of Starbucks Corporation from April 2005 to January 2008. From October 2004 to April 2005, Mr. Donald served as Starbuck's CEO designate. From October 2002 to October 2004, Mr. Donald served as President of Starbucks, North America. From October 1996 to October 2002, Mr. Donald served as Chairman, President and Chief Executive Officer of Pathmark Stores, Inc. and prior to that time he held a variety of senior management positions with Albertson's, Inc., Safeway, Inc. and Wal-Mart Stores, Inc.

        Michael A. Friedman, MD.    Dr. Friedman has been President and Chief Executive Officer of City of Hope, a National Cancer Institute-designated Comprehensive Cancer Center since May 2003. From October 2001 to April 2003, Dr. Friedman served as Chief Medical Officer for Biomedical Preparedness for the Pharmaceutical Research and Manufacturers of America, a pharmaceutical trade association. Additionally, he held the position of Senior Vice President of Research and Development, Medical and Public Policy for Pharmacia. He also has held executive positions in government and public health organizations. In addition to serving as Acting Commissioner of the U.S. Food and Drug Administration from 1997 to 1998, he was Associate Director of the Cancer Therapy Evaluation Program at the National Cancer Institute, National Institutes of Health from 1988 to 1995. He joined the National Cancer Institute in 1983 as Chief of the Clinical Investigations Branch of the Division of Cancer Treatment. Before that he spent nearly a decade at the University of California at San Francisco Medical Center in various positions, from Assistant Professor of Medicine in 1975 to Interim Director of the Cancer Research Institute from 1981 to 1983. Author of more than 150 scientific papers and books, Dr. Friedman has received commendations, including the Surgeon General's Medallion in 1999.

        David R. Jessick.    Mr. Jessick has served as a director of Rite Aid since April 2009. From July 2002 to February 2005, Mr. Jessick served as a consultant to Rite Aid's Chief Executive Officer and senior management and was Senior Executive Vice President, Chief Administrative Officer of Rite Aid from December 1999 to July 2002. From January 1997 to July 1999, Mr. Jessick was Chief Financial Officer and Executive Vice President, Finance and Investor Relations of Fred Meyer, Inc. Prior to joining Fred Meyer, Inc., Mr. Jessick spent 17 years with Thrifty PayLess Holdings, Inc., with his last position being Executive Vice President and Chief Financial Officer. Before that, he worked as an auditor with KPMG. Mr. Jessick currently serves as a director of Source Interlink Companies, Inc.,


Table of Contents


Dollar Financial Corp. and Big 5 Sporting Goods Corp. He also served as Chairman of the Board of Pathmark Stores, Inc. from August 2005 to December 2007.

        Robert G. Miller.    Mr. Miller has been Chief Executive Officer of Albertsons LLC since June 2006. Mr. Miller has been a member of Rite Aid's Board of Directors since December 1999, serving as our Chairman of the Board from December 1999 until June 2007. From December 1999 until June 2003, Mr. Miller was also Rite Aid's Chief Executive Officer. Previously, Mr. Miller served as Vice Chairman and Chief Operating Officer of The Kroger Company, a retail food company. Mr. Miller joined the Kroger Company in March 1999, when Kroger acquired Fred Meyer, Inc., a food, drug and general merchandise chain. From 1991 until the March 1999 acquisition, he served as Chief Executive Officer of Fred Meyer, Inc. Mr. Miller also is a director of Nordstrom, Inc.

        Michael N. Regan.    Mr. Regan is currently a self-employed private equity investor. Mr. Regan served as Chief Financial Officer of The St. Joe Company, a major real estate development company based in Florida, from November 2006 to May 2007. From 1997 to November 2006, he served as Senior Vice President, Finance and held various other positions with The St. Joe Company and was a member of the senior management team. Prior to joining St. Joe's, he served as Vice President and Controller of Harrah's Entertainment from 1991 to 1997. From 1980 until 1991 he held a series of progressively more responsible positions for Harrah's Entertainment, Inc. and its prior parent companies, Holiday Corporation and The Promus Companies.

        Philip G. Satre.    Mr. Satre is currently a self-employed private investor. Mr. Satre served as Chief Executive Officer of Harrah's Entertainment, Inc. from 1993 to January 2003. Mr. Satre was a director of Harrah's from 1988 through 2004, serving as Chairman of the Board of Harrah's from 1997 until his retirement in 2005. He presently serves as Chairman of the Board of Directors of NV Energy, Inc. and of the National Center for Responsible Gaming, and serves as a director of Nordstrom, Inc., International Game Technology and The National World War II Museum,, and is a trustee of Stanford University.

        Jonathan D. Sokoloff.    Mr. Sokoloff has been a Managing Partner of Leonard Green & Partners, L.P. since 1994. Leonard Green & Partners, L.P. is an affiliate of Green Equity Investors III, L.P. and is a private equity firm based in Los Angeles, California. Since 1990, Mr. Sokoloff has also been a partner in a merchant banking firm affiliated with Leonard Green & Partners, L.P. Mr. Sokoloff previously was elected as a director pursuant to director nomination rights granted to Green Equity Investors III, L.P. under an October 27, 1999 agreement between Rite Aid and Green Equity Investors with respect to the purchase of 3,000,000 shares of Rite Aid preferred stock.

        John T. Standley.    Mr. Standley was appointed President and Chief Operating Officer in September 2008. He was a consultant to Rite Aid from July 2008 to September 2008 and a self-employed private investor from January 2008 to July, 2008. Previously, Mr. Standley had served as Chief Executive Officer of Pathmark Stores, Inc. from August 2005 through December 2007. From June 2002 to August 2005, he served as Senior Executive Vice President and Chief Administrative Officer of Rite Aid and, in addition, in January 2004 was appointed Chief Financial Officer of Rite Aid. He had served as Senior Executive Vice President and Chief Financial Officer of Rite Aid from September 2000 to June 2002 and had served as Executive Vice President and Chief Financial Officer of Rite Aid from December 1999 until September 2000. Previously, he was Executive Vice President and Chief Financial Officer of Fleming Companies, Inc., a food marketing and distribution company from May 1999 to December 1999. Between July 1998 and May 1999, Mr. Standley was Senior Vice President and Chief Financial Officer of Fred Meyer, Inc. Mr. Standley served as Senior Vice President and Chief Financial Officer of Ralphs Grocery Company between January 1997 and July 1998. Mr. Standley also served as Senior Vice President of Administration at Smith's Food & Drug Stores, Inc. from May 1996


Table of Contents


to February of 1997 and as Chief Financial Officer of Smitty's Supervalue, Inc. from December 1994 to May 1996.

        Marcy Syms.    Ms. Syms has been Chief Executive Officer and a director of Syms Corp, a chain of retail clothing stores, since 1983. She currently serves on the Boards of Directors of the New Jersey Economic Growth Council. Ms. Syms also is a founding member of the Board of Directors of the Syms School of Business at Yeshiva University.

        Dennis Wood, O.C.    Mr. Wood is Chairman, President and Chief Executive Officer of Dennis Wood Holdings Inc., a privately owned portfolio company, a position he has held since 1973. Since April 2005, he has served as Interim President and Chief Executive Officer of GBO Inc. (formerly Groupe Bocenor Inc.), a window and door manufacturer, and also serves as a director and as Chair of its Executive Committee. Between 1992 and 2001, Mr. Wood served as Chairman, President and Chief Executive Officer of C-MAC Industries Inc., a designer and manufacturer of integrated electronic manufacturing solutions. Mr. Wood has been a member of the Board of Jean Coutu Group since March 2004. In April 2007, he was appointed Chairman of the Board of Azimut Exploration Inc. and serves as Chairman of the Board of 5N Plus Inc. Furthermore, Mr. Wood serves on the boards of National Bank Trust, Transat A.T. Inc. and Blue Mountain Wallcoverings Inc., a privately held company. He has been awarded Canada's top honor, the Order of Canada and has an honorary degree from the University of Sherbrooke.

Corporate Governance

        We recognize that good corporate governance is an important means of protecting the interests of our stockholders, associates, customers, suppliers and the community. The Board of Directors, through the Nominating and Governance Committee, monitors corporate governance developments and proposed legislative, regulatory and stock exchange corporate governance reforms.

        Website Access to Corporate Governance Materials.    Our corporate governance information and materials, including our Certificate of Incorporation, By-Laws, Corporate Governance Guidelines, current charters for each of the Audit Committee, Compensation Committee and Nominating and Governance Committee, Code of Ethics for the Chief Executive Officer and Senior Financial Officers, Code of Ethics and Business Conduct, and our Related Person Transactions Approval Policy, are posted on our website atwww.riteaid.comunder the headings "Our Company—Corporate Governance" and are available in print upon request to Rite Aid Corporation, 30 Hunter Lane, Camp Hill, Pennsylvania 17011, Attention: Secretary. The Board regularly reviews corporate governance developments and will modify these materials and practices from time to time as warranted.

        Codes of Ethics.    The Board has adopted a Code of Ethics that is applicable to our Chief Executive Officer and senior financial officers. The Board has also adopted a Code of Ethics and Business Conduct that applies to all of our officers, directors and associates. Any amendment to either code or any waiver of either code for executive officers or directors will be disclosed promptly on our website atwww.riteaid.comunder the headings "Our Company—Corporate Governance—Code of Ethics."

        Director Independence.For a director to be considered independent under the New York Stock ExchangeNYSE corporate governance listing standards, the Board of Directors must affirmatively determine that the director does not have any direct or indirect material relationship with the Company, including any of the relationships specifically proscribed byidentified in the NYSE independence standards. The Board considers all relevant facts and circumstances in making its independence determinations. Only independent directors may serve on our Audit Committee, Compensation Committee and Nominating and Governance Committee.


Table of Contents

As a result of this review, the Board affirmatively determined that the following directors, including each director serving on the Audit Committee, the Compensation Committee, and the Nominating and Governance Committee, satisfy the independence requirements of the NYSE listing standards: Joseph B. Anderson, Jr., André Belzile, François J. Coutu, James L. Donald, Michael A. Friedman, MD, George G. Golleher (served until April 14, 2009), David R. Jessick, Michael N. Regan, Philip G. Satre, Marcy Syms and Dennis Wood. The


Bruce G. Bodaken

Robert E. Knowling, Jr.

Kate B. Quinn

Bari Harlam

Arun Nayar
In addition, the Board also determined that the members of the Audit Committee satisfy the additional independence requirements of Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the NYSE requirements for audit committee members and that the members of the Compensation Committee satisfy the additional independence requirements for compensation committee members. In determining each individual's status as
As interim CEO, Ms. Burr is not an independent director theat this time. The Board considered the following transactions, relationships and arrangements:

    Joseph B. Anderson servespreviously determined that Kevin E. Lofton, who served as a director of Valassis Communications, Inc., which does business with Rite Aid. Because Mr. Anderson serves onlyuntil the 2022 Annual Meeting, and Louis P. Miramontes, who will serve as an outsidea director of, and is not an officer of or otherwise employed by, Valassis Communications, Inc.,until the Board determined that2023 Annual Meeting, satisfied the relationship between Rite Aid and Valassis Communications, Inc. does not constitute a material relationship between Mr. Anderson and Rite Aid.

    George G. Golleher serves as the Chairman and Chief Executive Officer of Smart & Final, a chain of warehouse grocery stores, which purchases ice cream from oneindependence requirements of the Company's subsidiaries. Because the purchases of ice cream are in an amount which is approximately .15% of Smart & Final's consolidated gross revenues, the Board determined that the relationship between Rite Aid and Smart & Final does not constitute a material relationship between Mr. Golleher and Rite Aid.

NYSE listing standards.

There is no family relationship between any of the nominees continuing directors and executive officers of Rite Aid, exceptAid.

RITE AID CORPORATION   2023 Proxy Statement | 15

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
CORPORATE GOVERNANCE PRACTICES
We recognize that directors François Coutugood corporate governance is an important means of promoting the long-term interests of our stockholders, associates, customers, suppliers, and Michel Coutu are brothers.

the community. The Board of Directors, including through the Nominating and Governance Committee, monitors corporate governance developments and proposed legislative, regulatory, and stock exchange corporate governance reforms.

Majority Voting Standard and Policy.Policy
Under the Company'sCompany’s By-Laws, a nominee for director in uncontested elections of directors (as is the case for this annual meeting) will be elected to the Board if the votes cast "for"“for” such nominee'snominee’s election exceed the votes cast "against"“against” such nominee'snominee’s election. In contested elections, directors will be elected by a plurality of votes cast. For this purpose, a contested election means any meeting of stockholders for which (i) the Secretary of the Company receives a notice that a stockholder has nominated a person for election to the Board in compliance with the advance notice requirements for stockholder nominees for director set forth in the By-Laws and (ii) such nomination has not been withdrawn by such stockholder on or prior to the 14th day preceding the date the Company first mails its notice of meeting for such meeting to the stockholders.

Under the Company'sCompany’s Corporate Governance Guidelines, (the "Guidelines"), a director who fails to receive the required number of votes for re-electionreelection in accordance with the By-Laws will, within five days following certification of the stockholder vote, tender his or her written resignation to the ChairmanChair of the Board for consideration by the Board, subject to the procedures set forth in the Guidelines.

Committeesguidelines.

Codes of Ethics
The Board has adopted a Code of Ethics that is applicable to our Chief Executive Officer and senior financial officers. The Company has also adopted a Code of Business Ethics and Conduct that applies to all of our officers, directors, and associates. Any amendment to either code or any waiver of either code for executive officers or directors will be disclosed promptly on our website at www.riteaid.com.
Anti-Hedging and Anti-Pledging Policies
The Company’s directors, officers and other associates are prohibited from engaging in hedging or monetization transactions, such as zero-cost collars, equity swaps, exchange funds and forward sale contracts, with respect to our securities. Because hedging transactions might allow a director, officer or other associate to continue to own our securities, whether obtained through our equity compensation plans or otherwise, without the full risks and rewards of ownership, such hedging transactions are prohibited. Directors, officers and other associates are also prohibited from holding in a margin account, or otherwise pledging, Company securities as collateral for a loan.
BOARD OVERSIGHT OF RISK MANAGEMENT
The Board of Directors, as a whole and through the various committees of the Board, oversees the Company’s management of risk, focusing primarily on four areas of risk (1) strategic, (2) operational, (3) financial, and (4) regulatory compliance.
The Board considers and discusses risks in connection with strategic, operating, financial, compliance, specific approval matters, and other special risk topics such as cybersecurity. The Board may delegate responsibility for oversight of selected risks to the appropriate Board committee as described below.
Management of the Company is responsible for developing and implementing the Company’s plans and processes for risk management. The Board believes that its leadership structure, described above, supports the risk oversight function of the Board. The Board of Directors,

at least annually, reviews with management its plans and processes for managing risk. The Board also receives periodic updates from the Company’s ethics and compliance and internal assurance services departments with regard to the overall effectiveness of the Company’s compliance and internal audit programs and significant areas of risk to the Company.

The Board delegated to the Audit Committee oversight of the Company’s compliance program, and therefore the Committee has the primary oversight role with respect to many of the risks of the Company. The Board and the Audit Committee also receive periodic updates from the Company’s Chief Information Officer and/or Chief Information Security Officer on cybersecurity matters, including information services security and security controls

16 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
over credit card, customer, associate, and patient data. These updates also include information regarding the Rite Aid Information Security Program, managed by Rite Aid’s Chief Information Security Officer, which is designed to protect information and critical resources from a wide range of threats in order to ensure business continuity, minimize business risk, and maximize return on investments and business opportunities. The objective in the development and implementation of the Information Security Program is to create effective administrative, technical, and physical safeguards in order to protect the data of Rite Aid and its subsidiaries and the data of any customers and clients of these entities. In addition, the Audit Committee focuses on assessing and mitigating financial reporting risks, including risks related to internal control over financial reporting as well as legal and regulatory compliance, cyber risk and enterprise risk management.
The Compensation Committee considers risks relating to the Company’s compensation programs and policies, reviews all incentive plans relative to established criteria and conducts an assessment to ensure that none of our incentive plans encourage excessive risk-taking by our executives or associates. The Compensation Committee reviews the risk profile and the relationship between the Company’s compensation programs to the overall risk profile of the Company. Some of the features of our compensation incentive programs that limit risk include:

Delivery of compensation through an appropriate mix of base salary, short-term cash incentive awards, long-term awards, and benefits.

Use of a mix of long-term incentive vehicles that reward both stock price appreciation and financial operating performance and have different risk profiles.

Incorporation of measures in the performance awards to assess our ability to drive stock performance through profitability, leverage reduction and growth, and to compare our stock performance against the Russell 3000 Index (total stockholder return).

Meaningful stock ownership requirements for executives.
The Compensation Committee has considered the risks arising from the Company’s compensation policies and practices for its executives and associates and has concluded that the compensation policies and practices are not reasonably likely to have a material adverse effect on the Company.

RITE AID CORPORATION   2023 Proxy Statement | 17

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
COMMITTEES OF THE BOARD OF DIRECTORS
The Board of Directors has four standing committees:
[MISSING IMAGE: tm217739d1-tbl_committeepn.jpg]
[MISSING IMAGE: tm217739d1_icon-computerpn.jpg]
Current copies of the charters for each of these committees are available on our website at www.riteaid.com under the headings “Corporate—Governance—Corporate Governance Committees—Committee Charters.”
The current members of the committees are identified in the following table.
Committees
DirectorIndependentAuditCompensationExecutiveNominating and
Governance
Bruce G. Bodaken(1) [MISSING IMAGE: ic_stark-bw.jpg]
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: ic_committee-pn.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
Elizabeth Burr(2)
Bari Harlam
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: ic_committee-pn.jpg]
Robert E. Knowling, Jr.(2)
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
Louis P. Miramontes(1)
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: ic_committee-pn.jpg][MISSING IMAGE: ic_calculator-bw.jpg]
Arun Nayar(1)
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg][MISSING IMAGE: ic_calculator-bw.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
Kate B. Quinn
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: ic_committee-pn.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
Number of Meetings in Fiscal 202310708
(1)
Effective as of the Annual Meeting, Mr. Miramontes will cease to serve on the Audit Committee and Mr. Bodaken will begin serving on the Audit Committee. Mr. Nayar will serve as Chair of the Audit Committee.
(2)
Ms. Burr was a member of the Audit Committee until January 7, 2023, when she was appointed Interim Chief Executive Officer. Mr. Knowling joined the Audit Committee at that time.
[MISSING IMAGE: ic_committee-pn.jpg]
Committee Chair
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
Committee Member
[MISSING IMAGE: ic_stark-bw.jpg]
Chair of the Board
[MISSING IMAGE: ic_calculator-bw.jpg]
Audit Committee Financial Expert

18 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
AUDIT COMMITTEEMeetings in Fiscal 2023: 10
Members

Louis P. Miramontes, Chair(1)

Robert E. Knowling, Jr.

Arun Nayar
Qualifications
[MISSING IMAGE: ic_checkgreen-pn.jpg]
The Board has determined that each member of the Audit Committee is an independent director under the NYSE listing standards and satisfies the additional independence requirements for audit committee members. The Board also has determined that Mr. Bodaken, who will begin serving on the Audit Committee effective as of the Annual Meeting, satisfies these additional independence requirements. See the section entitled “Corporate Governance—Director Independence” above.
[MISSING IMAGE: ic_checkgreen-pn.jpg]
The Board has determined that each of these individuals is also “financially literate” under the applicable NYSE listing standards.
[MISSING IMAGE: ic_checkgreen-pn.jpg]
The Board has determined that each of Louis P. Miramontes and Arun Nayar qualifies as an “audit committee financial expert” as that term is defined under applicable SEC rules.
Principal ResponsibilitiesCharter
The functions of the Audit Committee include the following:

Appointing, compensating, and overseeing our independent registered public accounting firm (“independent auditors”);

Overseeing management’s fulfillment of its responsibilities for financial reporting and internal control over financial reporting;

Overseeing the activities of the Company’s internal audit function; and

Reviewing the Company’s cybersecurity, information security and technology risks
For additional information, see the Audit Committee’s charter on our website at www.riteaid.com, under the headings “Corporate—Governance—Our Policies—Corporate Governance Committees—Audit Committee Charter.”
Audit Committee Report
The Audit Committee Report is located in “Proposal 2—Ratification of the Appointment of Independent Registered Public Accounting Firm” under the caption “Audit Committee Report.”
(1)
Effective as of the Annual Meeting, Mr. Miramontes will cease to serve on the Audit Committee and Mr. Bodaken will begin serving on the Audit Committee. Mr. Nayar will serve as Chair of the Audit Committee.

RITE AID CORPORATION   2023 Proxy Statement | 19

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
COMPENSATION COMMITTEEMeetings in Fiscal 2023: 7
Members

Kate B. Quinn, Chair

Robert E. Knowling, Jr.

Arun Nayar
Qualifications
[MISSING IMAGE: ic_checkgreen-pn.jpg]
The Board has determined that each member of the Compensation Committee is an independent director under the NYSE listing standards and satisfies the additional independence requirements for compensation committee members. See the section entitled “Corporate Governance—Director Independence” above.
Principal Responsibilities
The functions of the Compensation Committee include the following:

Administering Rite Aid’s equity incentive plans;

Reviewing and approving the base salaries of executive officers and reviewing and recommending to the Board the base salary of the CEO (along with other compensation elements as deemed necessary);

Reviewing and approving goals and objectives relevant to the incentive-based compensation of executive officers, evaluating the performance of executive officers, and determining and approving the incentive-based compensation of executive officers;

Setting corporate performance targets under all annual bonus and long-term incentive compensation plans and determining annually the individual bonus award opportunities for executive officers;

Reviewing and approving executive officers’ employment agreements and severance arrangements;

Reviewing the Company’s succession planning for the CEO and other executive officers; and

Reviewing and making recommendations to the Board on employee engagement and DEI initiatives, objectives and progress.
Independent Compensation Consultant
As provided in its charter, the Compensation Committee has the authority to engage an external compensation consultant and to determine the scope of any services provided. The Compensation Committee may terminate the engagement at any time. The external compensation consultant reports to the Compensation Committee Chair.
Charter
For additional information, see the Compensation Committee’s charter on our website at www.riteaid.com, under the headings “Corporate—Governance—Our Policies—Corporate Governance Committees—Compensation Committee Charter.”
Compensation Committee Report
The Compensation Committee Report is located at the end of the “Compensation Discussion and Analysis” under the caption “Compensation Committee Report.”
Compensation Committee Interlocks and Insider Participation
The Compensation Committee currently consists of Kate B. Quinn (Chair), Robert E. Knowling, Jr., and Arun Nayar. In addition to the current members, Louis P. Miramontes also served on the Compensation Committee during fiscal year 2023. During fiscal year 2023, no member of the Compensation Committee was an employee, former employee, or executive officer of the Company, nor does any such member have any interlocking relationships as defined by applicable SEC rules.

20 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
NOMINATING AND GOVERNANCE COMMITTEEMeetings in Fiscal 2023: 8
Members

Bari Harlam, Chair

Bruce G. Bodaken

Kate B. Quinn
Qualifications
[MISSING IMAGE: ic_checkgreen-pn.jpg]
The Board has determined that each member of the Nominating and Governance Committee is an independent director under the NYSE listing standards. See the section entitled “Corporate Governance—Director Independence” above.
Principal Responsibilities
The functions of the Nominating and Governance Committee include the following:

Identifying and recommending to the Board individuals qualified to serve as Rite Aid directors;

Recommending to the Board individual directors to serve on committees of the Board;

Advising the Board with respect to matters of Board composition and procedures;

Developing and recommending to the Board a set of corporate governance principles applicable to Rite Aid and overseeing corporate governance matters generally;

Overseeing the annual evaluation of the Board and management;

Reviewing and approving or ratifying related person transactions in which the Company is a participant; and

Overseeing the ESG policies, trends and activities of the Company.
Charter
For additional information, see the Nominating and Governance Committee’s charter on our website at www.riteaid.com, under the headings “Corporate—Governance—Our Policies—Corporate Governance Committees—Nominating and Governance Committee Charter.”
EXECUTIVE COMMITTEEMeetings in Fiscal 2023: 0
Members

Bruce G. Bodaken, Chair

Arun Nayar
Principal ResponsibilitiesCharter
The Executive Committee did not meet during fiscal year 2023.
The Executive Committee, except as limited by Delaware law, is empowered to exercise all of the powers of the Board of Directors.
For additional information, see the Executive Committee’s charter on our website at www.riteaid.com, under the headings “Corporate—Governance—Our Policies—Corporate Governance Committees—Executive Committee Charter.”
Board Committee Refreshment
The Nominating and Governance Committee considers the periodic rotation of Committee members and Committee Chairs to introduce fresh perspectives and to broaden and diversify the views and experience represented on the Committees. Through this periodic refreshment, the Nominating and Governance Committee considers, among other things, the benefits from continuity and depth of experience with the Executive Committee. Current copiesbenefits of fresh perspectives and exposing our directors to different aspects of our business.
As part of the charters for eachCommittee refreshment process, in June 2022, Arun Nayar joined the Compensation Committee, Louis P. Miramontes’ service on the Compensation Committee ended and Bari Harlam became Chair of these committees are availablethe Nominating and Governance Committee. In addition, in January 2023 in connection with her appointment as interim CEO, Ms. Burr’s service on our website atwww.riteaid.comunder the headings "Our Company—Corporate Governance—Committee Charters."

        Audit Committee.    The Audit Committee whichended, and Robert E. Knowling, Jr. joined the Audit Committee.

BOARD MEETING ATTENDANCE
The Board of Directors held eleven12 meetings during fiscal year 2009, currently consists of Philip G. Satre (Chairman), André Belzile, Michael N. Regan and Marcy Syms. The Board has determined that each of these individuals is an independent2023. Each director under the NYSE listing standards and satisfies the additional independence requirements of Rule 10A-3 under the


Table of Contents


Exchange Act and the additional requirementsattended at least 75% of the NYSE listing standards for audit committee members. See the section entitled "Corporate Governance—Director Independence" above. The Board has determined that Philip G. Satre qualifies as an "audit committee financial expert" as that term is defined under applicable SEC rules. It is expected that David R. Jessick will be appointed to the Audit Committee.

        The functionsaggregate number of the Audit Committee include the following:

    Appointing, compensating and overseeing our independent registered public accounting firm ("independent auditors");

    Overseeing management's fulfillmentmeetings of its responsibilities for financial reporting and internal control over financial reporting; and

    Overseeing the activities of the Company's internal audit function.

        The independent auditors and internal auditors meet with the Audit Committee with and without the presence of management representatives. For additional information, see the section entitled "Audit Committee Report," as well as the Audit Committee's charter, which is posted on our website atwww.riteaid.comunder the headings "Our Company—Corporate Governance."

        Compensation Committee.    The Compensation Committee, which met eight times during fiscal year 2009, currently consists of James L. Donald, Michael A. Friedman, MD and Dennis Wood. The Board has determined that each of these individuals is an independent director under the NYSE listing standards. See the section entitled "Corporate Governance—Director Independence" above. George G. Golleher served as Chairman of the Compensation Committee until his resignation from the Board in April 2009.

        The functions of the Compensation Committee include the following:

    Administering Rite Aid's stock option and other equity incentive plans;

    Reviewing and approving the Company's goals and objectives relevant to the compensation of the Chief Executive Officer, evaluating the CEO's performance in light of these goals and objectives and determining and approving the CEO's compensation level based on this evaluation; and

    Reviewing and approving compensation with respect to all other senior management.

        The Compensation Committee reviews the performance of the Company's executive personnel and develops and makes recommendations to the Board of Directors with respectand meetings held by all committees on which such director served during the period for which such director served.


RITE AID CORPORATION   2023 Proxy Statement | 21

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
It is our policy that directors are invited and encouraged to executive compensation policies. The Compensation Committee is empowered byattend the annual meeting of stockholders. All directors serving on the Board of Directorsor nominated to award to executive officers appropriate bonuses, stock options, stock appreciation rights ("SARs") and stock-based awards. The detailsserve on the Board at the time of the processes and procedures formeeting attended the consideration and determination2022 Annual Meeting of executive and director compensation are described in the section entitled "Compensation Discussion and Analysis."

        The Compensation Committee also has access to independent compensation data and from time to time engages outside compensation consultants. In fiscal year 2009, the Compensation Committee considered the report of outside compensation consultants with respect to executive compensation and equity compensation strategy.

        The objectives of the Compensation Committee are to support the achievement of desired company performance, to provide compensation and benefits that will attract and retain superior talent and reward performance and to fix a portion of compensation to the outcome of the Company's performance.

Stockholders.

DIRECTOR NOMINATIONS

Table of Contents

        Nominating and Governance Committee.

The Nominating and Governance Committee which held two meetings during fiscal year 2009, currently consistsidentifies potential candidates by asking current directors and executive officers to notify the committee if they become aware of Joseph B. Anderson, Jr. (Chairman), François J. Coutu and Michael A. Friedman, MD.persons, meeting the criteria described below, who have had a change in circumstances that might make them available to serve on the Board—for example, retirement as a CEO or CFO of a public company or exiting government or military service. The Board has determined that each of these individuals is an independent director under the NYSE listing standards. See the section entitled "Corporate Governance—Director Independence" above.

        The functions of the Nominating and Governance Committee include the following:

    Identifying and recommendingalso, from time to the Board individuals qualified to serve as Rite Aid directors;

    Recommending to the Board individual directors to serve on committees of the Board;

    Advising the Board with respect to matters of Board composition and procedures;

    Developing and recommending to the Board a set of corporate governance principles applicable to Rite Aid and overseeing corporate governance matters generally;

    Overseeing the annual evaluation of the Board and management; and

    Reviewing, evaluating and recommending for approval by the Board related person transactionstime, may engage firms that specialize in which the Company is a participant.

        Executive Committee.    The members of the Executive Committee currently are Michel Coutu, Robert G. Miller, Mary F. Sammons and Philip G. Satre. The Executive Committee did not meet during fiscal year 2009. However, on four occasions, the Executive Committee acted by Unanimous Written Consent. The Executive Committee, except as limited by Delaware law, is empowered to exercise all of the powers of the Board of Directors.

Nomination of Directors

identifying director candidates.

The Nominating and Governance Committee will consider director candidates recommended by stockholders. In considering such recommendations, the Nominating and Governance Committee will take into consideration the needs of the Board and the qualifications of the candidate. The Nominating and Governance Committee may also take into consideration the number of shares held by the recommending stockholder and the length of time that such shares have been held. To have a candidate considered by the Nominating and Governance Committee, a stockholder must submit the recommendation in writing and must include the following information:


The name of the stockholder and evidence of the person'sperson’s ownership of Rite Aid stock, including the number of shares owned and the length of time of ownership; and


The name of the candidate, the candidate'scandidate’s resume or a listing of his or her qualifications to be a Rite Aid director, and the person'sperson’s consent to be named as a director if selected by the Nominating and Governance Committee and nominated by the Board.

The stockholder recommendation and information described above must be sent to Rite Aid Corporation, 30 Hunter Lane, Camp Hill, Pennsylvania 17011,PO Box 3165 Harrisburg, PA 17105, Attention: Corporate Secretary. The Nominating and Governance Committee will accept recommendations of director candidates throughout the year; however,year. Generally, in order for a recommended director candidate to be considered for nomination to stand for election at an upcoming annual meeting of stockholders, the recommendation must be received by the Secretary not lessfewer than 120 days prior to the anniversary date of Rite Aid'sAid’s most recent annual meeting of stockholders.

The Nominating and Governance Committee believes that the minimum qualifications for serving as a Rite Aid director are that a candidate demonstrate, by significant accomplishment in his or her field, an ability to make a meaningful contribution to the Board's oversight of Rite Aid's business and affairs and have an impeccable record and reputation for honest and ethical conduct in his or her


Table of Contents


professional and personal activities. In addition, the Nominating and Governance Committee examines a candidate's specific experiences and skills, time availability in light of other commitments, potential conflicts of interest and independence from management and the Company. The Nominating and Governance Committee also seeks to have the Board represent a diversity of backgrounds and experience.

        The Nominating and Governance Committee identifies potential candidates by asking current directors and executive officers to notify the committee if they become aware of persons, meeting the criteria described above, who have had a change in circumstances that might make them available to serve on the Board—for example, retirement as a CEO or CFO of a public company or exiting government or military service. The Nominating and Governance Committee also, from time to time, may engage firms that specialize in identifying director candidates. As described above, the committee will also consider candidates recommended by stockholders.

        Once a person has been identified by the Nominating and Governance Committee as a potential candidate, the committee may collect and review publicly available information, regarding the personconduct an interview and/or check references to assess whether the person should be considered further. If the Nominating and Governance Committee determines that the candidate warrants further consideration, the Chairman or another member of the committee contacts the person. Generally, if the person expresses a willingness to be considered and to serve on the Board, the Nominating and Governance Committee requests information from the candidate, reviews the person'sperson’s accomplishments and qualifications including in light of the needs of the Board and the accomplishments and qualifications of any other candidates that the committee might be considering, and conducts one or more interviews with the candidate. In certain instances, committee members may contact one or more references provided by the candidate or may contact other members of the business community or other persons that may have greater first-hand knowledge of the candidate's accomplishments.considering. The committee'scommittee’s evaluation process does not vary based on whether or not a candidate is recommended by a stockholder, although, as stated above, the Board may take into consideration the number of shares held by the recommending stockholder and the length of time that such shares have been held.

        James Donald

The Board seeks to maintain an engaged, independent Board with broad experience and David R. Jessick were appointedjudgment that is committed to representing the Boardlong-term interests of Directors in May 2008 and April 2009, respectively, on the recommendation of theour stockholders. The Nominating and Governance Committee. Messrs. DonaldCommittee believes that the minimum qualifications for serving as a Rite Aid director are:

that a candidate demonstrates, by significant accomplishment in his or her field, an ability to make a meaningful contribution to the Board’s oversight of Rite Aid’s business and Jessick were recommendedaffairs, and

that a candidate has an impeccable record and reputation for consideration byhonest and ethical conduct in his or her professional and personal activities.
In addition, the Nominating and Governance Committee examines a candidate’s specific experiences and skills, availability in light of other commitments, potential conflicts of interest, and independence from management and the Company. The Nominating and Governance Committee also takes into account a candidate’s ability to contribute to the diversity of background and experience represented by Mary Sammons, our Chairmanthe Board. The Nominating and Chief Executive Officer.

Executive SessionsGovernance Committee assesses its achievement of Non-Management Directors

diversity through the review of Board composition as part of the Board’s annual self-assessment process.


22 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
EXECUTIVE SESSIONS OF NON-MANAGEMENT DIRECTORS
In order to promote discussion among the non-management directors, regularly scheduled executive sessions (i.e., meetings(meetings of non-management directors without management present) are held to review such topics as the non-management directors determine. The non-management directors met in executive session seven times during fiscal year 2009 and were presided over by the Non-Executive Co-Chairmanregularly. Mr. Bodaken, Chair of the Board, of Directors.

Communications with the Board of Directors

presides at our executive sessions.

COMMUNICATIONS WITH THE BOARD OF DIRECTORS
The Board has established a process to receive communications from stockholders and other interested parties. Stockholders and other interested parties may contact any member (or all members) of the Board, any Board committee, or any chair of any such committee by mail or electronically. To communicate with the Board of Directors, the non-management directors, any individual directors or committee of directors, correspondencemail. Correspondence should be addressed to the Board of Directors or any such individual directors, or committee of directors by either name or title. All such correspondence should be sent to Rite Aid Corporation, c/o Secretary, P.O. Box 3165, Harrisburg, Pennsylvania 17105. To communicate with any of the directors electronically, stockholders should go to our website atwww.riteaid.com. Under the headings "Our Company—Corporate Governance—Contact Our Board" you will find an on-line form that may be used for writing an electronic message to the Board, the non-management directors, any individual directors, or any committee of directors. Please follow the instructions on the web site in order to send your message.

All such correspondence should be
sent to:
[MISSING IMAGE: ic_mail-pn.jpg]
Rite Aid Corporation
c/o Corporate Secretary
PO Box 3165
Harrisburg, PA 17105

Table of Contents

All communications received as set forth above will be opened by the Corporate Secretary for the purpose of determining whether the contents represent a messagelegitimate communication to the directors,directors. Such communications, other than business solicitations or advertisements, junk mail and depending on the factsmass mailings, new product suggestions, product complaints, product inquiries, resumes and circumstances outlined in the communication,other forms of job inquiries, spam, and surveys, will be distributed to the Board, the non-management directors, an individual director, or a committee of directors, as appropriate.

ENVIRONMENTAL, SOCIAL & GOVERNANCE MATTERS
The Secretary will make sufficient copies ofdisclosure in our voluntary annual ESG report is intended to align with the contents to send to each director whoSustainability Accounting Standards Board (SASB) framework and is a member of the Board or of the committee to which the envelope or e-mail is addressed.

Directors' Attendance at Board, Committeebroken into four pillars: Thriving Planet, Thriving Business, Thriving Workplace and Annual Meetings

        The Board of Directors held ten meetings duringThriving Community.

In fiscal year 2009. Each incumbent director attended at least 75% of the aggregate of the meetings2023, we provided quarterly updates on ESG matters to our Nominating and Governance Committee of the Board of Directors. In addition, our Corporate Sustainability Committee, comprised of cross functional leadership across the organization, with representation from legal, finance, internal assurance, human resources, facilities, operations and more, met regularly to discuss reporting strategy, disclosure topics and key performance indicators.
[MISSING IMAGE: ic_computer-pn.jpg]
Further information about our commitment to sustainability is available on our website under the headings “Corporate—Investor Relations—Sustainability.” Website content is not incorporated into this proxy statement.

RITE AID CORPORATION   2023 Proxy Statement | 23

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
CORPORATE GOVERNANCE MATERIALS
Website Access to Corporate Governance Materials
[MISSING IMAGE: ic_computer-pn.jpg]
Our corporate governance information and materials are posted on our website at riteaid.com/corporate/governance. Website content is not incorporated into this proxy statement.

CORPORATE GOVERNANCE GUIDELINES

AUDIT COMMITTEE CHARTER

COMPENSATION COMMITTEE CHARTER

EXECUTIVE COMMITTEE
CHARTER

NOMINATING AND GOVERNANCE COMMITTEE CHARTER

CODE OF ETHICS FOR THE CEO AND SENIOR FINANCIAL OFFICERS

CODE OF BUSINESS ETHICS AND CONDUCT

STOCK OWNERSHIP GUIDELINES

RELATED PERSON TRANSACTION POLICY

INSIDER TRADING POLICY

CERTIFICATE OFINCORPORATION

BY-LAWS OF RITE AID
CORPORATION

NYSE DOCUMENTS—ANNUAL CEO CERTIFICATION

NYSE DOCUMENTS—SECTION 303A WRITTEN AFFIRMATIONS OF COMPLIANCE
These documents are also available in print upon request, free of charge, by writing to:
[MISSING IMAGE: ic_mail-pn.jpg]
Rite Aid Corporation
Attention: Corporate Secretary
PO Box 3165
Harrisburg, PA 17105
The Board regularly reviews corporate governance developments and will modify these materials and practices from time to time as warranted.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Review and Approval of Related Person Transactions
Under our written policy, the Nominating and Governance Committee is responsible for the review, approval, or ratification of “related person transactions” between the Company or its subsidiaries and related persons. Under SEC rules, a related person is, or any time since the beginning of the last fiscal year was, a director, an executive officer, a nominee for director, a more than 5% stockholder of the Company, or an immediate family member (as defined under applicable SEC rules) of any of the foregoing. A related person transaction is any transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which the Company or a subsidiary is a participant, the amount involved exceeds $120,000, and a related person had, has or will have a direct or indirect material interest.
Directors, executive officers and meetings heldnominees must complete an annual questionnaire and disclose all potential related person transactions involving themselves and their immediate family members that are known to them.
Throughout the year, directors and executive officers must notify the Corporate Secretary and Chief Accounting Officer of any potential related person transactions as soon as they become aware of any such transaction. The Corporate Secretary and Chief Accounting Officer inform the Nominating and Governance Committee of any related person transaction of which they are aware. The Corporate Secretary and Chief Accounting Officer are responsible for conducting a preliminary analysis and review of potential related person transactions and presentation to the Nominating and Governance Committee for review, including provision of additional information to enable proper consideration by all committeesthe Nominating and Governance Committee.

24 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
The Corporate Secretary and Chief Accounting Officer determine whether the proposed transaction should be submitted to the Nominating and Governance Committee for consideration at the next committee meeting or, if the Corporate Secretary and Chief Accounting Officer, in consultation with the Chief Executive Officer or Chief Financial Officer, determine that it is not practicable or desirable for the Company to wait until the next committee meeting, to the Chair of the Nominating and Governance Committee (who will possess delegated authority to act between committee meetings). As necessary, the Nominating and Governance Committee reviews approved related person transactions on which such director served, duringa periodic basis throughout the periodduration of the transaction to ensure that the transactions remain in the best interests of the Company. The Nominating and Governance Committee may, in its discretion, engage outside counsel to review certain related person transactions. In addition, the Nominating and Governance Committee may request that the full Board of Directors consider the approval or ratification of related person transactions if the Nominating and Governance Committee deems it advisable.
[MISSING IMAGE: ic_computer-pn.jpg]
A copy of our full policy concerning transactions with related persons is available on the Governance section of our website at www.riteaid.com under the headings “Corporate—Governance—Our Policies—Related Person Transactions.” Website content is not incorporated into this proxy statement
Directors’ Compensation
Non-Management Director Service
Annual Cash Retainer
($)
(1)
Annual Stock Award
($)
Non-management director100,000160,000
Additional annual retainers, for service as:��
Chair of the Board165,000
Committee Chairs

Audit Committee
25,000

Compensation Committee
25,000

Nominating and Governance Committee
25,000
Audit Committee Member (other than the Chair)10,000
(1)
Fees payable quarterly in arrears.
The elements of Rite Aid’s fiscal year 2023 compensation program for which such director served.

        It is our policy thatnon-management directors are invited and encouraged to attendsummarized above. The Compensation Committee, with the annual meetingassistance of stockholders. Twelve ofMercer, the committee’s compensation consultant, regularly reviews our fourteen directors attended the 2008 Annual Meeting of Stockholders.

Directors' Compensation

        Except for Robert G. Miller, whose compensation arrangements are discussed in the section below entitled "Agreement with Mr. Miller," and except as noted below under thenon-management director compensation plan, each non-employeeand evaluates the competitiveness and reasonableness of the compensation program in light of general trends and practices. The Compensation Committee makes recommendations based on such review to our Board, which determines whether any changes should be made to our non-management director compensation program. Based on its review, in fiscal year 2023 the Compensation Committee recommended, and the Board determined, beginning in April 2022, to increase the Compensation Committee Chair’s annual cash retainer to better reflect market competitiveness, from $20,000 to $25,000, and that no other than Mr. Sokoloff (who is affiliated with Leonard Green & Partners L.P., an entity that provides serviceschanges to Rite Aid, as discussed under "Certain Relationships and Related Transactions") receivesthe non-management director compensation program were needed.

Non-management directors receive an annual cash payment of $70,000 in cash,$100,000, payable quarterly in arrears except thatand also receive an annual award of restricted stock units under the Company’s Amended and Restated 2020 Omnibus Equity Incentive Plan. The annual paymentaward of restricted stock units for fiscal year 2023 vested on the date of grant and the shares subject to each non-employee director who isthe grant will become payable on a memberdeferred basis upon the separation from service of the Audit Committeedirector.
A non-management director may also defer cash fees under the Rite Aid Corporation Director Deferred Compensation Plan. Cash fees deferred are allocated to a bookkeeping account for the non-management director and notionally invested in accordance with the director’s election among a subset of investment funds available under the Company’s 401(k) savings plan. A non-management director’s deferral is $80,000 andpaid on the annual paymentdirector’s separation from service in a single lump sum. None of our non-management directors elected to Michel Coutudefer cash fees earned in his capacity as Non-Executive Co-Chairman is $500,000. In addition, the chairrespect of the Audit Committee receives an additional annual payment of $10,000. Each non-employee director who chairs a committee of the Board other than the Audit Committee receives an additional annual payment of $7,500. fiscal year 2023.

RITE AID CORPORATION   2023 Proxy Statement | 25

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
Directors who are officers and full-timeand/or Rite Aid employees and Mr. Sokoloffassociates receive no separate compensation for service as directors or committee members. Directors are reimbursed for travel and lodging expenses associated with attending Board of Directors meetings.

        Each person who was first elected or appointed as a director after January 1, 2002 and who is eligibleBoard committee meetings.

Non-management directors are subject to receive compensation for serving as a director shall, on the date first elected or appointed, receive non-qualified stock options to purchase 100,000 shares of common stock. In addition, non-employee directors other than Mr. Sokoloff are entitled to annually receive 20,000 shares of restricted stock. All of the options received by the directors vest ratably and the restrictions applicable to the restricted stock shall lapse over a three-year period beginning on the first anniversary of the date they were granted. None of such options vests after the non-employee director ceases to be a director, exceptour Stock Ownership Guidelines discussed in the case of a director whose service terminates after he or she reaches age 72, in which case such options will vest immediately upon termination. All ofCompensation Discussion and Analysis under the options vest immediately upon a change in control. In accordance with the foregoing, the following number of shares of restricted stock were issued under Rite Aid's 2006 Omnibus Equity Plan to the following directors: on September 24, 2008, Ms. Symscaption “Director and Messrs. Anderson, Belzile, François Coutu, Michel Coutu, Friedman, Golleher, Miller, Regan, Satre and Wood each received 20,000 shares of restricted stock. On May 13, 2008, James L. Donald was appointed to the Board of Directors and received non-qualified stock options to purchase 100,000 shares with an exercise price equal to the market price of the Company's common stock as of the close of business on the date of grant.

        In fiscal year 2009, Rite Aid's non-employee directors also received $2,000Officer Stock Ownership Guidelines.”

Director Compensation Table for each Board of Directors meeting attended, $1,000 for each committee meeting attended or $2,500 for each meeting attended at which such non-employee director served as the chairman of a committee, except that Mr. Sokoloff received no such compensation.

Fiscal Year 2023

Table of Contents


DIRECTOR COMPENSATION TABLE FOR FISCAL YEAR 2009

The following Director Compensation Table sets forth fees, awards, and other compensation paid to or earned by our non-management directors (other than Named Executive Officers) who served during the fiscal year ended February 28, 2009:

March 4, 2023:
Name(1)
Fees Earned
or Paid in
Cash
($)
Stock
Awards
($)
(2),(3)
Option
Awards
($)
Non-Equity
Incentive
Plan
Compensation
($)
Change In
Nonqualified
Deferred
Compensation
($)
All Other
Compensation
($)
Total
($)
Bruce G. Bodaken265,000159,997424,997
Bari Harlam112,637159,997272,635
Robert E. Knowling, Jr.104,556159,997264,553
Kevin E. Lofton(4)62,50062,500
Louis P. Miramontes125,000159,997284,997
Arun Nayar110,000159,997269,997
Kate B. Quinn(5)123,750159,997283,747
Name
 Fees Earned
or Paid in
Cash
($)
 Stock
Awards
($)(4)(6)
 Option
Awards
($)(5)(7)
 All Other
Compensation
($)
 Total 

Joseph B. Anderson, Jr. 

  104,500  2,667  54,167     161,334 

André Belzile

  115,000  2,667  108,333     226,000 

François J. Coutu

  94,000  2,667  108,333     205,000 

Michel Coutu

  522,000  2,667  108,333     633,000 

James L. Donald

  67,231    35,667     102,898 

Michael A. Friedman, MD

  103,000  2,667  54,167     159,834 

George G. Golleher

  124,500  2,667  54,167     181,334 

Robert A. Mariano(1)

  21,000    4,514     25,514 

Robert G. Miller(2)

  154,731  2,667  54,167  507,544(3) 719,109 

Michael N. Regan

  115,000  2,667  108,333     226,000 

Philip G. Satre

  141,500  2,667  54,167    198,334 

Jonathan D. Sokoloff

            

Marcy Syms

  114,000  2,667  54,167     170,834 

Dennis Wood

  102,000  2,667  108,333    213,000 

(1)
Mr. Mariano resigned from the Board on May 13, 2008.

(2)
Represents annual base pay for Mr. Miller,
Elizabeth Burr served as discussed in the section entitled "Agreement with Mr. Miller".

(3)
All Other Compensation for Mr. Miller consistsa director during fiscal year 2023 through January 7, 2023 until her appointment as interim CEO of $240,000 contributed by the Company toon such date. Ms. Burr’s compensation as a supplemental executive retirement plandirector and $267,544 for personal use of aircraft. The methodology used to calculate the incremental cost of aircraft usageher service as interim CEO during fiscal year 2023 is set forthreflected in Note 6 to the Summary Compensation Table.

(4)
Table, found on page 56 of this proxy statement.
(2)
Represents the total expense recordedgrant date fair value of stock awards granted in fiscal 2009year 2023 in accordance with SFAS No. 123R for outstanding restricted stock awards. TheFinancial Accounting Standards Board (“FASB”) Topic 718. For information regarding the assumptions used in determining the fair value of an award, is set forth inplease refer to Note 1518 to our financial statements contained in ourthe Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2009. We recognize expense ratably overMarch 4, 2023, filed with the three-year vesting period.

(5)
RepresentsSEC on May 1, 2023. The restricted stock unit awards are immediately vested upon grant; however, shares underlying the total expense recorded in fiscal 2009 in accordance with SFAS No. 123R for outstandingrestricted stock units are held and not delivered until the directors’ separation from service.
(3)
As of March 4, 2023, no unvested restricted stock unit awards and no stock option awards. The assumptions used in determiningawards were held by any director.
(4)
Mr. Lofton resigned from the fair value of the outstanding options is set forth in Note 15Board effective July 27, 2022.
(5)
Ms. Quinn’s Compensation Committee chair retainer increased from $20,00 to our financial statements contained in our Annual Report on Form 10-K for the year ended February 28, 2009. We recognize expense ratably over the three-year vesting period.

Table of Contents

(6)
The number of stock awards outstanding as of February 28, 2009 for each director is detailed in the table below. The grant date fair value is included for all awards granted to our directors in fiscal 2009.
Name
 Grant Date Number of
Stock Awards
(#)
 Grant Date
Fair Value
($)
 

Joseph B. Anderson, Jr. 

  9/24/2008  20,000  0.96 

André Belzile

  9/24/2008  20,000  0.96 

François J. Coutu

  9/24/2008  20,000  0.96 

Michel Coutu

  9/24/2008  20,000  0.96 

James L. Donald

  9/24/2008  20,000  0.96 

Michael A. Friedman, MD

  9/24/2008  20,000  0.96 

George G. Golleher

  9/24/2008  20,000  0.96 

Robert G. Miller

  9/24/2008  20,000  0.96 

Michael N. Regan

  9/24/2008  20,000  0.96 

Philip G. Satre

  9/24/2008  20,000  0.96 

Marcy Syms

  9/24/2008  20,000  0.96 

Dennis Wood

  9/24/2008  20,000  0.96 
(7)
The number of unexercised options outstanding as of February 28, 2009 for each director is detailed in the table below. Note that the grant date fair value is included for those options granted to our directors in fiscal 2008 and 2009.
 
Name
 Grant Date Exercise
Price
($)
 Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
 Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
 Grant Date
Fair Value
($)
 
 

Joseph B. Anderson, Jr. 

  9/21/2005  3.65  100,000     
 

  6/21/2006  4.55  50,000     
 

  6/27/2007  6.15  16,667  33,333  3.25 
 

André Belzile

  6/4/2007  6.55  33,334  66,666  3.25 
 

François J. Coutu

  6/4/2007  6.55  33,334  66,666  3.25 
 

Michel Coutu

  6/4/2007  6.55  33,334  66,666  3.25 
 

James L. Donald

  5/13/2008  2.40    100,000  1.07 
 

Michael A. Friedman, MD

  10/7/2004  3.53  100,000     
 

  6/23/2005  4.11  50,000     
 

  6/21/2006  4.55  50,000     
 

  6/27/2007  6.15  16,667  33,333  3.25 
 

George G. Golleher

  1/30/2002  2.26  100,000     
 

  12/11/2002  2.10  50,000     
 

  4/7/2004  5.40  50,000     
 

  6/23/2005  4.11  50,000     
 

  6/21/2006  4.55  50,000     
 

  6/27/2007  6.15  16,667  33,333  3.25 
 

Robert G. Miller

  11/20/2000  2.75  4,200,000     
 

  2/13/2001  4.05  4,500,000     
 

  6/24/2004  5.38  50,000     
 

  6/23/2005  4.11  50,000     
 

  6/21/2006  4.55  50,000     
 

  6/27/2007  6.15  16,667  33,333  3.25 
 

Michael N. Regan

  6/27/2007  6.15  33,334  66,666  3.25 

Table of Contents

 
Name
 Grant Date Exercise
Price
($)
 Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
 Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
 Grant Date
Fair Value
($)
 
 

Philip G. Satre

  4/6/2005  3.77  100,000     
 

  6/23/2005  4.11  50,000     
 

  6/21/2006  4.55  50,000     
 

  6/27/2007  6.15  16,667  33,333  3.25 
 

Marcy Syms

  9/21/2005  3.65  100,000     
 

  6/21/2006  4.55  50,000     
 

  6/27/2007  6.15  16,667  33,333  3.25 
 

Dennis Wood

  6/4/2007  6.55  33,334  66,666  3.25 

Agreement with Mr. Miller

        Mr. Miller's April 9, 2003 employment agreement was amended$25,000 annually on April 28, 2005, pursuant to which, effective as of June 23, 2005, Mr. Miller continued serving solely as Chairman of the Board. On November 28, 2006, Rite Aid amended the April 9, 2003 agreement with Mr. Miller pursuant to which Mr. Miller stepped down as Chairman upon the closing of the Brooks Eckerd Transaction and continued to serve solely as a director through the date of the 2008 annual meeting, and the parties agreed that the Brooks Eckerd Transaction would not trigger change in control benefits. An additional amendment to Mr. Miller's employment agreement, pursuant to which Mr. Miller will continue to serve as a director until the Company's 2011 Annual Meeting of Stockholders, became effective on his re-election to the Board of Directors at the 2008 annual meeting. Additional terms of this agreement are as follows:

        Salary and incentive bonus.    Through June 25, 2008, the date of the 2008 Annual Meeting of Shareholders, Mr. Miller received annual base pay of $350,000 and was entitled to continued benefits, in their entirety, including participation in Rite Aid's fringe benefit and perquisite programs and savings plans, and continued deferred compensation as provided under the December 5, 1999 employment agreement. However, he was not entitled to participate in any incentive compensation or bonus plans. For the period starting on June 6, 2022.


26 2008 and ending on the later of (i) June 30, 2009 and (ii) the one year anniversary of the 2008 annual meeting (the "Term"), Mr. Miller receives a monthly base salary of $5,000 (pro-rated for any partial month) and continues to be eligible to participate in certain of the Company's fringe benefit and perquisite programs in which he was entitled to participate prior to the 2008 annual meeting, and continues to remain entitled to defer compensation as provided under the December 5, 1999 employment agreement. The Term may be extended at the mutual agreement of the parties. If the Term is not extended, Mr. Miller shall be entitled to receive solely the fees which are paid to our non-employee directors through the end of his service as a director.

        Restricted stock and options.    During his service as a director, Mr. Miller is eligible to receive option and restricted stock awards in accordance with Rite Aid's policy for members of the Board of Directors as in effect from time to time. Mr. Miller's existing stock options and shares of restricted stock continue to vest and be fully exercisable for the remainder of their stated terms.

        Termination of employment and change in control arrangements.    The termination provisions of the April 9, 2003 employment agreement became effective immediately and remain in effect until the agreement expires. Pursuant to the April 28, 2005 amendment to the April 9, 2003 agreement, if Mr. Miller was not re-elected as Chairman, he could be terminated and receive one year's base salary (as compared to three years provided under the previous agreements for a termination without cause). Under the November 28, 2006 agreement, Mr. Miller waived any right he would have pursuant to his

 | RITE AID CORPORATION   2023 Proxy Statement


Table of Contents


employment agreement upon his ceasing to serve as Chairman or a change in control triggered by the Brooks Eckerd Transaction.

Agreement with Michel Coutu

        Effective as of June 27, 2007, Michel Coutu was appointed as a director of Rite Aid and non-executive co-chairman of the Board of Directors for a term of two years following the completion of the Brooks Eckerd Transaction. In this capacity, Mr. Coutu is entitled to receive an annual retainer of $500,000, payable quarterly in arrears. In addition, Mr. Coutu is also entitled to receive certain benefits and annual equity awards to the same extent as our other directors, as described under the caption "Directors' Compensation," above. On April 8, 2009, the Board extended this agreement with Mr. Coutu, on the same terms, through the date of the 2010 annual meeting of stockholders.

TABLE OF CONTENTS
PROPOSAL NO. 3

STOCKHOLDER PROPOSAL—ADVISORY VOTE ON EXECUTIVE COMPENSATION

        The Comptroller of the City of New York, custodian and trustee of the New York City Employees' Retirement System and the New York City Teachers' Retirement System, which collectively own approximately 1,131,141 shares of Common Stock (based on information provided to us by the Comptroller of the City of New York), has notified the Company that it intends to present the following proposal at the Annual Meeting:

Supporting Statement

        Investors are increasingly concerned about mushrooming executive compensation especially when it is insufficiently linked to performance. In 2008, shareholders filed close to 100 "Say on Pay" resolutions. Votes on these resolutions have averaged 43% in favor, with ten votes over 50%, demonstrating strong shareholder support for this reform.

        An Advisory Vote establishes an annual referendum process for shareholders about senior executive compensation. We believe the results of this vote would provide the board and management with useful information about shareholder views on the company's senior executive compensation.

        In its 2008 proxy Aflac submitted an Advisory Vote resulting in a 93% vote in favor, indicating strong investor support for good disclosure and a reasonable compensation package. Daniel Amos, Chairman and CEO said, "An advisory vote on our compensation report is a helpful avenue for our shareholders to provide feedback on our pay-for-performance compensation philosophy and pay package."

        To date eight other companies have also agreed to an Advisory Vote, including Verizon, MBIA, H&R Block, Blockbuster, and Tech Data. TIAA-CREF, the country's largest pension fund, has successfully utilized the Advisory Vote twice.


Table of Contents

        Influential proxy voting service RiskMetrics Group recommends votes in favor, noting: "RiskMetrics encourages companies to allow shareholders to express their opinions of executive compensation practices by establishing an annual referendum process. An advisory vote on executive compensation is another step forward in enhancing board accountability."

        The Council of Institutional Investors has endorsed advisory votes and a bill to allow annual advisory votes passed the House of Representatives by a 2-to-1 margin. As presidential candidates, Senators Obama and McCain supported the Advisory Vote.

        We believe that existing U.S. Securities and Exchange Commission rules and stock exchange listing standards do not provide shareholders with sufficient mechanisms for providing input to boards on senior executive compensation. In contrast, in the Untied Kingdom, public companies allow shareholders to cast a vote on the "directors' remuneration report," which discloses executive compensation. Such a vote isn't binding, but gives shareholders a clear voice that could help shape senior executive compensation.

        We believe that a company that has a clearly explained compensation philosophy and metrics, reasonably links pay to performance, and communicates effectively to investors would find a management sponsored Advisory Vote a helpful tool.

        We urge our board to allow shareholders to express their opinion about senior executive compensation through an Advisory Vote.

THE BOARD OF DIRECTORS' STATEMENT IN OPPOSITION

THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE "AGAINST" THIS
PROPOSAL TO ADOPT AN ADVISORY VOTE ON EXECUTIVE COMPENSATION FOR
THE FOLLOWING REASONS:

        The Board has given careful consideration to this proposal and has concluded for the reasons described below that the adoption of this resolution is unnecessary and is not in the best interests of Rite Aid and its stockholders.

        The Board recognizes the importance of executive compensation to the overall long-term performance of Rite Aid. Rite Aid's compensation philosophy is to pay for performance that supports Rite Aid's business strategies and to pay competitively. In the "Compensation Discussion & Analysis" ("CD&A") section of this proxy statement, Rite Aid provides stockholders with a detailed and thorough description of the Company's compensation program, including the philosophy and strategy underpinning the program, the individual elements of the compensation program and how Rite Aid's compensation plans are administered. Rite Aid's compensation programs contain consistent elements designed to reward achievement of the Company's long-term objectives.

        Rite Aid's Compensation Committee, composed entirely of independent directors, is responsible for reviewing and approving the compensation of Rite Aid's chief executive officer and reviewing and recommending to the Board other senior officers' compensation levels. The Compensation Committee considers a variety of information to determine the appropriate level of competitive and equitable executive pay. By their very nature, compensation decisions require a knowledge of executive performance and confidential and sensitive strategic and operational information; expertise regarding competitive conditions and compensation practices and a familiarity with other confidential and proprietary information unavailable to stockholders.

        Some of the information could not be made available to stockholders without also providing proprietary competitive data to the Company's competitors. As proposed, stockholders would be asked to endorse or reject compensation decisions without complete information, or alternatively, the Company would have to disclose competitive information in a public document in order for stockholders to make an informed vote.


Table of Contents

        In addition, the Compensation Committee retains an independent outside executive compensation consultant to conduct pay for performance reviews, which are performed annually after the end of the fiscal year using peer group data to benchmark Rite Aid's compensation programs and performance. While the Compensation Committee is able to use this information to timely evaluate and make recommendations regarding executive pay for the relevant performance period, an advisory stockholder vote would take place approximately four (4) months after the relevant performance period has ended. Therefore, an advisory vote is likely to be more reflective of current market conditions, rather than a consideration of the compensation awarded or recommended by the Compensation Committee for the relevant performance period that was based on information and analysis available to the Compensation Committee at the time.

        Even if the proposal were adopted, the result of the requested advisory vote cannot be expected to provide the Company with meaningful results. If stockholders do not ratify compensation decisions, the Company will understand that stockholders are dissatisfied. However, the source of the stockholder dissatisfaction will not necessarily be clear, much less the action that should be taken to address their concerns.

        The proposal states that the United Kingdom allows an advisory vote on executive compensation. The Board believes that comparing U.S. compensation practices to those in the United Kingdom is inappropriate. Because an advisory stockholder vote on executive compensation is mandatory for all public United Kingdom companies, no one United Kingdom company is competitively disadvantaged by this requirement. Rite Aid, on the other hand, could find it more difficult to recruit and retain executive talent if it became one of the small number of U.S. companies to adopt an advisory vote, as the practice could lead to a perception that compensation opportunities at Rite Aid may be limited or negatively affected compared to opportunities at other companies that have not adopted this practice. Moreover, we have found no evidence of increased investor satisfaction with United Kingdom pay practices and we are not aware of any company in Rite Aid's peer group (as identified in the CD&A) that has adopted this practice.

        The Board believes that the Compensation Committee is in the best position to consider the extensive information and factors necessary to make independent, objective and competitive compensation recommendations and decisions that are in the best interest of Rite Aid and its stockholders. The Compensation Committee should have flexibility in making the appropriate compensation recommendations and decisions so that Rite Aid can motivate and competitively compensate Rite Aid executives in alignment with Rite Aid's performance. The Board appreciates that stockholders are a crucial stakeholder whose views must be heard and valued. Stockholders who wish to express their opinion on the Company's executive compensation strategy or any other matter are encouraged to do so in writing to the Board pursuant to the process described in the "Communications with the Board of Directors" section of this proxy statement. The Board believes that this approach facilitates a sharing of stockholder views and is ultimately more meaningful and useful to the Board than a non-binding advisory vote that is based on incomplete information.

RECOMMENDATION

FOR THE REASONS STATED ABOVE, THE BOARD OF DIRECTORS UNANIMOUSLY
RECOMMENDS THAT YOU VOTE "AGAINST" THIS STOCKHOLDER PROPOSAL.


PROPOSAL NO. 4

RATIFICATION OF THE APPOINTMENT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM

[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
PROPOSAL 2—RATIFICATION OF THE
APPOINTMENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM
The accounting firm of Deloitte & Touche LLP ("(“Deloitte & Touche"Touche”) has been selected as the independent registered public accounting firm for the Company for the fiscal year ending February 27,


Table of Contents


2010.March 2, 2024. Deloitte & Touche has audited the accounts and records of Rite Aid and its subsidiaries since 2000. Although the selection of accounting firms does not require ratification, the Board of Directors has directed that the appointment of Deloitte & Touche be submitted to the stockholders for ratification due to the significance of their appointment by the Company. If the stockholders do not ratify the appointment of Deloitte & Touche, the Board of DirectorsAudit Committee will consider the appointment of another independent registered public accounting firm. A representative of Deloitte & Touche will be present at the Annual Meeting, and will have the opportunity to make a statement, and will be available to respond to appropriate questions.

RECOMMENDATION

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE "FOR"
THE RATIFICATION OF DELOITTE & TOUCHE LLP AS THE COMPANY'S
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL YEAR 2010


EXECUTIVE OFFICERS

        Officers are appointed annually by the Board of Directors and serve at the discretion of the Board of Directors. Set forth below is information regarding the current executive officers of Rite Aid.

[MISSING IMAGE: ic_chksquare-pn.gif]
Name
AgePosition with Rite Aid

Mary F. Sammons(1)

The Board of Directors unanimously recommends that you vote FOR the ratification of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year 2024.
62

Chairman and Chief Executive Officer

John T. Standley(2)

46

President and Chief Operating Officer

Frank G. Vitrano

53

Senior Executive Vice President, Chief Financial Officer and Chief Administrative Officer

Kenneth A. Martindale

49

Senior Executive Vice President, Chief Merchandising, Marketing & Logistics Officer

Brian R. Fiala

48

Executive Vice President, Store Operations

Marc A. Strassler

61

Executive Vice President, General Counsel and Secretary

Douglas E. Donley

46

Senior Vice President, Chief Accounting Officer

AUDITOR FEES

(1)
Ms. Sammons' biographical information is provided above
As outlined in the section identifyingtable below, we incurred the Board of Directors.

(2)
Mr. Standley's biographical information is provided above in the section identifying the Board of Directors.

        Frank G. Vitrano.    Mr. Vitrano was appointed Senior Executive Vice President, Chief Financial Officer and Chief Administrative Officer in September 2008. He was a self-employed private investor from January 2008 to September 2008. Previously, Mr. Vitrano spent 35 years at Pathmark Stores, Inc., where most recently he served as President, Chief Financial Officer and Treasurer from October 2002 through December 2007. Prior to serving as President, Chief Financial Officer and Treasurer, Mr. Vitrano served in a variety of positions at Pathmark. Mr. Vitrano was a Director of Pathmark Stores, Inc. from 2000 to 2005.

        Kenneth A. Martindale.    Mr. Martindale was appointed Senior Executive Vice President, Chief Merchandising, Marketing and Logistics Officer in December 2008. He was a self-employed private investor from January 2008 to December 2008. Previously, Mr. Martindale served as Co-President, Chief Merchandising and Marketing Officer for Pathmark Stores, Inc. from January 2006 until December 2007. In January 2000, Mr. Martindale joined the Board of Directors of Intesource, Inc.; became Chairman of the Board in March 2004; and served as President, Chief Executive Officer and Chairman of the Board from November 2004 until January 2006. From September 1999 until


Table of Contents


November 2004, Mr. Martindale was Principal of Martindale Development Group, L.L.C. In September 1999 until July 2003, Mr. Martindale was Managing Director/CEO of Orchard Street, Inc., a privately held specialty food retailer which he founded and owned. Mr. Martindale was Executive Vice President of Sales and Procurement with Fred Meyer, Inc. from January 1998 until September 1999 and was Senior Vice President of Sales and Procurement with Smith's Food & Drug Centers, Inc. in June 1996 until January 1998.

        Brian R. Fiala.    Mr. Fiala was appointed Executive Vice President of Store Operations in June 2007. He was a self employed private investor from July 2006 to June 2007. Previously, Mr. Fiala spent 24 years with Target Corporation, where most recently he served as Senior Vice President on the East Coast until July 2006. Mr. Fiala joined Target in 1983 as a management trainee, was promoted into various positionsfollowing fees, including Store Team Leader, Regional Merchandise Manager, District Team Leader, and Regional Director. In 1998, Mr. Fiala was named Regional Vice President for the Northeast and in 2001 was promoted to Senior Vice President of Target.

        Marc A. Strassler.    Mr. Strassler was appointed Executive Vice President, General Counsel and Secretary in March 2009. From January 2008 until March 2009, Mr. Strassler was a self-employed private investor. Previously, Mr. Strassler served as Senior Vice President, General Counsel and Corporate Secretary with Pathmark Stores, Inc. from 1997 until its acquisition by the Great Atlantic & Pacific Tea Company in December 2007. From 1987 until 1997, he served as Vice President, General Counsel and Secretary of Pathmark. From 1974 until 1987, Mr. Strassler served in a variety of legal positions at Pathmark.

        Douglas E. Donley.    Mr. Donley was appointed Senior Vice President, Chief Accounting Officer in October 2005. He had been Group Vice President, Corporate Controller from 1999 to October 2005. Mr. Donley served as the acting principal financial officer of the Company from October 7 to October 8, 2008, and as a financial analyst for the Company from 1996 to 1999. He was an internal auditor for Harsco Corporation from 1994 to 1996. Prior to joining Harsco, he was an auditor for KPMG Peat Marwick. In March 2007, pursuant to a plea agreement, Mr. Donley pled guilty to state misdemeanor offenses related to driving under the influence. Mr. Donley has subsequently satisfied all terms of the plea agreement. The Company believes that this matter does not adversely affect Mr. Donley's fitness to serve as an officer.


EXECUTIVE COMPENSATION

COMPENSATION DISCUSSION AND ANALYSIS

Introduction

        Rite Aid Corporation is the third largest retail drugstore chain in the United States based on revenues and number of stores, operating approximately 4,900 stores in 31 states and the District of Columbia. A primary component of the Company's human resource strategy is to attract, motivate and retain highly talented individuals at all levels of the organization who are committedexpenses billed to the Company's core values of excellence, integrity and respect for people and have the ability to execute the Company's strategic and operational priorities.

Objectives of Executive Compensation

        All executive compensation and benefits programs are within the purview of the Compensation Committee, which bases these programs on the same objectives that guide the Company in establishing all of its compensation programs, outlined below. The Compensation Committee also administers the Company's equity incentive compensation plans. In establishing or approving the compensation of our Chief Executive Officer and the other executive officers named in the Summary Compensation Table


Table of Contents


(the "Named Executive Officers") in any given year, the Compensation Committee is generally guided by the following objectives:

            Compensation should be based on the level of job responsibility, individual performance, and company performance, and should foster the long-term focus required for success in the retail drugstore industry. As associates progress to higher levels in the organization, an increasing proportion of their pay should be linked to company performance and shareholder returns and to longer-term performance because they are in a position to have greater influence on longer-term results.

            Compensation should reflect the value of the job in the marketplace. To attract and retain a highly skilled, diverse work force, we must remain competitive with the pay of other employers who compete with us for talent.

            Compensation should reward performance. Our programs should deliver compensation in relationship to company performance. Where company performance falls short of expectations, the programs should deliver lower-tier compensation. In addition, the objectives of pay-for-performance and retention must be balanced. Even in periods of temporary downturns in company performance, the programs should continue to ensure that successful, high-achieving employees will remain motivated and committed to the Company to support the stability and future needs of the Company.

            To be effective, performance-based compensation programs should enable associates to easily understand how their efforts can affect their pay, both directly through individual performance accomplishments and indirectly through contributing to the Company's achievement of its strategic and operational goals.

            Compensation and benefit programs should be set across consistent measures and goals at all levels of the organization. While the programs and individual pay levels will always reflect differences in job responsibilities, geographies, and marketplace considerations, the overall structure of compensation and benefit programs should be broadly similar across the organization.

            Compensation and benefit programs should attract associates who are interested in a career at Rite Aid.

The Committee's Processes

        The Compensation Committee has established a number of processes to assist it in ensuring that the Company's executive compensation program is achieving its objectives. Among those are:

            Assessment of Company performance.    The Compensation Committee uses company performance measures in two ways. First, in establishing total compensation ranges, the Compensation Committee considers various measures of Company and industry performance, including, but not limited to, comparable store sales growth, Adjusted EBITDA (earnings before interest, taxes, depreciation, amortization and certain other adjustments), earnings growth, return on sales, return on average invested capital and assets and total shareholder return. In determining relative performance to the Company's peer group, the Compensation Committee does not apply a formula or assign these performance measures relative weights. Instead, it makes a subjective determination after considering such measures collectively. Second, as described in more detail below, the Compensation Committee has established specific Company target incentive/award levels and performance measures that determine the size of payouts under the Company's two formula-based incentive programs—the cash incentive bonus program and the long-term incentive program.


Table of Contents

            Assessment of individual performance.    Individual performance has a strong impact on the compensation of all employees, including the CEO and the other executive officers. With respect to the CEO, the independent directors meet with the CEO in executive session annually at the beginning of the year to agree upon the CEO's performance objectives (both individual and Company objectives) for the year. At the end of the year, the independent directors meet in executive session to conduct a performance review of the CEO based on his or her achievement of the agreed-upon objectives, contribution to the Company's performance, and other leadership accomplishments. This evaluation is shared with the CEO and is provided to the Compensation Committee for its consideration in setting the CEO's compensation.

            For the other Named Executive Officers, the Compensation Committee receives a performance assessment and compensation recommendation from the CEO and also exercises its judgment based on the Board of Directors' interactions with the executive officer. As with the CEO, the performance evaluation of these executives is based on achievement of pre-agreed objectives by the executive and his or her organization, his or her contribution to the Company's performance, and other leadership accomplishments.

            Benchmarking.    The Compensation Committee benchmarks the Company's programs with a peer group of retail organizations via external survey and compensation recommendations from Mercer Human Resources Consulting, a qualified, independent compensation consultant that reports its findings directly to the Compensation Committee. The independent compensation consultant is retained by the Compensation Committee to select the peer group of companies and conduct a market assessment of all components of executive compensation For the Company's 2009 fiscal year, this peer group consisted of the following companies: BJ's Wholesale; Costco; CVS/Caremark; Family Dollar Stores; Great Atlantic & Pacific Tea Co.; Home Depot; Longs Drug Store; Lowe's Companies; Safeway, Inc.; Target Corp. and Walgreen Co. The peer group companies that were selected fall within a similar revenue range and industry as Rite Aid. The Compensation Committee compares the peer group companies' executive compensation programs as a whole, and also compares the pay of individual executives if the jobs are sufficiently similar to make the comparison meaningful. The Compensation Committee uses the peer group data primarily to ensure that the executive compensation program as a whole is competitive, meaning generally within the broad middle range of comparative pay of the peer group companies when the Company achieves the targeted performance levels. The independent compensation consultant assessed Rite Aid's performance relative to its peer group and observed alignment of performance with actual total direct compensation levels.

            Total compensation review.    The Compensation Committee reviews each executive's base pay, bonus, long-term incentives and retirement benefits annually with the guidance of the Compensation Committee's independent consultant. Following the fiscal year 2009 review, the Compensation Committee determined that these elements of compensation were reasonable in the aggregate.

Components of Executive Compensation for Fiscal Year 2009

        For fiscal year 2009, the compensation of executives consisted of four primary components—base salary, a cash incentive bonus award under the Company's annual incentive bonus plan, long-term incentives consisting of stock options, restricted stock and performance units and a benefits package. The Compensation Committee believes that this program balances both the mix of cash and equity compensation, the mix of currently-paid and longer-term compensation, and the security of base benefits in a way that furthers the compensation objectives discussed above. Following is a discussion of the Compensation Committee's considerations in establishing each of the components for the executive officers.


Table of Contents

Base Salary

        Base salary is one element of an executive's annual cash compensation during employment. The value of base salary reflects the employee's long-term performance, skill set and the market value of that skill set. In setting base salaries for fiscal year 2009, the Compensation Committee considered the following factors:

            The median of comparable companies.    The Compensation Committee generally attempts to provide base compensation approximating the median of the selected group of peer companies listed above. In April 2008, the Compensation Committee reviewed the base salaries of the Named Executive Officers relative to the peer companies and approved minimal adjustments to the base salaries of certain of the Named Executive Officers as set forth below.

    Internal relativity, meaning the relative pay differences for different job levels.

            Individual performance.    Except for increases associated with promotions or increased responsibility, increases in base salary for executives from year to year are generally limited to minimal adjustments to reflect individual performance.

    Peer group data specific to the executive's position, where applicable. As noted above, we used the peer group data to test for reasonableness and competitiveness of base salaries, but we also exercised subjective judgment in view of our compensation objectives.

            Consideration of the mix of overall compensation.    Consistent with our compensation objectives, as executives progress to higher levels in the organization, a greater proportion of overall compensation is directly linked to company performance and stockholder returns. Thus, for example, Ms. Sammons' overall compensation is more heavily weighted toward incentive compensation and equity compensation than that of the other executive officers.

            In establishing Ms. Sammons' base salary for fiscal year 2009, the Compensation Committee applied the principles described above under "The Committee's Processes." In an executive session including all independent directors, the Compensation Committee assessed Ms. Sammons' fiscal year 2008 performance. They considered the Company's and Ms. Sammons' accomplishment of objectives that had been established at the beginning of the year and its own subjective assessment of her performance. They noted that under Ms. Sammons' leadership, in fiscal year 2008 the Company completed the acquisition of Brooks Eckerd, performed integration and conversion activities in the acquired stores, improved customer satisfaction and continued to develop and execute its strategic plan to deliver long-term shareholder value. In recognition of her continued strong leadership in fiscal year 2008, the Compensation Committee set Ms. Sammons' base salary for fiscal year 2009 at $1,000,000, the same level that it was for fiscal years 2004 through 2008.

            The Compensation Committee reviewed similar considerations for each of the other Named Executive Officers and approved increases based upon a subjective assessment of their respective performance. The Compensation Committee approved Mr. Standley's annual salary upon his appointment as President and Chief Operating Officer in September 2008 and Mr. Vitrano's annual salary upon his appointment as Senior Executive Vice President, Chief Financial Officer and Chief Administrative Officer in September 2008. The Compensation Committee increased the annual salary for Mr. Twomey by three percent for fiscal year 2009 in consideration for his performance as Executive Vice President, Chief Financial Officer. Mr. Twomey subsequently left the Company in September 2008. The Compensation Committee did not increase the annual salary for fiscal year 2009 for Mr. Legault as Chief Administrative Officer, who left the Company in September 2008. The Compensation Committee increased the annual salary for Mr. Easley by five percent for fiscal year 2009 in consideration for his performance as Chief Operating Officer. Mr. Easley subsequently left the Company in September 2008. The Compensation Committee


Table of Contents


    increased Mr. Donley's annual salary by four percent in fiscal year 2009 based upon his performance as Senior Vice President, Chief Accounting Officer. The Compensation Committee increased Mr. Fiala's annual salary by four percent in fiscal year 2009 based upon his performance as Executive Vice President, Store Operations. The Compensation Committee increased Mr. Sari's annual salary by four percent in fiscal year 2009 based upon his performance as Executive Vice President, General Counsel. Mr. Sari subsequently left the Company on April 8, 2009.

Cash Incentive Bonuses

        The Company has established an annual incentive bonus plan in order to incentivize associates to meet the Company's Adjusted EBITDA and customer satisfaction targets for fiscal year 2009. Named Executive Officers, other executive officers and key managers of the Company participate in this cash bonus plan. The bonuses paid for fiscal year 2009 appear in the Summary Compensation Table under the "Non-Equity Incentive Plan Compensation" column. Under the plan, bonus target amounts, expressed as a percentage of base salary, are established for participants at the beginning of each fiscal year. Bonus payouts for the year are then determined by the Company's financial and customer satisfaction results for the year relative to predetermined performance measures. The Compensation Committee considered the following when establishing the awards for fiscal year 2009:

            Bonus targets.    Bonus targets as a percentage of base salary for each individual were based on job responsibilities, internal relativity, and peer group data. Our objective was to set bonus targets such that total annual cash compensation was within the broad middle range of peer group companies and a substantial portion of that compensation was linked to company performance. Consistent with our executive compensation policy, individuals with greater job responsibilities had a greater proportion of their total cash compensation tied to company performance through the bonus plan. Thus, the Compensation Committee established the following bonus targets for fiscal year 2009 (expressed as a percentage of base salary): Ms. Sammons, 200 percent; Mr. Standley, 125 percent; Mr. Vitrano, 110 percent; Mr. Martindale, 100 percent; Messrs. Fiala and Sari, 60 percent; and Mr. Donley, 50 percent.

            Company performance measures.    For all participants in the annual incentive bonus plan, including the Named Executive Officers, the Compensation Committee established fiscal year 2009 company performance measures between the minimum ($1,005 million) and the maximum ($1,105 million) Adjusted EBITDA targets and the minimum (71%) and maximum (80%) of overall customer satisfaction survey targets. The measures were determined in April 2008, near the beginning of the fiscal year. The Compensation Committee believes that this mix of performance measures encourages associates to focus appropriately on improving both operating results and customer service. The measures are also effective motivators because they are easy to track and clearly understood by associates. Under the plan formula, payouts can range from zero to 200 percent of bonus targets depending on company performance. In establishing the performance target for Adjusted EBITDA and customer satisfaction, the Compensation Committee considered the expected fiscal year 2009 performance of these measures. Although no earnings bonuses were paid in fiscal year 2009, a bonus for improvement in customer satisfaction (calculated based upon achievement of 98.7% of the customer satisfaction survey targets, which equates to a bonus payout equal to 17.2% of the fiscal year 2009 bonus target), was paid to field management and corporate personnel, including the Named Executive Officers, except for Ms. Sammons who declined her bonus in the amount of $344,000 for fiscal year 2009.

Long-Term Incentive Program

        In fiscal year 2009, we employed three forms of long term incentives: performance awards, stock options and restricted stock. For the executive officers, performance awards comprised 60 percent, stock option grants comprised 25 percent, and restricted stock comprised 15 percent of the total


Table of Contents


long-term incentive level established by the Compensation Committee. These incentives foster the long-term perspective necessary for continued success in our business. They also ensure that our leaders are properly focused on shareholder value. Stock options and restricted stock have traditionally been granted broadly and deeply within the organization, with approximately 1,500 management and field associates now participating in our long-term incentive program. In determining the value of grants for executives, the Compensation Committee's overall objective was to set combined grant values of stock options, restricted stock and performance awards that were competitive within the broad middle range of peer company long-term incentive grant amounts. The Compensation Committee's process for setting grant dates is discussed below. Then, on the grant date those values are converted to the equivalent number of shares based on the closing price of the Company's common stock on the date of grant for restricted shares and performance units, and using the Black-Scholes valuation method for stock options.

            Grant timing and price.    The Compensation Committee's procedure for timing of these grants (performance awards, restricted stock and stock options) provides assurance that grant timing is not being manipulated to result in a price that is favorable to associates. The annual grant date is typically in late June, however, for fiscal year 2009 the grant date for all eligible employees including the Named Executive Officers (approximately 1,500 associates) was changed to early October so that the long-term incentive program could be redesigned to provide for a closer pay for performance alignment, especially for the Named Executive Officers. The Compensation Committee plans to return to a late June grant timing for fiscal year 2010.

        For fiscal year 2009, the Compensation Committee decided that total grant values should remain unchanged from the prior fiscal year for each eligible position, having determined that there is appropriate alignment with long-term incentive target levels. In making this determination, the Compensation Committee reviewed available peer group data and found that the design of the long-term incentive program is reasonably aligned with those of the general retail industry market practice. Grant values for individual executive officers were determined by individual performance and internal relativity. Consistent with the Company's compensation philosophy, executive officers at higher levels received a greater proportion of total pay in the form of long-term incentives.

    Performance Awards

        Performance awards provide the Named Executive Officers and other executives with units, payable in cash if the designated Company performance goals are achieved, aligning interests of executives with those of shareholders. The awards, normally granted annually, are structured as a targeted number of units based on the Company's achievement of specific Adjusted EBITDA levels over a three-year period. The Company granted performance awards for fiscal year 2009 to the Named Executive Officers with possible payouts ranging from zero to 200 percent of the target number of units, depending on Adjusted EBITDA as compared to the target, set annually, for fiscal years 2009, 2010 and 2011. The Adjusted EBITDA target for fiscal 2009 was set at $1,005 million. The awards are paid in cash at the end of the three-year performance period.

        The Compensation Committee approved the terms of the fiscal year 2009 performance awards in October 2008, and took into consideration the following:

            Target grant size.    As noted above under "Long-Term Incentive Program," performance awards were 60 percent of the total grant values established by the Compensation Committee. The Compensation Committee decided that total grant values should remain unchanged from fiscal year 2008, but the percentage representing long-term performance-based awards should be increased to 60% of such total.


Table of Contents

            Company performance measure.    As in previous years, the Compensation Committee established the performance measure as Adjusted EBITDA for each fiscal year over a three-year period. The Compensation Committee believes Adjusted EBITDA is an effective motivator because it is closely linked to shareholder value and has the greater ability to be impacted by the executives. In setting the target Adjusted EBITDA for fiscal year 2009, the Compensation Committee considered the expected earnings performance of the Company. Pursuant to the performance plan adopted on June 20, 2006 and based on the Company's attainment of 96% of the combined Adjusted EBITDA target for the 2007, 2008 and 2009 fiscal years, cash performance awards were made in the 2009 fiscal year to senior management, including the Named Executive Officers, except for Ms. Sammons who declined her award in the amount of $27,446 for fiscal year 2009. Mr. Sari received an award of $6,099 and Mr. Donley received an award of $3,344. The other Named Executive Officers were not eligible for this award since they were not employed by the Company for the entire performance cycle. The value of these awards for the eligible Named Executive Officers was based upon the number of performance units earned by each officer multiplied by the closing price of our common stock on April 1, 2009.

            Longer-term focus and retention considerations.    To enhance the performance awards' incentives for longer-term focus and retention, the awards to Named Executive Officers for fiscal year 2009 are payable in cash that is subject to forfeiture if the executive leaves the Company prior to February 2011 or such later date that Adjusted EBITDA performance for the period is determined, except by reason of death, disability, retirement, or by consent of the Compensation Committee.

    Stock Options

        Stock options align associate incentives with the interests of shareholders because options have value only if the stock price increases over time. The Company's ten-year options, granted at the market price on the date of grant, help focus employees on long-term growth. In addition, options are intended to help retain key associates because they vest over a four-year period, which also helps keep employees focused on long-term performance. The Company does not reprice options; likewise, if the stock price declines after the grant date, we do not replace options.

        The Compensation Committee considered the following in establishing the fiscal year 2009 option grants to executive officers:

            Grant size.    As noted above under "Equity Incentive Program," stock option grants comprised 25 percent of the total equity grant values (measured in accordance with SFAS No. 123R) established by the Compensation Committee. The total grant values were unchanged from fiscal year 2008, but the percentage representing stock options was decreased to 25% of such total.

    Restricted Stock

        Restricted stock grants are intended to help retain key associates because they generally vest over a three-year period, which also helps keep employees focused on long-term performance. Combined grants (restricted stock, performance awards and stock options) provide a better balance for executive officers between risk and potential reward as compared to a grant consisting solely of stock options.

        The Compensation Committee considered the following in establishing the fiscal year 2009 restricted stock grants to executive officers:

            Grant size.    As noted above under "Long-Term Incentive Program," restricted stock grants were 15 percent of the total equity grant values (measured in accordance with SFAS No. 123R) established by the Compensation Committee. The total grant values were unchanged from fiscal year 2008, but the percentage representing restricted stock was decreased to 15% of such total.


Table of Contents

Post-Retirement Benefits

        Supplemental Executive Retirement Plans.    The Company has established retirement plans for its executive officers, including the Named Executive Officers, to provide a predetermined benefit upon retirement. Ms. Sammons and Mr. Miller receive benefits under a defined contribution supplemental retirement plan (the "SERP"). Each month, $20,000 is credited for investment for each of Ms. Sammons and Mr. Miller, respectively. Under the SERP, the participants are able to direct the deemed investment of the amounts by selecting one or more investment vehicles from a group of deemed investments offered pursuant to the plan. These deemed investments are made each month during the term of the participants' service with Rite Aid. Each of Ms. Sammons and Mr. Miller is fully vested at all times in their accounts under the SERP and will receive their vested account balance (or payment in installments in such election was made) upon the earlier to occur of: (i) termination of employment (or service as a director in the case of Mr. Miller) with the Company, including due to death or disability; and (ii) a hardship withdrawal pursuant to the terms of the SERP.

        Messrs. Standley, Vitrano, Fiala, Sari, Donley, Easley, Legault and Twomey receive benefits under a defined contribution supplemental executive retirement plan ("Supplemental Plan"), which is different from the plan maintained for Ms. Sammons and Mr. Miller noted above. Under the Supplemental Plan, Rite Aid credits a specific sum to an individual account established for Messrs. Standley, Easley, Vitrano, Legault, Twomey, Fiala, Sari and Donley and other participating executive officers, on a monthly basis while such officer is employed. The amount credited is equal to 2% of the executive officer's annual base compensation, up to a maximum of $15,000 per month. The participants are able to select among a choice of earnings indexes, and their accounts are credited with earnings which mirror the investment results of such indexes. Annually Rite Aid makes investments for all participants in the Supplemental Plan. Participants vest in their accounts at the rate of 20% per year for each full year of participation in the Supplemental Plan at a five-year rolling rate, provided that the entire account balance for each participant shall vest upon a "change in control" of the Company, as defined in the Supplemental Plan, only if such participant is involuntarily terminated without cause within twelve months of the change in control. Participants will receive their vested account balance upon the earliest to occur of: (i) their retirement at age 60 or greater, with at least five years of participation in the Plan; (ii) termination of employment with the Company (including due to death or disability); and (iii) a hardship withdrawal pursuant to the terms of the Supplemental Plan.

Other Post-Employment and Change in Control Benefits

        To attract and retain highly skilled executives and to provide for certainty of rights and obligations, Rite Aid has historically provided employment agreements to its executive officers and certain other key employees. On December 5, 1999, Rite Aid entered into an employment agreement with Ms. Sammons, which was subsequently amended on May 7, 2001, September 30, 2003, October 11, 2006, September 24 2008 and December 30, 2008. On September 24, 2008, Rite Aid entered into an employment agreement with Mr. Standley; on September 24, 2008, Rite Aid entered into an employment agreement with Mr. Vitrano; on June 26, 2007, Rite Aid entered into an employment agreement with Mr. Fiala, which was subsequently amended on December 18, 2008; on February 28, 2001, Rite Aid entered into an employment agreement with Mr. Sari, which was subsequently amended on December 18, 2008; on August 1, 2000, Rite Aid entered into an employment agreement with Mr. Donley, which was subsequently amended on December 18, 2008; on August 20, 2007, Rite Aid entered into an employment agreement with Mr. Easley; on February 2, 2007, Rite Aid entered into an employment agreement, effective as of June 4, 2007, with Mr. Legault; on September 1, 2003, Rite Aid entered into an employment agreement with Mr. Twomey. The terms of the employment agreements are described in more detail under the caption "Executive Employment Agreements." Under Ms. Sammons's employment agreement, any termination of employment by Ms. Sammons within the six month period commencing on the date of a change in control of Rite Aid will be treated as a


Table of Contents


termination of employment by the Executive for "good reason," as defined in the agreement. Additional information regarding the severance and change in control benefits provided under the employment agreements is described under the caption "Potential Payments Upon Termination or Change in Control."

Deductibility Cap on Executive Compensation

        The Compensation Committee is aware that Section 162(m) of the Internal Revenue Code of 1986, as amended, treats certain elements of executive compensation in excess of $1,000,000 a year as an expense not deductible by the Company for federal income tax purposes. Payments in excess of the $1,000,000 limit will be deductible if they meet the definition of "performance-based compensation" as defined in Section 162(m). However, certain payments made to the Named Executive Officers will not qualify as performance-based compensation under Section 162(m). The Compensation Committee reserves the right to pay compensation that may be non-deductible to the Company if it determines that it would be in the best interests of the Company.

Changes to Executive Compensation for Fiscal Year 2010

        For fiscal year 2010 (commencing March 1, 2009), base salary for the Named Executive Officers and other executive officers of the Company will remain unchanged from fiscal year 2009. Although the executives performed well on an individual basis, the focus will continue on the potential value that these executives might gain through the performance-based cash incentive bonus and the long-term incentive program. The Compensation Committee supports this salary freeze, which increases the alignment of compensation with Company performance and the objectives of our stockholders.

        The performance measures for the cash incentive bonus opportunity for the Named Executive Officers and other executive officers of the Company for fiscal year 2010 will be based solely on the attainment of Adjusted EBITDA thresholds and will not contain a customer satisfaction component or target. Although improvements in customer satisfaction continue to be a focus of the Company, this change more closely aligns compensation with the Company's financial performance goals.


COMPENSATION COMMITTEE REPORT

        The Compensation Committee of the Board of Directors has reviewed and discussed the foregoing Compensation Discussion and Analysis with management and, based on that review and discussion, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this proxy statement.

    George G. Golleher, Chairman (fiscal year 2009)
    James L. Donald
    Michael A. Friedman, MD
    Dennis Wood


Table of Contents


SUMMARY COMPENSATION TABLE

        The following summary compensation table sets forth the cash and non-cash compensation for the fiscal years ended March 4, 2023 and February 28, 2009, March 1, 200826, 2022 by our independent registered public accounting firm, Deloitte & Touche LLP, the member firms of Deloitte Touche Tohmatsu and March 3, 2007, respectively, paidtheir respective affiliates.

Year Ended
Fee CategoryMarch 4, 2023
($ millions)
February 26, 2022
($ millions)
Audit fees(1)2.22.3
Audit-related fees(2)0.2
Tax fees(3)
All other fees
Total fees2.22.5
(1)
Audit fees. Represents fees for audit of annual financial statements and reviews of interim financial statements, registration statement filings and comfort letters related to or earned by (i) our principal executive officer, (ii) all individuals serving as the principal financial officer during fiscal year 2009, and (iii) the other three most highly compensated executive officers of the Company (collectively, the "Named Executive Officers"), as well as two additional individuals for whom disclosure would have been required under the SEC's rules butvarious refinancing activities.
(2)
Audit-related fees. The fees for the fact that the individual was not serving as an executive officer of the Company at the end of our last completed fiscal year.

Name and
Principal Position
 Fiscal
Year
 Salary
($)
 Bonus
($)(1)
 Stock
Awards
($)(2)
 Option
Awards
($)(3)
 Non-Equity
Incentive
Plan
Compensation
($)(4)
 Change In
Nonqualified
Deferred
Compensation
Earnings
($)(5)
 All Other
Compensation
($)(6)
 Total
($)
 

Mary F. Sammons

  2009  1,000,000    582,494  597,695      356,207(7) 2,536,396 
 

(Chairman & CEO)

  2008  1,000,000  1,500,000  1,169,975  674,521  322,000  16,355  565,125(8) 5,247,976 
 

  2007  1,000,000    666,569  602,593  1,543,631  6,719  451,454(9) 4,270,966 

John T. Standley

  
2009
  
373,846

(10)
 
  
6,317
  
205,737
  
96,750
  
  
72,840

(11)
 
755,490
 
 

(President & COO)

                            

Frank G. Vitrano

  
2009
  
290,769

(12)
 
  
4,907
  
85,643
  
66,220
  
  
67,944

(13)
 
515,483
 
 

(Senior Executive VP, CAO & CFO)

                            

Brian R. Fiala

  
2009
  
457,261
  
  
125,354
  
209,160
  
47,224
  
  
74,637

(13)
 
913,636
 
 

(Executive VP, Store Operations)

                            

Robert B. Sari

  
2009
  
448,118
  
  
84,130
  
112,512
  
209,648
  
  
135,413

(14)
 
989,821
 
 

(Exec VP, GC)

  2008  415,694  424,800  167,177  121,121  40,186    182,280(15) 1,351,258 

Douglas E. Donley

  
2009
  
330,725
  
  
54,428
  
67,780
  
28,463
  
  
58,302

(16)
 
539,698
 
 

(Sr VP, Chief Accounting Officer)

                            

Robert J. Easley

  
2009
  
468,750

(17)
 
  
435,029
  
603,112
  
  
  
3,476,417

(18)
 
4,983,308
 
 

(Former COO)

                            

Pierre Legault

  
2009
  
447,115

(19)
 
  
698,900
  
900,662
  
  
  
3,180,332

(20)
 
5,227,009
 
 

(Former Executive

  2008  504,807  7,500  209,964  300,220  99,619    135,357(21) 1,257,467 
 

VP, Chief Admin. Officer)

                            

Kevin Twomey

  
2009
  
279,283

(22)
 
  
128,332
  
233,819
  
  
  
1,676,999

(23)
 
2,318,433
 
 

(Former Executive

  2008  454,936  436,578  184,872  128,365  43,978  44,868  152,676(24) 1,446,273 
 

VP & CFO)

  2007  437,505    109,769  97,288  270,290    147,328(25) 1,062,180 

(1)
Amounts consist of a special award paid in connection with the Brooks Eckerd Transaction and, for Mr. Legault, a signing bonus paid in connection with his commencement of employment with us in the 2008 fiscal year.

(2)
Represents the total expense recorded in the indicated fiscal year in accordance with SFAS No. 123R for outstanding stock awards, including restricted stock awards and performance share awards. For information regarding the assumptions used in determining the fair value of an award, please refer to Note 15 of the Company's Annual Report on Form 10-K as filed with the SEC on April [    ], 2009, April 29, 2008 or April 30, 2007, as applicable.

(3)
Represents the total expense recorded in the indicated fiscal year in accordance with SFAS No. 123R for outstanding stock option awards. For information regarding the assumptions used in determining the fair value of an award, please refer to Note 15 of the Company's Annual Report on Form 10-K as filed with the SEC on April [    ], 2009, April 29, 2008 or April 30, 2007, as applicable.

(4)
Consists of an annual cash incentive bonus for performance in the applicable fiscal year.

Table of Contents

(5)
Represents above-market earnings (over 120% of the "applicable federal rate" or "AFR") under the Company's defined contribution supplemental executive retirement plans.

(6)
With respect to personal use of aircraft as described in these footnotes to the Summary Compensation Table, the Company determines the incremental cost of an officer's aircraft usage by calculating the variable flight-hour cost associated with the particular aircraft. Variable cost in general includes fuel, landing fees, maintenance costs per flight, per hour and catering.

(7)
All Other Compensation for Ms. Sammons for fiscal 2009 includes $13,242 for Company match for 401(k) plan, $240,000 for Company contributions to a supplemental executive retirement plan, $87,265 for personal use of aircraft, $12,000 for car allowance and $3,700 for personal financial services.

(8)
All Other Compensation for Ms. Sammons for fiscal 2008 includes $9,086 for Company match for 401(k) plan, $240,000 for Company contributions to a supplemental executive retirement plan, $87,656 of earnings equal to 120% of the AFR of said plan, $207,733 for personal use of aircraft, $12,000 for car allowance and $8,650 for personal financial services.

(9)
All Other Compensation for Ms. Sammons for fiscal 2007 includes $240,000 for Company contributions to a supplemental executive retirement plan, $104,911 of earnings equal to 120% of AFR under said plan, $89,343 for personal use of aircraft, $12,000 car allowance, and $5,200 for personal financial planning services.

(10)
Salary for Mr. Standley for fiscal 2009 is for the period commencing September 24, 2008, the date on which Mr. Standley commenced employment with the Company, through the end of fiscal 2009.

(11)
All Other Compensation for Mr. Standley for fiscal 2009 includes $21,000 for Company contributions to a supplemental executive retirement plan, $9,535 for Company matching contributions to our 401(k) plan, $19,920 for personal use of aircraft, $5,000 for car allowance, and $17,385 for personal financial planning services.

(12)
Salary for Mr. Vitrano for fiscal 2009 is for the period commencing September 24, 2008, the date on which Mr. Vitrano commenced employment with the Company, through the end of fiscal 2009.

(13)
All Other Compensation for Mr. Vitrano for fiscal 2009 includes $19,600 for Company contributions to a supplemental executive retirement plan, $5,000 for car allowance, and $14,731 for personal financial planning services, and $28,613 for other employer paid benefits.

(13)
All Other Compensation for Mr. Fiala for fiscal 2009 includes $43,648 for Company contributions to a supplemental executive retirement plan, $476 of earnings equal to 120% of the AFR of said plan, $18,513 for personal use of aircraft and $12,000 for car allowance.

(14)
All Other Compensation for Mr. Sari for fiscal 2009 includes $42,676 for Company contributions to a supplemental executive retirement plan, $6,437 of earnings equal to 120% of the AFR of said plan , $15,720 for Company matching contributions to our 401(k) plan, $58,015 for personal use of aircraft, $12,000 for car allowance, $565 for personal financial planning services.

(15)
All Other Compensation for Mr. Sari for fiscal 2008 includes $99,200 for Company contributions to a supplemental executive retirement plan, $9,714 for Company matching contributions to our 401(k) plan, $60,734 for personal use of aircraft, a $12,000 car allowance, $485 for personal financial planning services and $147 in other employer paid benefits.

(16)
All Other Compensation for Mr. Donley for fiscal 2009 includes $14,732 for Company matching contributions to our 401(k) plan, $31,569 for Company contributions to a supplemental executive retirement plan, and $12,000 for car allowance.

(17)
Salary for Mr. Easley for fiscal 2009 is for the period commencing at the beginning of fiscal 2009 and ending on September 24, 2008, the date on which Mr. Easley ceased to be employed by the Company.

(18)
All Other Compensation for Mr. Easley for fiscal 2009 includes $3,307,500 for severance pursuant to his employment agreement, $60,577 for vacation earned prior to termination, $90,762 for personal use of aircraft, $22,578 for other employer paid benefits and $7,000 for car allowance. Also included in All Other Compensation is the forfeiture of $12,000 of Company contributions to a supplemental executive retirement plan, which was recorded as a decrease in compensation.

(19)
Salary for Mr. Legault for fiscal 2009 is for the period commencing at the beginning of fiscal 2009 and ending on September 24, 2008, the date on which Mr. Legault ceased to be employed by the Company.

(20)
All Other Compensation for Mr. Legault for fiscal 2009 includes $3,150,000 for severance pursuant to his employment agreement, $12,981 for vacation earned prior to termination, $12,351 for Company matching contributions to our 401(k) plan, $10,000 for personal financial planning services, and $7,000 for car allowance. Also included in All Other Compensation is the forfeiture of $12,000 of Company contributions to a supplemental executive retirement plan, which was recorded as a decrease to compensation.

Table of Contents

(21)
All Other Compensation for Mr. Legault for fiscal 2008 includes $120,000 for Company contributions to a supplemental executive retirement plan, $4,963 for Company matching contributions to our 401(k) plan, a $7,711 car allowance and $2,683 in other employer paid benefits.

(22)
Salary for Mr. Twomey for fiscal 2009 is for the period commencing at the beginning of fiscal 2009 and ending on September 24, 2008, the date on which Mr. Twomey ceased to be employed by the Company.

(23)
All Other Compensation for Mr. Twomey for fiscal 2009 includes $1,641,212 for severance pursuant to his employment agreement, $36,071 for vacation earned prior to termination, and $7,000 for car allowance. Also included in All Other Compensation is the forfeiture of $7,284 of Company contributions to a supplemental executive retirement plan, which was recorded as a decrease to compensation.

(24)
All Other Compensation for Mr. Twomey for fiscal 2008 includes $108,562 for Company contributions to a supplemental executive retirement plan, $22,172 of earnings equal to 120% of AFR under such plan, $9,781 for Company matching contributions to our 401(k) plan, $12,000 for car allowance, and $161 in other employer paid benefits.

(25)
All Other Compensation for Mr. Twomey for fiscal 2007 includes $104,550 for Company contributions to a supplemental executive retirement plan, $21,900 of earnings equal to or less than 120% of AFR under said plan, $8,878 for Company matching contributions to our 401(k) plan, and a $12,000 car allowance.


GRANTS OF PLAN-BASED AWARDS TABLE FOR FISCAL 2009

        The following table summarizes grants of plan-based awards made to Named Executive Officers during our fiscal year ended February 28, 2009. Awards under the first row26, 2022 represent fees for audits of Non-Equity Incentive Plans relate to cash incentive bonuses as discussed in the Compensation Discussionemployee benefit plans’ financial statements.

(3)
Tax fees. Represents fees for tax compliance advice and Analysis under the caption "Cash Incentive Bonuses." Awards under the second row of Non-Equity Incentive Plans relate to performance awards that may be earned based on Company performance as further described in Note 1 below. All Other Stock Awards and All Other Option Awards relate to restricted share grants and stock option grants, respectively.

 
  
 Estimated Future
Payouts Under Non-Equity
Incentive Plan Awards(1)
 Estimated Future
Payouts Under Equity
Incentive Plan Awards
  
  
 Exercise
or Base
Price of
Option
Awards
($)
 Grant
Date Fair
Value of
Stock and
Option
Awards
($)(4)
 
 
  
 All Other
Stock
Awards
(#)(2)
 All Other
Option
Awards
(#)(3)
 
Name
 Grant
Date
 Threshold
50%
($)
 Target
100%
($)
 Max
200%
($)
 Threshold
(#)
 Target
(#)
 Max
(#)
 

Mary F. Sammons

  10/2/2008  1.000,000  2,000,000  4,000,000        202,700  669,600  0.89  461,635 

     450,000  900,000  1,800,000                      

John T. Standley

  
9/24/2008
  
  
  
  
  
  
  
  
3,500,000
  
0.96
  
1,575,000
 

  10/2/2008  562,500  1,125,000  2,250,000           51,100  168,800  0.89  116,375 

     113,400  226,800  453,600                      

Frank G. Vitrano

  
9/24/2008
  
  
  
  
  
  
  
  
1,400,000
  
0.96
  
630,000
 

  10/2/2008  385,000  770,000  1,540,000           39,700  131,300  0.89  90,479 

     88,200  176,400  352,800                      

Brian R. Fiala

  
10/2/2008
  
137,280
  
274,560
  
549,120
  
  
  
  
52,600
  
173,600
  
0.89
  
119,726
 

     116,700  233,400  466,800                      

Robert B. Sari

  
10/2/2008
  
165,000
  
330,000
  
660,000
  
  
  
  
49,700
  
164,200
  
0.89
  
113,197
 

     110,300  220,600  441,200                      

Douglas E. Donley

  
10/2/2008
  
82,742
  
165,485
  
330,970
  
  
  
  
26,800
  
88,700
  
0.89
  
61,106
 

     59,550  119,100  238,200                      

Robert J. Easley

     
  
  
  
  
  
  
  
  
  
 

Pierre Legault(5)

  
6/24/2008
  
  
  
  
  
  
  
100,000
  
  
1.72
  
172,000
 

Kevin Twomey

     
  
  
  
  
  
  
  
  
  
 

(1)
On October 2, 2008, the Named Executive Officers received grants of performance-based units that will be earned based upon the achievement of a percentage of a three-year cumulative EBITDA goal. Vesting for the performance units will occur, provided performance targets are met, on February 26, 2011 (the end of the Company's fiscal year 2011) or such later date as the EBITDA performance for fiscal years 2009-2011 is determined. The award payout will be equivalent to $1.00 for each unit earned.

Table of Contents

(2)
On October 2, 2008, the Named Executive Officers received a grant of restricted stock, as described in the Compensation Discussion and Analysis, under the caption "Equity Incentives—Restricted Stock." One-third of these restricted shares will vest on each of the first three anniversaries of the grant date.

(3)
On October 2, 2008, the Named Executive Officers received a grant of stock options, as described in the Compensation Discussion and Analysis, under the caption "Equity Incentives—Stock Options." These stock options will vest in equal installments on each of the first four anniversaries of the grant date. In addition, on September 24, 2008, Mr. Standley and Mr. Vitrano received awards of stock options in connection with their commencement of employment in fiscal 2009. These awards will vest in equal installments on each of the first four anniversaries of the grant date.

(4)
Represents the grant date fair value, measured in accordance with SFAS No. 123R of stock and option awards made in fiscal year 2009. Grant date fair values are calculated pursuant to assumptions set forth in Note xx of the Company's 2009 Annual Report on Form 10-K filed with the SEC on April xx, 2009. The grant date fair value of stock awards was $0.96 on September 24, 2008 and $0.89 on October 2, 2008. The fair value of stock options granted was $0.45 on September 24, 2008 and $0.42 on October 2, 2008.

(5)
One-third of the stock awards listed for Mr. Legault were forfeited by Mr. Legault upon termination of his employment.


EXECUTIVE EMPLOYMENT AGREEMENTS

        Rite Aid has entered into employment agreements with each of the Named Executive Officers, the material terms of which are described below.

    Ms. Sammons was appointed President and Chief Operating Officer of Rite Aid and was appointed to Rite Aid's Board of Directors, and is now Chairman and Chief Executive Officer;

    Mr. Standley was appointed and is President and Chief Operating Officer;

    Mr. Vitrano was appointed and is Senior Executive Vice President, Chief Financial Officer and Chief Administrative Officer;

    Mr. Fiala was appointed and is Executive Vice President, Store Operations;

    Mr. Sari was appointed Senior Vice President, Deputy General Counsel, Secretary and then served as our Executive Vice President, General Counsel and Secretary until he stepped down on March 9, 2009. Mr. Sari assisted with the transition to his successor until he ceased to be employed by us on April 8, 2009;

    Mr. Donley was appointed Group Vice President, Comptroller, and is now Senior Vice President, Chief Accounting Officer;

    Mr. Easley was appointed and served as our Chief Operating Officer until he ceased to be employed by us in September 2008;

    Mr. Legault was appointed and served as our Senior Executive Vice President, Chief Administrative Officer, until he ceased to be employed by us in September 2008; and

    Mr. Twomey was appointed Senior Vice President, Chief Accounting Officer and then served as our Executive Vice President, Chief Financial Officer until he ceased to be employed by us in September 2008.

        Term.    The term of each executive's employment agreement commenced on the effective date of his or her employment agreement, as set forth in the "Other Post-Employment and Change in Control Benefits" section of the Compensation Discussion and Analysis, above. Unless terminated earlier, each employment agreement, other than in the case of Ms. Sammons, will terminate on its third anniversary and in the case of Messrs. Standley, Vitrano, Fiala, Sari and Donley's employment agreements, the agreements will terminate on the second anniversary (such respective period, the "Initial Term"). Each agreement will automatically renew for an additional one year term (the "Renewal Term"), unless either the executive or Rite Aid provides the other with notice of non-renewal at least 180 days (120 days in the case of Mr. Fiala) prior to the expiration of the Initial Term or a Renewal Term, as applicable.


Table of Contents

        Salary and Incentive Bonus.    The respective agreements provide each executive with a base salary and incentive compensation (which may be reviewed periodically for increase by the Compensation Committee) that includes, with respect to fiscal year 2009:

    Ms. Sammons is entitled to receive an annual base salary of not less than $750,000 (and received an annualized base salary of $1,000,000 in fiscal year 2009). If Rite Aid's performance meets certain targets in the future, Ms. Sammons may receive an annual bonus that, if awarded, will equal or exceed 200% of her annual base salary then in effect.

    Mr. Standley is entitled to an annual base salary of not less than $900,000 (and received an annualized base salary of $900,000 in fiscal year 2009). If Rite Aid's performance meets certain targets in the future, Mr. Standley may receive an annual bonus that, if awarded, will equal or exceed 125% of his annual base salary then in effect.

    Mr. Vitrano is entitled to an annual base salary of not less than $700,000 (and received an annualized base salary of $700,000 in fiscal year 2009). If Rite Aid's performance meets certain targets in the future, Mr. Vitrano may receive an annual bonus that, if awarded, will equal or exceed 110% of his annual base salary then in effect.

    Mr. Fiala is entitled to receive an annual base salary of not less than $440,000 (and received an annualized base salary of $457,600 in fiscal year 2009). If Rite Aid's performance meets certain targets in the future, Mr. Fiala may receive an annual bonus that, if awarded, will equal or exceed 60% of his annual base salary then in effect.

    Mr. Sari is entitled to an annual base salary of not less than $225,000 (and received an annualized base salary of $432,640, which was increased effective January 1, 2009 to $550,000 in fiscal year 2009). Mr. Sari is not entitled to receive a bonus for any period following the end of fiscal year 2009. As previously announced, Mr. Sari left the Company on April 8, 2009.

    Mr. Donley is entitled to receive an annual base salary of not less than $225,000 (and received an annualized base salary of $330,970 in fiscal year 2009). If Rite Aid's performance meets certain targets in the future, Mr. Donley may receive an annual bonus that, if awarded, will equal or exceed 50% of his annual base salary then in effect.

    Mr. Easley was entitled to receive an annual base salary of not less than $750,000 (and received an annualized base salary of $787,500 in fiscal year 2009) before his resignation in September 2008. Mr. Easley was not entitled to receive a bonus for the portion of the fiscal year that he worked prior to September 2008.

    Mr. Legault was entitled to an annual base salary of not less than $750,000 (and received an annualized base salary of $750,000 in fiscal year 2009) until his resignation in September 2008. Mr. Legault was not entitled to receive a bonus for the portion of the fiscal year that he worked prior to September 2008.

    Mr. Twomey was entitled to receive an annual base salary of not less than $317,000 (and received an annualized base salary of $468,918 in fiscal year 2009) before his resignation in September 2008. Pursuant to the terms of his employment agreement, Mr. Twomey received an annual incentive bonus in respect of fiscal year 2009, pro-rated for the portion of the fiscal year that he worked prior to September 2008.

        Other Benefits.    Pursuant to their employment agreements, each of the Named Executive Officers is also entitled to participate in Rite Aid's welfare benefits, fringe benefit and perquisite programs and savings plans.


Table of Contents

        Restrictive Covenants.    The employment agreement of each Named Executive Officer prohibits the officer from competing with Rite Aid during his or her employment period and for a period of two years, or with respect to Ms. Sammons and Messrs. Standley and Vitrano, one year, thereafter.

        Termination and Change in Control Benefits.    The provisions of the employment agreements relating to termination of employment are described under the caption "Potential Payments Upon Termination or Change in Control" below.


OUTSTANDING EQUITY AWARDS AT FISCAL 2009 YEAR-END

        The following table summarizes the number of securities underlying outstanding equity awards for the Named Executive Officers as of February 28, 2009:

 
 Option Awards Stock Awards 
Name
 Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
 Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
(1)(2)
 Option
Exercise
price
($)
 Option
Expiration
Date
 Number of
Shares or
Units of
Stock that
Have Not
Vested
(#)(1)(2)
 Market Value
of Shares
or Units of
Stock That
Have Not
Vested
($)(3)
 Equity Incentive
Plan Awards:
# of Unearned
Shares or Units
That Have
Not Vested
(#)(1)
 Equity Incentive
Plan Awards:
Market or Payout
Value of Shares or
Units of Stock That
Have Not Vested
($)(3)
 

Mary F. Sammons

  1,800,000     2.75  12/5/2009  66,500  18,620  61,779  17,298 

  1,050,000     2.75  6/29/2010  8,144  2,280       

  3,500,000     4.05  2/13/2011  41,186  11,532       

  497,216     2.26  1/30/2012  202,700  56,756       

  500,000     2.10  12/11/2012             

  292,208     5.38  6/24/2014             

  200,251  66,750  4.11  6/23/2015             

  139,972  139,971  4.42  6/20/2016             

  61,780  185,337  6.07  6/26/2017             

     669,600  0.89  10/2/2018             

John T. Standley

  
312,700
     
2.75
  
12/5/2009
  
51,100
  
14,308
       

     3,500,000  0.96  9/24/2018             

     168,800  0.89  10/2/2018             

Frank G. Vitrano

     
1,400,000
  
0.96
  
9/24/2018
  
39,700
  
11,116
       

     131,300  0.89  10/2/2018             

Brian R. Fiala

  
61,553
  
184,658
  
6.07
  
6/26/2017
  
41,035
  
11,490
  
11,553
  
3,235
 

     173,600  0.89  10/2/2018  52,600  14,728       

Robert B. Sari

  
10,500
     
5.38
  
11/10/2009
  
9,708
  
2,718
  
14,563
  
4,078
 

  139,500     4.05  2/13/2011  49,700  13,916       

  37,380     5.40  4/7/2014             

  26,949  8,982  4.11  6/23/2015             

  31,106  31,104  4.42  6/20/2016             

  14,564  43,690  6.07  6/26/2017             

     164,200  0.89  10/2/2018             

Douglas E. Donley

  
58,000
     
23.00
  
4/16/2009
  
6,234
  
1,746
  
7,864
  
2,202
 

  64,000     5.38  11/10/2009  992  278       

  75,000     4.05  2/13/2011  5,242  1,468       

  25,000     2.10  12/11/2012  26,800  7,504       

  24,173     5.40  4/7/2014             

  24,511  8,170  4.11  6/23/2015             

  17,054  17,052  4.42  6/20/2016             

  7,865  23,592  6.07  6/26/2017             

     88,700  0.89  10/2/2018             

(1)
Refer to "Potential Payments Upon Termination or Change in Control," below for circumstances under which the terms of the vesting of equity awards would be accelerated.

Table of Contents

(2)
These stock options will generally vest in equal installments on each of the first four anniversaries of the grant date, based on continued employment. On September 24, 2008, Messrs. Standley and Vitrano each received an award of stock options in connection with his commencement of employment with us in the 2009 fiscal year. These awards will generally vest in equal installments on each of the first four anniversaries of the grant date, based on continued employment. With respect to the restricted stock awards listed, one-third of the restricted shares will vest on each of the first three anniversaries of the grant date, based on continued employment.

(3)
Determined with reference to $0.28, the closing price of a share of Rite Aid common stock on the last trading day before February 28, 2009.


OPTIONS EXERCISES AND STOCK VESTED TABLE FOR FISCAL 2009

        The following table summarizes for each Named Executive Officer the stock option exercises and shares vested during fiscal year 2009:

 
 Option Awards Stock Awards 
Name
 Number of
Shares Acquired
on Exercise
(#)
 Value
Realized on
Exercise
($)
 Number of
Shares Acquired
on Vesting
(#)
 Value
Realized on
Vesting
($)
 

Mary F. Sammons

      257,136  598,772 

John T. Standley

         

Frank G. Vitrano

         

Brian R. Fiala

      20,518  27,699 

Robert B. Sari

      23,967  48,983 

Douglas E. Donley

      23,640  54,147 

Robert J. Easley

      110,297  114,885 

Pierre Legault

      189,834  227,253 

Kevin Twomey

      63,189  113,632 


NONQUALIFIED DEFERRED COMPENSATION FOR FISCAL 2009

        The following table provides information concerning the non-qualified defined contribution and deferred compensation of each of the Named Executive Officers in the 2009 fiscal year:

Name
 Executive
Contributions
in Last FY
($)
 Registrant
Contributions
in Last FY
($)
 Aggregate
Earnings (Loss)
in Last FY
($)
 Aggregate
Withdrawals/
Distributions
($)
 Aggregate
Balance at
Last FYE
($)(3)
 

Mary F. Sammons

    240,000  (1,037,566)   1,623,587 

John T. Standley

    75,000  (143,267) (234,875) 197,652 

Frank G. Vitrano

    70,000  (10,548)   59,452 

Brian R. Fiala

    109,120  476    183,180 

Robert B. Sari

    105,515  6,437    754,263 

Douglas E. Donley

    78,924  (309,733)    359,471 

Robert J. Easley

    105,000  (28,272) (176,807) 8,523 

Pierre Legault

    105,000  (18,048) (163,303) 7,661 

Kevin Twomey

    65,646  (646) (287,471) 478,529 

(1)
Amounts shown relate to a supplemental executive retirement plan for Ms. Sammons. Please refer to the Compensation Discussion and Analysis under the caption "Post-Retirement Benefits" for a description of the material terms of this plan.

(2)
Amounts shown relate to a supplemental executive retirement plan covering the Named Executive Officers other than Ms. Sammons. Please refer to the Compensation Discussion and Analysis under the caption "Post-Retirement Benefits" for a description of the material terms of this plan.

Table of Contents

(3)
Includes contributions to the supplemental executive retirement plans that were previously disclosed in prior Summary Compensation Tables for Ms. Sammons of $2,421,200, Mr. Twomey of $701,000, Mr. Sari of $642,300 and Mr. Legault of $0.

        Rite Aid established a defined contribution supplemental executive retirement plan for the benefit of Mr. Miller and Ms. Sammons, which is described in Compensation Discussion and Analysis above. Messrs. Standley, Vitrano, Fiala, Sari and Donley receive benefits under a different defined contribution supplemental executive retirement plan, which is also described in the Compensation Discussion and Analysis above.


POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL

        As discussed above under the caption "Executive Employment Agreements," the Company has entered into employment agreements with each of the Named Executive Officers. Upon written notice, the employment agreement of each of the Named Executive Officers is terminable by either Rite Aid or the individual officer seeking termination.

      �� If Ms. Sammons is terminated by Rite Aid without "cause" or if she terminates her employment for "good reason" (as such terms are defined in Ms. Sammons' employment agreement), then:

    Ms. Sammons will be paid an amount equal to three times the sum of the annual base salary and target bonus; a pro-rated bonus for the fiscal year of termination (determined with reference to the maximum amount payable for such year); and any accrued but unpaid salary and bonus;

    Ms. Sammons will be paid the deferred compensation amounts that would otherwise have been credited to her pursuant to the supplemental executive retirement plan (discussed in the Compensation Discussion and Analysis) had she continued employment with Rite Aid through the end of the then-remaining employment period and she will continue to receive medical benefits (or be reimbursed for the cost of such benefits) for life; and

    All outstanding stock options will immediately vest and be exercisable for the remainder of their stated terms, the restrictions on outstanding restricted common stock will immediately lapse and any performance or other conditions applicable to any other equity incentive awards will be considered to have been satisfied.

        If Ms. Sammons' employment is terminated as a result of her death or "disability" (as such term is defined in her employment agreement), she (or her estate as the case may be) will be entitled to an amount equal to her pro-rated bonus for the fiscal year of termination (determined with reference to the maximum amount payable for such year), and continued medical benefits (or reimbursement for the cost of such benefits) for her life or the life of her spouse, payment of any accrued but unpaid salary and bonus and full vesting of all outstanding stock options, restricted stock and other equity incentive awards (with performance goals being deemed to have been satisfied at targeted levels).

        Upon termination of employment for any reason other than "cause" (as such term is defined in her employment agreement), Ms. Sammons is entitled to receive an annual payment following termination and continuing for life (and the life of her spouse) equal to the cost of purchasing medical coverage comparable to the coverage provided to the Company's senior executives immediately prior to such termination, excepting payments for periods that the Company provides such coverage described above.

        Pursuant to their employment agreements with the Company, if any of Messrs. Standley, Vitrano, Fiala, Sari, Donley, Easley, Legault and Twomey is terminated by Rite Aid without "cause" or if such


Table of Contents


officer's employment is terminated by the officer for "good reason" (as such terms are defined in the applicable employment agreement), then the officer will be entitled to receive:

    an amount equal to two times the sum of the annual base salary and target bonus in severance, a pro-rata bonus for the fiscal year of termination for all officers other than Messrs. Fiala, Easley and Legault and any accrued but unpaid salary and benefits. The severance amount is payable in installments over the two year period following the termination; and

    all outstanding stock options will immediately vest and be exercisable, generally, for a period of 90 days following the termination of employment and the restrictions on the restricted common stock will immediately lapse to the extent the options would have vested and restrictions would have lapsed had he remained employed by Rite Aid for two years following the termination.

        If Rite Aid terminates any of the Named Executive Officers for "cause," or if any of the Named Executive Officers terminates his or her employment without "good reason" (with the exception of Ms. Sammons, whose termination provision is described above):

    Rite Aid shall pay the officer all accrued but unpaid salary and benefits;

    any portion of any then-outstanding stock option grant that was not exercised prior to the date of termination shall immediately terminate; and

    any portion of any restricted stock award, or other equity incentive award, as to which the restrictions have not lapsed or as to which any other conditions were not satisfied prior to the date of termination shall be forfeited.

        If the employment of any of the Named Executive Officers is terminated as a result of death or "disability" (other than Ms. Sammons, whose benefits upon such a termination are described above), the officer will be entitled to receive all accrued but unpaid salary and benefits payable under death or disability benefit plans in which the officer participates, continued health insurance for two years and vesting of an amount of stock options and restricted stock as would have vested had the officer remained employed for two years following the date of termination.

        Upon Mr. Easley's ceasing to be employed by the Company in September 2008, he became entitled to receive a total of $3,307,500 in severance under his employment agreement with us, based on the triggering event of a termination by the Company without cause. As of February 28, 2009, the end of our last completed fiscal year, Mr. Easley had received $505,817 of this amount, as shown in the "All Other Compensation" column of the Summary Compensation Table. The remainder of this severance amount will be paid to Mr. Easley in substantially equal bi-weekly installments, subject to his compliance with restrictive covenants. Because Mr. Easley was not employed by us as of the end of fiscal year 2009, no table quantifying the potential payments that would have been made based on a termination of employment on the last day of fiscal year 2009 is provided.

        Upon Mr. Legault's ceasing to be employed by the Company in September 2008, he became entitled to receive a total of $3,150,000 in severance under his employment agreement with us, based on the triggering event of a termination by the Company without cause. As of February 28, 2009, the end of our last completed fiscal year, Mr. Legault had received $460,000 of this amount, as shown in the "All Other Compensation" column of the Summary Compensation Table. The remainder of this severance amount will be paid to Mr. Legault in substantially equal bi-weekly installments, subject to his compliance with restrictive covenants. Because Mr. Legault was not employed by us as of the end of fiscal year 2009, no table quantifying the potential payments that would have been made based on a termination of employment on the last day of fiscal year 2009 is provided.

        Upon Mr. Twomey's ceasing to be employed by the Company in September 2008, he became entitled to receive a total of $1,641,212 in severance under his employment agreement with us, based on the triggering event of a termination by the Company without cause. As of February 28, 2009, the


Table of Contents


end of our last completed fiscal year, Mr. Twomey had received $310,207 of this amount, as shown in the "All Other Compensation" column of the Summary Compensation Table. The remainder of this severance amount will be paid to Mr. Twomey in substantially equal bi-weekly installments, subject to his compliance with restrictive covenants. Because Mr. Twomey was not employed by us as of the end of fiscal year 2009, no table quantifying the potential payments that would have been made based on a termination of employment on the last day of fiscal year 2009 is provided.

        Upon the termination of employment of any of the Named Executive Officers, the officer would generally become entitled to receive a distribution of his or her vested account balance under the nonqualified deferred compensation plans maintained by the Company. Pursuant to applicable tax regulations, any such distributions will generally be delayed for a period of six months following the Named Executive Officer's separation from service. The account balance of each Named Executive Officer is shown in the Nonqualified Deferred Compensation for Fiscal 2009 table, above.

        Change in Control Arrangements.    Under Ms. Sammons' December 5, 1999 employment agreement, any termination of employment by the executive within the six month period commencing on the date of a "change in control" of Rite Aid (as such term is defined below) will be treated as a termination of employment by the executive for "good reason." On October 11, 2006, Ms. Sammons' Employment Agreement was amended to provide that the Brooks Eckerd Transaction would not trigger the change in control benefits described above.

        Under Mr. Standley's employment agreement, upon a change in control, all of his stock options awarded pursuant to his employment agreement and all stock options awarded pursuant to the Company's executive equity program then held by him shall immediately vest and be exercisable. Under Mr. Vitrano's employment agreement, upon a change in control, all stock options awarded pursuant to his employment agreement would immediately vest and be exercisable. Under Messrs. Fiala, Legault and Easley's employment agreements, upon a change in control, all of their stock options awarded pursuant to the employment agreement would immediately vest and be exercisable and any restrictions on restricted stock awarded pursuant to the employment agreement would immediately lapse. Under Mr. Sari's employment agreement, upon a "change in control," all of his stock options held as of the date of his employment agreement would have immediately vested and become exercisable and any restrictions on restricted stock would have immediately lapsed. Under Mr. Twomey's employment agreement, upon a "change in control," any restrictions on restricted stock granted pursuant to his employment agreement would have immediately lapsed.

        Each employment agreement provides that the Named Executive Officer will receive an additional payment to reimburse the officer for any excise taxes imposed pursuant to Section 4999 of the Internal Revenue Code, together with reimbursement for any additional taxes incurred by reason of such payments.

        The unvested account balance of the supplemental executive retirement plan in which Messrs. Standley, Vitrano, Fiala, Sari, Donley, Easley, Legault and Twomey participate will vest upon a change in control of the Company as defined in the supplemental executive retirement plan, only if such Named Executive Officer is involuntarily terminated without cause within twelve months of the change in control. For more information regarding the supplemental executive retirement plan, refer to the Compensation Discussion and Analysis under the caption "Post-Retirement Benefits."

        Mr. Donley has no change in control benefits under his employment agreement, as amended.


Table of Contents

        For purposes of the employment agreements with the Named Executive Officers, where applicable, the term "change in control" generally means an acquisition of 25% percent (35% in the case of Messrs. Vitrano and Standley) or more of the Company's combined voting power; the incumbent directors (generally including current directors and future directors whose election or nomination is approved by the Board) ceasing to constitute a majority of the Board; the consummation of a merger or similar transaction, other than (i) such a transaction in which the voting securities outstanding immediately prior to such transaction continue to represent at least 60% of the voting power of the Company immediately after the transaction or (ii) a recapitalization or similar transaction in which no person becomes the beneficial owner of 25% (35% in the case of Mr. Vitrano and Mr. Standley) or more of the Company's combined voting power; or the stockholders approve a plan of complete liquidation or dissolution of the Company.

Quantification

        The termination and change in control payments that would have been made to the Named Executive Officers had their employment been terminated as of February 28, 2009 under the circumstances described in the tables below are quantified in the tables below.

Mary F. Sammons
 Death
($)
 Disability
($)
 Change in
Control
($)
 Termination by
the Company
Without Cause or
by the Executive
for Good Reason
($)
 Voluntary
Termination of
Employment by the
Executive Within
Six Months After
Change in Control
($)
 

3 × Base Salary

  N/A  N/A  N/A  3,000,000  3,000,000 

3 × Bonus

  N/A  N/A  N/A  6,000,000  6,000,000 

Pro-Rated Bonus for Fiscal Year of Termination

      N/A     

Continued Health Benefits(a)

  190,000  190,000  N/A  190,000  190,000 

SERP Contribution Continuation for 3 Years

  720,000  720,000  N/A  720,000  720,000 

Vesting of Options and Restricted Stock(1)

  89,188  89,188  89,188  89,188  89,188 

Excise Tax Gross-up

  N/A  N/A  0  3,654,000(b) 3,654,000 

(a)
Refer to the "Potential Payments Upon Termination or Change in Control" section above for a description of the benefits provided to Ms. Sammons following certain terminations of employment.

(b)
This payment is shown under the assumption that the termination occurred on or after a change in control.

Table of Contents

John T. Standley
 Death
($)
 Disability
($)
 Change in
Control
($)
 Termination by
the Company
Without Cause or
by the Executive
for Good Reason
($)
 Voluntary
Termination of
Employment by the
Executive Within
Six Months After
Change in Control
($)
 

2 × Base Salary

  N/A  N/A  N/A  1,800,000  1,800,000 

2 × Bonus

  N/A  N/A  N/A  2,250,000  2,250,000 

Pro-Rated Bonus for Fiscal Year of Termination

  96,750  96,750  N/A  96,750  96,750 

Continued Health Benefits

  18,084  18,084  N/A  18,084  18,084 

SERP Vesting

  56,765  56,765  56,765  56,765  56,765 

Vesting of Options and Restricted Stock(1)

  9,539  9,539  9,539  9,539  9,539 

Excise Tax Gross-up

  N/A  N/A  N/A  1,553,000  1,553,000 


Frank G. Vitrano
 Death
($)
 Disability
($)
 Change in
Control
($)
 Termination by
the Company
Without Cause or
by the Executive
for Good Reason
($)
 Voluntary
Termination of
Employment by the
Executive Within
Six Months After
Change in Control
($)
 

2 × Base Salary

  N/A  N/A  N/A  1,400,000  1,400,000 

2 × Bonus

  N/A  N/A  N/A  1,540,000  1,540,000 

Pro-Rated Bonus for Fiscal Year of Termination

  66,220  66,220  N/A  66,220  66,220 

Continued Health Benefits

  14,352  14,352  N/A  14,352  14,352 

SERP Vesting

  52,511  52,511  52,511  52,511  52,511 

Vesting of Options and Restricted Stock(1)

  7,411  7,411  7,411  7,411  7,411 

Excise Tax Gross-up

  N/A  N/A  N/A  1,269,000  1,269,000 


Brian R. Fiala
 Death
($)
 Disability
($)
 Change in
Control
($)
 Termination by
the Company
Without Cause or
by the Executive
for Good Reason
($)
 Voluntary
Termination of
Employment by the
Executive Within
Six Months After
Change in Control
($)
 

2 × Base Salary

  N/A  N/A  N/A  915,200  915,200 

2 × Bonus

  N/A  N/A  N/A  N/A  N/A 

Pro-Rated Bonus for Fiscal Year of Termination

  N/A  N/A  N/A  N/A  N/A 

Continued Health Benefits

  32,481  32,481  N/A  32,481  32,481 

SERP Vesting

  139,034  139,034  139,034  139,034  139,034 

Vesting of Options and Restricted Stock(1)

  9,819  9,819  9,819  9,819  9,819 

Excise Tax Gross-up

  N/A  N/A  N/A  N/A  N/A 
planning.

Table of Contents


Robert Sari
 Death
($)
 Disability
($)
 Change in
Control
($)
 Termination by
the Company
Without Cause or
by the Executive
for Good Reason
($)
 Voluntary
Termination of
Employment by the
Executive Within
Six Months After
Change in Control
($)
 

2 × Base Salary

  N/A  N/A  N/A  1,100,000  1,100,000 

2 × Bonus

  N/A  N/A  N/A  660,000  660,000 

Pro-Rated Bonus for Fiscal Year of Termination

  44,648  44,648  N/A  44,648  44,648 

Continued Health Benefits

  31,878  31,878  N/A  31,878  31,878 

SERP Vesting

  131,986  131,986  131,986  131,986  131,986 

Vesting of Options and Restricted Stock(1)

  11,996  11,996  11,996  11,996  11,996 

Excise Tax Gross-up

  N/A  N/A  N/A  N/A  N/A 


Douglas E. Donley
 Death
($)
 Disability
($)
 Change in
Control
($)
 Termination by
the Company
Without Cause or
by the Executive
for Good Reason
($)
 Voluntary
Termination of
Employment by the
Executive Within
Six Months After
Change in Control
($)
 

2 × Base Salary

  N/A  N/A  N/A  661,939  661,939 

2 × Bonus

  N/A  N/A  N/A  330,970  330,970 

Pro-Rated Bonus for Fiscal Year of Termination

  28,463  28,463  N/A  28,463  28,463 

Life Benefits

  16,269  16,269  N/A  16,269  16,269 

SERP Vesting

  8,216  8,216  8,216  8,216  8,216 

Vesting of Options and Restricted Stock(1)

  N/A  N/A  N/A  N/A  N/A 

Excise Tax Gross-up

  N/A  N/A  0  0  N/A 

(1)
As described above in the "Potential Payments Upon Termination or Change in Control" narrative, upon a change in control (as defined in the employment agreements), the Named Executive Officers would become fully vested in certain outstanding stock option and restricted stock grants that were not yet vested on the date of the change in control. The value of stock options shown is based on the excess of $0.28, the closing price of a share of Rite Aid common stock on the last trading day before February 28, 2009, over the exercise price of such options, multiplied by the number of unvested stock options held by the officer. The value of restricted stock shown is determined by multiplying the number of shares of restricted stock that would vest as of February 28, 2009 and $0.28, the closing price of a share of Rite Aid common stock on the last trading day before February 28, 2009.

Table of Contents


AUDIT COMMITTEE REPORT

The Board of Directors has adopted a written charter of the Audit Committee which further describes the role of the Audit Committee. The Audit Committee, among other things, appoints and engages our independent registered public accounting firm and oversees our financial reporting and internal control over financial reporting processes on behalf of the Board. Management has the primary responsibility for our financial statements, our accounting principles and our internal control over financial reporting. Our independent registered public accounting firm is responsible for auditing our financial statements and expressing an opinion as to their conformity with accounting principles generally accepted in the United States. Our independent registered public accounting firm also is responsible for expressing an opinion on the effectiveness of our internal control over financial reporting.


RITE AID CORPORATION   2023 Proxy Statement | 27

TABLE OF CONTENTS
PROPOSAL 2—RATIFICATION OF THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
In fulfilling its oversight responsibilities, the Audit Committee met eleven10 times during fiscal year 2009.

2023.

During those meetings, the Audit Committee:


Met with our internal auditors and independent registered public accounting firm, with and without management present, to discuss the overall scope and plans for their respective audits, the results of their examinations, their evaluations of our internal control over financial reporting and the overall quality of our financial reporting.


Reviewed and discussed with management and our independent registered public accounting firm, for their respective purposes, the audited financial statements included in our Annual Report on Form 10-K for fiscal 2009.year 2023. The discussions included the quality, not just the acceptability, of the accounting principles, the reasonableness of significant judgments and the clarity of disclosures in the financial statements and the Annual Report on Form 10-K for fiscal 2009.

year 2023.

Reviewed the unaudited interim financial statements and Forms 10-Q prepared each quarter by the Company.


Received management representations that the Company'sCompany’s financial statements were prepared in accordance with accounting principles generally accepted in the United States of America.


Reviewed and updated the Audit Committee charter.


Reviewed and discussed with our independent registered public accounting firm those matters required to be communicateddiscussed by the standardsapplicable requirements of the Public Company Accounting Oversight Board ("PCAOB"), as well as critical accounting policies and practices, alternative accounting treatments, and other material written communications between management and our independent registered public accounting firm, as required by Rule 2-07 of Regulation S-X under the Securities Exchange Act of 1934, as amended.

Discussed with our independent registered public accounting firm the matters required to be discussed by PCAOB AU 380 ("Communication with Audit Committees"(“PCAOB”) and Statement on Auditing Standards No. 114 ("Communication with Audit Committees").

the SEC.

Discussed with our independent registered public accounting firm matters relating to their independence and received the written disclosures and the letter from our independent registered public accounting firm required by applicable requirements of the Public Company Accounting Oversight BoardPCAOB regarding the independent accountant'saccountant’s communications with the Audit Committee concerning independence. The Audit Committee has considered whether the

Table of Contents

      level of non-audit related services provided by our independent registered public accounting firm is consistent with maintaining their independence.


Pre-approved audit, other audit-related and tax services performed by our independent registered public accounting firm.

In addition to pre-approving the audit and other audit-relatedaudit related and tax services performed by our independent registered public accounting firm, the Audit Committee requests fee estimates associated with each proposed service. Providing a fee estimate for a service incorporates appropriate oversight and control of the independent registered public accounting firm relationship. On a quarterly basis, the Audit Committee reviews the status of services and fees incurred year-to-date against pre-approved services and fee estimates.

        As outlined in the table below, we incurred the following fees, including expenses billed to the Company for the fiscal years ended February 28, 2009 and March 1, 2008 by our independent registered public accounting firm, Deloitte & Touche LLP, the member firms of Deloitte Touche Tohmatsu, and their respective affiliates.

 
 Year Ended 
Description of Fees
 Feb. 28,
2009
 March 1,
2008
 
 
 (Amounts in millions)
 

Audit Fees, including audit of annual financial statements and reviews of interim financial statements, registration statement filings and comfort letters related to various refinancing activities

 $2.8 $3.9 

Audit-Related Fees:

       
 

Acquisition due diligence fees and audits of employee benefit plans' financial statements

  0.2  0.2 

Tax Fees, tax compliance advice and planning

  0.4  0.3 
      
 

Total

 $3.4 $4.4 
      

Based on the review and discussions referred to above, the Audit Committee recommended to the Board of Directors that the audited financial statements be included in our Annual Report on Form 10-K for the fiscal year ended February 28, 2009March 4, 2023 for filing with the SEC.


THE AUDIT COMMITTEE

Louis P. Miramontes, Chair
Arun Nayar
Robert E. Knowling, Jr.

28 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS

[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
PROPOSAL 3—ADVISORY VOTE ON THE
COMPENSATION OF OUR NAMED EXECUTIVE
OFFICERS
In accordance with the requirements of Section 14A of the Exchange Act, stockholders have the opportunity to approve on an advisory, nonbinding basis the compensation of the named executive officers disclosed in this proxy statement. This is commonly referred to as a “say on pay” advisory vote. The Board of Directors recommends that you vote “FOR” this proposal.
As discussed in greater detail in the “Compensation Discussion and Analysis” ​(CD&A) section of this proxy statement, our executive compensation program is designed to attract, motivate, and retain the most talented and dedicated executives and to align the interests of our named executive officers with the interests of our stockholders. The Company’s compensation program is designed to:

reward our named executive officers for the achievement of annual and long-term strategic and operational goals and the achievement of increased total stockholder return, and

avoid the encouragement of unnecessary or excessive risk-taking.
The Company encourages stockholders to review the executive compensation disclosure in the CD&A and executive compensation tables in this proxy statement for complete details of its compensation program for its named executive officers and how the program is designed to achieve the Company’s compensation objectives.
We are asking our stockholders to indicate their support for the compensation of our named executive officers as described in this proxy statement. This vote is not intended to address any specific item of compensation; rather, the vote relates to the overall compensation of our named executive officers as described in this proxy statement.
The Board is presenting this proposal, which gives stockholders the opportunity to endorse or not endorse our executive pay program, on an advisory basis, by voting on the following resolution:
RESOLVED, that the stockholders of the Company approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed pursuant to Item 402 of Securities and Exchange Commission Regulation S-K, including the Compensation Discussion and Analysis, the compensation tables and narrative disclosures.”
Although the advisory vote is non-binding, the Board of Directors values the opinions of stockholders. The Compensation Committee will review the results of the vote and will consider stockholders’ concerns and take into account the outcome of the vote when considering future decisions concerning our executive compensation program.
[MISSING IMAGE: ic_chksquare-pn.gif]
The Board of Directors unanimously recommends that you vote FOR the approval of the compensation of its named executive officers, as disclosed in this proxy statement.

RITE AID CORPORATION   2023 Proxy Statement | 29

TABLE OF CONTENTS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
PROPOSAL 4—ADVISORY VOTE ON THE
FREQUENCY OF FUTURE ADVISORY VOTES ON
THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS
Section 14A of the Exchange Act requires that we include in this proxy statement a non-binding stockholder vote on whether future advisory votes on the compensation of our named executive officers should occur every one, two or three years. Stockholders have the option to vote for any one of the three options, or to abstain on the matter. In July 2017, our stockholders voted to hold an advisory vote on executive compensation every year. The next advisory vote on the frequency of future advisory votes on the compensation of our named executive officers is expected to be held at the 2029 annual meeting. For the reasons discussed below, the Board recommends that future advisory votes on the compensation of our named executive officers take place every “ONE YEAR.”
After careful consideration and input from our stockholders, our Board has determined that an advisory vote on executive compensation that occurs annually is the most appropriate alternative for the Company. In formulating its recommendation, our Board considered that an annual advisory vote on executive compensation will allow stockholders to provide us with their direct input on our compensation philosophy, policies and practices as disclosed in the proxy statement every year. Additionally, an annual advisory vote on executive compensation is consistent with our policy of seeking input from, and engaging in discussions with, our stockholders on corporate governance matters and our executive compensation philosophy, policies and practices. We will continue to engage with our stockholders regarding our executive pay programs between stockholder advisory votes as part of our governance process.
The Company recognizes that stockholders may have different views as to the best approach for the Company, and therefore the Company and Board encourage stockholders to express their preferences as to the frequency of an advisory vote on the compensation of our named executive officers.
This vote is advisory and not binding on the Company or the Board, but the Board and the Compensation Committee will take into account the outcome of the vote when making decisions about how often the Company conducts advisory votes on the compensation of our named executive officers.
The proxy card provides stockholders with the opportunity to choose among four options (holding the vote every one, two or three years, or abstaining). The frequency (every one, two or three years) receiving the greatest number of votes, even if not a majority, will be considered the preference of our stockholders.
[MISSING IMAGE: ic_chksquare-pn.gif]
The Board of Directors unanimously recommends that you vote for ONE YEAR as the preferred frequency of future advisory votes on the compensation of our named executive officers.

30 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
Letter from the Chair of Our Compensation Committee
DEAR FELLOW STOCKHOLDERS:
On behalf of the Compensation Committee of the Board of Directors of Rite Aid, I would like to share with you the Committee’s perspective on our recent CEO transition, say-on-pay results, stockholder engagement, and the impact of our financial performance on executive pay.
Rite Aid’s fiscal year 2023 financial performance results were lower than we anticipated, which is reflected in the pay outcomes for our executive team and is in alignment with the experience of Rite Aid stockholders. However, the year ended on a positive note with strong fourth quarter results and a strategic turnaround plan in place that is designed to drive future growth. As we engage in our search for a permanent CEO, we understand the importance of continuing to motivate and retain our dedicated leaders who are prepared to deliver on our new strategy to grow the Company and create long-term stockholder value.
[MISSING IMAGE: ph_katherinekatebbox-pn.jpg]
CEO Transition
In January of this year, the Board of Directors appointed Ms. Burr, then a member of the Company’s Board, as interim CEO, and Ms. Donigan, our former President and CEO, departed the Company. Given her experience in the health and retail industries, including expertise in innovation, business strategy, retail and brand management, Ms. Burr is well suited to prepare Rite Aid for future growth while we conduct a search for a permanent CEO. To compensate Ms. Burr for her services as interim CEO, the Company is providing her a base salary of $300,000 a month, which the Board will review if she remains in the role for more than six months. As interim CEO, Ms. Burr does not receive short- or long-term incentive awards, employee benefits, or severance benefits. Also, she is not receiving compensation for her service as a director.
Say on Pay and Stockholder Outreach
The Compensation Committee is committed to gathering your feedback each year through our say-on-pay vote results and stockholder engagement efforts and to consider this important information in making executive pay decisions. Stockholder support for our executive compensation program in fiscal year 2023 was approximately 77%, a decline from approximately 83% in fiscal year 2022. We were disappointed in this result and responded with a rigorous stockholder engagement campaign, reaching out to stockholders holding over 40% of our outstanding shares to seek feedback on our pay program. Attending these meetings provided me and other Rite Aid leaders, including our Board Chair, CEO, and CFO, an opportunity to listen to any concerns raised by our stockholders and to gain insight into your perspectives on our executive pay plans. In part in response to this feedback, we made changes to our fiscal year 2023 pay program, including:

Incorporating new performance metrics into our annual and long-term incentive plans to eliminate overlapping metrics between the two plans

Revising the annual incentive plan metrics to remove total revenue and focus on two metrics that drive stockholder value: Adjusted EBITDA and Operating Cash Flow

Replacing the relative total shareholder return (TSR) modifier in our long-term incentive plan with a 25%-weighted Relative TSR metric to enhance the incentive to create sustainable long-term value and increase alignment of the interests of our executives with those of our stockholders
We will continue to reach out to our stockholders to gather feedback on executive pay and governance matters as part of our ongoing stockholder engagement process. We appreciate your valuable input.

RITE AID CORPORATION   2023 Proxy Statement | 31

TABLE OF CONTENTS
LETTER FROM THE CHAIR OF OUR COMPENSATION COMMITTEE
Fiscal Year 2023 Performance
The Company faced several challenges in fiscal year 2023 that impacted our financial results, including a reduction in revenue from COVID-19 vaccines and testing, and the loss of a large commercial client at Elixir. However, our executive team demonstrated its resilience by meeting several operational goals, including growing our market share in pharmacy and front-end lines of business, increasing our third-party e-commerce business, launching our first Rx-focused small-format stores, and improving our rebates at Elixir. We also reduced our operating costs through expense control and closing underperforming stores. These accomplishments helped us continue to make progress toward our goal of transforming Rite Aid into a leading pharmacy services company.
To improve financial performance and enhance stockholder value, our leadership team has established a turnaround plan designed to prepare for future challenges and drive earnings growth. We have already demonstrated the potential of this new approach, with fiscal year 2023 fourth quarter results at the higher end of Company guidance, due to positive results in retail pharmacy, non-COVID-19 script growth, expense control and improvement at Elixir.
Fiscal Year 2023 Compensation Outcomes
Given our financial results for fiscal year 2023 were lower than we expected, the Company did not meet the Adjusted EBITDA or Operating Cash Flow threshold performance levels under our annual incentive plan. As a result, our senior leadership team received no annual incentive plan payouts.
In setting the fiscal year 2023 performance targets for the annual incentive plan, the Compensation Committee chose challenging goals to motivate executives to achieve the Company’s short-term financial objectives and enhance stockholder value. Fiscal year 2023 annual incentive plan targets and results were as follows:

The Adjusted EBITDA target was set at $520 million, which was above the fiscal year 2022 target of $490 million and the fiscal year 2022 actual performance of $506 million. Actual fiscal year 2023 performance was $429.2 million, which was below the plan’s threshold of $442 million.

The Operating Cash Flow performance target was set at $8 million based on the financial plan targets. Actual fiscal year 2023 Operating Cash Flow was negative $276.3 million, which was below the threshold of negative $45 million.
For the long-term incentive plan, our executives received a combination of time-vested restricted stock (45%) and performance stock units (55%). The performance stock units vest over a three-year period based 75% on meeting three performance goals related to growth: Cumulative Scripts (30%), Elixir membership (30%), and Total Front-end Revenue (15%). These metrics were chosen to provide executives with enhanced line of sight to their goals and to focus the leadership team on growth and profitability. The remaining 25% is based on the Company’s TSR compared to the Russell 3000 Index to enhance alignment of long-term executive pay with stockholder experience.
Consistent with our pay-for-performance philosophy, our named executive officers did not receive an annual incentive plan award for fiscal year 2023.
In Closing
The Compensation Committee is committed to establishing pay programs that will continue to drive sustainable financial growth and create long-term stockholder value. We value your feedback and appreciate your continued support.
Sincerely,
[MISSING IMAGE: sg_katherinekatebquinn-bw.jpg]
KATHERINE “KATE” B. QUINN
Compensation Committee Chair

32 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS

[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
EXECUTIVE COMPENSATION
COMPENSATION DISCUSSION AND ANALYSIS
CD&A Contents
Introduction
We encourage you to read this Compensation Discussion and Analysis for a detailed discussion and analysis of our fiscal year 2023 executive compensation program for all individuals serving as Chief Executive Officer (“CEO”) during our last completed fiscal year, the Chief Financial Officer (“CFO”) and the three most highly compensated executive officers of the Company other than the CEO and CFO serving as of the end of our last completed fiscal year, as named below. We refer to these individuals throughout this Compensation Discussion and Analysis and the accompanying tables as our “Named Executive Officers” or “NEOs.”
Elizabeth Burr(1)
Heyward Donigan(2)
Matthew Schroeder
Interim Chief Executive OfficerFormer President and Chief Executive OfficerExecutive Vice President, Chief Financial Officer
Paul Gilbert(3)
Justin Mennen
Andre Persaud(4)
Former Executive Vice President, Chief Legal Officer & SecretaryExecutive Vice President, Chief Digital and Technology OfficerFormer Executive Vice President, Chief Retail Officer
(1)
Ms. Burr was appointed interim CEO effective January 7, 2023.
(2)
Ms. Donigan departed the Company on January 7, 2023.
(3)
Mr. Gilbert departed the Company on April 7, 2023.
(4)
Mr. Persaud departed the Company on March 6, 2023.

RITE AID CORPORATION   2023 Proxy Statement | 33

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Executive Summary
Our Company
Rite Aid Corporation is on the front lines of delivering health care services and retail products to over one million Americans daily. Our pharmacists are uniquely positioned to engage with customers and improve their health outcomes. In fiscal year 2023, we provided an array of whole being health products and services for the entire family through over 2,300 retail pharmacy locations across 17 states. Through Elixir, our pharmacy services company, we provided access to life saving and life enhancing prescriptions, and managed pharmacy benefits, pharmacy costs and healthcare outcomes to our members.
Leadership Transition
On January 7, 2023, the Board of Directors appointed Elizabeth Burr, then a member of the Company’s Board, as interim CEO, and Heyward Donigan, our former President and CEO, departed from the Company on that date. Rite Aid has initiated a search to identify a permanent CEO and has retained a leading executive search firm. Ms. Burr has extensive experience in the health and retail industries, and proven expertise in innovation, business strategy, retail and brand management and is prepared to execute on the Company’s business strategy.
In addition, two executives departed after the end of the 2023 fiscal year. Andre Persaud, Executive Vice President, Chief Retail Officer, departed from the Company on March 6, 2023, and Paul Gilbert, Executive Vice President, Chief Legal Officer and Secretary, departed from the Company on April 7, 2023. See “Executive Compensation: Potential Payments Upon Termination or Change in Control—Named Executive Officer Departures” for additional details regarding Ms. Donigan’s and Messrs. Persaud’s and Gilbert’s departures from the Company.
Strategy Execution
As a healthcare company with a retail footprint operating in diverse communities throughout the country, we are positioned to create meaningful customer, client, and member experiences for the millions of lives we touch.
We are focused on three key strategic drivers of growth:
1.
Growing our pharmacy business by improving our access to networks, strategically acquiring prescription files, increasing medication adherence, and making more clinical services available to our customers.
2.
Deepening our customer loyalty and engagement, by improving our in-store experience, optimizing our products and services, leveraging personalized marketing and communications, and expanding our digital solutions.
3.
Scaling our Elixir business by delivering on a value proposition unique to the mid-market including competitive pricing, leveraging our platform to deliver white-label services, optimizing our specialty pharmacy, and improving our operational efficiency.
Each of these strategic imperatives is furthered by our significant ongoing investments in our people and infrastructure, including our distributions centers, central fill operations, and systems for customer and client support.
Stockholder Vote on Executive Compensation and Stockholder Engagement
Stockholder endorsement of the design and administration of our executive compensation programs was evidenced by a vote of approval of our named executive officers’ compensation at our 2022 annual meeting of stockholders by approximately 77% of the votes cast. We recognize that the favorable vote regarding our named executive officers’ compensation was not as high as had been achieved in the prior fiscal year. The Compensation Committee considered the current program in effect, and it was determined that certain changes

34 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
would be made, as discussed below, to increase the effectiveness of our executive compensation design and administration. Our intention was to continually drive improved company performance and we remain committed to a significant focus on our stockholder outreach. In fiscal year 2023, we continued the same rigor to address any stockholder feedback we received through our scheduled outreach and any stockholder meetings we had during the ordinary course of business. The Compensation Committee will continue to review the results of future advisory say on pay votes and consider stockholder concerns in NEO compensation decisions and governance practices.
During the 2023 fiscal year, we reached out to stockholders holding over 40% of our stock to gather feedback on our pay and governance policies and practices. Our meetings were conducted virtually through online video conferencing or teleconference. We also held our first ever retail stockholder meeting, allowing our retail stockholders to submit various questions that were answered in a video streamed format through our investor relations website.
The feedback we received from stockholders reinforced the actions we have taken over the past couple of years. With stockholder input in mind, the Company continues its commitments to the following:

Diversified financial metrics between our annual bonus and our three-year long term incentive plans,

Developed three-year DEI strategy roadmap and began execution on initial initiatives, and

Continued stockholder outreach.
RESPONSE TO STOCKHOLDER FEEDBACK. For fiscal year 2023, the Compensation Committee revised the metrics in the annual and long-term incentive plans. By diversifying the performance metrics across Rite Aid’s performance-based program of annual and long-term incentives, the Company seeks to ensure that the program drives Company performance across multiple metrics and that the variable pay components are appropriately challenging. The annual incentive plan metrics were revised to focus on improving operating results which ultimately drive stockholder value. Adjusted EBITDA and Operating Cash Flow were selected as metrics to minimize overlap with the long-term incentive plan and because they provide executives with line of sight to their goals and are measures executives are able to impact. They also enhance alignment with stockholder value creation. Adjusted EBITDA is the most heavily weighted measure at 70% and Operating Cash Flow, weighted 30%, is a critical metric for our Company as it represents the cash we generate from our normal business operations to support and grow our business. Total revenue was eliminated as an annual incentive plan metric in fiscal year 2023.
The Compensation Committee incorporated new performance metrics for the performance-based units granted under the long-term incentive plan in fiscal year 2023. The metrics were revised to eliminate overlap with the annual plan, relate more directly to stockholder return and provide a greater focus on three metrics related to growth: Cumulative Scripts, Elixir Membership and Total Front-end Revenue. These growth metrics provide executives a greater line of sight to their goals and are tangible metrics in their day-to-day work. The financial metrics of our long-term success for the 2023 awards are weighted as follows:

TSR relative to the Russell 3000 Index, weighted 25%

30-day Cumulative Scripts, weighted 30%

Two-year Elixir Membership, weighted 30%

Two-year Total Front-end Revenue, weighted 15%
For 2023, the Compensation Committee added the 25%-weighted Relative TSR metric to provide an incentive for executives to create sustainable long-term value for the Company and to enhance the alignment of the interests of our executives with those of our stockholders. This metric replaces the relative TSR modifier of +/− 25% that was in place in prior years.
SAY ON PAY FREQUENCY VOTE. We believe that a stockholder advisory vote every year on the compensation of our named executive officers most closely aligns with the interests of stockholders. Stockholders have an opportunity to vote on the frequency of the advisory vote on executive compensation this year in Proposal 4 (Advisory Vote on the Frequency of Advisory Votes to Approve Named Executive Officer Compensation). At our 2017 annual meeting of stockholders, our stockholders voted to hold an advisory vote on named executive officer compensation every year. The Compensation Committee accepted the stockholders’ recommendation,

RITE AID CORPORATION   2023 Proxy Statement | 35

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
and stockholders will have another opportunity to consider and approve, in a non-binding advisory vote, the compensation of our named executive officers at the Annual Meeting. The Compensation Committee recommends stockholders vote to approve an annual say on pay vote at the Annual Meeting.
Stockholder Engagement Efforts
The Company engaged with stockholders in fiscal year 2023, as follows:
YEAR-ROUND EFFORTS.

Solicit feedback and seek to understand investor perspectives on issues of importance to them

Hold quarterly earnings calls

Monitor investor relations website and other related correspondence

Attend analyst conferences and participate in meetings with current stockholders and potential investors

Hold a call with management specifically targeted toward retail stockholders

Communicate company strategy and progress on various retail stockholder forums

Update our investor relations website
LATE SPRING / EARLY SUMMER EFFORTS.

Communicate pay decisions and changes to our pay program to our stockholders through our annual report and proxy statement

Extend first biannual invitation to our largest stockholders (together constituting holders of at least 40% or more of our outstanding shares of common stock) to discuss matters to be voted on at our upcoming annual meeting of stockholders

Discuss with stockholders’ topics of interest such as company performance, executive compensation, governance, DEI and ESG
LATE SUMMER / EARLY FALL EFFORTS.

Evaluate results of stockholder voting including our annual say on pay proposal and proxy advisor recommendations to establish the priorities for our stockholder engagement and to ensure that any significant concerns are identified and addressed

Assess results and review recommendations based on the Company’s strategic priorities
LATE FALL / EARLY WINTER EFFORTS.

Review stockholder and proxy advisory policy changes and recent feedback to identify common concerns and themes
LATE WINTER / EARLY SPRING EFFORTS.

Respond to stockholder feedback or concerns and evolving practices by modifying our programs or enhancing our disclosure as appropriate

Extend second biannual invitation to discuss current concerns with our largest stockholders (together constituting holders of at least 40% or more of our outstanding shares of common stock)
2023 Fiscal Year Key Business Highlights
In fiscal year 2023, Rite Aid continued to position the Company for future growth and expense efficiency by focusing on implementing our strategic initiatives aimed at operating as a fully-integrated healthcare company with a retail footprint. The Company faced several challenges in fiscal year 2023, primarily related to a reduction in revenue and gross profit from COVID-19 vaccines and testing and the loss of a large commercial client at Elixir as previously announced. However, the Company is making progress in its turnaround program to drive performance acceleration that is expected to help mitigate future challenges related to reimbursement, COVID-19

36 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
headwinds and enrollment at Elixir, and to drive meaningful EBITDA growth over the long term. For example, fiscal year 2023 fourth quarter results were at the higher end of Company guidance and exceed fiscal year 2022 fourth quarter results, driven by strong non-COVID-19 script growth, good expense control and improvement in procurement economics at Elixir.
Our financial highlights in fiscal year 2023 included:

Revenues of $24.1 billion, declined compared to prior year revenues of $24.6 billion

Retail comparable same store prescriptions increased 3.5%—comparable same store prescriptions, excluding COVID-19 impacts, increased 6.9%

Same store front-end sales, excluding tobacco, increased 1.6%

Elixir Adjusted EBITDA margins expanded by 62 bps

Net loss per share was $13.71, compared to prior year net loss per share of $9.96

Adjusted EBITDA was $429.2 million
Our key accomplishments in fiscal 2023 included:

Growing our market share in both the pharmacy and front-end lines of business

Reducing our operating SG&A costs by over $240 million, through implementation of expense control initiatives and the closing of about 150 underperforming stores

Growing our third-party e-commerce business by over 60% by deepening our relationships with an expanding range of partners

Improving our rebates at Elixir, enabling us to expand gross margin and become more competitive in the marketplace

Improving our capital structure which included paying off approximately $280 million of our 7.5% Senior Secured Notes, $52 million of our 7.7% Notes, and $27 million of our 6.875% Notes
In fiscal 2023, prescription drug sales accounted for over 71% of our total drugstore sales. We believe that our pharmacy operations will continue to represent a significant part of our business due to a combination of our efforts to expand the role of our over 6,400 pharmacists as whole-being health advocates; demographic trends such as an aging population and increased life expectancy; our focus on growth customers, particularly women between the ages of 25 to 49 who take care of themselves, their children, aging parents, and even pets; anticipated growth in the federally funded Medicare Part D prescription program as “baby boomers” continue to enroll; increased regulatory efforts to improve access and affordability of prescription drugs; and, the discovery of new and better prescription drug and over-the-counter therapies.
In addition, we offer a wide assortment of front-end merchandise to complement our pharmacy services and to provide convenience to our customers. We carry a full assortment of front end products, which accounted for the remaining nearly 29% of our total drug store sales in fiscal 2023. Front end products include over the counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, pet care, and numerous other every day and convenience products.

RITE AID CORPORATION   2023 Proxy Statement | 37

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Below are the details related to key financial indicators used as performance measures in our incentive programs for fiscal year 2023:
ADJUSTED EBITDA:
OPERATING CASH FLOW:

Our Adjusted EBITDA from continuing operations for fiscal year 2023 was $429.2 million or 1.8 percent of revenues, compared to $505.9 million or 2.1 percent of revenues for fiscal year 2022.

The decrease in Adjusted EBITDA from continuing operations was due primarily to a decrease of $104.6 million in the Retail Pharmacy segment partially offset by an increase of $27.8 million in the Pharmacy Services segment.

The decrease in the Retail Pharmacy Segment Adjusted EBITDA was due to decreased gross profit, partially offset by a decrease in SG&A expenses of $164.5 million. Gross profit was negatively impacted by the decline in COVID-19 vaccinations and testing, partially offset by the increase in non-COVID-19 prescriptions sold. SG&A expenses benefitted from lower payroll, occupancy, and other operating costs due to store closures and cost control initiatives, partially offset by an extra week.

The increase in the Pharmacy Services Segment Adjusted EBITDA was due to increased gross profit resulting from improved procurement economics, reductions in SG&A expense and the absence of prior year receivable reserves and write-downs, partially offset by lower membership.

Our Operating Cash Flow performance for the Rite Aid annual bonus plan calculation for fiscal year 2023 was negative $276.3 million. The Operating Cash Flow calculation for the purpose of our compensation metrics included cash flow from operating activities less capital expenditures. The Company did not achieve the $8 million target due to not achieving target EBITDA, higher than expected interest expense and other negative impacts from working capital changes.

Capital expenditures were negative $225 million as we continued to invest in store construction, relocation and remodel projects; technology enhancements; and prescription file buys.
See Appendix A for a reconciliation of our Adjusted EBITDA, which is a non-GAAP measure, to net income under GAAP.
Our Executive Compensation Philosophy
We believe strongly that pay should align with performance, and this focus is reflected in our executive compensation program. We seek to provide our NEOs with opportunities to earn total direct compensation (base salary, annual incentives, and long-term incentives) that is generally comparable to compensation levels provided to peer company executives and executives within other similarly-sized retailers and health services companies more broadly. Because of our desire to reinforce a performance-based culture, the Company emphasizes a compensation mix that is comprised primarily of variable pay. As a result, base salary makes up the smallest portion of total direct compensation for the NEOs, with variable pay in the form of annual and long- term incentives comprising the largest portion. The compensation mix varies by position, taking into account each position’s ability to influence Company results, as well as competitive practice.
Pay Mix
Our executive compensation program aims to appropriately balance the mix of cash and equity compensation, the mix of currently-paid and longer-term compensation, and the security of base benefits in a way that best furthers the compensation objectives discussed above. However, based on share usage constraints over the past few years, the mix of pay for our top executives has necessarily been weighted less toward equity compensation than is typical of our peers. Commencing in fiscal year 2021, we increased the relative weighting of the equity portion of executives’ target total remuneration opportunities to ensure greater alignment with stockholder interests and promote the retention of key new executive talent. Those equity opportunities consist of both performance-based equity that rewards executives based on Rite Aid’s financial achievements, and time-vested equity to promote the retention of critical executive talent and appropriately enhance current ownership levels.
The charts below show the overall mix of base salary, target annual incentives, and target long-term incentives for fiscal year 2023 for our former CEO, Ms. Donigan, and for our other NEOs, Messrs. Schroeder, Gilbert, Mennen

38 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
and Persaud. The majority of our NEOs’ target total direct compensation opportunity in fiscal year 2023 was provided in the form of performance-based compensation (variable pay), 89% for Ms. Donigan and 74% on average for our other NEOs serving at the end of the prior fiscal year. For fiscal year 2023, our interim CEO, Ms. Burr, was not eligible for the annual or long-term incentive plan and received all of her compensation as base salary so her compensation is excluded from the charts below. (See “CEO Transition-Related Compensation Decisions” below for a discussion of Ms. Burr’s compensation.)
Total Target Compensation
[MISSING IMAGE: pc_totaltarget-pn.jpg]
Compensation Governance and Best Practices
The table below summarizes compensation governance and best practices Rite Aid follows.
[MISSING IMAGE: ic_check-pn.jpg]WHAT WE DO
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]WHAT WE DO NOT DO
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Conduct annual stockholder advisory vote on the compensation of our named executive officers
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Maintain dialogue with stockholders on various topics, including executive pay practices
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Retain an independent executive compensation consultant to the Compensation Committee
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Ensure that a significant portion of executive officer total target remuneration is at risk
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Provide annual and long-term incentive plans with performance targets aligned to business goals
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Require a designated level of stock ownership for all named executive officers and non-management directors
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Require shares subject to the annual non-management director grant to be deferred until separation from service
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Require equity awards to have a double trigger (qualifying termination of employment and change in control)
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Complete an annual incentive compensation risk assessment
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Maintain a formal clawback policy for executive officers
[MISSING IMAGE: tm228886d1-icon_crossred4c.jpg]
Provide gross-up payments to cover personal income taxes or excise taxes related to executive severance benefits
[MISSING IMAGE: tm228886d1-icon_crossred4c.jpg]
Permit executives to engage in hedging or pledging of Rite Aid securities
[MISSING IMAGE: tm228886d1-icon_crossred4c.jpg]
Reward executives for imprudent, inappropriate, or unnecessary risk-taking
[MISSING IMAGE: tm228886d1-icon_crossred4c.jpg]
Allow the repricing of equity awards without stockholder approval
Our Fiscal Year 2023 Pay Decisions
In establishing performance measures for our fiscal year 2023 incentive programs, we diversified our financial metrics between our annual bonus and our three-year long-term incentive plans, in part in response to stockholder feedback.
ANNUAL BONUS PLAN. The Rite Aid annual bonus plan metrics were Adjusted EBITDA (70%) and Operating Cash Flow (30%). Operating Cash Flow replaced Free Cash Flow to increase the focus on the cash we generate from our normal business operations to support and grow our business. Total Revenue was removed from the annual bonus plan, and growth metrics were added to the long-term incentive plan, as discussed below, to enhance the focus of our NEOs on long-term growth.

RITE AID CORPORATION   2023 Proxy Statement | 39

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
For fiscal year 2023, Rite Aid’s bonus plan established an Adjusted EBITDA threshold of $442 million and an Operating Cash Flow threshold of negative $45 million. The Operating Cash Flow calculation, for the purpose of our compensation metrics, included elements of cash flow that the management team has some level of control over (Adjusted EBITDA plus or minus the change in inventory less capital expenditures).
Our Adjusted EBITDA performance for the Rite Aid annual bonus plan calculation for fiscal year 2023 was $429.2 million, which was below our threshold of $442 million. Operating Cash Flow was negative $276.3 million, which was below the threshold performance of negative $45 million due to lower EBITDA than planned, higher interest expense than planned and other working capital changes.
Performance below threshold for each metric resulted in no payout for the NEOs under the annual bonus plan for 2023.
The table below illustrates the performance targets that were set under the annual bonus plan and the actual performance against such targets in fiscal year 2023. Performance under the annual incentive plan was based on achieving below threshold results for Adjusted EBITDA and Operating Cash Flow and resulted in a 0% payout.
Performance LevelWeightingThreshold
(50%)
Target
(100%)
Maximum
(200%)
Actual
Performance
Achievement% of Weighted
Target
Attainment
Adjusted EBITDA (millions)70%$442$520$598$429.2Below threshold0%
Operating Cash Flow (millions)30%$(45)$8$86$(276.3)Below threshold0%
Total Resulting Payout0%
LONG-TERM INCENTIVE PLAN. The Compensation Committee structured the Long-Term Incentive Plan to include grants in the form of 45% restricted stock and 55% share-settled performance units for our Named Executive Officers. The restricted stock grants will vest ratable in 1/3 increments over three years, based on continued employment. The performance units cliff vest after three years based on meeting performance goals measured at the end of the performance period. The performance units are conditioned on performance against four performance metrics: Relative Total Shareholder Return (TSR) versus the Russell 3000 Index (weighted 25%); 30-day Cumulative Script Goals (weighted 30%); two-year Elixir Memberships (weighted 30%); and two-year Total Front-end Revenue (weighted 15%). These metrics are distinct from the metrics used for Rite Aid’s annual bonus plan.
Objectives of Our Executive Compensation Program
All of our executive compensation and executive benefits programs are within the purview of the Compensation Committee, which bases these programs on the same objectives that guide the Company in establishing all of its compensation programs. The Compensation Committee also administers the Company’s equity incentive compensation plans. In establishing or approving the compensation of our Named Executive Officers in any given year, the Compensation Committee is generally guided by the following objectives:

Compensation is based on the level of job responsibility, individual performance, and corporate performance, and fosters the long-term focus required for success in the pharmacy, health care services and retail health care industry. As associates progress to higher levels in the organization, an increasing proportion of their pay is linked to Company performance and stockholder returns and to longer-term performance because they are in a position to have greater influence on longer-term results.

Compensation reflects the value of the job in the marketplace. To attract and retain a highly skilled, diverse work force, we must remain competitive with the pay of other employers who compete with us for talent in the current, highly competitive market.

Compensation rewards performance. Our programs deliver compensation that is related to our corporate performance. Where corporate performance falls short of expectations, the programs deliver lower-tier compensation. In addition, the objectives of pay-for-performance and retention must be balanced. Even in periods of temporary downturns in overall corporate performance, the programs continue to ensure that successful, high-achieving associates will remain motivated and committed to the Company to support the stability and future needs of the Company.

40 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION

To be effective, performance-based compensation programs enable associates to easily understand how their efforts can affect their pay, both directly through individual performance accomplishments and indirectly through contributing to the Company’s achievement of its strategic and operational goals.

Compensation programs reward performance relative to consistent measures and goals at all levels of the organization. While the programs and individual pay levels will always reflect differences in job responsibilities, geographies, and marketplace considerations, the overall structure of compensation and benefit programs are broadly similar across the organization.

Compensation and benefit programs attract and retain associates who are interested in being a part of the Rite Aid team.
Compensation Committee’s Processes
In making executive pay decisions, the Compensation Committee assesses Company performance and reviews competitive compensation levels at a peer group of companies to ensure the Company’s executive compensation program is achieving its objectives.
The Compensation Committee uses Company performance measures in two ways:

In assessing the linkage between actual total compensation and performance, the Compensation Committee considers various measures of Company and industry performance, such as comparable store sales and script count growth, pharmacy services segment revenue growth, EBITDA growth, debt leverage ratios, return on average invested capital and net assets, relevant strategic initiatives, and total stockholder return. In determining performance relative to the Company’s peer group (as discussed further below), the Compensation Committee does not apply a formula or assign these performance measures relative weights. Instead, it makes a subjective determination after considering such measures collectively.

The Compensation Committee has established specific Company target incentive/award levels and performance measures that determine the size of payouts under the Company’s two formula-based incentive programs—the annual cash incentive bonus program and long-term incentive program.
Peer Group and Competitive Pay
For fiscal year 2023, the Compensation Committee, with the help of its independent compensation consultant, Mercer, assessed the Company’s programs relative to a peer group of organizations and published survey data. Because the Company has a limited number of publicly-traded direct competitors and because pharmacy sales (which account for over two-thirds of the Company’s retail revenue) are governed by third-party contracts, we reviewed potential peers relative to multiple criteria including:

INDUSTRY: Retail, health care services/pharmacy, and pharmacy benefits management (adjacent industries with similar operating models and/or product mix were considered);

BUSINESS MODEL CHARACTERISTICS: Health care services and pharmacy benefits management offerings, pharmacy retail, small ticket retail, and grocery/convenience store operating models, national presence (users and/or employees); and

COMPANY SIZE: Companies of similar size based on revenue (.25x to 4x the revenue of Rite Aid).
After reviewing potential peers relative to the criteria above, it was determined the peer group would be the same as the one used to set 2022 compensation. The peer group was last updated in 2022 to better align with the Company’s size based on revenue and to better reflect the industry of the Company. The peer group used to set pay in fiscal year 2023 includes the following 14 companies:

RITE AID CORPORATION   2023 Proxy Statement | 41

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Fiscal Year 2023 Peer Group
Peer Company
Revenue
($ Millions)
(1)
Centene Corporation114,130
Target Corporation103,348
Humana Inc.82,201
Albertsons Companies, Inc.68,956
Alimentation Couche-Tard Inc.53,194
Best Buy Co., Inc.52,333
Dollar General Corporation33,984
Molina Healthcare, Inc.24,656
AutoZone, Inc.14,630
Laboratory Corporation of America Holdings16,555
Bed Bath & Beyond Inc.9,176
DICK’S Sporting Goods, Inc.12,067
Ulta Beauty, Inc.8,100
Sprouts Farmers Market, Inc.6,209
75th Percentile72,267
Median29,320
25th Percentile11,344
Rite Aid24,308
Percentile Rank46th
(1)
Represents financials for trailing 12-month period as of 11/10/2021 from Standard & Poor’s Capital IQ.
The Compensation Committee compares the compensation levels of Rite Aid’s NEOs to peer company compensation levels in the aggregate and compares the pay of individual executives if the jobs are sufficiently similar to make the comparison meaningful.
In addition to peer group data, the Compensation Committee reviews market data based on specific functional responsibility for each executive from published survey data. The survey analysis targets data from similarly sized retail organizations based on each executive’s functional responsibility. The surveys used in the analysis include Mercer’s 2022 Executive Remuneration Suite, Mercer’s 2022 Retail Compensation and Benefits Survey, Mercer’s US IHN Healthcare System and Hospital Executives Survey and WTW General Executives Survey.
The Compensation Committee considers peer group and survey data to evaluate the degree to which the executive compensation program as a whole is competitive, and generally aims to establish target total direct compensation opportunities that are appropriately aligned with the medians of these comparator groups. The incentive plans were designed so executives can earn above competitive pay levels for superior performance and below competitive pay levels if performance is below expectations. The Compensation Committee assesses overall alignment of the compensation program rather than benchmarking a specific target position with consideration of factors, such as Company and individual performance, how executive roles function within Rite Aid, concerns about executive retention, and competitive positioning of equity compensation. The Compensation Committee assesses Rite Aid’s performance relative to its peer group on both a one- and three- year basis and observed alignment of performance with actual total direct compensation levels for the executives in the aggregate.
The Compensation Committee retained Mercer (US) LLC, a wholly-owned subsidiary of Marsh & McLennan Companies, Inc. (“MMC”), as its independent compensation consultant for fiscal year 2023. Mercer’s fees for executive compensation consulting in fiscal year 2023 were $469,262. Rite Aid also paid Mercer fees for other services of approximately $26,000 in fiscal year 2023. Rite Aid management retained an MMC affiliate for risk

42 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
management and business consulting services resulting in fees of approximately $658,226. The Compensation Committee conducted an independence assessment of Mercer, including considering the fees for other services provided by Mercer and its affiliates to the Company, consistent with NYSE listing standards, and concluded that the engagement of Mercer did not raise any conflicts of interest or similar concerns.
With respect to fiscal year 2023, Mercer reviewed recommendations and analysis prepared by management and provided advice and counsel to the Compensation Committee for the applicable periods during which they were engaged.
TOTAL COMPENSATION REVIEW. The Compensation Committee reviews each named executive officer’s base pay, annual bonus, and long-term incentives annually with input from the Compensation Committee’s independent compensation consultant. Following the fiscal year 2023 review, the Compensation Committee determined base salary levels were not aligned with the market and increased base salaries as shown in the Base Salary chart below to remain competitive.
Components of Executive Compensation for Fiscal Year 2023
For fiscal year 2023, the regular compensation program for our Named Executive Officers consisted of four primary components: (i) base salary, (ii) a cash incentive bonus opportunity under the Company’s annual incentive bonus plan, (iii) long-term incentives consisting of restricted stock and performance-based units, and (iv) a benefits package, including retirement and welfare benefits (which are generally provided to all associates of Rite Aid on a non-discriminatory basis), and limited perquisites. A significant portion of total compensation under the fiscal year 2023 program is variable, meaning it is subject to meeting specified performance goals and is comprised of target annual incentives and target long-term incentives.
Our executive compensation program aims to appropriately balance the mix of cash and equity compensation, the mix of currently-paid and longer-term compensation, and the security of base benefits consistent with the compensation objectives discussed above. Share usage constraints over the past few years, has caused the mix of pay for our top executives to be weighted less toward equity compensation than is typical of our peers. For fiscal year 2023, we leveraged the equity plan stockholders approved at the 2022 Annual Meeting to continue to provide a significant portion of executives’ target total remuneration opportunities in equity to ensure greater alignment with stockholder interests and promote the retention of key new executive talent. Our NEOs’ equity opportunities consist of both performance-based equity that rewards executives based on Rite Aid’s financial achievements, and time-vested equity that promotes retention of critical executive talent and enhances current ownership levels.
Base Salary
Base salary is one element of an executive’s annual cash compensation and reflects the executive’s long-term performance, skill set, and the market value of that skill set. In setting base salaries for fiscal year 2023, the Compensation Committee considered the following factors:

Base salary levels at peer group companies to test for reasonableness and competitiveness

Subjective judgment in view of the Company’s compensation objectives

Relative internal pay levels and pay equity

Individual performance

Promotions or increased responsibility

Overall pay mix

Preference towards increased performance-based pay
Consistent with our compensation objectives, as executives progress to higher levels in the organization, a greater proportion of overall compensation is directly linked to Company performance and stockholder returns.
For 2023, the Compensation Committee reviewed the Named Executive Officers’ base salaries, considering the principles described above under “The Compensation Committee’s Processes.” The Compensation Committee

RITE AID CORPORATION   2023 Proxy Statement | 43

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
determined that increases in base salaries were necessary to reasonably maintain market competitiveness and to reflect increases in executives’ responsibilities. Specifically, Andre Persaud’s base salary was increased 17% to continue to bring him closer to market competitive levels, compensate him for taking on additional responsibilities and in an effort to retain this key executive. Justin Mennen’s base salary was increased 7% to reflect his new role as Chief Digital and Technology Officer and to maintain market competitiveness. On average, NEO salaries have remained close to the peer group median.
Ms. Burr’s base salary is $300,000 per month to compensate her for serving as interim CEO of the Company until a replacement is appointed. Ms. Burr’s compensation was determined by the Compensation Committee based on conversations with Mercer, referencing both median market total cash compensation levels and the cash compensation of the former CEO as well as the limited duration expected for the role. The Compensation Committee determined her base salary considering that, while serving as interim CEO, Ms. Burr will not receive compensation payable to non-employee members of the Board and she will not participate in the Company’s executive annual or long-term incentive plans. If Ms. Burr serves as interim CEO for more than six months, the Board will review her monthly salary. For details on her compensation, see “CEO Transition-Related Compensation Decisions.”
The table below details base salaries for our Named Executive Officers as of the end of fiscal year 2023 and describes the rationale for base salary increases:
ExecutiveBase Salary at
End of FY 2022
Base Salary
at End of
FY 2023
Change from
Prior Fiscal
Year
Rationale
Elizabeth Burr(1)N/A$3,600,000None
Heyward Donigan(2)$1,150,000$1,184,5003%To maintain market competitiveness
Matthew Schroeder$748,000$769,9253%To maintain market competitiveness
Paul Gilbert(3)$602,000$619,8543%To maintain market competitiveness
Justin Mennen$510,000$545,7007%To maintain market competitiveness;
significantly below median for the position
Andre Persaud(4)$500,000$586,00017%To maintain market competitiveness;
significantly below median for the position
(1)
Elizabeth Burr was appointed interim CEO effective January 7, 2023.
(2)
Heyward Donigan departed the Company on January 7, 2023.
(3)
Paul Gilbert departed the Company on April 7, 2023.
(4)
Andre Persaud departed the Company on March 6, 2023.
Annual Incentive Awards
The Company’s annual incentive plan is designed to be consistent with the goals of our executive compensation philosophy to drive performance and increase stockholder value and reward the NEOs for meeting the Company’s financial objectives. For each fiscal year, the Compensation Committee establishes a target percentage of salary for each participant at the beginning of the fiscal year and approves the financial goals required for the Company to pay an award. Payouts for the NEOs are based on the Company’s financial results for the year relative to the predetermined performance measures.
ANNUAL INCENTIVE TARGET OPPORTUNITIES. Target opportunities for each NEO were based on job responsibilities, internal relativity, and peer group and survey data. The Compensation Committee’s objective was to set bonus targets so total annual cash compensation (including base salary and annual incentive assuming a target payout) was generally aligned with the market with a substantial portion of that compensation linked to corporate performance.
Consistent with our executive compensation philosophy, individuals with greater job responsibilities had a greater proportion of their total cash compensation tied to Company performance through the incentive plan. Under the plan formula, payouts can range from 0% to 200% of target depending on Company performance. The

44 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
NEOs’ incentive targets did not increase in fiscal year 2023. The Compensation Committee established the following threshold, target and maximum payouts as a percentage of base salary for fiscal year 2023:
Annual Incentive Opportunity
ExecutiveThreshold Payout
(as a % of Salary)
Target Payout
(as a % of Salary)
Maximum Payout
(as a % of Salary)
Elizabeth Burr(1)0%0%0%
Heyward Donigan(2)100%200%400%
Matthew Schroeder50%100%200%
Paul Gilbert(3)37.5%75%150%
Justin Mennen50%100%200%
Andre Persaud(4)50%100%200%
(1)
Our interim CEO, Elizabeth Burr, did not participate in the 2023 Rite Aid Annual Incentive Plan.
(2)
Based on actual achievement against the metrics established under the 2023 Rite Aid Annual Incentive Plan, Heyward Donigan did not receive a payout under the 2023 Rite Aid Annual Incentive Plan consistent with other plan participants.
(3)
Paul Gilbert departed the Company on April 7, 2023 and is not eligible for a payout under the 2023 Rite Aid Annual Incentive Plan.
(4)
Andre Persaud departed the Company on March 6, 2023 and is not eligible for a payout under the 2023 Rite Aid Annual Incentive Plan.
ANNUAL INCENTIVE PLAN METRICS. To drive appropriate performance through the Annual Incentive Plan and to continue to balance stockholders’ concerns that the plan should use more than a single performance metric, the Compensation Committee retained the Adjusted EBITDA performance metric (weighted 70%) and replaced the Free Cash Flow metric with Operating Cash Flow (weighted 30%). Adjusted EBITDA is the most heavily weighted measure because it appropriately encourages the NEOs to focus on improving operating results which ultimately drive stockholder value. Operating Cash Flow is a critical metric for our Company as it represents the cash we generate from our normal business operations to support and grow our business. Adjusted EBITDA and Operating Cash Flow were selected as metrics to minimize overlap with the long-term incentive plan and because they provide executives with line of sight to their goals and are measures executives are able to impact. They also enhance alignment with stockholder value creation.
The target performance level for the Adjusted EBITDA target of $520 million for fiscal year 2023 was set above the fiscal year 2022 target of $490 million and the fiscal year 2022 actual performance of $506 million. The Compensation Committee also established a threshold at which management could be rewarded at 50% of bonus target at achievement of Adjusted EBITDA of $442 million (above the fiscal year 2022 threshold), and a maximum at which management could be rewarded at 200% of bonus target at achievement of Adjusted EBITDA of $598 million (above the fiscal year 2022 target of $539 million). The performance goals were set at these levels so that the plan continues to motivate executives to achieve the Company’s short-term financial objectives and to support executive retention during these challenging times. Given the challenges in fiscal year 2023, the Company did not meet the threshold performance levels for Adjusted EBITDA or Operating Cash Flow and the NEOs received $0 payouts under the annual bonus plan.

RITE AID CORPORATION   2023 Proxy Statement | 45

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Annual Incentive
Plan Metrics
WeightingDescription
Adjusted EBITDA
[MISSING IMAGE: pc_adjustedebitda-pn.jpg]
Adjusted EBITDA is the more heavily weighted measure because it appropriately encourages the NEOs to focus on improving operating results which ultimately drive stockholder value. EBITDA growth has historically shown a strong positive correlation with three-year and five-year total stockholder return for Rite Aid and its peer group. The majority of Rite Aid’s peer companies use an EBITDA measure in their annual incentive plans. Based on Rite Aid’s current financial situation and capital structure, the Compensation Committee believes that Adjusted EBITDA is the best indicator of Rite Aid’s operating performance. The measure is tracked regularly and is clearly understood by the officers and they can impact the measure by taking actions to improve the operating performance of our stores. In addition, the Company regularly communicates Adjusted EBITDA to the investment community.
The Compensation Committee established an Adjusted EBITDA performance target of $520 million for fiscal year 2023, based on the financial plan targets. The Compensation Committee established a threshold at which management could be rewarded at 50% of bonus target at achievement of Adjusted EBITDA of $442 million (85% of target), and a maximum at which management could be rewarded at 200% of bonus target at achievement of Adjusted EBITDA of $598 million (115% of target).
In fiscal year 2023, Consolidated Adjusted EBITDA was $429.2 million, which was below threshold due to a reduction in revenue from COVID-19 vaccines and testing, store closures and the loss of a large commercial client at Elixir.
Consolidated Adjusted EBITDA consists of Adjusted EBITDA from continuing operations. As discussed in greater detail in Appendix A, we define Adjusted EBITDA as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments, charges or credits for facility exit and impairment, goodwill and intangible asset impairment charges, inventory write-downs related to store closings, gains or losses on debt modifications and retirements, and other items (including stock-based compensation expense, merger and acquisition-related costs, non-recurring litigation settlements, severance, restructuring-related costs, costs related to facility closures, gain or loss on sale of assets, gain or loss on Bartell acquisition, and the change in estimate related to manufacturer rebate receivables). We emphasize Adjusted EBITDA, a non-GAAP financial measure, as a basis for incentive compensation and also in our corporate decision-making because it provides information that facilitates internal comparisons to the historical operating performance of prior periods and external comparisons to competitors’ historical operating performance.

46 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Annual Incentive
Plan Metrics
WeightingDescription
Operating Cash Flow
[MISSING IMAGE: pc_operatingcashflow-pn.jpg]
Operating cash flow is defined as cash flow from operating activities minus capital expenditures.
Operating Cash Flow is a critical metric for our Company as it represents the cash we generate to support and grow our business, and includes benefits generated from ongoing inventory and working capital management. A key aspect of our market value and future opportunities are derived from our ability to continue to reduce total debt outstanding and our corresponding leverage ratio.
Based on our current debt position, we believe Operating Cash Flow is the best indicator of our ability to continue to meet our debt obligations, pay down debt and to enhance the Company’s capital structure. The use of Operating Cash Flow provides executives enhanced line of sight and aligns our management to the key objective of delivering enhanced stockholder value.
The Compensation Committee established an Operating Cash Flow performance target of $8 million for fiscal year 2023, based on the financial plan targets. In addition, the Compensation Committee established a threshold at which management could be rewarded at 50% of bonus target at achievement of Operating Cash Flow of negative $45 million, and a maximum at which management could be rewarded at 200% of bonus target at achievement of Free Cash Flow of $86 million.
In fiscal year 2023, Operating Cash Flow as defined for the purpose of the compensation metric was negative $276.3 million, which was below the threshold for payout. Operating Cash Flow was impacted by a decrease in Adjusted EBITDA, an increase in interest expense and other changes in working capital.
The threshold, target, maximum and actual performance against the goals for the annual incentive plan for fiscal year 2023 are each set out in the table below. For fiscal year 2023, our Adjusted EBITDA for the Rite Aid annual bonus plan calculation was $429.2 million, which was below our threshold of $442 million and Operating Cash Flow was negative $276.3 million, which was below the threshold of negative $45 million, due to lower than planned EBITDA, higher than planned interest expenses and lower than expected working capital benefits due to inventory inflation.
Fiscal Year 2023 Rite Aid Annual Incentive Plan Performance Goal
Performance
Level
WeightingThreshold
(50%)
Target
(100%)
Maximum
(200%)
Actual
Performance
AchievementResulting Weighted
Payout
as a % of
Target Award
Adjusted EBITDA (millions)70%$442$520$598$429.2Below threshold0%
Operating Cash Flow (millions)30%$(45)$8$86$(276.3)Below threshold0%
Total Resulting Payout0%
Adjusted EBITDA and Operating Cash Flow performance relative to the goals listed above resulted in short-term incentive plan payouts of 0% of target award opportunities for fiscal year 2023.

RITE AID CORPORATION   2023 Proxy Statement | 47

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
The actual plan payouts and their percentage of target for fiscal year 2023 are set out in the table below:
Fiscal Year 2023 Rite Aid Annual Incentive Plan Payouts
ExecutiveTarget Bonus Opportunity% of TargetCalculated Payout
Elizabeth Burr(1)$00%$0
Heyward Donigan(2)$2,369,0000%$0
Matthew Schroeder$769,9250%$0
Paul Gilbert(3)$464,8910%$0
Justin Mennen$545,7000%$0
Andre Persaud(4)$586,0000%$0
(1)
Ms. Burr did not participate in the 2023 Rite Aid Annual Incentive Plan.
(2)
Based on actual achievement against the metrics established under the 2023 Rite Aid Annual Incentive Plan, Heyward Donigan did not receive a payout under the 2023 Rite Aid Annual Incentive Plan consistent with other participants.
(3)
Mr. Gilbert was not eligible to receive the fiscal year 2023 Annual Incentive Plan award as a result of his departure from the Company on April 7, 2023, prior to the payment date.
(4)
Mr. Persaud was not eligible to receive the fiscal year 2023 Annual Incentive Plan award as a result of his departure from the Company on March 6, 2023, prior to the payment date.
Long-Term Incentive Program
The purpose of the long-term incentive program is to support the long-term perspective necessary for continued success in our business and focus our NEOs on creating long-term, sustainable stockholder value.
LONG-TERM INCENTIVE TARGET OPPORTUNITY. Our annual long-term incentive (“LTI”) target opportunities for each NEO are shown below:
Long-Term Incentive Target Opportunities
ExecutiveTarget Opportunity
(as a % of Salary)
Elizabeth Burr(1)0%
Heyward Donigan(2)600%
Matthew Schroeder250%
Paul Gilbert(3)150%
Justin Mennen150%
Andre Persaud(4)175%
(1)
Our interim CEO, Ms. Burr, is not eligible for the Long-Term Incentive Program.
(2)
Ms. Donigan is no longer eligible to earn the fiscal year 2023-2025 long-term performance-based unit awards as a result of her departure on January 7, 2023.
(3)
Mr. Gilbert is no longer eligible to earn the fiscal year 2023-2025 long-term performance-based unit awards, as a result of his departure on April 7, 2023.
(4)
Mr. Persaud is no longer eligible to earn the fiscal year 2023-2025 long-term performance-based unit awards, as a result of his departure on March 6, 2023.
The Compensation Committee reviewed peer group data and found that the design of the long-term incentive program is reasonably aligned with general retail industry market practice. Target grant values for individual executive officers were established based on individual performance, ability to effect results and internal relativity. Consistent with the Company’s compensation philosophy, executive officers at higher levels received a

48 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
greater proportion of total pay in the form of long-term incentives. For fiscal year 2023, the Company maintained each NEOs’ target opportunities, which were last increased in fiscal year 2021 to provide a larger portion of their total target compensation in the form of equity and create better alignment with Company performance and stockholders’ interests.
LONG-TERM INCENTIVE MIX. Under the LTI program, we grant a combination of performance-based units and restricted stock. Restricted stock grants generally vest over a multi-year period (three years or longer) and are tied to the value of our stock. Performance-based awards, where the ultimate payout may vary, require Rite Aid to count more shares against the number of shares available for issuance if above-target performance is achieved to the benefit of all stakeholders. We are also careful to manage share usage and are sensitive to our share burn rate and dilution. We have maintained the equity mix of performance-based units at 55% in fiscal year 2023, in light of these considerations. Performance-based compensation provides an upside for extraordinary performance and less or no compensation when the pre-established performance objectives are not achieved. An adequate share reserve is needed to grant variable performance-based units which can be earned at or above target depending on performance.
VehicleApproximate Proportion of
2023 Long-Term Incentive
Target Opportunity
Purpose
Performance-Based Units
[MISSING IMAGE: tm217739d1-pc_vehiclepbupn.jpg]
Links compensation to multi-year operating results on key measures tied to stockholder value creation
Restricted Stock
[MISSING IMAGE: tm217739d1-pc_vehiclerestpn.jpg]
Supports retention and provides a vehicle with more stability and less risk. Aligns executive and stockholder interests and focuses executives on value creation
In determining the overall mix of long-term incentive vehicles, the following factors were considered:

Risk/reward tradeoffs: Using multiple long-term incentive vehicles can balance the need for a strong performance-based program against risk to executives.

Performance measurement: Using a combination of vehicles allows the Company to focus executives on both stock price appreciation and achievement of consistent operating results, which we believe leads to creation of value for stockholders.

Management of share usage and market practice: Rite Aid considers market practice concerning both share usage and competitive long-term incentive levels. Rite Aid uses either a stock-based performance vehicle or a cash-based performance vehicle which is aligned with peer companies and retailers of similar size. The target LTI mix has been selected to align the compensation opportunity for executives and associates with our stockholder return.
The Compensation Committee’s process for setting grant dates is discussed below. On the approval date, those values are converted to the equivalent number of shares based on the closing price of the Company’s common stock on the date of approval.
GRANT TIMING. The Compensation Committee has a policy that, in the normal course, annual long-term incentive awards (other than special or new hire grants) will be approved by the Compensation Committee once a year at its annual meeting held in connection with the annual stockholders’ meeting, with a grant date of the later of the second business day after release of the Company’s first quarter earnings or the date of approval. Grants are made to the NEOs at the same time awards are made to all other associates as part of the annual grant process.
SPECIAL AWARDS. From time to time, the Company may make grants in addition to the annual equity grant, including to NEOs. Typically, these grants include awards such as new hire inducement awards, promotional awards, or retention awards. Special awards can also be used to provide performance incentives in connection with specific corporate or financial goals of the Company. In 2023, a special one-time award of $255,000 in

RITE AID CORPORATION   2023 Proxy Statement | 49

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
restricted stock was granted to Justin Mennen to reflect his increased responsibilities for the digital business without a corresponding salary increase for the change in duties and to encourage his retention given the importance of his more significant role. The award will vest in full after three years if he remains employed with the Company.
Performance Awards
Performance awards are intended to align the interests of the executives with those of stockholders through the use of measures the Company believes drive its long-term success. Performance awards are normally granted annually and are structured as a targeted number of units based on the Company’s achievement of specific performance levels with payout generally occurring after a three-year period.
2023 Performance-based Units
For the 2023 performance-based unit grants (“2023-2025 Plan”), the Compensation Committee incorporated new performance metrics as the financial indicators of our long-term success. In 2023, the metrics were revised to eliminate overlap with the annual plan, relate more directly to stockholder return and provide a greater focus on three metrics related to growth: Cumulative Scripts, Elixir Membership and Total Front-end Revenue. These growth metrics provide executives a greater line of sight to their goals and are more tangible metrics in their day-to-day work. Also, by diversifying the performance metrics across Rite Aid’s performance-based program of annual and long-term incentives, the Company seeks to ensure that the program drives Company performance across multiple metrics and that the variable pay components are suitably challenging. The 2023 awards are based on the following four performance metrics:

TSR relative to the Russell 3000 Index (weighted 25%)

30-day Cumulative Scripts (excluding controlled substances) (weighted 30%)

Two-year Elixir Membership (excluding Elixir Insurance) (weighted 30%)

Two-year Total Front-end Revenue (excluding Pharmacy, tobacco and Elixir Insurance) (weighted 15%)
The Compensation Committee decided to use two-year performance periods for the Elixir Membership and Total Front-end Revenue given the timing of our CEO transition and the challenges of setting three-year performance metrics in a volatile market environment.
For 2023, the Compensation Committee added a 25%-weighted Relative TSR metric to provide an incentive for executives to create sustainable long-term value for the Company and to enhance the alignment of the interests of our executives with those of our stockholders. At the same time, the Committee eliminated the relative TSR modifier of +/− 25% that was in place in prior years.
As shown in the table below, payouts can range from 0% (for performance below threshold) to 150% of the target number of units (for performance at or above maximum), with 37.5% earned for performance at the threshold levels.
2023-2025 Plan: Performance-based Units
ExecutiveThreshold Award
($)
Target Award
($)
Maximum Award
($)
Elizabeth Burr(1)000
Heyward Donigan(2)1,465,8193,908,8505,863,274
Matthew Schroeder396,9921,058,6451,587,968
Paul Gilbert(2)191,765511,374767,060
Justin Mennen168,826450,202675,303
Andre Persaud(2)196,709524,557786,836
(1)
Ms. Burr is not eligible to participate in the Long-Term Incentive Plan.

50 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
(2)
Ms. Donigan, Mr. Gilbert and Mr. Persaud are no longer eligible to earn the fiscal year 2023-2025 long-term performance-based unit awards granted to each executive on July 27, 2022 as a result of each executive’s departure from the Company.
2022 Performance-based Units
For the 2022 performance-based unit grants (“2022-2024 Plan”), the Compensation Committee maintained the metrics used in the 2021-2023 Plan. Revisions were made to the weighting to better balance the incentives toward profitability, growth and financial health. The 2022 awards were based on the following performance metrics:

Three-year Leverage Ratio weighted 34% (continued from FY21 Plan Design but decreased from 50% to 34%)

Three-Year Cumulative Revenue weighted 33% (continued from FY21 Plan Design but increased from 25% to 33%)

Three-Year Cumulative Scripts weighted 33% (continued from FY21 Plan Design but increased from 25% to 33%)
As in prior years, to further align the interests of our executives with those of our stockholders and add an additional incentive for them to create sustainable long-term value for the Company, the Compensation Committee also determined to subject the award to modification of +/− 25% based on our relative stockholder return versus the Russell 3000 Index over the three-year cliff vesting period, which ends after certification of fiscal year 2024 results.
As shown in the table below, payouts can range from 0% (for performance below threshold) to 187.5% of the target number of units (for performance at or above maximum), with 37.5% earned for performance at the threshold levels.
2022-2024 Plan: Performance-based Units
ExecutiveThreshold Award
($)
Target Award
($)
Maximum Award
($)
Heyward Donigan(1)1,423,1203,794,9887,115,602
Matthew Schroeder385,6871,028,4971,928,433
Paul Gilbert(1)186,243496,647931,213
Justin Mennen157,777420,739788,886
Andre Persaud(1)180,467481,245902,335
(1)
Ms. Donigan, Mr. Gilbert and Mr. Persaud are no longer eligible to earn the fiscal year 2022-2024 long-term performance-based unit awards granted to each executive on July 7, 2021 as a result of each executive’s departure from the Company.
2021 Performance-based Units
For the 2021 performance-based unit grants (“2021-2023 Plan”), the Compensation Committee established performance metrics that were the financial indicators of our long-term success. The 2021 awards were earned based on the following performance metrics:

Three-year Leverage Ratio weighted 50%

Two-Year Cumulative Revenue weighted 25%

Two-Year Cumulative Scripts weighted 25%
As in prior years, to further align the interests of our executives with those of our stockholders and add an additional incentive for them to create sustainable long-term value for the Company, the Compensation Committee also determined to subject the award to modification of +/− 25% based on our relative stockholder return versus the Russell 3000 Index over the three-year cliff vesting period, which ended after certification of fiscal year 2023 results.

RITE AID CORPORATION   2023 Proxy Statement | 51

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
As shown in the table below, payouts can range from 0% (for performance below threshold) to 187.5% of the target number of units (for performance at or above maximum), with 37.5% earned for performance at the threshold levels.
The following charts summarize the financial performance calculation and the cash payment that was earned:
Financial Performance Calculation: 2021-2023 Plan
Component
Metric
Component
Weighting
Threshold
Performance
(50% Payout)
Target
Performance
(100% Payout)
Maximum
Performance
(200% Payout)
Actual
Performance
Component
Payout %
2021-2023
Leverage Ratio
[MISSING IMAGE: tm228886d1-pc_ebitdapn.jpg]
4.5%4.0%3.5%6.49%0%
2021-2022
Cum. Revenue
[MISSING IMAGE: tm228886d1-pc_ratiopn.jpg]
$16,885$17,774$20,440$17,08915.4%
2021-2022
Cum. Scripts
(in millions)
[MISSING IMAGE: tm228886d2-pc_ratio1bw.jpg]
422.1444.3511.0459.227.8%
Weighted Sub-Total43.2%
TSR Relative to
Russell 3000
ModifierSee Note (a)
below.
-25%
Final Calculated
Payout
32.4%
(a)
The TSR of negative 72.37% over the performance period ended March 4, 2023 corresponded to a percentile rank of 8th (2,407 out of 2,607), which was in the bottom third and resulted in a TSR multiple of .75x.
2021-2023 Plan Payouts
ExecutiveShares Underlying
Award at Target
(#)
Payout
(%)
Calculated Payout/
Shares Settled
(#)
Matthew Schroeder49,76332.416,123
Justin Mennen22,96832.47,441
Restricted Stock—Awards Under Fiscal Year 2023 Plan
Restricted stock grants are intended to support retention of executives and focus them on long-term performance because they vest over a multi-year period (ratably over the three years from the date of grant) and are tied to the value of our stock. The risk profile of restricted stock is aligned with stockholders, as it can motivate executives to both increase and preserve stock price. The table below summarizes 2023 restricted stock awards:

52 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
2023 Restricted Stock Awards
ExecutiveAward Value
($)
Number of Shares
(#)
Heyward Donigan(1)3,198,144429,858
Matthew Schroeder866,165116,420
Paul Gilbert(2)418,39656,236
Justin Mennen623,14775,509
Andre Persaud(3)429,18457,686
(1)
Ms. Donigan is not eligible for one-third of the restricted stock awards granted on July 27, 2022 as a result of her separation from the Company on January 7, 2023.
(2)
Mr. Gilbert is not eligible for the restricted stock awards granted on July 27, 2022 as a result of his separation from the Company on April 7, 2023.
(3)
Mr. Persaud is not eligible for the restricted stock awards granted on July 27, 2022 as a result of his separation from the Company on March 6, 2023.
CEO Transition-Related Compensation Decisions
On January 7, 2023, the Board appointed Ms. Burr as interim CEO in connection with the related departure of Heyward Donigan, our former President and CEO. The Company entered into an offer letter with Ms. Burr, dated as of January 7, 2023, which provides Ms. Burr a base salary of $300,000 a month while serving as interim CEO of the Company. While serving as interim CEO of the Company, Ms. Burr will not receive the compensation payable to non-employee members of the Board and she will not participate in the Company’s short- or long-term incentive plans, 401(k) plan, group medical, dental and vision insurance plans. Ms. Burr’s compensation was determined by the Compensation Committee based on conversations with Mercer, referencing both median market total cash compensation levels and the cash compensation of the former CEO as well as the limited duration expected for the role. If Ms. Burr serves as interim CEO for more than six months, the Board will review her monthly salary. For details on her offer letter, see “Executive Employment Agreements—Interim CEO Offer Letter with Elizabeth Burr.”
The Board determined that Ms. Donigan’s departure from the Company constituted a termination without cause under her employment agreement with us, entitling her to the severance benefits provided under the employment agreement. For details regarding the severance benefits provided to Ms. Donigan under the separation agreement entered into upon her departure from the Company, see “Executive Compensation: Potential Payments Upon Termination or Change in Control—Named Executive Officer Departures.”
Post-Employment and Change in Control Benefits
To attract highly skilled executives and to provide for certainty of rights and obligations, Rite Aid has historically provided employment agreements to its executive officers, including our Named Executive Officers. The terms of the employment agreements are described in more detail under the caption “Executive Employment Agreements.” Additional information regarding the severance and change in control benefits provided under the employment agreements is described under the section entitled “Executive Compensation—Potential Payments Upon Termination or Change in Control.”
Other Benefits
Our compensation program for our Named Executive Officers also features other benefits, including participation in our 401(k) savings plan, a tax-qualified defined contribution plan under which participants can save for retirement subject to IRS limits, and life, disability and health insurance benefits on the same general terms as other participants in these programs. We provide very limited perquisites to officers of the Company including the Named Executive Officers pursuant to the officer’s employment agreements, such as financial planning and automobile allowances.

RITE AID CORPORATION   2023 Proxy Statement | 53

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Deductibility Cap on Executive Compensation
To maintain flexibility and the ability to pay competitive compensation, we do not require all compensation to be deductible. Section 162(m) of the Internal Revenue Code generally limits to $1.0 million the amount of remuneration that the Company may deduct in any calendar year for certain executive officers. Prior to 2018, we structured our annual incentive awards and long-term incentive awards with the intention of meeting the exception to this limitation for “performance-based” compensation, as defined in Section 162(m), so that these amounts could be fully deductible for income tax purposes. The performance-based exception was eliminated effective January 1, 2018, and compensation paid to our NEOs in excess of $1.0 million will not be deductible unless it qualifies for transition relief applicable to certain arrangements in place as of, and not modified after, November 2, 2017. To maintain the flexibility to provide compensation programs for our NEOs that will best incentivize them to achieve our key business objectives and create sustainable long-term stockholder value, the Compensation Committee reserves the right to pay compensation that may not be deductible to the Company if it determines that doing so would be in the best interests of the Company.
Policy Regarding Recoupment of Certain Compensation
The Company has adopted a formal compensation recovery or “clawback” policy for its executive officers, including all NEOs, which covers all compensation paid or awarded. Under the policy, the Board of Directors may seek to recoup from executives certain incentive compensation, including cash bonuses and equity incentive awards paid based on the achievement of financial performance metrics, in the event the Company is required to restate its financial statements. In March 2020, the Board amended the Company’s clawback policy to (1) expand its scope to cover executive officers’ misconduct in violation of law, Company policy or the code of conduct, including an executive officer’s material failure to exercise his or her assigned oversight responsibilities, that results in material financial, operational or reputational harm to the Company (collectively, “Detrimental Harm”) and (2) require public disclosure of recoupment of compensation where the underlying facts are disclosed, subject to certain legal and privacy rights considerations. The Board of Directors may seek to recoup, or cause to be forfeited, all or a portion of the bonus, incentive compensation or equity-based compensation received by, or awarded in respect of the period of misconduct in cases of Detrimental Harm.
In 2022, the SEC adopted final rules implementing the incentive-based compensation recovery provisions of the Dodd-Frank Act. The Company intends to review and revise its current recoupment policies and/or adopt a new recoupment policy, as necessary to comply with the new requirements once the NYSE listing standards become effective.
Prohibition on Margin Accounts and Hedging and Similar Transactions
Our directors, officers and other associates are prohibited from engaging in hedging or monetization transactions, such as zero-cost collars, equity swaps, exchange funds and forward sale contracts, with respect to our securities. Because hedging transactions might allow a director, officer or other associate to continue to own our securities, whether obtained through our equity compensation plans or otherwise, without the full risks and rewards of ownership, such hedging transactions are prohibited. Directors, officers and other employees are also prohibited from holding in a margin account, or otherwise pledging, Company securities as collateral for a loan.
Director and Officer Stock Ownership Guidelines
Our Stock Ownership Guidelines have been established to further the investment of our non-management directors, executive officers, and Senior Vice Presidents in the success of the Company and to encourage a long-term perspective in managing the Company.

54 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
The current stock ownership requirements are:
PositionMinimum Ownership Requirements
Chief Executive Officer5 times base salary
Senior Executive Vice Presidents3 times base salary
Executive Vice Presidents2 times base salary
Senior Vice Presidents1 times base salary
Non-Management Directors5 times annual cash retainer
Newly appointed or promoted executives who are or become subject to our Stock Ownership Guidelines and newly elected non-management directors have five years from the time they are appointed, promoted, or elected, to meet the stock ownership requirements. In June 2022, the plan was modified to provide that participants are considered to be in compliance with the guidelines if they have previously met the requirements, as long as the individual’s number of shares did not decrease. Given how new each of our Named Executive Officers is in his or her role, and how modest current equity holdings are as a result, it will be critical to continue to promote the alignment of our Named Executives Officers’ interests with those of our stockholders.
For purposes of determining stock ownership levels, the following forms of equity interests in the Company are included:

Shares owned outright by the participant or his or her immediate family members residing in the same household;

Restricted stock and restricted stock units whether or not vested; and

Shares underlying Rite Aid stock options whether or not vested.
Restricted stock and restricted stock units, whether or not vested, and shares owned count as one (1) share equivalent per share beneficially owned and stock options, whether or not vested, count as one-half (.5) share equivalent per stock option.
The Compensation Committee is responsible for interpreting and administering the Stock Ownership Guidelines, and may, from time to time, reevaluate and revise the Stock Ownership Guidelines, including when there are changes to the Company’s capital structure or where implementation of the Stock Ownership Guidelines would cause a non-management director, executive officer, or Senior Vice President to incur a hardship due to his or her unique financial circumstances.
COMPENSATION COMMITTEE REPORT
The Compensation Committee of the Board of Directors has reviewed and discussed the foregoing Compensation Discussion and Analysis with management and based on that review and discussion, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this proxy statement.
THE COMPENSATION COMMITTEE
Kate B. Quinn, Chair
Robert E. Knowling, Jr.
Arun Nayar

RITE AID CORPORATION   2023 Proxy Statement | 55

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION TABLES
Summary Compensation Table
The following summary compensation table sets forth the cash and non-cash compensation for the fiscal year ended March 4, 2023 paid to or earned by (i) all persons who served as our principal executive officer, (ii) all persons who served as our principal financial officer, and (iii) the three most highly compensated executive officers of the Company other than the principal executive officer or the principal financial officer who were serving at the end of the 2023 fiscal year (collectively, the “Named Executive Officers”). The summary compensation table also sets forth the cash and non-cash compensation for the fiscal years ended February 26, 2022 and February 27, 2021, respectively, for such individuals who were Named Executive Officers in the applicable fiscal year or as otherwise required by SEC rules.
Name and
Principal Position
Fiscal
Year
Salary
($)
Bonus
($)
Stock
Awards
($)
(1)
Non-Equity
Incentive
Plan 
Compensation
($)
(2)
All Other
Compensation
($)
(3)
Total
($)
Elizabeth Burr(4)
(interim CEO)
2023588,462159,997110,000858,459
Heyward Donigan(5)
(Former President
and CEO)
20231,043,7137,106,993617,1058,767,811
20221,126,9236,547,4272,208,00029,1579,911,507
20211,000,0001,160,0007,389,08722,0009,571,087
Matthew Schroeder
(Executive VP, CFO)
2023796,9211,924,81025,6002,747,331
2022732,9431,774,444912,99116,6833,437,061
2021648,177377,0582,001,211137,41212,0003,175,858
Justin Mennen(6)
(Executive VP, Chief
Digital and Technology
Officer)
2023562,4321,073,34925,2551,661,036
2022510,000764,983367,20012,7261,654,909
2021500,000217,500923,63613,6551,654,791
Paul Gilbert(7)
(Former Executive
VP, Chief Legal
Officer, and Secretary)
2023641,566929,76926,5751,597,910
2022600,154856,856433,44018,5601,909,010
Andre Persaud(8)
(Former Executive
VP, Chief Retail
Officer)
2023570,058953,74126,7501,550,549
(1)
The amounts reported reflect the aggregate grant date fair value of each stock award computed in accordance with FASB ASC Topic 718 under the assumptions noted. For information regarding the assumptions used in determining the fair value of an award shown in this column, please refer to Note 18 of the Company’s Annual Report on Form 10-K as filed with the SEC on May 1, 2023, Note 18 of the Company’s Annual Report on Form 10-K as filed with the SEC on April 25, 2022, and Note 18 of the Company’s Annual Report on Form 10-K as filed with the SEC on April 27, 2021. The value presented for fiscal year 2023 includes the grant date fair value of restricted stock awards (restricted stock units for Ms. Burr, granted while serving as a director of the Company) and performance awards at target, as shown in the chart below. Assuming the maximum level of achievement under the performance awards, the grant date fair value of such awards for each of the Named Executive Officers are estimated to be as follows: Ms. Donigan, $5,863,274; Mr. Schroeder, $1,587,968; Mr. Gilbert, $767,060; Mr. Mennen, $675,303; and Mr. Persaud, $786,836. The performance awards are subject to liability accounting under FASB ASC Topic 718 and the value reported represents the value for the reporting period ended March 4, 2023, assuming the stock price of $3.58.

56 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
NameRestricted Stock
Units
($)
Restricted Stock
Award
($)
Performance Award
Target Performance
($)
Total Stock
Award
($)
Ms. Burr(a)159,997159,997
Ms. Donigan(b)3,198,1443,908,8507,106,993
Mr. Schroeder866,1651,058,6451,924,810
Mr. Mennen623,147450,2021,073,349
Mr. Gilbert(b)418,396511,374929,769
Mr. Persaud(b)429,184524,557953,741
(a)
Represents the grant date value of restricted stock units granted in fiscal year 2023 while serving as a director of the Company.
(b)
Ms. Donigan, Mr. Gilbert and Mr. Persaud each forfeited the performance award shown upon their departure from the Company on January 7, 2023, April 7, 2023 and March 6, 2023, respectively.
(2)
Represents annual cash incentive bonuses earned in the applicable fiscal year.
(3)
The amounts in the “All Other Compensation” column for fiscal year 2023 consist of the following:
NameFinancial
Planning
($)
COBRA
Payment
($)
Severance
($)
Automobile
Allowance
($)
Director
Fees
($)
(a)
401(k) Match
($)
Ms. Burr110,000
Ms. Donigan(b)10,00037,413546,69211,00012,000
Mr. Schroeder1,60012,00012,000
Mr. Mennen1,25512,00012,000
Mr. Gilbert2,57512,00012,000
Mr. Persaud2,75012,00012,000
(a)
Represents fees earned and paid in cash for Ms. Burr’s service as a director during fiscal year 2023.
(b)
Ms. Donigan departed the Company on January 7, 2023. Details regarding her separation and release agreement entered into pursuant to Section 5.3 of Ms. Donigan’s employment agreement are provided below under the caption “Potential Payments Upon Termination or Change in Control—Named Executive Officer Departures.” The severance amount reported in this table does not include the value of any accelerated vesting of equity awards Ms. Donigan was entitled to receive upon her departure. For a summary of such amounts, see same caption below.
(4)
Ms. Burr has been a director of the Company since 2019 and was appointed interim CEO effective January 7, 2023. The compensation reported in this table reflects cash fees earned and restricted stock units granted in fiscal year 2023 while serving as a director of the Company, and $588,462 in base salary earned while serving as interim CEO. See “Executive Employment Agreements” below, for additional details related to the terms of Ms. Burr’s compensation while serving as interim CEO.
(5)
Ms. Donigan joined the Company on August 12, 2019 and departed on January 7, 2023.
(6)
Mr. Mennen joined the Company in December 2018. He was previously a Named Executive Officer of the Company in fiscal year 2021 and, accordingly, we are disclosing the cash and non-cash compensation for each of the Company’s three prior completed fiscal years.
(7)
Mr. Gilbert first became a Named Executive Officer of the Company in fiscal year 2022 and departed on April 7, 2023 after the end of our 2023 fiscal year.
(8)
Mr. Persaud joined the Company in February 2020 and departed on March 6, 2023 after the end of our 2023 fiscal year.

RITE AID CORPORATION   2023 Proxy Statement | 57

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Grants of Plan-Based Awards Table for Fiscal Year 2023
The following table summarizes grants of Contentsplan-based awards made to Named Executive Officers during our fiscal year ended March 4, 2023.
Estimated Future Payouts
Under Non-Equity
Incentive Plan Awards
(1)
Estimated Future
Payouts Under Equity
Incentive Plan Awards
(2)
NameGrant DateThreshold
($)
Target
($)
Max
($)
Threshold
(#)
Target
(#)
Max
(#)
All Other
Stock
Awards
(#)
(3)
Grant Date Fair
Value of Stock
and Option
Awards
($)
(4)
Elizabeth Burr7/27/202221,505(5)159,997
Heyward Donigan7/27/2022197,019525,383985,0933,908,850
7/27/2022429,8583,198,144
1,184,5002,369,0004,738,000
Matthew Schroeder7/27/202253,359142,291266,7961,058,645
7/27/2022116,420866,165
384,963769,9251,539,850
Justin Mennen7/27/202222,69260,511113,458450,202
3/22/202226,000254,800
7/27/202249,509368,347
272,850545,7001,091,400
Paul Gilbert7/27/202225,77568,733128,874511,374
7/27/202256,236418,396
232,445464,891929,781
7/27/202226,43970,505132,197524,557
Andre Persaud7/27/202257,686429,184
272,500586,0001,090,000
(1)
Reflects each such officer’s opportunity to earn an annual cash incentive bonus, as discussed in the Compensation Discussion and Analysis under the caption “Annual Incentive Awards.” No annual cash incentives were earned for the 2023 fiscal year, as shown in the Summary Compensation Table.
(2)
On July 27, 2022, each Named Executive Officer (with the exception of Ms. Burr) received a grant of performance stock units that will be earned at the end of the Company’s 2025 fiscal year based upon the achievement of a two-year cumulative revenue goal and two-year Elixir membership goal, subject to a +/- 25% TSR modifier, provided that the Named Executive Officer is continuously employed at the Company through the date the Compensation Committee certifies the fiscal 2025 earnings results.
(3)
On July 27, 2022, the Named Executive Officers (with the exception of Ms. Burr) received a grant of restricted stock, as described in the Compensation Discussion and Analysis, under the caption “Components of Executive Compensation for Fiscal Year 2023-Restricted Stock Awards Under Fiscal Year 2023 Plan.” These grants will vest based on continued employment with respect to one third on each of the first three anniversaries of the grant date.
(4)
Represents the grant date fair value, measured in accordance with FASB ASC Topic 718 of stock awards made in fiscal year 2023. Grant date fair values are calculated pursuant to assumptions set forth in Note 18 of the Company’s Annual Report on form 10-K filed with the SEC on May 1, 2023. The performance awards are subject to liability accounting under FASB ASC Topic 718 and the value reported represents the value for the reporting period ended March 4, 2023, assuming the stock price of $3.58.
(5)
Represents the annual award of restricted stock units for fiscal year 2023, granted in connection with Ms. Burr’s service as a director of the Company. The restricted stock units were vested on the date of grant and the shares subject to the grant will become payable on a deferred basis upon her separation from service as a director.
Executive Employment Agreements
Rite Aid entered into employment agreements with each of the Named Executive Officers, which governed the material terms of their employment and were in effect during the Company’s last completed fiscal year during the duration of the Named Executive Officer’s employment with us.

58 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS

EXECUTIVE COMPENSATION
Interim CEO Offer Letter with Elizabeth Burr
TERM; BASE SALARY; INCENTIVES. The Company entered into an offer letter with Ms. Burr, dated as of January 7, 2023. The offer letter provides Ms. Burr with a base salary of $300,000 per month while serving as interim CEO of the Company. Ms. Burr will not receive the compensation payable to non-employee members of the Board while serving as interim CEO of the Company. The offer letter also provides that Ms. Burr will not participate in or receive benefits under the Company’s employee benefit plans and programs including, but not limited to, the Company’s bonus incentive plans, 401(k) plan, group medical, dental and vision insurance plans. If Ms. Burr serves as interim CEO for more than six (6) full months, the Board will review the monthly salary and consider in good faith whether to increase the monthly salary for interim CEO service in excess of six (6) months.
Employment Agreement with Former CEO Heyward Donigan
TERM; BASE SALARY; INCENTIVES. The Company entered into an employment agreement with Ms. Donigan, dated as of August 8, 2019. The agreement provided Ms. Donigan with a base salary and an incentive compensation target. The following base salary amount and incentive targets applied to Ms. Donigan during fiscal 2023: base salary was increased to $1,184,500, her target annual bonus opportunity was set at 200% of base salary, and her target long-term incentive compensation award opportunity continued to be set at 600% of her base salary. See “Named Executive Officer Departures—Separation Agreement with Heyward Donigan” below for details on her separation agreement.
Employment Agreements with Matthew Schroeder, Justin Mennen, Paul Gilbert and Andre Persaud
IN GENERAL. Each of the employment agreements entered into with Messrs. Schroeder, Mennen, Gilbert and Persaud, respectively, provide for a term of employment that is automatically renewed from year to year, unless either party provides the other with 120 (180 for Mr. Schroeder) days’ notice of an intent not to renew.
SALARY AND INCENTIVES. The respective agreements provide each executive with a base salary and incentive compensation targets (which may be reviewed periodically for increase by the Compensation Committee). The following base salary amounts and incentive targets applied to the Named Executive Officers during fiscal year 2023: Mr. Schroeder’s base salary was increased to $769,925, his target annual bonus opportunity was set at 100% of base salary, and his target long-term incentive compensation award opportunity was set at 250% of his base salary; Mr. Mennen’s base salary was increased to $545,700, his target annual bonus opportunity was set at 100% of base salary, and his target long-term incentive compensation award opportunity was set at 150% of his base salary; Mr. Gilbert’s base salary was increased to $619,854, his target annual bonus opportunity was set at 75% of base salary, and his target long-term incentive compensation award opportunity was set at 150% of his base salary; and Mr. Persaud’s base salary was increased to $586,000, his target annual bonus opportunity was set at 100% of base salary, and his target long-term incentive compensation award opportunity was set at 175% of his base salary.
See “Named Executive Officer Departures—Paul Gilbert Departure” and “Named Executive Officer Departures—Andrew Persaud Departure” below for details on their departures following the end of fiscal year 2023.
Terms Applicable to All Named Executive Officers Under Employment Agreements (Other than Ms. Burr)
OTHER BENEFITS. Pursuant to their employment agreements, while employed, each of the Named Executive Officers is entitled to participate in Rite Aid’s tax-qualified savings plan, welfare benefits, fringe benefit and perquisite programs as in effect from time to time.
RESTRICTIVE COVENANTS. The employment agreement of each Named Executive Officer prohibits the officer from competing with Rite Aid during his or her employment period and for a period of one year (two years for Mr. Schroeder) thereafter.

RITE AID CORPORATION   2023 Proxy Statement | 59

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
TERMINATION AND CHANGE IN CONTROL BENEFITS. The provisions of the employment agreements relating to termination of employment are described under the caption “Potential Payments Upon Termination or Change in Control” below.
Outstanding Equity Awards at Fiscal Year 2023 Year-End
The following table summarizes the number of securities underlying outstanding equity awards for the Named Executive Officers as of the end of fiscal year 2023.
Option AwardsStock Awards
NameDate of
Grant
Number of
Securities
Underlying
Unexercised
Options
Exercisable
(#)
Number of
Securities
Underlying
Unexercised
Options
Unexercisable
(#)
Equity
Incentive
Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options
(#)
Option
Exercise
Price
($)
Option
Expiration
Date
Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)
(2)(3)
Market
Value of
Shares or
Units of
Stock That
Have Not
Vested
($)
(4)
Equity
Incentive
Plan
Awards:
# of
Unearned
Shares or
Units That
Have Not
Vested
(#)
(2)(5)
Equity
Incentive
Plan 
Awards:
Market or
Payout
Value of
Unearned
Shares or
Units of
Stock That
Have Not
Vested
($)
(4)
Elizabeth Burr(1)
Heyward Donigan8/12/2019502,9137.024/7/2023
Matthew Schroeder6/24/201369455.206/24/2023
6/23/2014740141.606/23/2024
6/24/2015745173.606/24/2025
7/8/202013,57148,58449,763178,152
7/7/202137,226133,26968,248244,328
7/27/2022116,420416,784142,291509,402
Justin Mennen7/8/20206,26422,42522,96882,225
7/7/202115,22854,51627,91999,950
3/22/202226,00093,080
7/27/202249,509177,24260,511216,629
Paul Gilbert(6)
8/17/202011,20040,096
7/7/202117,97664,35432,956117,982
7/27/202256,236201,32568,733246,064
Andre Persaud(7)
7/8/20205,95021,30121,81978,112
7/7/202117,41862,35631,934114,324
7/27/202257,686206,51670,505252,408
(1)
Elizabeth Burr did not have any outstanding equity awards at 2023 fiscal year-end.
(2)
Refer to “Potential Payments Upon Termination or Change in Control” below for circumstances under which the terms of the vesting of equity awards would be accelerated.
(3)
Restricted shares will generally vest one-third on each of the first three anniversaries of the grant date, based on continued employment.
(4)
Determined with reference to $3.58, the closing price of a share of Rite Aid common stock on the last trading day before March 4, 2023.
(5)
For a discussion of the terms and conditions of the performance units granted on July 27, 2022, see “Compensation Discussion and Analysis, Long-Term Incentive Program, 2023 Performance Based Units.” For a discussion of the terms and conditions of the performance units granted on July 7, 2021, see “Compensation Discussion and Analysis, Long-Term Incentive Program, 2022 Performance Based Units.” For a discussion of the terms and conditions of the performance units granted on July 8, 2020, see “Compensation Discussion and Analysis, Long-Term Incentive Program, 2021 Performance Based Units.”
(6)
Mr. Gilbert forfeited all outstanding equity upon his departure from the Company due to resignation effective April 7, 2023.
(7)
Mr. Persaud forfeited all outstanding equity upon his departure from the Company due to resignation effective March 6, 2023.

60 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Option Exercises and Stock Vested Table for Fiscal Year 2023
The following table summarizes for each Named Executive Officer the stock option exercises and shares vested during fiscal year 2023.
Option AwardsStock Awards
NameNumber of Shares
Acquired on Exercise
(#)
Value Realized on
Exercise
($)
Number of Shares
Acquired on Vesting
(#)
(1)
Value Realized on
Vesting
($)
(2)
Elizabeth Burr(3)21,505159,997
Heyward Donigan687,7983,562,927
Matthew Schroeder42,785310,277
Justin Mennen21,912184,403
Paul Gilbert20,188158,547
Andre Persaud20,661129,262
(1)
Represents the number of shares of restricted stock and earned performance shares held by each Named Executive Officer that vested during the fiscal year.
(2)
The value reported is the closing market price of a share of our common stock on the NYSE on the date of vesting multiplied by the number of shares that vested on that date.
(3)
Represents the annual award of restricted stock units for fiscal year 2023, granted in connection with Ms. Burr’s service as a director of the Company prior to her appointment as interim CEO. The restricted stock units were vested on the date of grant and the shares subject to the grant will become payable on a deferred basis upon her separation from service.
Pension; Nonqualified Deferred Compensation
The Company does not maintain a non-qualified deferred compensation plan for the benefit of the Named Executive Officers and none of the Named Executive Officers participate in a defined benefit pension plan maintained by the Company.
Potential Payments Upon Termination or Change in Control
As discussed above under the caption “Executive Employment Agreements,” the Company has entered into employment agreements with each of the Named Executive Officers. Upon written notice, the employment agreement of each of the Named Executive Officers is terminable by either Rite Aid or the individual officer seeking termination. The circumstances resulting in severance entitlements under the employment agreements is discussed below. During the last completed fiscal year, the Company entered into a separation agreement with its former CEO. Also, two Named Executive Officers resigned following the end of the last fiscal year, as discussed below in the caption “Named Executive Officer Departures.”
Description of Triggering Events—Individual Agreements
MS. ELIZABETH BURR.
Ms. Burr is not entitled to any severance under the terms of her offer letter dated January 7, 2023, entered into in connection with her appointment as interim CEO.
MS. HEYWARD DONIGAN.
Circumstances Resulting in Severance. In connection with Ms. Donigan’s termination of employment by Rite Aid without “cause” ​(as such term is defined in her employment agreement) Ms. Donigan became entitled to the following severance benefits in accordance with the terms of her employment agreement, upon her execution of a general release of claims in favor of the Company and continuing compliance with the restrictive covenants.

RITE AID CORPORATION   2023 Proxy Statement | 61

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
See “Named Executive Officer Departures—Separation Agreement with Heyward Donigan” below for additional details on her separation agreement:

she was entitled to receive a severance amount equal to two times the sum of her annual base salary and target bonus, a pro-rata bonus for the fiscal year of termination based on actual performance, and any accrued but unpaid salary and benefits through the date of termination. The severance amount is payable in installments over the two-year period following the termination; any pro-rata bonus for the fiscal year would have been paid following determination of performance at the same time that payments are made to other bonus-eligible associates;

she was entitled to receive a payment equal to the cost of continued health benefits under COBRA for two years following the termination, paid in a lump sum; and

any unvested stock options immediately vested and became exercisable, generally, for a period of 90 days following her termination of employment and the restrictions on time-based restricted stock immediately lapsed, each to the extent the options would have vested and restrictions would have lapsed, had she remained employed by Rite Aid for two years following the qualifying termination.
MR. MATTHEW SCHROEDER.
Circumstances Resulting in Severance. Pursuant to his employment agreement with the Company, if Mr. Schroeder is terminated by Rite Aid without “cause” or if he terminates his employment for “good reason” (as such terms are defined in his employment agreement), then:

he will be entitled to receive a severance amount equal to two times the sum of the annual base salary and target bonus, a pro-rata target bonus for the fiscal year of termination, and any accrued but unpaid salary and benefits through the date of termination. The severance amount would be payable in installments over the two-year period following the termination; any pro-rata bonus for the fiscal year would be paid at the same time that payments are made to other bonus-eligible associates;

he will be entitled to receive continued health benefits for two years following the termination; and

any unvested stock options will immediately vest and be exercisable, generally, for a period of 90 days following the termination of employment to the extent the options would have vested had he remained employed by Rite Aid for two years following the termination.
MR. JUSTIN MENNEN.
Circumstances Resulting in Severance. Pursuant to his employment agreement with the Company, if Mr. Mennen is terminated by Rite Aid without “cause” or if he terminates his employment for “good reason” ​(as such terms are defined in his employment agreement), then:

he will be entitled to receive a severance amount equal to two times his annual base salary as of the date of termination of employment, a pro-rata bonus for the fiscal year of termination based on actual performance, and any accrued but unpaid salary and benefits through the date of termination. The severance amount would be payable in installments over the two-year period following the termination; any pro-rata bonus for the fiscal year would be paid following determination of performance at the same time that payments are made to other bonus-eligible associates;

he will be entitled to receive continued health benefits for one year following the termination; and

any unvested stock options will immediately vest and be exercisable, generally, for a period of 90 days following the termination of employment and the restrictions on the restricted common stock will immediately lapse, each to the extent the options would have vested and restrictions would have lapsed, had he remained employed by Rite Aid for one year following the termination.
The foregoing severance benefits are subject to Mr. Mennen’s execution of a general release of claims in favor of the Company and compliance with restrictive covenants.
MR. PAUL GILBERT.
Circumstances Resulting in Severance. Pursuant to his employment agreement with the Company, if Mr. Gilbert had been terminated by Rite Aid without “cause” or if he had terminated his employment for “good reason” ​(as such terms are defined in his employment agreement), then:

62 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION

he would have been entitled to receive a severance amount equal to two times his annual base salary, a pro-rata bonus for the fiscal year of termination based on actual performance, and any accrued but unpaid salary and benefits through the date of termination. The severance amount would have been payable in installments over the two-year period following the termination; any pro-rata bonus for the fiscal year would be paid following determination of performance at the same time that payments are made to other bonus-eligible associates;

he would have been entitled to receive a payment equal to the cost of continued health benefits under COBRA for two years following the termination; and

any unvested stock options would have immediately vested and become exercisable, generally, for a period of 90 days following the termination of employment and the restrictions on time-based restricted stock would have immediately lapsed, each to the extent the options would have vested and restrictions would have lapsed, had he remained employed by Rite Aid for two years following the termination.
The foregoing severance benefits would be subject to Mr. Gilbert’s execution of a general release of claims in favor of the Company and compliance with restrictive covenants.
MR. ANDRE PERSAUD.
Circumstances Resulting in Severance. Pursuant to his employment agreement with the Company, if Mr. Persaud had been terminated by Rite Aid without “cause” or if he had terminated his employment for “good reason” ​(as such terms are defined in his employment agreement), then:

he would have been entitled to receive a severance amount equal to two times his annual base salary as of the date of termination of employment, a pro-rata bonus for the fiscal year of termination based on actual performance, and any accrued but unpaid salary and benefits through the date of termination. The severance amount would be payable in installments over the two-year period following the termination; any pro-rata bonus for the fiscal year would be paid following determination of performance at the same time that payments are made to other bonus-eligible associates;

he would have been entitled to receive continued health benefits for eighteen months following the termination; and

any unvested stock options would have immediately vested and become exercisable, generally, for a period of 90 days following the termination of employment and the restrictions on the restricted common stock would have immediately lapsed, each to the extent the options would have vested and restrictions would have lapsed, had he remained employed by Rite Aid for one year following the termination.
The foregoing severance benefits would be subject to Mr. Persaud’s execution of a general release of claims in favor of the Company and compliance with restrictive covenants.
Named Executive Officer Termination as a Result of Death or Disability
If the employment of any of the Named Executive Officers (with the exception of Ms. Burr) were to be terminated as a result of death or “disability” ​(as such term is defined in each employment agreement), the officer will be entitled to receive all accrued but unpaid salary and benefits payable under death or disability benefit plans in which the officer participates, continued health insurance (or reimbursement for the cost of such benefits) for two years (one year in the case of Messrs. Gilbert, Mennen and Persaud) for the officer and/or his or her immediate family, as applicable, vesting of all stock options and, for all Named Executive Officers other than Mr. Schroeder, vesting of an amount of restricted stock that, in each case, would have vested had the officer remained employed for one year (two years for Ms. Donigan and Mr. Schroeder) following the date of termination. Ms. Burr does not participate in Rite Aid’s employee benefit plans.
Change in Control Arrangements
UNDER EMPLOYMENT AGREEMENTS—DOUBLE TRIGGER ARRANGEMENTS. Severance benefits are not triggered pursuant to a change in control unless the change in control is followed by a termination of the Named Executive Officer’s employment under the circumstances resulting in severance described above. The Named

RITE AID CORPORATION   2023 Proxy Statement | 63

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Executive Officer’s severance entitlement is governed by their individual employment agreements with the Company. Ms. Burr’s arrangements with the Company do not include severance entitlements.
The employment agreements with the Named Executive Officers (other than Ms. Burr) provide that any portion of any payment that is subject to tax imposed by Section 4999 of the Code will be reduced to the extent necessary so that the Named Executive Officer would retain a greater amount on an after-tax basis than had the excise tax been imposed on the unreduced amount of the payments.
UNDER RITE AID’S EQUITY PROGRAM. Pursuant to the terms of the Company’s Amended and Restated 2020 Omnibus Equity Incentive Plan, unless otherwise provided in a Named Executive Officer’s employment agreement or individual award agreement, if outstanding equity awards are assumed or substituted in connection with a change in control, the change in control will not cause the vesting of such awards to accelerate unless the change in control is followed by a qualifying termination of employment within the 24-month period following the change in control. In the event of a qualifying termination of employment within the 24-month period following a change in control, all outstanding awards granted pursuant to the Company’s equity program will become fully vested and exercisable, free of applicable restrictions, and all awards that are subject to performance-based conditions will vest pro-rata based on the participant’s service during the applicable performance period, assuming the target level of performance. All outstanding equity awards granted pursuant to the Company’s equity program that are not assumed or substituted in connection with a change in control transaction will become fully vested and exercisable, free of applicable restrictions, and all awards that are subject to performance-based conditions will be deemed to be achieved at target levels. The foregoing treatment upon a change in control is reflected in the form of award agreements currently utilized in connection with long-term incentive awards under the Company’s Amended and Restated 2020 Omnibus Equity Incentive Plan. In addition, the employment agreements maintained by Rite Aid do not provide for accelerated vesting of any performance-based awards, including upon qualifying termination of employment (with or without a change in control).
For purposes of Rite Aid’s equity program, including any inducement awards, a “change in control” means, in general: (i) a person or entity acquires securities of Rite Aid representing 50% or more of the combined voting power of Rite Aid; (ii) an unapproved change in the majority membership of the Board; (iii) consummation of a merger or consolidation of Rite Aid or any subsidiary of Rite Aid, other than a merger or consolidation that results in the Rite Aid voting securities continuing to represent 50% or more of the combined voting power of the surviving entity or its parent, or a merger or consolidation effected to implement a recapitalization or similar transaction involving Rite Aid in which no person or entity acquires at least 35% of the combined voting power of Rite Aid; or (iv) stockholder approval of a plan of complete liquidation or dissolution of Rite Aid or the consummation of an agreement for the sale or disposition of all or substantially all of Rite Aid’s assets, other than a sale or disposition to an entity, at least 60% of the combined voting power of which is owned by Rite Aid stockholders in substantially the same proportions as their ownership of Rite Aid immediately prior to such sale. For more information regarding the equity program, refer to the Compensation Discussion and Analysis under the caption “Long-Term Incentive Program.”
Quantification of Payments Described
The tables below quantify the termination and change in control payments that would have been made to the Named Executive Officers (other than Ms. Donigan, who separated from the Company prior to the end of the fiscal year and became entitled to severance under the terms of her employment agreement (as described under “Named Executive Officer Departures—Separation Agreement with Heyward Donigan” below) and Messrs. Gilbert and Persaud, who resigned from the Company following the end of the fiscal year and did not receive any severance payments in connection with such resignation consistent with the terms of their employment agreements), had their employment been terminated as of March 4, 2023 under the circumstances described in the tables below. Consistent with Ms. Burr’s offer letter entered into in connection with her appointment as interim CEO, none of the below potential separation payments or benefits are applicable.

64 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Elizabeth BurrDeath
($)
Disability
($)
Termination Without
Cause or Quit for
Good Reason
($)
Termination Without
Cause or Quit for Good
Reason Following a
Change in Control
($)
Base Salary
Bonus
Pro-Rated Incentive Bonus Earned for Past Fiscal Year
Benefits
Vesting of Equity
Matthew SchroederDeath
($)
Disability
($)
Termination Without
Cause or Quit for
Good Reason
($)
Termination Without
Cause or Quit for Good
Reason Following a
Change in Control
($)
2 × Base Salaryn/an/a1,539,8501,539,850
2 × Bonusn/an/a1,539,8501,539,850
Pro-Rated Incentive Earned Bonus for Past Fiscal Year
Benefits58,05258,05258,05258,052
Vesting of Equity(1)459,711459,711459,7111,530,518(2)
Justin MennenDeath
($)
Disability
($)
Termination Without
Cause or Quit for
Good Reason
($)
Termination Without
Cause or Quit for Good
Reason Following a
Change in Control
($)
2 × Base Salaryn/an/a1,091,4001,091,400
Bonusn/an/an/an/a
Pro-Rated Incentive Earned Bonus for Past Fiscal Year
Benefits17,48817,48817,48817,488
Vesting of Equity(1)108,764108,764108,764746,068(2)
(1)
Includes the value of service-based restricted stock awards held by the Named Executive Officer that would become vested under the applicable circumstances. The value of restricted stock shown is determined by multiplying $3.58, the closing price of a share of Rite Aid common stock on the last trading day before March 4, 2023 and the number of shares of restricted stock that are settled in stock held by the officer that would become vested under the applicable circumstances.
(2)
This value would apply based upon a qualifying termination following a change in control or upon a change in control under the assumption that outstanding equity awards are not assumed or substituted in the change in control transaction, resulting in full vesting upon the change in control, as described above in the “Potential Payments Upon Termination or Change in Control-Change in Control Arrangements” narrative. In addition to the amounts stated above in respect of service-based restricted stock, figure includes the value of pro-rata performance-based equity awards held by such officer, assuming the target level of performance. The value shown is determined by multiplying $3.58, the closing price of a share of Rite Aid common stock on the last trading day before March 4, 2023 and the number of shares of restricted stock and performance-based stock held by the officer that would become vested under the applicable circumstances.

RITE AID CORPORATION   2023 Proxy Statement | 65

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Named Executive Officer Departures
SEPARATION AGREEMENT WITH HEYWARD DONIGAN.
As a result of the decision made by the Board on the strategic priorities of the Company and to appoint Ms. Burr as interim CEO until the appointment of a permanent chief executive officer, Ms. Donigan’s employment with the Company was terminated on January 7, 2023. As previously disclosed on Form 8-K, the circumstances of Ms. Donigan’s departure from the Company constituted a termination without cause for purposes of Ms. Donigan’s employment agreement with us, and, in accordance with the terms of Section 5.3 of her employment agreement, we entered into a separation agreement with Ms. Donigan as of January 7, 2023 providing for the following severance benefits: (i) payment of $7,107,000 representing two times the sum of her then current base salary and annual target bonus, payable in equal installments over 24 months, (ii) a pro-rata bonus for the 2023 fiscal year based on actual performance, payable at the same time as bonuses are paid to the Company’s executive team generally (which amount was $0 based on actual performance for the 2023 fiscal year and accordingly, no pro-rata bonus was paid), (iii) $37,413 representing payments equal to the aggregate cost of COBRA continuation for a total of 24 months, (iv) reimbursement of legal fees incurred in connection with the review of the separation agreement up to $10,000, (v) accelerated vesting with respect to those stock options and time-based restricted stock awards that would have vested within the two-year period following the termination (with an aggregate value of $1,649,623 at the time of vesting) and (vi) $97,356, representing payment of base salary in lieu of providing 30 days’ notice of termination. The foregoing severance benefits described in clauses (i) - (v) were subject to Ms. Donigan’s execution of a general release of claims in favor of the Company and continuing compliance with restrictive covenants.
PAUL GILBERT DEPARTURE.
Mr. Gilbert resigned from the Company effective April 7, 2023. Mr. Gilbert did not receive any severance in connection with his separation.
ANDRE PERSAUD DEPARTURE.
Andre Persaud resigned from the Company effective March 6, 2023. Mr. Persaud did not receive any severance in connection with his separation.

66 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
PAY RATIO DISCLOSURE
As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(u) of Regulation S-K under the Exchange Act, we are providing the following information about the relationship of the annual total compensation of our employees other than Heyward Donigan, our former Chief Executive Officer (our “CEO” for purposes of the pay ratio disclosure) and the annual total compensation of our CEO. This pay ratio is a reasonable estimate calculated in a manner consistent with SEC rules based on our payroll and employment records and the methodology described below. We determined that the 2023 annual total compensation of the median employee, other than our CEO, was $32,850 and our CEO’s 2023 annual total compensation for pay ratio purposes was $8,950,543. The ratio of these amounts is 272:1.
To identify the median employee among our associates other than the CEO, we used wages taxable for federal medical health insurance purposes for the calendar year 2022, with such amounts annualized for those permanent employees who were hired during the year. After identifying the median employee (who is a full-time technician in training) as of the determination date, December 31, 2022, we calculated annual total compensation for such employee using the same methodology we use to determine Named Executive Officer annual total compensation in the Summary Compensation Table for fiscal year 2023.
The Company had two CEOs who served during fiscal year 2023, one of whom is an interim CEO. We accordingly calculated the CEO’s annual total compensation by selecting Ms. Donigan as the CEO serving in that position on the final day of our payroll year, December 31, 2022, which was the same date selected to identify the median team member, and annualized appropriate portions of Ms. Donigan’s annual total compensation for fiscal year 2023 (i.e., Ms. Donigan’s base salary and automobile allowance because no annual incentive award was payable in respect of fiscal year 2023) and added the grant date fair value of stock awards (i.e., long-term incentives) and all other compensation paid in fiscal year 2023. Because the CEO’s compensation was annualized solely for purposes of this calculation, the CEO’s annual total compensation found in this section is not the same as the compensation disclosed in the Summary Compensation Table beginning on page 56. This calculation resulted in the annual total compensation for Ms. Donigan in fiscal year 2023 of $8,950,543 for purposes of the pay ratio provided in the first paragraph above.
The SEC rules for identifying the median employee and calculating the pay ratio based on that employee’s annual total compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their compensation practices. As such, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies may have different employment and compensation practices and may use different methodologies, exclusions, estimates, and assumptions in calculating their own pay ratios.
EQUITY COMPENSATION PLAN INFORMATION

TABLE

The following table provides information as of February 28, 2009,March 4, 2023, with respect to the compensation plans under which our common stock may be issued:

issued.
Plan CategoryNumber of Securities
to be issued upon
exercise of
outstanding options,
warrants and rights
(a)
Weighted-Average
exercise price of
outstanding options,
warrants and rights
(b)
(1)
Number of Securities
remaining available
for future issuance
under equity
compensation plans
(excluding securities
reflected in
column (a))
(c)
(2)
Equity Compensation plans approved by
stockholders
(3)
1,244,973(4)$112.933,627,626
Equity compensation plans not approved
by stockholders
(5)
502,913$7.020
Total(6)1,747,886$12.853,627,626
Plan Category
 Number of
Securities to be
Issued Upon
Exercise of
Outstanding
Options,
Warrants
and Rights
 Weighted-
Average
Exercise
Price of
Outstanding
Options,
Warrants
and Rights
 Number of
Securities
Remaining
Available for
Further
Issuance
Under Equity
Compensation
Plans (Excluding
Securities
Reflected in
Column (a))
 
 
 (a)
 (b)
 (c)
 

Equity compensation plans approved by stockholders

  46,330,187 $3.65  28,544,954 

Equity compensation plans not approved by stockholders*

  24,015,906 $4.10  5,005,593 
 

Total

  70,346,093     33,550,547 

*
These plans include
(1)
The weighted average exercise price does not take into account the Company's 1999 Stock Optionshares issuable upon settlement of outstanding

RITE AID CORPORATION   2023 Proxy Statement | 67

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
vested Director restricted stock units (“RSUs”), which settle upon separation from service, or unvested, unearned performance stock units (“PSUs”), which have no exercise price.
(2)
Of the 3,627,626 shares shown in column (c), there are 2,501,811 shares available for the grant of awards other than stock options or stock appreciation rights, applying the fungible share ratio of 1.45 set forth in the Company’s Amended and Restated 2020 Omnibus Equity Incentive Plan.
(3)
Pursuant to the Company’s Amended and Restated 2020 Omnibus Equity Incentive Plan underand prior equity plans.
(4)
Includes 402,476 RSUs and 813,207 PSUs. The remaining balance consists of outstanding stock options.
(5)
Includes nonqualified stock options granted pursuant to the Employment Inducement Award Agreement for Ms. Donigan, which 10,000,000is exempt from stockholder approval requirements pursuant to NYSE Listed Company Manual Rule 303A.08. The Employment Inducement Award Agreement provided for the award of nonqualified stock options to Ms. Donigan in connection with her recruitment by us, as previously disclosed. The options expired unexercised as of April 7, 2023.
(6)
On a fully diluted basis, which reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock, the number of shares of common stock are authorizedoutstanding was 56,628,875.
PAY VERSUS PERFORMANCE
The following table reports the compensation of our Principle Executive Officer (“PEO” or “CEO”) and the average compensation of the other non-CEO NEOs as reported in the Summary Compensation Table for the grantingpast three fiscal years, as well as Compensation Actually Paid (“CAP”) as calculated under new SEC Pay-Versus-Performance disclosure requirements, and certain performance measures required by the rules. The disclosure covers our three most recent fiscal years, which will expand incrementally over the next two years to a rolling five years. Dollar amounts reported as CAP are computed in accordance with Item 402(v) of Regulation S-K, and the Board believes that it is important to recognize that these amounts do not reflect the actual amount of compensation earned by or paid to our CEO and non-CEO NEOs during the applicable years.
Fiscal
Year
Summary
Compensation
Table Total for
Heyward
Donigan
(1)
($)
Summary
Compensation
Table Total for
Elizabeth
Burr
(1)
($)
Compensation
Actually Paid
to Heyward
Donigan
(2)
($)
Compensation
Actually Paid
to Elizabeth
Burr
(2)
($)
Average
Summary
Compensation
Table Total for
Non-PEO
Named
Executive
Officers
(1)
($)
Average
Compensation
Actually Paid
to Non-PEOs
Named
Executive
Officers
(3)
($)
Value of initial fixed $100
investment based on:
Net
Income
(5)
($)
Adjusted
EBITDA
(6)
($)
Total
Shareholder
Return
($)
Peer Group
Total
Shareholder
Return
(4)
($)
20238,767,811858,459(1,877,638)858,4591,889,206638,34628.63139.14(749,936)429,180
20229,911,507(1,881,568)3,082,2191,048,26368.28140.98(538,478)505,905
20219,571,08712,857,7742,878,7702,782,908143.76113.59(100,070)437,665
(1)
Our CEO for fiscal year 2023 was Ms. Donigan until her departure from the Company on January 7, 2023, with Ms. Burr acting as interim CEO for the remainder of the 2023 fiscal year, and for each of fiscal years 2021 and 2022 our CEO was Ms. Donigan. Our non-CEO NEOs for fiscal year 2023 were Messrs. Schroeder, Mennen, Gilbert and Persaud; for fiscal year 2022, Messrs. Schroeder, Gilbert, Peters and Ms. Konrad; and for fiscal year 2021, Messrs. Schroeder, Peters, Mennen, Robson and Ms. Konrad.
(2)
The amounts in the following table represent each of the amounts deducted and added to the equity award values for each PEO for the applicable year, for purposes of computing the CAP amount:

68 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
FY21FY22FY23
AdjustmentsHeyward
Donigan
($)
Elizabeth
Burr
($)
Heyward
Donigan
($)
Elizabeth
Burr
($)
Heyward
Donigan
($)
Elizabeth
Burr
($)
Deduction for amounts reported under the
“Stock Awards” and “Option Awards”
columns in the Summary Compensation
Table for covered fiscal year
(7,389,087)(6,547,427)(7,106,993)(159,997)
Increase for fair value as of the end of the
covered fiscal year of all awards granted
during year that remain unvested as of
year end
7,122,1064,233,26800
Increase for awards that are granted and
vest in the same year, the fair value as of
the vesting date
00997,271159,997
Increase/deduction for change in fair
value from prior year-end to current
year-end of awards granted in any prior
fiscal year that are unvested as of the end
of the covered fiscal year
3,312,904(8,135,158)00
Increase/deduction for change in fair
value from prior year-end to vesting date
of awards granted in any prior fiscal year
that vested during the covered fiscal year
240,764(1,343,759)(1,324,518)0
Deduction of fair value of awards granted
in any prior fiscal year that were forfeited
during the covered fiscal year
00(3,211,209)0
Increase based on dividends or other earnings paid during the covered fiscal year prior to the vesting date of award0000
Increase based on incremental fair value
of awards modified during year
0000
Total Adjustments3,286,687(11,793,075)(10,645,449)0
(Subject to rounding.)
(3)
The following table represents each of the amounts deducted and added to the equity award values for the non-CEO NEOs for the applicable year for purposes of computing the CAP amount.
FY21FY22FY23
AdjustmentsAverage non-
PEO NEOs
Average non-
PEO NEOs
Average non-
PEO NEOs
Deduction for amounts reported under the “Stock Awards” and
“Option Awards” columns in the Summary Compensation
Table for covered fiscal year
(1,776,460)(1,571,617)(1,220,417)
Increase for fair value as of the end of the covered fiscal year
of all awards granted during year that remain unvested as of
year end
1,418,482982,441479,787
Increase for awards that are granted and vest in the same year, the fair value as of the vesting date000
Increase/deduction for change in fair value from prior year-end
to current year-end of awards granted in any prior fiscal year
that are unvested as of the end of the covered fiscal year
214,003(1,231,819)(455,907)
Increase/deduction for change in fair value from prior year-end
to vesting date of awards granted in any prior fiscal year that
vested during the covered fiscal year
117,159(212,962)(54,322)
Deduction of fair value of awards granted in any prior fiscal year that were forfeited during the covered fiscal year(66,920)00
Increase based on dividends or other earnings paid during the
covered fiscal year prior to the vesting date of award
000
Increase based on incremental fair value of awards modified during year000
Total Adjustments(93,735)(2,033,956)(1,250,860)

RITE AID CORPORATION   2023 Proxy Statement | 69

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
(Subject to rounding.)
(4)
As permitted by SEC rules, the peer group referenced is the Russell 3000 Consumer Staples Industry used for purposes of Item 201(e) of Regulation S-K. Please see Item 5 “Market for Registrant’s Common Equity, Related Stockholder Matters and issuer Purchases of Equity Securities” included on the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 for further discussion of the peer group.
(5)
The dollar amounts reported represent the amount of net income reflected in the Company’s audited consolidated financial statements for the applicable year.
(6)
See “Compensation Discussion and Analysis—Annual Incentive Awards” for a description of Adjusted EBITDA. Please also see Appendix A for a reconciliation of our Adjusted EBITDA, which is a non-GAAP measure, to net income under GAAP.
Relationship Between Pay and Performance
The following graphs illustrate the relationship between the CAP for our CEOs and average non-CEO NEOs and company performance as well as peer performance.
CAP to Cumulative TSR of the Company and Cumulative TSR of the Peer Group
The following graph describes the relationship between (a) CAP for the applicable CEO and the average CAP for the non-CEO NEOs to (b) the Company’s cumulative total shareholder return (TSR), value of initial fixed $100 investment, for the three most recently completed fiscal years and (c) the cumulative total shareholder return for our peer group across the same period:
Compensation Actually Paid vs. Company TSR
vs. Peer Group TSR
[MISSING IMAGE: lc_paidvscompanytsr-pn.jpg]

70 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
CAP and Net Income
The following graph describes the relationship between (a) CAP for the applicable CEO and the average CAP for the non-CEO NEOs to (b) the Company’s Net Income for the three most recently completed fiscal years:
Compensation Actually Paid vs. Net Income
[MISSING IMAGE: lc_paidvsnetincome-pn.jpg]
CAP and Adjusted EBITDA
The following graph describes the relationship between (a) CAP for the applicable CEO and the average CAP for the non-CEO NEOs to (b) the Company’s company-selected measure, Adjusted EBITDA, for the three most recently completed fiscal years:
Compensation Actually Paid vs. Adj. EBITDA
[MISSING IMAGE: lc_paidvsadjebitda-pn.jpg]

RITE AID CORPORATION   2023 Proxy Statement | 71

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Tabular List of Important Financial Performance Measures
The most important financial performance measures used by the Committee for the most recently completed fiscal year to link compensation actually paid to our named executive officers to the Company’s performance are shown in the table below. For further information regarding these performance metrics and their function in our executive compensation program, see Compensation, Discussion and Analysis under the headings “2023 Fiscal Year Key Business Highlights,” “Annual Incentive Awards” and “Performance Awards.”
Most Important Performance Measures
Adjusted EBITDA
Operating Cash Flow
30-day equivalent scripts excluding controllable
Front-End Revenue excluding tobacco
Elixir Membership (excluding Elixir Insurance)

72 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
PROPOSAL 5—APPROVAL OF THE AMENDMENTS TO THE RITE AID CORPORATION AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO ELIMINATE SUPERMAJORITY VOTING PROVISIONS
We are committed to reviewing and adopting corporate governance practices that are in the best interests of both Rite Aid and its stockholders. After reviewing our governance practices, the Board unanimously adopted, and recommends that our stockholders approve, certain amendments (collectively, the “Charter Amendments”) to Rite Aid’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to remove the supermajority voting provisions described herein. The text of the Charter Amendments, marked to show the proposed revisions, is set forth in Appendix B.
The Certificate of Incorporation currently contains four provisions calling for a supermajority vote of stockholders:

Paragraph B of Article ELEVENTH currently requires the affirmative vote of the holders of at least 75% of the shares of stock optionsof Rite Aid entitled to vote in elections of directors to adopt or authorize a Business Combination (as defined in the Certificate of Incorporation) with any Related Person (as defined in the Certificate of Incorporation) unless certain conditions are satisfied.

Paragraph D of Article ELEVENTH currently requires the affirmative vote of the holders of at least 75% of the shares of stock of Rite Aid entitled to vote in elections of directors to take any corporate action by the written consent of the stockholders of Rite Aid.

Paragraph E of Article ELEVENTH currently requires the affirmative vote of the holders of at least 75% of the shares of stock of Rite Aid entitled to vote in elections of directors to take any corporate action at a special meeting of the stockholders of Rite Aid called by the Board, a majority of which Board are not Continuing Directors (as defined in the Certificate of Incorporation).

Paragraph G of Article ELEVENTH currently requires the affirmative vote of the holders of at least 75% of the shares of stock of Rite Aid entitled to vote in elections of directors to amend Article ELEVENTH, unless such amendment is recommended to the stockholders of Rite Aid by a majority of the Continuing Directors.
If approved by our stockholders, the Charter Amendments would amend the provisions described above to require the affirmative vote of the holders of a majority—rather than at least 75%—of the shares of stock of Rite Aid entitled to vote in elections of directors to take the following actions:

adopt or authorize a Business Combination with any Related Person;

take any corporate action by the written consent of the stockholders of Rite Aid;

take any corporate action at a special meeting of the stockholders of Rite Aid called by the Board, a majority of which Board are not Continuing Directors; and

amend Article ELEVENTH.
This general description of the Charter Amendments is qualified in its entirety by reference to the proposed amendments to the Certificate of Incorporation set forth in Appendix B.
If approved by our stockholders, the Charter Amendments will become effective upon the filing of a Certificate of Amendment with the Secretary of State of the State of Delaware, which we would file promptly following the Annual Meeting. If the Charter Amendments are not approved by the stockholders, the Certificate of Incorporation will remain unchanged and the supermajority provisions described above will remain in place.
[MISSING IMAGE: ic_chksquare-pn.gif]
The Board of Directors unanimously recommends that you vote FOR the approval of the amendments to the Rite Aid Corporation Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions.

RITE AID CORPORATION   2023 Proxy Statement | 73

TABLE OF CONTENTS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
STOCKHOLDER PROPOSALS
We expect the following proposals (Proposal No. 6 and Proposal No. 7 on the proxy card) to be presented by stockholders at the Annual Meeting. The proposals and supporting statements may contain assertions about Rite Aid or other statements that we believe are incorrect. We have not attempted to refute all of the inaccuracies in the proposals and supporting statements, and the Company is not responsible for the content of the proposals. The Board has recommended a vote against these proposals for the reasons set forth following each proposal.
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
PROPOSAL 6—STOCKHOLDER PROPOSAL TO REQUIRE AN ANNUAL ADVISORY VOTE ON THE COMPENSATION OF RITE AID’S DIRECTORS
Steven Krol, who owns 9,588 shares of common stock (based on information provided to us by Mr. Krol) and whose address will be provided by the Company promptly upon oral or written request, has notified us that he intends to present the following proposal at the Annual Meeting. The Board of Directors strongly opposes adoption of the proposal and asks stockholders to review the Board’s response, which follows the proposal and the proponent’s supporting statement below.
Stockholder Proposal and Supporting Statement
Proponent states no assertions or statements below are incorrect, notwithstanding Company boilerplate language above.
RESOLVED, Shareholders request our board adopt a policy providing shareholders the annual, non-binding, opportunity to vote on a proxy proposal, “FOR” or “AGAINST”, entitled “Advisory Vote on the Compensation of Our Named Directors” as provided in “Director Compensation Table”.
Shareholders already vote on executive pay. This proposal extends a voting opportunity on directors’ compensation, who oversee all corporate activities and assess performance.
Compensation consultants generally don’t review competence or performance for management or directors; it’s limited to the compensation paid their peer group companies. Last year’s proxy indicated our compensation consultant believed “elements of the director compensation program were not aligned with the market”. Our stock price, at all-time lows this year can, in part, be considered directors’ report card, judging directors’ oversight, judicious hiring and timely firing decisions and giving executives effective “marching orders”.
Given our dismal stock price, total director pay should be aligned with shareholders, not the market. Especially because current directors have never purchased any shares from their own wallets. Yet our Compensation Committee continues increasing directors’ annually guaranteed value of restricted stock, now $160,000 (previously $120,000), divided by stock price at granting date to determine annual stock allocation, previously a fixed number of shares. Shareholders have no guaranteed stock value, subject to directors’ business decisions and oversight. The lower the price, the more shares they receive. Committee Chair annual cash retainers have also recently increased.
Even top holders have complained about Compensation Committee pay decisions (2019 proxy, page 37). Apparent futility, since after their discussions and only 2 months after Mr. Bodaken became Chairman, full vesting of annual restricted stock previously taking 3 years was changed; now vesting immediately.
In last years’ proxy, our board stated the Equity Incentive Plan is “intended to attract, motivate and retain highly competent, effective and loyal officers, associates and non-executive directors in order to create per share intrinsic value for shareholders”. Since 2 Chief Executive Officers (“CEO”) have stepped down within last 4 years, the COO within one, the Pharmacy head within one and Chief Legal Officer within last three years, that quote is highly questionable, including all-time low stock prices recently.
Shockingly, our interim CEO’s base monthly salary is nearly 3 times that of all permanent CEO predecessors (mostly combined Chairman/CEO’s) in the last 22 years, at $300,000 per month, while retaining 3 outside board

74 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
STOCKHOLDER PROPOSALS
memberships appearing to violate published “overboarding” guidelines of Glass Lewis, Vanguard and top holder Blackrock, who thereafter cut its stake. This deprives shareholders her full attention here, which again questions some Compensation Committee and board decisions. They retire richer, shareholders poorer.
*
Proponent’s operations involved 22-year investment (9588 shares after a 1 for 20 reverse stock split) and 4 bylaw amendments with prior submitted proposals, demand board accountability.
*
Your Voice/Feedback is Important-Vote “FOR” Proposal 6.
The Board of Directors’ Statement in Opposition
The Board of Directors unanimously recommends that you vote “AGAINST” this proposal for the following reasons:
The Board of Directors believes that Rite Aid’s compensation program for non-employee directors is reasonable and appropriate for a company of Rite Aid’s size and scope and justified in view of the time directors devote to Rite Aid throughout the year. Only directors not employed by Rite Aid are compensated for their service on the Board. In addition, a substantial portion of the annual compensation for Rite Aid’s non-employee directors is equity-based to further align the long-term interests of Rite Aid’s non-employee directors with Rite Aid’s stockholders. The value of the compensation is competitive in order to encourage the retention of non-employee directors, whose work is essential to the Company.
Rite Aid has robust governance practices with respect to its director compensation program. The Compensation Committee is responsible for reviewing and recommending the compensation for non-employee directors, and any change in director compensation is made upon the recommendation of the Compensation Committee following discussion and concurrence by the full Board. The Compensation Committee, with the assistance of Mercer, its independent compensation consultant, regularly reviews Rite Aid’s non-employee director compensation and evaluates the competitiveness and reasonableness of the compensation program in light of general trends and best practices. In 2021, after the Compensation Committee’s review of the study of director compensation prepared by Mercer, the Compensation Committee recommended, and the Board approved, updates to the non-employee director compensation program for fiscal year 2022 to align Rite Aid’s program with median of the market practices.
In addition, non-employee directors are subject to Rite Aid’s Stock Ownership Guidelines, which require minimum stock ownership equal to five times the non-employee director’s annual cash retainer in order to further encourage a long-term perspective in overseeing the management of Rite Aid. The Compensation Committee is responsible for interpreting and administering the Stock Ownership Guidelines, and may, from time to time, reevaluate and revise the Stock Ownership Guidelines.
Finally, the proponent’s criticism of Ms. Burr’s compensation as interim CEO is misplaced and unrelated to our compensation program for non-employee directors. With the advice of its independent compensation consultant, the Compensation Committee recommended, and the Board approved, the compensation afforded to Ms. Burr for taking on the responsibilities of interim CEO as reasonable and appropriate while Rite Aid transitions this key leadership role. While she is serving in the interim CEO role, Ms. Burr does not participate in or receive benefits under the Company’s equity and annual incentive plans or employee benefit plans and programs and does not receive the compensation payable to non-employee directors.
The Board believes that its corporate governance practices and robust stockholder engagement efforts provide numerous ways for stockholders to express their views to the Board, including with respect to director compensation. Rite Aid has encouraged, and continues to encourage, stockholders to communicate directly with the Board regarding any concerns about Rite Aid, including the compensation of directors, and regularly seeks the perspectives of stockholders on issues important to them through our stockholder engagement efforts.
[MISSING IMAGE: tm228886d1-icon_against4c.gif]
The Board of Directors unanimously recommends that you vote AGAINST the stockholder proposal to require an annual advisory vote on the compensation of Rite Aid’s directors.

RITE AID CORPORATION   2023 Proxy Statement | 75

TABLE OF CONTENTS
STOCKHOLDER PROPOSALS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
PROPOSAL 7—STOCKHOLDER PROPOSAL TO ADOPT AN EXECUTIVE
COMPENSATION ADJUSTMENT POLICY
The Philadelphia Public Employees Retirement System (“PhilaPERS”), which owns shares of common stock worth at least $2,000 (based on information provided to us by PhilaPERS) and whose address will be provided by the Company promptly upon oral or written request, has notified us that it intends to present the following proposal at the Annual Meeting. The Board of Directors strongly opposes adoption of the proposal and asks stockholders to review the Board’s response, which follows the proposal and the proponent’s supporting statement below.
Stockholder Proposal and Supporting Statement
RESOLVED that shareholders of Rite Aid Corporation urge the Board of Directors to adopt a policy that no financial performance metric shall be adjusted to exclude Legal or Compliance Costs when evaluating performance for purposes of determining the amount or vesting of any senior executive Incentive Compensation award. “Legal or Compliance Costs” are expenses or charges associated with any investigation, litigation or enforcement action related to drug manufacturing, sales, marketing or distribution, including legal fees; amounts paid in fines, penalties or damages; and amounts paid in connection with monitoring required by any settlement or judgement of claims of the kind described above. “Incentive Compensation” is compensation paid pursuant to short-term and long-term incentive compensation plans and programs. The policy should be implemented in a way that does not violate any existing contractual obligation of the Company or the terms of any compensation or benefit plan. The Board shall have discretion to modify the application of this policy in specific circumstances for reasonable exceptions and in that case shall provide a statement of explanation.
SUPPORTING STATEMENT
We support compensation arrangements that incentivize senior executives to drive growth while safeguarding company operations and reputation over the long-term. Rite Aid adjusts certain financial metrics when calculating progress for executive incentive compensation. While some adjustments may be appropriate, we believe senior executives should not be insulated from all legal costs as a matter of policy.
These considerations are especially critical at Rite Aid given the risks it faces over its role in the nation’s opioid epidemic. The Investors for Opioid and Pharmaceutical Accountability (IOPA), a coalition of 67 investors with $4.2 trillion in assets under management has been engaging companies on this issue for several years. As shareholders bear the financial impacts of record-setting legal settlements related to inadequate assessment of how business decisions would impact the opioid crisis, the IOPA believes executives should similarly be accountable for the financial impacts of those decisions.
In July, Rite Aid agreed to pay a $10.5 million settlement with counties in the states of Georgia, North Carolina and Ohio related to claims that Rite Aid failed to properly distribute and/or dispense prescription opioids.1 Rite Aid excludes litigation settlements from the Adjusted EBIDTA metric that drives executive compensation pay-outs. A default decision to exclude the impact of litigation from metrics originally designed to align executive pay with shareholder interests means executives know in advance their incentive pay will remain intact no matter how large the negative financial impact on shareholders.
In response to discussions with the IOPA and other shareholders, AmerisourceBergen, Cardinal Health, and McKesson reduced CEO pay in light of opioid-related litigation settlements. While the IOPA views the amounts of the reductions as less than warranted, we applaud the decision to acknowledge that incentives matter as do the approximately 700,000 lives lost due to opioid-related drug overdoses since 1999.2
We urge shareholders to vote for this proposal.
1
https://www.reuters.com/legal/government/rite-aid-reaches-opioid-litigation-ceasefire-105-million-settlement-2022-07-14/
2
“The Drug Overdose Epidemic: Behind the Numbers.” Centers for Disease Control and Prevention,” June 1, 2022, available at: https://www.cdc.gov/opioids/data/index.html.

76 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
STOCKHOLDER PROPOSALS
The Board of Directors’ Statement in Opposition
The Board of Directors unanimously recommends that you vote “AGAINST” this proposal for the following reasons:
Rite Aid’s executive compensation program is designed to evaluate and reward management performance and is overseen by the Compensation Committee of the Board, which is composed entirely of independent directors. Assessing and, when appropriate, adjusting financial performance metrics entails a complex process, informed by the knowledge and experience of the Compensation Committee and the 2001 Stock Option Plan, under which 20,000,000 sharesBoard of common stock are authorized forDirectors. Imposing the granting of stock options, also atbroad and indiscriminate policy sought by the discretionproposal would constrain the flexibility of the Compensation Committee. Both plans provideCommittee and the Board to consider factors that are critical in assessing whether and how legal and compliance costs should be accounted for in determining senior executive incentive compensation.
For example, legal and compliance matters often relate to events that occurred prior to the appointment of current senior executives. As a result, the proposal would discourage current senior executives from taking appropriate steps to either defend of resolve existing matters, to manage risk in the best interests of the Company. Under the proposed policy, a senior executive’s incentive compensation could be inequitably penalized for litigation matters that pre-date the executive’s time with Rite Aid. Moreover, a policy leading to this outcome likely will make it more difficult for Rite Aid to attract and retain senior executive talent in a competitive marketplace for talent. This presents an acute concern as Rite Aid is actively looking to identify its next CEO, an already complex process that would only be hindered by the adoption of the policy sought by this proposal.
Rite Aid is often subject to frivolous and meritless suits that Rite Aid, in the best interests of its stockholders, defends against. Under the proposed policy, the costs and expenses of a successful defense of any such matter could not be excluded from performance metrics used to determine senior executive incentive compensation. The responsibility for managing those risks are complex, and the rigid and arbitrary policy requested by the proposal ignores many important considerations. Rite Aid believes the Compensation Committee and the Board are best suited to determine both whenconsider the interplay of legal and compliance costs with the need to attract, retain and motivate management.
In addition, the Compensation Committee is best equipped to make decisions with respect to performance metric selection and adjustments for use in what manner options mayRite Aid’s incentive compensation program, which is currently aligned with our stated strategic objectives and the long-term interests of our stockholders. The Compensation Committee carefully selects performance metrics for executive compensation, taking into account feedback from our stockholder engagement efforts, and sets goals based on available information at the time the goals are set. The proponent’s proposal would unduly restrict the Compensation Committee’s judgment in determining executive compensation levels and structure, and limit the Compensation Committee’s ability to be exercised; however, option terms may not extend for more than 10 years fromflexible and responsive.
In summary, the applicable dateBoard believes the proposal would unnecessarily limit the ability of grant. The plans providethe Compensation Committee and the Board to design and administer Rite Aid’s incentive compensation program. Rite Aid also believes that stock options may onlyadoption of the policy requested by the proposal would be granted with exercise pricesdetrimental to a compensation decision-making process that are not less than the fair market value of a share of common stockis focused on the date of grant. In addition to the options issued under the aforementioned plans, approximately 5,463,000 options are outstanding pursuant to option grants made in accordance with the provisions of individual agreements with certain of our executives. These options are included in the number of securities to be issued upon exercise of outstanding options, warrants and rights in column (a) above.


SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

        Section 16(a) of the Exchange Act requires Rite Aid's executive officers, directors and persons who own more than 10%long-term performance of Rite Aid, common stock to file reports of ownershiptaking into account best practices, market competitiveness and changesour strategic, operational and financial goals and other appropriate factors in ownership with the SEC and the NYSE. Such persons are required by SEC regulations to furnish Rite Aid with copies of all Section 16(a) forms they file. Based solely on a review of the copies of such forms furnished to Rite Aid, we have determined that during fiscal year 2009, no persons subject to Section 16(a) reporting submitted late filings under Section 16(a) of the Exchange Act.

Compensation Committee’s judgment.

[MISSING IMAGE: tm228886d1-icon_against4c.gif]
The Board of Directors unanimously recommends that you vote AGAINST the stockholder proposal to adopt an executive compensation adjustment policy.

RITE AID CORPORATION   2023 Proxy Statement | 77

TABLE OF CONTENTS
SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT

[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth, as of [April 28, 2009]June 27, 2023 (except as otherwise noted), certain information concerning the beneficial shareholdingsownership of (a) each director (b) each Jean Coutu Groupand nominee for director, designee, (c)(b) each of our "named executive officers"“Named Executive Officers” (as such term is defined in Item 402(a)(3) of Regulation S-K under the Exchange Act), (d)(c) each holder ofknown to us to beneficially own more than five percent5% of theour common stock and (e)(d) all current directors and executive officers and Jean Coutu Group director designees as a group (based on [830,490,174][•] shares of common stock outstanding as [April 28, 2009], plus the number of shares of common stock into which the outstanding shares of LGP preferred stock are convertible)June 27, 2023). Each of the persons named


Table of Contents


below has sole voting power and sole investment power with respect to the shares set forth opposite his or her name, except as otherwise noted.

Beneficial Owners
Number of Common Shares
Beneficially Owned
(1)
Percentage
of Class
Named Executive Officers and Directors:
Bruce G. Bodaken[74,920](2)*
Elizabeth Burr[54,204](3)*
Heyward Donigan[601,504](4)[•]%
Paul Gilbert[—][—]
Bari Harlam[44,522](5)*
Robert E. Knowling, Jr.[61,996](6)*
Justin Mennen[145,488]*
Louis P. Miramontes[61,996](7)*
Arun Nayar[61,996](8)*
Andre Persaud[26,429]
Kate B. Quinn[54,204](9)*
Matthew Schroeder[228,589](10)*
All Executive Officers and Directors ([11] persons)[894,362](11)[•]%
5% Stockholders:
BlackRock, Inc.
55 East 52
nd Street
New York, NY 10055
3,795,009(12)6.7%
Beneficial Owners
 Number of Common
Shares Beneficially Owned(1)
 Percentage of Class

Named Executive Officers and Directors:

     
 

Joseph B. Anderson, Jr. 

  203,334(2)*
 

André Belzile

  86,667(3)*
 

François J. Coutu

  86,667(4)*
 

Michel Coutu

  86,667(5)*
 

James Donald

  33,334(6)*
 

Douglas Donley

  335,213(7)*
 

Robert Easley

  65,540(8)*
 

Brian Fiala

  237,259(9)*
 

Michael A. Friedman, MD

  253,334(10)*
 

David R. Jessick

  0  
 

Pierre Legault

  114,285(11)*
 

Robert G. Miller

  9,442,912(12)1.06%
 

Michael Regan

  86,667(13)*
 

Mary F. Sammons

  10,248,673(14)1.15%
 

Robert B. Sari

  415,014(15)*
 

Philip G. Satre

  361,834(16)*
 

Jonathan D. Sokoloff

  26,796,164(17)2.94%
 

John T. Standley

  568,782(18)*
 

Marcy Syms

  203,334(19)*
 

Kevin Twomey

  97,254(20)*
 

Frank Vitrano

  39,700(21)*
 

Dennis Wood

  86,667(22)*

 

     

All Executive Officers and Directors

     

24 persons

  50,080,842 5.38%

 

     

5% Stockholders:

     

Green Equity Investors III, L.P. 

  26,090,728(23)2.86%

11111 Santa Monica Blvd.

     

Suite 2000

     

Los Angeles, CA 90025

     

 

     

FMR Corp

  40,260,919(24)4.699%

82 Devonshire St

     

Boston, MA 02109

     

 

     

Thornburg Investment Management Inc. 

  62,097,198(25)7.34%

119 E. Marcy Street

     

Santa Fe, NM 87501

     

 

     

The Jean Coutu Group (PJC), Inc

  251,975,262(26)28.44%

530 Bériault Street

     

Longueuil, Quebec J4G 1S8

     

*

Percentage less than 1% of class.

(1)

Beneficial ownership has been determined in accordance with Rule 13d-3 under the Exchange Act, thereby including options exercisable aswithin 60 days of June 27, 2009.2023.

Table

(2)
This amount represents [•] restricted stock units that have vested or will vest before August 26, 2023, at which time said units will be payable in shares of Contents

(2)
common stock when Mr. Bodaken leaves the Board.
(3)
This amount represents [•] restricted stock units that have vested or will vest before August 26, 2023, at which time said units will be payable in shares of common stock when Ms. Burr leaves the Board.
(4)
This amount includes 183,334[•] shares which may be acquired within 60 days by exercising stock options.

(3)
(5)
This amount represents [•] restricted stock units that have vested or will vest before August 26, 2023, at which time said units will be payable in shares of common stock when Ms. Harlam leaves the Board.
(6)
This amount represents [•] restricted stock units that have vested or will vest before August 26, 2023, at which time said units will be payable in shares of common stock when Mr. Knowling leaves the Board.
(7)
This amount represents [•] restricted stock units that have vested or will vest before August 26, 2023, at which time said units will be payable in shares of common stock when Mr. Miramontes leaves the Board.
(8)
This amount represents [•] restricted stock units that have vested or will vest before August 26, 2023, at which time said units will be payable in shares of common stock when Mr. Nayar leaves the Board.

78 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
(9)
This amount represents [•] restricted stock units that have vested or will vest before August 26, 2023, at which time said units will be payable in shares of common stock when Ms. Quinn leaves the Board.
(10)
This amount includes 66,667[•] shares which may be acquired within 60 days by exercising stock options.

(4)
(11)
This amount includes 66,667[•] shares which may be acquired within 60 days by exercising stock options.

(5)
This amount includes 66,667 shares which mayoptions by all directors and executive officers and [•] restricted stock units that have vested or will best before August 26, 2023 and will be acquired within 60 days by exercising stock options.

(6)
This amount includes 33,334 shares which may be acquired within 60 days by exercising stock options.

(7)
This amount includes 262,163 shares which may be acquired within 60 days by exercising stock options.

(8)
This amount represents 65,540 shares owned by Mr. Easley, who ceased to be employed by the Company on September 24, 2008.

(9)
This amount includes 123,106 shares which may be acquired within 60 days by exercising stock options.

(10)
This amount includes 233,334 shares which may be acquired within 60 days by exercising stock options.

(11)
This amount represents 114,285 shares owned by Mr. Legault, who ceased to be employed by the Company on September 24, 2008.

(12)
The amount includes 8,883,334 shares which may be acquired within 60 days by exercising stock options.

(13)
This amount includes 66,667 shares which may be acquired within 60 days by exercising stock options.

(14)
This amount includes 52,779 shares owned by Ms. Sammon's spouse and 8,239,942 shares which may be acquired within 60 days by exercising stock options.

(15)
This amount includes 299.097 shares which may be acquired within 60 days by exercising stock options. Mr. Sari ceased to be employed by the Company on April 8, 2009.

(16)
This amount includes 233,334 shares which may be acquired within 60 days by exercising stock options.

(17)
This amount includes 705,436 shares owned jointly by Mr. Sokoloff and his spouse and 26,090,728 shares beneficially owned by Green Equity Investors III, L.P., which is affiliated with Leonard Green & Partners, L.P., of which Mr. Sokoloff is an executive officer and equity owner.

(18)
This amount includes 312,700 shares which may be acquired within 60 days by exercising stock options.

(19)
This amount includes 183,334 shares which may be acquired within 60 days by exercising stock options.

(20)
This amount represents 97,254 shares owned by Mr. Twomey, who ceased to be employed by the Company on September 24, 2008.

(21)
This amount represents 39,700 shares of restricted common stock.

Table of Contents

(22)
This amount includes 66,667 shares which may be acquired within 60 days by exercising stock options.

(23)
Green Equity Investors III, L.P. beneficially owns 26,090,728payable in shares of common stock.

(24)
Basedstock when the directors leave the Rite Aid Board of Directors.
(12)
This information is as of December 31, 2022 and based solely on a Schedule 13G/A filed by BlackRock, Inc. with the CommissionSEC on December 10, 2008, which indicates that as of November 30, 2008, these shares are beneficially ownedFebruary 1, 2023.

RITE AID CORPORATION   2023 Proxy Statement | 79

TABLE OF CONTENTS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
INFORMATION ABOUT THE ANNUAL MEETING
AND VOTING
[MISSING IMAGE: tm217739d1-icon_calendarpn.jpg]WHEN
[MISSING IMAGE: ic_mic-pn.jpg]
VIRTUAL MEETING
[MISSING IMAGE: ic_pencil-pn.jpg]RECORD DATE
August 18, 2023
11:30 a.m., Eastern
Daylight Time
www.virtualshareholdermeeting.com/RAD2023Close of business on June 27, 2023
QUESTIONS AND ANSWERS
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
Why did I receive a “Notice of Internet Availability of Proxy Materials” but no proxy materials?
We distribute our proxy materials to stockholders via the Internet under the “Notice and Access” approach permitted by FMR Corp. ("FMR") and various FMR subsidiaries and related persons and entities, including Fidelity Management & Research Company, which is a wholly-owned subsidiary of FMR and an investment adviser ("Fidelity"), Edward C. Johnson III, Chairman of FMR, and other entities. The Schedule 13G/A reports sole power to vote or direct the voting of 12,923,501 shares and sole power to dispose or direct the disposition of 40,260,919 shares.

(25)
Based solely on a Schedule 13G/A filed with the Commission on March 2, 2009 which indicates that as of February 27, 2008, these shares are beneficially owned by Thornburg Investment Management, Inc. The Schedule 13G/A reports sole power to vote or direct the voting of 62,097,198 shares and sole power to dispose or direct the disposition of 62,097,198 shares.

(26)
Based upon shares acquired on June 4, 2007 in connection with the closingrules of the stock purchase agreementU.S. Securities and shares acquiredExchange Commission (the “SEC”). This approach expedites stockholders’ receipt of proxy materials while conserving natural resources and reducing our distribution costs. On or about [June 29], 2023, we mailed a Notice of Internet Availability of Proxy Materials containing instructions on October 5, 2007 pursuanthow to Section 1.4access the proxy materials on the Internet to participating stockholders.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
Who may attend the Annual Meeting?
This year’s Annual Meeting will be held “virtually” through a live audio webcast on Friday, August 18, 2023, at 11:30 a.m., Eastern Daylight Time. There will be no physical meeting location. The meeting will only be conducted via an audio webcast. We have designed the format of the stockholder agreement.


CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Reviewvirtual Annual Meeting to ensure that stockholders who attend the meeting will be afforded comparable rights and Approvalopportunities to participate as they would at an in-person meeting.

All stockholders are invited to attend the virtual Annual Meeting. Persons who are not stockholders may attend only if invited by the Board of Related Person Transactions

        WeDirectors. If you are the beneficial owner of shares held in the name of your broker, bank, or other nominee and do not have adopted a written policy concerning the review, approvalcontrol number, please contact your broker, bank, or ratification of transactions with related persons. The Nominating and Governance Committee is responsible for review, approval or ratification of "related person transactions" between the Company or its subsidiaries and related persons. Under SEC rules, a related person is, or anytime since the beginning of the last fiscal year was, a director, officer,other nominee for director, an immediate family member (as defined under applicable SEC rules) of such persons, or a 5% stockholder of the Company. A related person transaction is any transaction or series of transactions in which the Company or a subsidiary is a participant, the amount involved exceeds $120,000, and a related person has a direct or indirect material interest.

        Directors, executive officers and nominees must complete an annual questionnaire and disclose all potential related person transactions involving themselves and their immediate family members that are known to them. Throughout the year, directors and executive officers must notify the Corporate Secretary and Chief Accounting Officer of any potential Related Person Transactions as soon as they become aware of any such transaction. The Corporate Secretarypossible and Chief Accounting Officer inform the Nominating and Governance Committee of any related person transaction of which they are aware. The Corporate Secretary and Chief Accounting Officer are responsible for conductingno later than August 11, 2023, so that you can be provided with a preliminary analysis and review of potential related person transactions and presentationcontrol number.

[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
How can I attend the Annual Meeting?
This year’s Annual Meeting will be held virtually through a live audio webcast on Friday, August 18, 2023, at 11:30 a.m., Eastern Daylight Time. There will be no physical meeting location.
Online access to the Nominatingaudio webcast of the Annual Meeting will open approximately 15 minutes prior to the start of the meeting to allow time for you to log in and Governance Committee for review including provisiontest the computer audio system. We encourage our stockholders to access the meeting prior to the start time.
To attend the virtual Annual Meeting, log in at www.virtualshareholdermeeting.com/RAD2023. Stockholders will need their unique control number which appears on the Notice of additional information to enable proper considerationInternet Availability of Proxy Materials or, if you received a paper copy of the proxy materials, the proxy card (printed in the box and marked by the Committee. As necessary, the Nominating and Governance Committee shall review approved related person transactions on a periodic basis throughout the duration of the transaction to ensure that the transactions remains in the best interests of the Company. The Nominating and Governance Committee may, in its discretion, engage outside counsel to review certain related person transactions. In addition, the Nominating and Governance Committee may request that the full Board of Directors consider the approval or ratification of related person transactions if it deems advisable. A copy of our full policy concerning transactions with related persons is available on the Corporate Governance section of our website atwww.riteaid.com.


Table of Contents

Agreement with John T. Standley

        Prior to being employed by the Company, Rite Aid paid Mr. Standley a fee of $32,500 per week for consulting services rendered in July, August and September 2008. The consulting agreement was on a week-to-week basis, which also provided for the reimbursement of out-of-pocket expenses incurred by Mr. Standley. During fiscal year 2009 and prior to his employment as President and Chief Operating Officer, Rite Aid paid Mr. Standley a consulting fee of $293,551.

Deferred Compensation for David R. Jessick's Prior Service

        Pursuant to the terms of a deferred compensation program in place during Mr. Jessick's prior service with the Company, Mr. Jessick received a payment of approximately $109,000 in fiscal 2009 and a final payment of approximately $61,000 in March 2009.

Relationship with Leonard Green & Partners L.P.

        Rite Aid has entered into a one-year agreement with Leonard Green & Partners L.P., or Leonard Green, effective January 1, 2006, whereby Rite Aid has agreed to pay Leonard Green a fee of $300,000 per year (reduced to $150,000 per year on June 4, 2007 when John Danhakl ceased to be a director on the Company's Board of Directors) for its consulting services. The consulting agreement was extended effective January 1, 2007 on a month-to-month basis, which also provides for the reimbursement of out-of-pocket expenses incurred by Leonard Green. This agreement is an extension of Rite Aid's existing consulting agreement with Leonard Green. Pursuant to the consulting agreement, Rite Aid may engage Leonard Green to provide financial advisory and investment banking services in connection with major financial transactions that it undertakes in the future. During fiscal year 2009, Rite Aid paid Leonard Green a consulting fee of $137,500. This transaction was reviewed and ratified by our Board in April 2007 under our related person transactions approval policy described above. Jonathan D. Sokoloff, a director of Rite Aid, is an equity owner of Leonard Green.

Agreements with Jean Coutu Group

        In connection with Rite Aid's acquisition of the Brooks and Eckerd drugstore chains from Jean Coutu Group, Rite Aid and Jean Coutu Group became a party to a series of agreements which are described below.

Stock Purchase Agreement

        Rite Aid entered into a stock purchase agreement with Jean Coutu Group to acquire all of the capital stock of The Jean Coutu Group (PJC) USA, Inc., or Jean Coutu USA, which was a wholly-owned subsidiary of Jean Coutu Group and the holding company for the Brooks and Eckerd drugstore chains. Pursuant to the stock purchase agreement, certain of the provisions extend beyond the closing of the Brooks Eckerd Transaction.

        Non-Competition Covenant.    Jean Coutu Group has agreed that for five years after the closing of the Brooks Eckerd Transaction it will not (other than as a stockholder of Rite Aid and through its designees on Rite Aid's Board of Directors) engage in the retail pharmacy business in the United Statesarrow) or the pharmacy benefits management business ininstructions that accompanied the United States. In a related agreement, Michel Coutu, our Non-Executive Co-Chairman, has agreed that for three years after the closing of the Brooks Eckerd Transaction, he will not (other than as a stockholder of Rite Aid and in his capacity as a Rite Aid director), engage in the retail pharmacy business in the United States or the pharmacy benefits management business in the United States.

        Indemnification.    The stock purchase agreement provides for indemnification for losses arising from breaches of representations and warranties, breaches of covenants and certain actions relating to


Table of Contents


the conduct of the business of Jean Coutu Group (other than Jean Coutu USA). Each party's indemnification obligation for breaches of representations and warranties is subject to a $35 million deductible and each party's indemnification obligation for breaches of representations and warranties and for breaches of covenants is subject to an aggregate cap of $450 million. The deductible and cap do not apply to losses arising from or relating to the conduct of the business of Jean Coutu Group. No claim for a breach of a representation and warranty may be brought by either party or included in the aggregate losses for purposes of satisfying the deductible unless it exceeds a minimum threshold of $10,000.

        Jean Coutu Group also has agreed to indemnify Rite Aid for losses arising from pre-closing taxes of Jean Coutu USA, any breaches of tax representations and warranties or breaches of tax covenants and for half of any transfer taxes resulting from the transaction. The deductible and cap do not apply to losses arising from tax matters.

Stockholder Agreement

        Concurrently with entering into the stock purchase agreement, Rite Aid, Jean Coutu Group and certain Coutu family members entered into a stockholder agreement. The stockholder agreement contains provisions relating to board and board committee composition, corporate governance, stock ownership, stock purchase rights, transfer restrictions, voting arrangements and other matters.

        Board and Board Committee Representation.    The stockholder agreement provides that Jean Coutu Group initially will have the right to designate four members of Rite Aid's Board of Directors. Thereafter, Jean Coutu Group will have the right to designate a certain number of director nominees for election to our Board, taking into account Jean Coutu Group designees then serving in a class or classes of directors whose terms are not yet expiring, subject to Jean Coutu Group's maintenance of specified percentage thresholds of Rite Aid total voting power.

Percentage of Total Voting Power
Number of Directors/Director Nominees

25% and above

4

17.9% - 24.9%

3

10.7% - 17.8%

2

5% - 10.6%

1

        For so long as Jean Coutu Group is entitled to designate at least two directors and subject to NYSE independence requirements for directors, Jean Coutu Group will have the right to designate one of its designees to each of the Audit, Compensation and Nominating and Governance Committees of the Rite Aid Board.proxy materials. In the event that only one of Jean Coutu Group's designees qualifiesyou do not have a control number, please contact your broker, bank, or other nominee as an independent director of Rite Aid,soon as possible and no later than August 11, 2023, so that designee will be appointed to one of the three committees and other Jean Coutu Group designees willyou can be provided "observer status" to attend committee meetings (subjectwith a control number and gain access to the committees meeting in executive session) of the other two committees.

        Voting Arrangements.    The stockholder agreement provides that for a period of five years after the closing of the Brooks Eckerd Transaction, Jean Coutu Group agrees to vote its shares for each Rite Aid director nominee recommended by the Board. Thereafter, Jean Coutu Group will vote its shares for each Rite Aid director nominee it designated and, in its discretion, either for each other Rite Aid director nominee recommended by the Board or for each other Rite Aid director nominee recommended by the Board and for nominees recommended by other persons in the same proportion as votes cast by all other Rite Aid stockholders for those nominees.

        Right to Purchase Securities.    For so long as Jean Coutu Group owns at least 20% of the total Rite Aid voting power, Jean Coutu Group will have the right to purchase securities in future issuances of Rite Aid voting securities (other than in certain types of issuances described below) to permit Jean

meeting.


80 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS

Table of Contents


Coutu Group to maintain the same percentage of total voting power it held prior to the issuance. These purchase rights will not apply to issuances of Rite Aid stock in connection with conversions of convertible preferred stock, equity compensation plan awards, acquisitions by Rite Aid, equity-for-debt exchanges and certain other types of issuances. Subject to certain conditions, under circumstances in which Jean Coutu Group is not permitted to purchase voting securities in a Rite Aid issuance of voting securities, Jean Coutu Group will be permitted to make open market purchases

INFORMATION ABOUT THE ANNUAL MEETING AND VOTING
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
Who is entitled to vote at the Annual Meeting?
Holders of Rite Aid common stock as of the close of business on the record date, June 27, 2023, will receive notice of, and be eligible to vote at, the Annual Meeting and any adjournment or postponement of the Annual Meeting. At the close of business on the record date, Rite Aid had outstanding and entitled to vote [•] shares of common stock. No other shares of Rite Aid capital stock are entitled to notice of and to vote at the Annual Meeting.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
How can I vote during the Annual Meeting?
To log in order to maintain the same percentageAnnual Meeting and to cast your vote electronically during the meeting, you will need the unique control number which appears on the Notice of total voting power itInternet Availability of Proxy Materials or, if you received a paper copy of the proxy materials, the proxy card (printed in the box and marked by the arrow) or the instructions that accompanied the proxy materials. In the event that you are the beneficial owner of shares held in the name of your broker, bank, or other nominee and do not have a control number, please contact your broker, bank, or other nominee as soon as possible and no later than August 11, 2023, so that you can be provided with a control number.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
How can I submit a question at the Annual Meeting?
Stockholders may submit questions in writing during the Annual Meeting on www.virtualshareholdermeeting.com/RAD2023. Stockholders will need their unique control number which appears on their Notice of Internet Availability of Proxy Materials or, if you received a paper copy of the proxy materials, the proxy card (printed in the box and marked by the arrow) or the instructions that accompanied the proxy materials.
As part of the Annual Meeting, we intend to answer questions that are submitted during the meeting in accordance with the annual meeting procedures and are pertinent to the Company and the meeting matters, as time permits. Questions and answers may be grouped by topic and substantially similar questions may be grouped and answered as one. Questions and answers to any pertinent questions not addressed during the Annual Meeting will be published following the Annual Meeting on our website at https://investors.riteaid.com.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
What if I need technical assistance?
Beginning 15 minutes prior to the issuance.

        Standstill Restrictions.start of and during the virtual Annual Meeting, we will have a support team ready to assist stockholders with any technical difficulties they may have accessing or hearing the virtual meeting. If you encounter any difficulties accessing the virtual meeting during the check-in or meeting time, you should call our support team at the phone number listed on the login page located at www.virtualshareholdermeeting.com/RAD2023.

[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
Will a replay of the Annual Meeting be available?
A replay of the Annual Meeting will be made publicly available 24 hours after the meeting at www.virtualshareholdermeeting.com/RAD2023 and will be available for one year following the Annual Meeting.

RITE AID CORPORATION   2023 Proxy Statement | 81

TABLE OF CONTENTS
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
What matters will be voted on at the Annual Meeting, and how does the Board recommend that I vote?
There are seven proposals that are scheduled to be considered and voted on at the Annual Meeting:
ProposalBoard RecommendationFor More
Information
1Election of six directors to hold office until the 2024 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR all of the
Board’s nominees
Page 9
2Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
Page 27
3Advisory vote to approve the compensation of our named executive officers
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
Page 29
4Advisory vote on the frequency of future advisory votes to approve the compensation of our named executive officers
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
Page 30
5Approval of the amendments to the Rite Aid Corporation Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
Page 73
6Consider and vote on a stockholder proposal, if properly presented at the Annual Meeting
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]
AGAINST
Page 74
7Consider and vote on a stockholder proposal, if properly presented at the Annual Meeting
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]
AGAINST
Page 76
Stockholders also will be asked to consider and vote at the Annual Meeting on any other matter that may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
At this time, the Board of Directors is otherwise unaware of any matters, other than those set forth above and the possible submission of the Krol Proposal, as described in the section entitled “Other Matters,” that may properly come before the Annual Meeting. If any other matters properly come before the Annual Meeting, the persons named in the enclosed proxy, or their duly constituted substitutes acting at the Annual Meeting or any adjournment or postponement of the Annual Meeting, will be deemed authorized to vote or otherwise act on such matters in accordance with their judgment.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
What is the difference between holding shares as a stockholder of record and as a beneficial owner?
If your shares are registered directly in your name with our transfer agent, Broadridge Corporate Issuer Services, you are the “stockholder of record” with respect to those shares.
If your shares are held in a stock brokerage account or by a bank or other nominee, those shares are held in “street name” and you are considered the “beneficial owner” of the shares. As the beneficial owner of those shares, you have the right to direct your broker, bank, or nominee how to vote your shares, and you will receive separate instructions from your broker, bank, or other holder of record describing how to vote your shares.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
How can I vote my shares before the Annual Meeting?
If you hold your shares in your own name, you may submit a proxy by telephone, via the Internet, by tablet or smartphone by scanning the QR code, or by mail.

82 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING
Have your proxy card in hand, with your individual control number, and follow the instructions.
[MISSING IMAGE: ic_phone-pn.jpg]
PHONE
[MISSING IMAGE: tm217739d1_icon-computerpn.jpg]
INTERNET
[MISSING IMAGE: tm217739d1_icon-qrreaderpn.jpg]
MOBILE DEVICE
[MISSING IMAGE: ic_mail-pn.jpg]
MAIL
Call
1-800-690-6903
(toll-free), 24/7
Visit
www.proxyvote.com,
24/7
Scan the
QR code
[MISSING IMAGE: ic_qrcodeproxyvote-bw.jpg]
Mark, sign and date your
proxy card and
return it in the postage-paid
envelope

SUBMITTING A PROXY BY TELEPHONE. You can submit a proxy for your shares by telephone until 11:59 p.m. Eastern Daylight Time on August 17, 2023, by calling the toll-free telephone number on the enclosed proxy card, 1-800-690-6903. Telephone proxy submission is available 24 hours a day. Easy-to-follow voice prompts allow you to submit a proxy for your shares and confirm that your instructions have been properly recorded. Our telephone proxy submission procedures are designed to authenticate stockholders’ identities by using individual control numbers.

SUBMITTING A PROXY VIA THE INTERNET. You can submit a proxy for your shares via the Internet until 11:59 p.m. Eastern Daylight Time on August 17, 2023, by accessing the website listed on the enclosed proxy card, www.proxyvote.com, and following the instructions you will find on the website. Internet proxy submission is available 24 hours a day. As with telephone proxy submission, you will be given the opportunity to confirm that your instructions have been properly recorded.

SUBMITTING A PROXY BY TABLET OR SMARTPHONE. You can submit a proxy for your shares online with your tablet or smartphone until 11:59 p.m. Eastern Daylight Time on August 17, 2023 by scanning the QR code above and following the instructions. Proxy submission via the QR code is available 24 hours a day. As with telephone and internet proxy submission, you will be given the opportunity to confirm that your instructions have been properly recorded.

SUBMITTING A PROXY BY MAIL. If you choose to submit a proxy for your shares by mail, simply mark the enclosed proxy card (if you received a paper copy of this Proxy Statement), date and sign it, and return it in the postage paid envelope provided.
By casting your vote in any of the ways listed above, you are authorizing the individuals listed on the proxy to vote your shares in accordance with your instructions. You may also attend and vote at the virtual Annual Meeting.
If your shares are held in the name of a bank, broker or other nominee, you will receive instructions from the holder of record that you must follow for your shares to be voted. The availability of telephonic or Internet voting will depend on the bank’s, broker’s, or other nominee’s voting process. Please check with your bank, broker, or other nominee and follow the voting procedures your bank, broker, or other nominee provides to vote your shares. The 16-digit control number that grants access to the virtual meeting will also empower you to vote at the virtual meeting. In the event that you are the beneficial owner of shares held in the name of your broker, bank or other nominee and do not have a control number, please contact your broker, bank, or other nominee as soon as possible and no later than August 11, 2023, so longthat you can be provided with a control number.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
If I am the beneficial owner of shares held in “street name” by my broker, will my broker automatically vote my shares for me?
New York Stock Exchange (“NYSE”) rules applicable to brokers grant your broker discretionary authority to vote your shares without receiving your instructions on certain matters. Your broker has discretionary voting authority under NYSE rules to vote your shares on the ratification of Deloitte & Touche LLP as Jean Coutu Group (orour independent registered public accounting firm. However, unless you provide voting instructions to your broker, your broker does not have discretionary authority to vote on the election of directors, the advisory vote on the compensation of our named executive officers, the advisory vote on the frequency of future advisory votes on the compensation of our named executive officers, the approval of the amendments to the Rite Aid Corporation Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions, or the two stockholder proposals, if properly presented at the Annual Meeting. Accordingly, it is particularly important that beneficial owners instruct their brokers how they wish to vote their shares.

RITE AID CORPORATION   2023 Proxy Statement | 83

TABLE OF CONTENTS
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
Is there a list of registered stockholders entitled to vote at the Annual Meeting?
The names of registered stockholders entitled to vote at the Annual Meeting will be available for 10 days prior to the Annual Meeting for any Coutu familypurpose germane to the Annual Meeting, during normal business hours, at Rite Aid Collaboration Center, 1200 Intrepid Avenue, 2nd Floor, Philadelphia, PA 19112, by contacting our Corporate Secretary at PO Box 3165 Harrisburg, PA 17105. Registered stockholders must make an appointment.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
How will my shares be voted if I give my proxy but do not specify how my shares should be voted?
If you provide specific voting instructions, your shares will be voted at the Annual Meeting in accordance with your instructions. If you hold shares in your name and sign and return a proxy card without giving specific voting instructions, your shares will be voted:
ProposalYour Shares Will Be Voted
1On the election of directors
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR all of the Board’s nominees
2On ratification of our independent registered public accounting firm
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
3On the advisory vote to approve the compensation of our named executive officers
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
4On the advisory vote on the frequency of future advisory votes on the compensation of our named executive officers
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
ONE YEAR
5On approval of the amendments to the Rite Aid Corporation Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
6On the stockholder proposal to require an annual advisory vote on the compensation of Rite Aid’s directors, if properly presented at the Annual Meeting
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]
AGAINST
7On the stockholder proposal to adopt an executive compensation adjustment policy, if properly presented at the Annual Meeting
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]
AGAINST
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
What is an “abstention” and how would it affect the vote?
An “abstention” occurs when a stockholder sends in a proxy with explicit instructions to decline to vote regarding a particular matter. Abstentions are counted as present for purposes of determining a quorum. An abstention with respect to the election of directors is neither a vote cast “for” a nominee nor a vote cast “against” the nominee and, therefore, will have no effect on the outcome of the vote. Abstentions with respect to the ratification of Deloitte & Touche LLP as our independent registered public accounting firm, the advisory vote on the compensation of our named executive officers, the approval of the amendments to the Rite Aid Corporation Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions, and the two stockholder proposals, if properly presented at the Annual Meeting, will have the same effect as voting “against” the proposal. An abstention will have no effect on the outcome of the advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
What is a broker “non-vote” and how would it affect the vote?
A broker non-vote occurs when a broker or groupother nominee who holds shares for the beneficial owner is unable to vote those shares for the beneficial owner because the broker or other nominee does not have discretionary

84 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING
voting power for the proposal and has not received voting instructions from the beneficial owner of Coutu family stockholders) ownsthe shares. Brokers will have discretionary voting power to vote shares for which no voting instructions have been provided by the beneficial owner only with respect to the ratification of Deloitte & Touche LLP as our independent registered public accounting firm. Brokers will not have such discretionary voting power to vote shares with respect to the election of directors, the advisory vote on the compensation of our named executive officers, the advisory vote on the frequency of future advisory votes on the compensation of our named executive officers, the approval of the amendments to the Rite Aid Corporation Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions or the two stockholder proposals, if properly presented at least 5%the Annual Meeting. Shares that are the subject of a broker non-vote are included for quorum purposes. A broker non-vote with respect to each of Proposals 1-4 and 6-7 will not be counted as a vote cast and will not be counted as a vote represented at the meeting and entitled to vote and, consequently, will have no effect on the outcome of the vote. A broker non-vote with respect to Proposal 5 will have the same effect as a vote “against” such proposal. Accordingly, it is particularly important that beneficial owners of Rite Aid shares instruct their brokers how to vote their shares.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
What are the quorum and voting requirements for the proposals?
In deciding the proposals that are scheduled for a vote at the Annual Meeting, each holder of common stock as of the record date is entitled to one vote per share of common stock. In order to take action on the proposals, a quorum, consisting of the holders of [•] shares (a majority of the aggregate number of shares of Rite Aid common stock) issued and outstanding and entitled to vote as of the record date for the Annual Meeting, must be present in person or by proxy. This is referred to as a “quorum.” In accordance with Delaware law and our By-Laws, stockholders and proxy holders attending the virtual annual meeting will be deemed present “in person.” Proxies marked “Abstain” and broker non-votes will be treated as shares that are present for purposes of determining the presence of a quorum.

PROPOSAL NO. 1—ELECTION OF DIRECTORS
The affirmative vote of a majority of the total voting powernumber of Rite Aidvotes cast is required for the election of each director nominee named in Proposal No. 1. This means that the votes cast “for” that nominee must exceed the votes cast “against” that nominee. Any shares not voted (whether by abstention, broker non-vote or otherwise) will not be counted as votes cast and will have no effect on the outcome of the vote.

PROPOSAL NO. 2—RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The affirmative vote of a majority of the shares represented at the meeting and entitled to vote thereon is required for nine months thereafter, Jean Coutu Groupthe ratification of Deloitte & Touche LLP as our independent registered public accounting firm in Proposal No. 2. Any shares represented at the meeting and entitled to vote on the matter and not voted (whether by abstention or such Coutu family stockholdersotherwise) will have the same effect as a vote “against” the proposal.

PROPOSAL NO. 3—ADVISORY VOTE ON COMPENSATION OF NAMED EXECUTIVE OFFICERS
The affirmative vote of a majority of the shares represented at the meeting and entitled to vote thereon is required for the approval of the advisory vote on the compensation of our named executive officers in Proposal No. 3. Any shares represented at the meeting and entitled to vote on the matter and not voted (whether by abstention or groupotherwise) will have the same effect as a vote “against” the proposal. Any broker non-votes with respect to the advisory vote on the compensation of Coutu family stockholdersour named executive officers will not be counted as shares represented at the meeting and entitled to vote and, consequently, will have no effect on the outcome of the vote.

PROPOSAL NO. 4—ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF NAMED EXECUTIVE OFFICERS
The frequency (every one, two or three years) receiving the greatest number of votes, even if not a majority, will be subject to restrictionsconsidered the preference of our stockholders. Abstentions and broker non-votes are not counted for the advisory vote on the acquisitionfrequency of additional Rite Aid voting securities, other than with Rite Aid's consent or throughfuture advisory votes on the stock purchase rights discussed above, as well as restrictionscompensation of our named executive officers and, therefore, will have no effect on taking certain actions relating to Rite Aid.

        Transfer Restrictions.    For so long as Jean Coutu Group owns 5% or morethe outcome of the voting powerproposal.


RITE AID CORPORATION   2023 Proxy Statement | 85

TABLE OF CONTENTS
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING

PROPOSAL NO. 5—APPROVAL OF THE AMENDMENTS TO THE RITE AID CORPORATION AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO ELIMINATE SUPERMAJORITY VOTING PROVISIONS
The affirmative vote of Rite Aid's securities and for nine months thereafter, Rite Aid voting securities owned by Jean Coutu Group will be subject to restrictions on transfer included in the stockholder agreement, other than transfers in accordance with Rule 144, in a registered public offering, in connection with a pro rata dividend, spinoff or distribution to Jean Coutu Group stockholders and certain other permitted transfers.

        In addition, subject to the foregoing, Jean Coutu Group may not transfer shares to someone who, as a result of the transfer, would own more than 5%majority of the outstanding shares of Rite Aid common stock.

        Supermajority Board Approval.    For so long as Jean Coutu Group owns at least 25% of the total voting power of Rite Aid, certain matters will requireis required for the approval of two-thirds of all ofthe amendments to the Rite Aid BoardCorporation Amended and Restated Certificate of Directors, including increasesIncorporation to eliminate supermajority voting provisions in Proposal No. 5. Any shares represented at the numbermeeting and entitled to vote on the matter and not voted (whether by abstention or otherwise) will have the same effect as a vote “against” the proposal. Any broker non-votes with respect to the approval of authorizedthe proposal to eliminate supermajority voting provisions will have the same effect as a vote “against” the proposal.


PROPOSAL NO. 6—STOCKHOLDER PROPOSAL TO REQUIRE AN ANNUAL ADVISORY VOTE ON THE COMPENSATION OF RITE AID’S DIRECTORS
The affirmative vote of a majority of the shares significant issuancesrepresented at the meeting and entitled to vote thereon is required for the approval of Rite Aid equity securities, mergers, reorganizations, consolidations or similar business combinations involving Rite Aid, significant asset sales and certain other actions specified in the stockholder agreement.

Registration Rights Agreement

        Concurrentlyproposal in Proposal No. 6. Any shares represented at the meeting and entitled to vote on the matter and not voted (whether by abstention or otherwise) will have the same effect as a vote “against” the proposal. Any broker non-votes with entering into the stock purchase agreement, Rite Aid, Jean Coutu Group and certain Coutu family members entered into a registration rights agreement. Pursuantrespect to the registration rights agreement, subjectapproval of the stockholder proposal will not be counted as shares represented at the meeting and entitled to certain conditions, Jean Coutu Group hasvote and, consequently, will have no effect on the right,outcome of the vote.


PROPOSAL NO. 7—STOCKHOLDER PROPOSAL TO ADOPT AN EXECUTIVE COMPENSATION ADJUSTMENT POLICY
The affirmative vote of a majority of the shares represented at the meeting and entitled to vote thereon is required for the approval of the stockholder proposal in Proposal No. 7. Any shares represented at the meeting and entitled to vote on six occasions,the matter and not voted (whether by abstention or otherwise) will have the same effect as a vote “against” the proposal. Any broker non-votes with respect to demand that Rite Aid registerthe approval of the stockholder proposal will not be counted as shares represented at the meeting and entitled to vote and, consequently, will have no effect on the outcome of the vote.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
What happens if a quorum is not present at the Annual Meeting?
If the shares present in person or represented by proxy at the virtual Annual Meeting are not sufficient to constitute a quorum, the stockholders by a vote of the holders of a majority of votes present in person or represented by proxy (which may be voted by the proxyholders) may, without further notice to any stockholder (unless a new record date is set), adjourn the meeting to a different time and place to permit further solicitations of proxies sufficient to constitute a quorum.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
Who will count the votes?
Representatives of Broadridge Financial Solutions, Inc. will tabulate the votes and act as inspectors of election.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
How can I change my vote?
You may revoke your proxy at any time before it is exercised by:

Delivering to the Secretary a written notice of revocation, dated later than the proxy, before the vote is taken at the Annual Meeting;

Delivering to the Secretary an executed proxy bearing a later date, before the vote is taken at the Annual Meeting;

Submitting a proxy on a later date by telephone, via the Internet or by tablet or smartphone by scanning the QR code (only your last such proxy will be counted), before 11:59 p.m. Eastern Daylight Time on August 17, 2023; or

86 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING

Attending the virtual Annual Meeting and voting (your attendance at the Annual Meeting, in and of itself, will not revoke the proxy).
Any written notice of revocation, or later dated proxy, should be delivered to:
[MISSING IMAGE: ic_mail-pn.jpg]
Rite Aid Corporation
Attention: Corporate Secretary
PO Box 3165
Harrisburg, PA 17105
If your shares of Rite Aid common stock are held by Jean Coutu Groupa bank, broker, or other nominee, you must follow the instructions provided by the bank, broker or other nominee if you wish to change your vote.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
Who will conduct the proxy solicitation and how much will it cost?
We are soliciting proxies from stockholders on behalf of our Board and will pay for resale in an underwritten public offering, provided that the anticipated aggregate offering price would exceed $100 million or the registration is for at least 25% of the Rite Aid common stock heldall costs incurred by Jean Coutu Group. Jean Coutu Group also may request that Rite Aid include those shares in certain registration statements that Rite Aid may file in the future in connection with underwritten offerings.

Transition Services Agreement

        Effective as of June 4, 2007, Rite Aid and Jean Coutu Group entered into a transition services agreement consistent with certain principles set forth in the stock purchase agreement. Pursuant to the transition services agreement, Jean Coutu Group provided for a period of up to nine months following the closing date, subject to up to three, three-month extensions, certain transition services, including information technology, network and support services, to Jean Coutu USA to facilitate the transition of the businesses to Rite Aid. The Company has exercised all of the extensions available under the transition services agreement, which terminated in September 2008.


Table of Contents

        The transactions with Jean Coutu Group were reviewed by our Boardit in connection with the closingsolicitation. In addition to solicitation by mail, the directors, officers and associates of the Brooks Eckerd Transaction and ratified under our related person transactions approval policy described above.


STOCKHOLDER PROPOSALS FOR
THE 2010 ANNUAL MEETING OF STOCKHOLDERS

        Any stockholder desiring to present a proposal for inclusion in Rite Aid's proxy statement for the 2010 Annual Meeting of Stockholders must deliver the proposal to the Secretary at the address below not later than [January 14, 2010]. Only those proposals that comply with the requirements of Rule 14a-8 under the Exchange Act will be included in Rite Aid's proxy statement for the 2010 Annual Meeting.

        In order for proposals of stockholders made outside of Rule 14a-8 under the Exchange Act to be considered "timely" within the meaning of Rule 14a-4(c) under the Exchange Act, such proposals must be received by the Secretary at the address below by March 27, 2010.

        Stockholders may present proposals that are proper subjects for consideration at an annual meeting, even if the proposal is not submitted by the deadline for inclusion in the proxy statement. To do so, the stockholder must comply with the procedures specified in Rite Aid's by-laws. The by-laws, which are available on Rite Aid's website atwww.riteaid.com under "Our Company—Corporate Governance—By-Laws" and in print upon request from the Secretary, require all stockholders who intend to make proposals at an annual meeting of stockholders to submit their proposals to the Secretary not fewer than 90 and not more than 120 days before the anniversary date of the previous year's annual meeting of stockholders. The by-laws also provide that nominations for director may only be made by the Board of Directors (or an authorized Board committee) or by a stockholder of record entitled to vote who sends notice to the Secretary not fewer than 90 nor more than 120 days before the anniversary date of the previous year's annual meeting of stockholders. Any nomination by a stockholder must comply with the procedures specified in Rite Aid's by-laws. To be eligible for consideration at the 2010 Annual Meeting, proposals which have not been submitted by the deadline for inclusion in the proxy statement and any nominations for director must be received by the Secretary between February 25, 2010 and March 27, 2010. This advance notice period is intended to allow all stockholders an opportunity to consider all business and nominees expected to be considered at the meeting. All submissions to, or requests from, the Secretary should be made to:

Rite Aid Corporation
30 Hunter Lane
Camp Hill, Pennsylvania 17011
Attention: Marc A. Strassler, Secretary


INCORPORATION BY REFERENCE

        In accordance with SEC rules, notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act of 1933, as amended, or the Exchange Act, that might incorporate this proxy statement or future filings made by Rite Aid under those statutes, the information included under the caption "Compensation Committee Report" and those portions of the information included under the caption "Audit Committee Report" required by the SEC's rules to be included therein, shall not be deemed to be "soliciting material" or "filed" with the SEC and shall not be deemed incorporated by reference into any of those prior filings or into any future filings made by Rite Aid under those statutes, except to the extent we specifically incorporate these items by reference.


Table of Contents


OTHER MATTERS

        The Board of Directors knows of no other matters that have been submitted for consideration at this Annual Meeting. If any other matters come before stockholders at this Annual Meeting, the persons named on the enclosed proxy intend to vote the shares they represent in accordance with their best judgment.


INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

        Deloitte & Touche LLP served as Rite Aid's independent registered public accounting firm for fiscal year 2009 and Rite Aid's Audit Committee is in the process of negotiating with Deloitte & Touche LLP the terms of an arrangement to audit the consolidated financial statements of the Company and its subsidiaries may solicit proxies from stockholders of Rite Aid in person or by telephone, facsimile, or email without additional compensation other than reimbursement for fiscal year 2010. A representativetheir actual expenses.

We have retained Morrow Sodali, LLC, a proxy solicitation firm, to assist us in the solicitation of Deloitte & Touche LLP is expected to be present atproxies for the Annual Meeting, and the representativeMeeting. Rite Aid will have the opportunity to makepay Morrow Sodali a statement andfee of approximately $20,000, plus reasonable out-of-pocket expenses.
Arrangements also will be availablemade with brokerage firms and other custodians, nominees, and fiduciaries for the forwarding of solicitation material to respondthe beneficial owners of stock held of record by such persons, and we will reimburse such custodians, nominees, and fiduciaries for their reasonable out-of-pocket expenses in connection with the forwarding of solicitation materials to appropriate questions.


the beneficial owners of our stock.

If you have any questions about voting your shares or attending the Annual Meeting, please call our Investor Relations Department:
[MISSING IMAGE: ic_phone-pn.jpg]
(717) 975-3710
IMPORTANT NOTICE REGARDING DELIVERY
OF STOCKHOLDER DOCUMENTS

The SEC has adopted rules that permit companies and intermediaries such as brokers to satisfy proxy material delivery requirements with respect to two or more stockholders sharing the same address by delivering a single copy of the proxy statementmaterials addressed to those stockholders. This process, which is referred to as "householding,"“householding,” potentially provides extra convenience for stockholders and reduces printing and postage costs for companies.

Rite Aid and some brokers utilize the householding process for proxy materials. In accordance with a notice sent to certain stockholders who share a single address, only one copy of thisthe proxy statementmaterials is being sent to that address, unless we received contrary instructions from any stockholder at that address. Stockholders who participate in householding will continue to receive separate proxy cards. Householding will continue until you are notified otherwise or until one or more stockholders at your address revokes consent. If you revoke consent, you will be removed from the householding program within 30 days of receipt of the revocation. If you hold your Rite Aid stock in "street“street name," additional information regarding householding of proxy materials should be forwarded to you by your broker.


RITE AID CORPORATION   2023 Proxy Statement | 87

TABLE OF CONTENTS
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING
However, if you wish to receive a separate copy of thisthe proxy statement, ormaterials, we will promptly deliver one to you upon request.
You can notify us by sending a written request to:
[MISSING IMAGE: ic_mail-pn.jpg]
Rite Aid Corporation
Attention: Corporate Secretary
PO Box 3165
Harrisburg, PA 17105
Or by calling the Corporate Secretary at:
[MISSING IMAGE: ic_phone-pn.jpg]
(717) 761-2633
In addition, if you would like to receive separate proxy statements and annual reports of Rite Aid in the future, or if you are receiving multiple copies of annual reports and proxy statements at an address shared with another stockholder and would like to participate in householding, please notify your broker if your shares are held in a brokerage account or us if you hold registered shares. You can notify us by sending

88 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
OTHER INFORMATION
STOCKHOLDER PROPOSALS FOR THE 2024 ANNUAL MEETING
Any stockholder desiring to present a written requestproposal for inclusion in Rite Aid’s proxy statement for the 2024 Annual Meeting of Stockholders must deliver the proposal to Rite Aid Corporation, 30 Hunter Lane, Camp Hill, Pennsylvania 17011, Attention: Marc A. Strassler, Secretary, or by calling the Secretary at (717) 975-5833.

the address below not later than March 1, 2024. However, if the date of our 2024 Annual Meeting of Stockholders is changed by more than 30 days from the date of the previous year’s meeting, then Rite Aid will disclose the new deadline in a document filed with the SEC. Only those proposals that comply with the requirements of Rule 14a-8 under the Exchange Act will be included in Rite Aid’s proxy statement for the 2024 Annual Meeting. In order for proposals of stockholders made outside of Rule 14a-8 under the Exchange Act to be considered “timely” within the meaning of Rule 14a-4(c) under the Exchange Act, such proposals must be received by the Secretary at the address below by May 20, 2024 (subject to the discussion below).

Stockholders may present proposals that are proper subjects for consideration at an annual meeting, even if the proposal is not submitted by the deadline for inclusion in the proxy statement. To do so, the stockholder must comply with the procedures specified in Rite Aid’s By-Laws. The By-Laws, which are available upon request from the Secretary, require all stockholders who intend to make proposals at an annual meeting of stockholders to submit their proposals to the Secretary not fewer than 90 and not more than 120 days before the anniversary date of the previous year’s annual meeting of stockholders. The By-Laws also provide that nominations for director may only be made by the Board of Directors (or an authorized Board committee) or, unless made under the proxy access provisions of the By-Laws described below, by a stockholder of record entitled to vote who sends notice to the Secretary not fewer than 90 nor more than 120 days before the anniversary date of the previous year’s annual meeting of stockholders. Any such nomination by a stockholder must comply with the procedures specified in Rite Aid’s By-Laws. To be eligible for consideration at the 2024 Annual Meeting, proposals which have not been submitted by the deadline for inclusion in the proxy statement and any nominations for director other than those under the proxy access provisions of the By-Laws must be received by the Secretary between April 20, 2024 and May 20, 2024. This advance notice period is intended to allow all stockholders an opportunity to consider all business and nominees expected to be considered at the meeting. However, if the Company holds its annual meeting on a date that is not within 25 days before or after the anniversary date of the previous year’s annual meeting of stockholders, the Company must receive the notice no later than the close of business on the tenth day following the day on which notice of the date of the annual meeting was mailed or public disclosure of the date of the annual meeting was made, whichever first occurs.
In addition, Rite Aid’s By-Laws provide that, under certain circumstances, a stockholder or group of stockholders may include director candidates that they have nominated in our annual meeting proxy materials. The proxy access provisions of the By-Laws provide, among other things, that a stockholder or group of up to 20 stockholders seeking to include director candidates in our annual meeting proxy materials must own 3% or more of Rite Aid’s outstanding common stock continuously for at least the previous three years. The number of stockholder-nominated candidates appearing in any annual meeting proxy statement cannot exceed 20% of the number of directors then serving on the Board. If the 20% calculation does not result in a whole number, the maximum number of stockholder nominees included in our proxy statement would be the closest whole number below 20%. If the number of stockholder-nominated candidates exceeds 20%, each nominating stockholder or group of stockholders may select one nominee for inclusion in our proxy materials until the maximum number is reached. The order of selection would be determined by the amount (largest to smallest) of shares of Rite Aid common stock held by each nominating stockholder or group of stockholders. The nominating stockholder or group of stockholders also must deliver the information required by Rite Aid’s By-Laws and comply with the procedures specified therein, and each nominee must meet the qualifications required by the By-Laws. Requests to include stockholder-nominated candidates in our proxy materials for the 2024 Annual Meeting must be received by the Secretary no earlier than January 31, 2024 and no later than March 1, 2024. However, if the Company holds its annual meeting on a date that is more than 30 days before or more than 60 days after the anniversary date of the previous year’s annual meeting of stockholders, the Company must receive the request not more than 165 days prior to the date of the annual meeting and not later than the close of business on the later of

RITE AID CORPORATION   2023 Proxy Statement | 89

TABLE OF CONTENTS
OTHER INFORMATION
(x) the 135th day prior to the date of the annual meeting or (y) the tenth day following the day on which notice of the date of the annual meeting was mailed or public disclosure of the date of the annual meeting was made, whichever occurs first.
All submissions to the Secretary should be made to:
[MISSING IMAGE: ic_mail-pn.jpg]
Rite Aid Corporation
Attention: Corporate Secretary
PO Box 3165
Harrisburg, PA 17105
INCORPORATION BY REFERENCE
In accordance with SEC rules, notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act of 1933, as amended, or the Exchange Act, that might incorporate this proxy statement or future filings made by Rite Aid under those statutes, the information included under the caption “Compensation Committee Report” and those portions of the information included under the caption “Audit Committee Report” required by the SEC’s rules to be included therein, shall not be deemed to be “soliciting material” or “filed” with the SEC and shall not be deemed incorporated by reference into any of those prior filings or into any future filings made by Rite Aid under those statutes, except to the extent we specifically incorporate these items by reference.
The Proxy Statement includes website addresses and references to additional materials found on those websites. These websites and materials are not incorporated by reference into, and do not form a part of, this Proxy Statement.

90 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
OTHER INFORMATION
OTHER MATTERS
The Board of Directors knows of no other matters that have been submitted for consideration at the Annual Meeting other than those referred to in this proxy statement and the possible submission of the Krol Proposal, as discussed below, which is not included in this proxy statement but may be presented by Steven Krol at the Annual Meeting. If the Krol Proposal is presented at the Annual Meeting, the persons named in the proxy (the “proxy holders”) will have discretionary authority pursuant to Rule 14a-4(c) under the Exchange Act with respect to the Krol Proposal and intend to exercise such discretion to vote “AGAINST” the proposal. If any other matters come before stockholders at the Annual Meeting, the proxy holders intend to vote the shares they represent in accordance with their best judgment.
Steven Krol has advised the Company that he plans to present a proposal (the “Krol Proposal”) at the Annual Meeting. The proposal requests that the Board of Directors take the steps necessary to amend the Company’s governance documents to give stockholders of record and beneficial stockholders an equal right to call for a special meeting of stockholders so long as they hold at least 10% of the Company’s stock. The Krol Proposal was not submitted under Rule 14a-8 of the Exchange Act, and Mr. Krol did not seek to have the Krol Proposal included in this proxy statement. If presented at the Annual Meeting, the adoption of the Krol Proposal would require the approval of the affirmative vote of a majority of the outstanding shares represented of Rite Aid entitled to vote thereon.
ANNUAL REPORT

        A

We have either mailed to you with this proxy statement a copy of Rite Aid'sAid’s Annual Report on Form 10-K for fiscal year 20092023 or sent you a Notice of Internet Availability of Proxy Materials with the web address for accessing Rite Aid’s Annual Report on Form 10-K for fiscal year 2023 online. Copies of these materials are also available online through the SEC at www.sec.gov.
HELP SUPPORT OUR SUSTAINABILITY
EFFORTS—CHOOSE ELECTRONIC DELIVERY
[MISSING IMAGE: ic_leaf-ko.gif]
We encourage our stockholders to elect to receive future proxy and annual report materials electronically by e-mail to help support our sustainability efforts. There is no charge for requesting a copy. You will need your 16-digit control number included on your proxy card or the instructions that accompanied your proxy materials.
Voting by Registered Holders
[MISSING IMAGE: ic_computer-pn.jpg]
By Internetwww.proxyvote.com
[MISSING IMAGE: ic_phone-pn.jpg]
By Phone1-800-690-6903
[MISSING IMAGE: ic_mail-pn.jpg]
By Email
sendmaterial@proxyvote.com
Send a blank e-mail with your 16-digit
control number in the subject line
Voting by Beneficial Owners
Contact your bank, broker, or other nominee
A copy of our Annual Report on Form 10-K, including the financial statements included therein, is also available without charge by visiting the Company’s website or upon written request to:
[MISSING IMAGE: ic_mail-pn.jpg]
Rite Aid Corporation
Attention: Corporate Secretary
PO Box 3165
Harrisburg, PA 17105

RITE AID CORPORATION   2023 Proxy Statement | 91

TABLE OF CONTENTS
OTHER INFORMATION
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
These proxy materials, as well as our other public filings or public statements, include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by terms and phrases such as “anticipate,” “believe,” “intend,” “estimate,” “expect,” “continue,” “should,” “could,” “may,” “plan,” “project,” “predict,” “will,” and similar expressions and include references to assumptions and relate to our future prospects, developments, and business strategies.
Factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:

the impact of widespread health developments, such as the global coronavirus (“COVID-19”) pandemic, the changing consumer behavior and preferences (including preferred shopping locations, vaccine hesitancy and the emergence of new variants), and the impact of those factors on the broader economy, financial and labor markets, wages, availability and access to credit and capital, our front-end and pharmacy operations and services, supply chain challenges including shipping delays, container and trucker shortages, port congestion and other logistics problems, our associates and executive and administrative personnel, our third-party service providers (including suppliers, vendors and business partners), and customers. In addition, continued shortages of pharmacists, pharmacy technicians and other employee turnover in the markets in which we operate, may inhibit our ability to maintain store hours at preferred levels. Any of these developments could result in a material adverse effect on our business, financial conditions and results of operations;

our ability to successfully implement our strategy, attract and retain a sufficient number of our target consumers, integrate operations such as Elixir, our pharmacy benefit management (“PBM”) operations, and any acquisitions, implement and integrate information technology and digital services, obtain permits required for store remodels, and improve the operating performance of our stores and PBM operations;

our high level of indebtedness, the ability to refinance such indebtedness on acceptable terms (including the impact of rising interest rates, market volatility, and continuing actions by the United States Federal Reserve), and our ability to satisfy our obligations and the other covenants contained in our credit and debt agreements;

the nature, cost, impact and outcome of pending and future litigation, other legal or regulatory proceedings, or governmental investigations and actions, including those related to opioids, “usual and customary” pricing, government payer programs, business practices, or other matters;

general competitive, economic, industry, market, political (including healthcare reform) and regulatory conditions, including continued impacts of inflation or other pricing environment factors on our costs, liquidity and our ability to pass on price increases to our customers, including as a result of inflationary and deflationary pressures, a decline in consumer spending or deterioration in consumer financial position, whether due to inflation or other factors, as well as other factors specific to the markets in which we operate;

the severity and resulting impact of the cough, cold and flu season;

the impact on retail pharmacy business as PBM payors seek to reduce payments to retail pharmacies and incent or mandate movement away from retail pharmacies to PBM mail order pharmacies;

our ability to achieve the benefits of our efforts to reduce the purchasing cost of our generic drugs;

the risk that changes in federal or state laws or regulations, including to those relating to labor or wages, the Health Care Education Affordability Reconciliation Act, the repeal of all or part of the Patient Protection and the Affordable Care Act (or “ACA”), and decisions of agencies and courts including the United States Supreme Court regarding those and other matters relevant to Rite Aid Corporation or its operations, and any regulations enacted thereunder may occur;

the impact of the loss of one or more major third-party payor contracts and the risk that providers and state contract changes may occur;

the risk that we may need to take further impairment charges if our future results do not meet our expectations;

92 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
OTHER INFORMATION

our ability to sell our Centers of Medicare and Medicaid Services (“CMS”) receivables, in whole or in part, and on reasonably available terms, which could negatively impact our liquidity and leverage ratio if we do not consummate a sale;

our ability to grow prescription count, realize front-end sales growth, and improve and grow the operations of our PBM;

our ability to achieve cost savings and the other benefits of our organizational restructuring within our anticipated timeframe, if at all;

decisions to close additional stores and distribution centers or undertake additional refinancing activities, which could result in further charges;

our ability to manage expenses, our liquidity and our investments in working capital;

the continued impact of gross margin pressure in the PBM industry due to continued consolidation and client demand for lower prices while providing enhanced service offerings;

risks related to breaches of our (or our vendors’) information or payment systems or unauthorized access to confidential or personal information of our associates or customers;

our ability to maintain our current pharmacy services business and obtain new pharmacy services business and clients, including maintaining renewals of expiring contracts, avoiding contract termination rights that may permit certain of our clients to terminate their contracts prior to their expiration, early price renegotiations prior to contract expirations, the risk that we cannot meet client guarantees and the impact of pricing decisions on our ability to retain our customer base;

our chief executive officer search process, and our ability to manage the transition to a new chief executive officer and other management;

our ability to manage our Medicare Part D plan medical loss ratio (“MLR”) and meet the financial obligations of the plan;

the risk that we could experience deterioration in our current Star rating with the CMS or incur CMS penalties and/or sanctions;

our ability to achieve the benefits of our efforts of our performance acceleration program;

the expiration or termination of our Medicare or Medicaid managed care contracts by federal or state governments;

changes in future exchange or interest rates or credit ratings, changes in tax laws, regulations, rates and policies; and

other risks and uncertainties described from time to time in our filings with the U.S. Securities and Exchange Commission (the “SEC”).
We undertake no obligation to update or revise the forward-looking statements included in these proxy materials, whether as a result of new information, future events or otherwise, after the date of these proxy materials. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Factors that could cause or contribute to such differences are discussed in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations—Overview and Factors Affecting Our Future Prospects” included in our Annual Report on Form 10-K for fiscal year 2023. Additionally, the continued impact of COVID-19 could heighten many of the risk factors described herein.

RITE AID CORPORATION   2023 Proxy Statement | 93

TABLE OF CONTENTS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
APPENDIX A—NON-GAAP FINANCIAL MEASURES
ADJUSTED EBITDA, ADJUSTED NET INCOME (LOSS), ADJUSTED NET INCOME (LOSS) PER DILUTED SHARE AND OTHER NON-GAAP MEASURES
In addition to net income (loss) determined in accordance with GAAP, we use certain non-GAAP measures, such as “Adjusted EBITDA,” in assessing our operating performance. We believe the non-GAAP measures serve as an appropriate measure in evaluating the performance of our business. We define Adjusted EBITDA as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments (which removes the entire impact of LIFO, and effectively reflects the results as if we were on a FIFO inventory basis), charges or credits for facility exit and impairment, goodwill and intangible asset impairment charges, inventory write-downs related to store closings, gains or losses on debt modifications and retirements, and other items (including stock-based compensation expense, merger and acquisition-related costs, non-recurring litigation and other contractual settlements, severance, restructuring-related costs, costs related to facility closures, gain or loss on sale of assets, the gain or loss on Bartell acquisition, and the change in estimate related to manufacturer rebate receivables). We reference this particular non-GAAP financial measure frequently in our decision-making because it provides supplemental information that facilitates internal comparisons to the historical periods and external comparisons to competitors. In addition, incentive compensation is being mailed togetherprimarily based on Adjusted EBITDA and we base certain of our forward-looking estimates on Adjusted EBITDA to facilitate quantification of planned business activities and enhance subsequent follow-up with this proxy statementcomparisons of actual to all stockholders entitledplanned Adjusted EBITDA.
We present these non-GAAP financial measures in order to noticeprovide transparency to our investors because they are measures that management uses to assess both management performance and the financial performance of our operations and to vote atallocate resources. In addition, management believes that these measures may assist investors with understanding and evaluating our initiatives to drive improved financial performance and enables investors to supplementally compare our operating performance with the Annual Meeting.


Tableoperating performance of Contentsour competitors including with those of our competitors having different capital structures. While we have excluded certain of these items from historical non-GAAP financial measures, there is no guarantee that the items excluded from non-GAAP financial measures will not continue into future periods. For instance, we expect to continue to experience charges for facility exit and impairment charges and inventory write-downs related to store closures as we continue to complete a multi-year strategic initiative designed to improve overall performance. We also expect to continue to experience and report restructuring-related charges associated with continued execution of our strategic initiatives.

March 4, 2023
(53 weeks)
February 26, 2022
(52 weeks)
February 27, 2021
(52 weeks)
(Dollars in thousands)
Net loss from continuing operations$(749,936)$(538,478)$(100,070)
Interest expense224,399191,601201,388
Income tax benefit(6,467)(3,780)(20,157)
Depreciation and amortization276,583295,686327,124
LIFO charge (credit)53,0281,314(51,692)
Facility exit and impairment charges211,385180,19058,403
Goodwill and intangible asset impairment charges371,200229,00029,852
Loss (gain) on debt modifications and retirements, net(80,142)3,235(5,274)
Merger and Acquisition-related costs12,79710,549


TABLE OF CONTENTS


Appendix

APPENDIX A


Proposed Amendment

March 4, 2023(53 weeks)February 26, 2022(52 weeks)February 27, 2021(52 weeks)
(Dollars in thousands)
Stock-based compensation expense11,53713,05013,003
Restructuring-related costs108,62635,12184,552
Inventory write-downs related to store closings14,2705,2983,709
Litigation and other contractual settlements53,88250,212
Loss (gain) on sale of assets, net(68,586)5,505(69,300)
Loss (gain) on Bartell acquisition5,346(47,705)
Change in estimate related to manufacturer rebate receivables15,068
Other9,4014,7403,283
Adjusted EBITDA$429,180$505,905$437,665
The following is a reconciliation of our net loss to Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share for fiscal 2023, 2022 and 2021. Adjusted Net Income (Loss) is defined as net income (loss) excluding the impact of amortization expense, merger and acquisition-related costs, non-recurring litigation and other contractual settlements, gains or losses on debt modifications and retirements, LIFO adjustments (which removes the entire impact of LIFO, and effectively reflects the results as if we were on a FIFO inventory basis), goodwill and intangible asset impairment charges, restructuring-related costs, the gain or loss on Bartell acquisition, and the change in estimate related to manufacturer rebate receivables. We calculate Adjusted Net Income (Loss) per Diluted Share using our above-referenced definition of Adjusted Net Income (Loss). We believe Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share are useful indicators of our operating performance over multiple periods. Adjusted Net Income (Loss) per Diluted Share is calculated using our above referenced definition of Adjusted Net Income (Loss).
March 4, 2023
(53 weeks)
February 26, 2022
(52 weeks)
February 27, 2021
(52 weeks)
(Dollars in thousands)
Net loss$(749,936)$(538,478)$(100,070)
Add back—Income tax benefit(6,467)(3,780)(20,157)
Loss before income taxes(756,403)(542,258)(120,227)
Adjustments:
Amortization expense74,02478,04789,020
LIFO charge (credit)53,0281,314(51,692)
Goodwill and intangible asset impairment charges371,200229,00029,852
Loss (gain) on debt modifications and retirements, net(80,142)3,235(5,274)
Merger and Acquisition-related costs12,79710,549
Restructuring-related costs108,62635,12184,552
Loss (gain) on Bartell acquisition5,346(47,705)
Change in estimate related to manufacturer rebate receivables15,068
Litigation and other contractual settlements53,88250,212
Adjusted loss before income taxes(175,785)(112,118)(10,925)
Adjusted income tax benefit(1)(1,494)(782)(1,832)
Adjusted net loss(174,291)(111,336)(9,093)
Net loss per diluted share$(13.71)$(9.96)$(1.87)
Adjusted net loss per diluted share$(3.19)$(2.06)$(0.17)
(1)
The fiscal year 2023, 2022 and 2021 adjustments to the Restated Certificateincome tax provision include adjustments to the GAAP basis tax provision commensurate with non-GAAP adjustments and certain discrete tax items, when applicable, was used for the fifty-three weeks ended March 4, 2023 and the fifty two weeks ended February 26, 2022 and February 27, 2021, respectively.

A-2 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
APPENDIX A
In addition to Adjusted EBITDA, Adjusted Net (Loss) Income and Adjusted Net (Loss) Income per Diluted Share, we occasionally refer to several other Non-GAAP measures, on a less frequent basis, in order to describe certain components of Incorporation
our business and how we utilize them to Declassify Our Board of Directors (Proposal No. 1)

describe our results. These measures include but are not limited to Adjusted EBITDA Gross Margin and Gross Profit (gross margin/gross profit excluding non-Adjusted EBITDA items), Adjusted EBITDA SG&A (SG&A expenses excluding non-Adjusted EBITDA items), FIFO Gross Margin and FIFO Gross Profit (gross margin/gross profit before LIFO charges), and Free Cash Flow (Adjusted EBITDA less cash paid for interest, rent on closed stores, capital expenditures, restructuring-related costs and the change in working capital).


RITE AID CORPORATION   2023 Proxy Statement | A-3

TABLE OF CONTENTS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
APPENDIX B—PROPOSED AMENDMENTS TO THE RITE AID CORPORATION AMENDED AND
RESTATED CERTIFICATE OF INCORPORATION
TO ELIMINATE SUPERMAJORITY VOTING
PROVISIONS
The proposed amendments, with deletions reflected by “strike-through” text below is the portion of ourand additions reflected by “underline” text, to Rite Aid’s Amended and Restated Certificate of Incorporation proposed to be amended byeliminate the supermajority voting provisions described in Proposal No. 1. Proposed additions5 are indicated by underlining and proposed deletionsas follows:
INTRODUCTORY PARAGRAPH OF PARAGRAPH B OF ARTICLE ELEVENTH
B.
Unless the conditions set forth in subparagraphs (1) or (2) of this paragraph B are indicated by strike-outs.

    EIGHTH: Forsatisfied, the managementaffirmative vote of not less than seventy-five percent (75%)a majority of the business and for the conductoutstanding shares of the affairsstock of the corporation andentitled to vote in further definition, limitation and regulationelections of directors, considered for the purposes of this Article ELEVENTH as one class, shall be required for the adoption or authorization of a Business Combination with any Related Person. Such affirmative vote shall be required notwithstanding the fact that no vote, or a lesser percentage, may be required by law or in any agreement with any national securities exchange or otherwise, but such vote shall not be applicable if:

PARAGRAPH D OF ARTICLE ELEVENTH
D.
Any corporation action which may be taken by the written consent of stockholders entitled to vote upon such action pursuant to Article SEVENTH Section 4 of this Certificate of Incorporation or pursuant to the General Corporation Law shall be only by the written consent of holders of not less than seventy-five percent (75%)a majority of the powersshares of stock of the corporation and of its directors and stockholders, or any class thereof, asentitled to vote thereon, notwithstanding the casefact that a lesser percentage may be it is further provided:

1. The managementrequired by law or otherwise.

PARAGRAPH E OF ARTICLE ELEVENTH
E.
Any corporate action which may be taken at a special meeting of the business and the conduct of the affairs of the corporation, including the election of the Chairman ofstockholders called by the Board of Directors, if any,a majority of which Board are not Continuing Directors, shall be only by the President,affirmative vote of the Treasurer,holders of not less than seventy-five percent (75%)a majority of the Secretary, and other principal officersoutstanding shares of stock of the corporation entitled to vote in elections of directors, considered for purposes of this Article ELEVENTH as one class, notwithstanding the fact that a lesser percentage may be required by law or otherwise.
PARAGRAPH G OF ARTICLE ELEVENTH
G.
No amendments to this Certificate of Incorporation of the corporation shall be vested in its Boardamend, alter, change or repeal any of Directors. The numberthe provisions of Directorsthis Article ELEVENTH, unless the amendment effecting such amendment, alteration, change or repeal shall receive the affirmative vote of not less than seventy-five percent (75%)a majority of the shares of stock of the corporation shall be fixed by the By-Laws of the corporation and may be altered from timeentitled to time as provided therein, butvote in no event shall the numberelections of directors, of the corporation be less than three nor more than fifteen. A director shall be elected to hold office until the expiration of the term for which such person is elected, and until such person's successor shall be duly elected and qualified.Commencing at the annual meeting of stockholders that is held in calendar year 2009 (the "2009 Annual Meeting"),Tthe directors of the corporation shall bedivided into three classes, as nearly equal in number as possible, designated Class I, Class II and Class III. The term of office of the initial Class I directors shall expire at the annual meeting of stockholders to be held in 1977; the term of office of the initial Class II directors shall expire at the annual meeting of stockholders to be held in 1978; and the term of office of the initial Class III directors shall expire at the annual meeting of stockholders to be held in 1979.elected annually for terms of one year, except that any director in office at the 2009 Annual Meeting whose term expires at the annual meeting of stockholders in calendar year 2010 or calendar year 2011 (a "Continuing Classified Director") shall continue to hold office until the end of the term for which such director was elected and until such director's successor shall have been elected and qualified. Accordingly, at each annual meeting of stockholderscommencing with the annual meeting to be held in 1977considered for the purposepurposes of electing athis Article ELEVENTH as one class of directors, persons; provided that this paragraph G shall be electednot apply to, hold office asand such class of directors for a period of three years and until the third succeeding annual meeting of stockholders following the meeting at which they are elected. When the number of directors is changed, any newly created directorships or any decrease in directorshipsseventy-five percent (75%) vote shall be so apportioned among the classes so as to make all classes as nearly equal in number as possibleafter the terms of all Continuing Classified Directors have expired, all directors shall be elected for terms expiring at the next annual meeting of stockholders and until such directors' successors shall have been elected and qualified. Any vacancies created in the Board of Directors throughan increase in the number of directors or otherwise, may be filled in accordance with the By-Laws of the corporation and the applicable laws of the State of Delaware. Election of directors need not be by written ballot.Any director,required for, any amendment, alteration, change or repeal recommended to the entire Board of Directors, may be removed, with or without cause,stockholders by the holders of a majority of the votesContinuing Directors.

RITE AID CORPORATION   2023 Proxy Statement | B-1

TABLE OF CONTENTS
[MISSING IMAGE: cv_obcriteaid-pnlr.jpg]

TABLE OF CONTENTS
[MISSING IMAGE: px_riteaidproxy1pg1-bw.jpg]
Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) DateTO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:KEEP THIS PORTION FOR YOUR RECORDSTHIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION ONLYV18976-P96107RITE AID CORPORATIONATTN: BYRON PURCELLP.O. BOX 3165HARRISBURG, PA 17105RITE AID CORPORATIONPlease sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each signpersonally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer.For Against AbstainFor Against Abstain1. Election of capital stock then entitled to voteDirectorsNominees:The Board of Directors unanimously recommends that you voteFOR the following:3. Approve, on an advisory basis, the compensation of our namedexecutive officers as presented in the electionproxy statement.4. Approve, on an advisory basis, the frequency of directorsfutureadvisory votes to approve the compensation of ournamed executive officers.5. Approve amendments to the Rite Aid Corporation Amended andRestated Certificate of Incorporation to eliminate supermajorityvoting provisions.2. Ratify the appointment of Deloitte & Touche LLP as our independentregistered public accounting firm.6. Consider a stockholder proposal, if properly presented at theAnnual Meeting, to require an annual advisory vote on thecompensation of Rite Aid’s directors.7. Consider a stockholder proposal, if properly presented at theAnnual Meeting, to adopt an executive compensation adjustmentpolicy.The Board of Directors unanimously recommends that you voteAGAINST Proposals 6 and 7.The Board of Directors unanimously recommends that you voteFOR Proposals 2 and 3.The Board of Directors unanimously recommends that you voteFOR Proposal 5.The Board of Directors unanimously recommends thatyou vote for ONE YEAR on Proposal 4.NOTE: Such other business as may properly come before the meeting orany adjournment thereof.For Against AbstainFor Against Abstain! ! !! ! !! ! !! ! !! ! !! ! !! ! !! ! !! ! !! ! !! ! !1a. Bruce G. Bodaken ! ! ! !1b. Elizabeth Burr1c. Bari Harlam1e. Arun Nayar1d. Robert E. Knowling, Jr.1f. Kate B. QuinnThreeYearsOneYearTwoYears AbstainVOTE BY INTERNETBefore The Meeting - Go to www.proxyvote.com or scan the QR Barcode aboveUse the Internet to transmit your voting instructions and for electronic delivery of stockholders calledinformation up until 11:59P.M. Eastern Daylight Time, August 17, 2023. Have your proxy card in hand when you access the websiteand follow the instructions to obtain your records and to create an electronic voting instruction form.During The Meeting - Go to www.virtualshareholdermeeting.com/RAD2023You may attend the meeting via the Internet and vote during the meeting. Have the information that isprinted in the box marked by the arrow available and follow the instructions.ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALSIf you would like to reduce the costs incurred by our company in mailing proxy materials, you canconsent to receiving all future proxy statements, proxy cards and annual reports electronicallyvia e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to voteusing the Internet and, when prompted, indicate that purpose, except that Continuing Classified Directorsyou agree to receive or access proxy materialselectronically in future years.VOTE BY PHONE - 1-800-690-6903Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M.Eastern Daylight Time, August 17, 2023. Have your proxy card in hand when you call and any director appointedthen followthe instructions.VOTE BY MAILMark, sign and date your proxy card and return it in the postage-paid envelope we have providedor return it to fill a vacancyVote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.SCAN TOVIEW MATERIALS & VOTE w

TABLE OF CONTENTS
[MISSING IMAGE: px_riteaidproxy1pg2-bw.jpg]
V18977-P96107Important Notice Regarding the Availability of any Continuing Classified Director mayProxy Materials for the Annual Meeting:The Notice and Proxy Statement and Form 10-K are available at www.proxyvote.com.Continued and to be removed only for cause.


PRELIMINARY COPY

RITEsigned on reverse sideRITE AID CORPORATION

PROXY

FOR ANNUAL MEETING OF STOCKHOLDERS — JUNE 25, 2009

THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

The undersignedCORPORATIONAnnual Meeting of StockholdersAugust 18, 2023 at 11:30 a.m., Eastern Daylight TimeThis proxy is solicited by the Board of DirectorsThe stockholder(s) hereby appoints Robert G. Miller, Frank G. Vitranoappoint(s) Elizabeth Burr and Marc A. Strassler,Matthew Schroeder, or any oneeither of them, as proxies, each with fullthe power of substitution,to appoint a substitute, and hereby authorize(s) them to represent and to vote, as designated on the reverse side of this proxy card, all of the shares of common stock of Rite Aid Corporation (the “Company”), as set forth below,RITE AID CORPORATION that the undersigned would be entitledstockholder(s) is/areentitled to vote if personally present at the Annual Meeting of Stockholders of the Company to be held at Skadden, Arps, Slate, Meagher & Flom LLP, Four Times Square, 37th Floor, New York, New York at 10:11:30 a.m., local time,Eastern Daylight Time on June 25, 2009, and at any adjournments or postponements thereof.  IfAugust 18, 2023 atwww.virtualshareholdermeeting.com/RAD2023.If applicable, the proxy shall also govern the voting of stock held for the account of the undersigned in the Company’s Investment Opportunity Plan, or any applicable employee benefit plan.

The Company provides its annual reports andvalidity of this proxy solicitation materials, including notices to stockholders of annual meetings and proxy statements, overis governed by the Internet.  If you give your consent to access these documents over the Internet, the Company will advise you when these documents become available on the Internet.  Providing these documents over the Internet will reduce the Company’s printing and postage costs.  Once you give your consent, it will remain in effect until you notify the Company that you wish to resume mail deliverylaws of the annual reports andState of Delaware. This proxy statement.  Even though you give your consent, you still havedoes not revoke any prior powers of attorney except for prior proxies given in connection with the right at any time to request copiesAnnual Meeting of these documents.

THIS PROXY MAY BE REVOKED AT ANY TIME BEFORE IT IS EXERCISED.  THISStockholders.THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS SPECIFIED, OR, IF NO SPECIFICATIONS ARE MADE, WILL BE VOTED (1) “FORIN ACCORDANCE WITH THE AMENDMENT OF THE COMPANY’S RESTATED CERTIFICATE OF INCORPORATION TO DECLASSIFY OUR BOARD OF DIRECTORS, (2) “FOR” THE ELECTION OF ALL THE NOMINEES OF THE BOARD IN THE ELECTION OF DIRECTORS, (3) “AGAINST” THE STOCKHOLDER PROPOSAL AND (4) “FOR” THE RATIFICATION OF THE APPOINTMENT OF OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.DIRECTORS' RECOMMENDATIONS. IF ANY OTHER MATTER IS PROPERLY PRESENTED AT THE ANNUAL MEETING OF STOCKHOLDERS, THIS PROXY WILL BE VOTED IN THE NAMED PROXIES’PROXIES' DISCRETION ON SUCH MATTERS.

THE UNDERSIGNED HEREBY ACKNOWLEDGES RECEIPT OF THE NOTICE OF MEETING AND PROXY STATEMENT FURNISHED HEREWITH, AND HEREBY CONFIRMS THAT THIS PROXY SHALL BE VALID AND MAY BE VOTED WHETHER OR NOT THE STOCKHOLDER’S NAME IS SET FORTH BELOW OR A SEAL IS AFFIXED OR THE DESCRIPTION, AUTHORITY OR CAPACITY OF THE PERSON SIGNING IS GIVEN OR OTHER DEFECT OF SIGNATURE EXISTS.

PLEASEMATTER.PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY CARD PROMPTLY IN THE ENCLOSED POSTAGE PAIDPOSTAGE-PAID ENVELOPE.

THIS PROXY IS CONTINUED ON THE REVERSE SIDE




ANNUAL MEETING OF STOCKHOLDERS OF

RITE AID CORPORATION

June 25, 2009

Please sign, date and mail

your proxy card in the

envelope provided as soon

as possible.

Please detach along perforated line and mail in the envelope provided.

PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.
PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE
x

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” PROPOSAL 1.

Proposal No. 1:

Amend the Company’s Restated Certificate of Incorporation to declassify our Board of Directors.

FOR

AGAINST

ABSTAIN

o

o

o

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” PROPOSAL 2.

Proposal No. 2:

Elect five directors to hold office until the 2010 Annual Meeting of Stockholders (or until the 2012 Annual Meeting of Stockholders if Proposal No. 1 is not approved, as described in the proxy statement).

NOMINEES

o

FOR ALL NOMINEES

o

Joseph B. Anderson, Jr.

o

WITHHOLD AUTHORITY FOR ALL NOMINEES

o

Michel Coutu

o

FOR ALL EXCEPT (See instructions below)

o

James L. Donald

o

John T. Standley

o

Marcy Syms

INSTRUCTIONS: To withhold authority to vote for any individual nominee(s), mark
“FOR ALL EXCEPT” and fill in the circle next to each nominee you wish to withhold, as shown here:
x

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “AGAINST” PROPOSAL 3.

Proposal No. 3:

Consider a stockholder proposal requesting that the Board of Directors provide stockholders the opportunity at each annual meeting of stockholders to vote on an advisory resolution to ratify the compensation of the named executive officers set forth in the proxy statement.

FOR

AGAINST

ABSTAIN

o

o

o

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” PROPOSAL 4.

Proposal No. 4:

Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm.

FOR

AGAINST

ABSTAIN

o

o

o

Please mark, sign, date, and return this voting instruction card promptly in the enclosed postage paid envelope. If you receive more than one proxy card please vote with respect to each card you receive.


0000084129 5 2022-02-27 2023-03-04

ELECTRONIC ACCESS TO FUTURE DOCUMENTS

If you would like to receive future shareholder communications over the Internet exclusively, and no longer receive any material by mail please visit http://www.amstock.com. Click on Shareholder Account Access to enroll. Please enter your account number and tax identification number to log in, then select Receive Company Mailings via E-Mail and provide your e-mail address.

To change the address on your account, please mark the box at right and indicate your new address in the address

space above.

o

Please note that changes to the registered name(s) on the account may not be submitted via this method.

Signature of
Stockholder

Date:

Signature of
Stockholder

Date:

Note:

Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person.